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1. INTRODUCTION 
1.1 Chromosomal aberrations in neoplasia 
The hypothesis that chromosomal changes play a fundamen-
tal role in the process of neoplastic transformation was pos-
tulated almost a century ago by Von Hansemann (1890) and Boveri 
(1914). The discovery in 1960, of a specific chromosomal mar-
ker, the Philadelphia (Ph1 ) chromosome (Nowell and Hungerford, 
1960) in chronic myelocytic leukemia (CML) supported this hypo-
thesis. However, for a long time this Ph1 chromosome was regar-
ded as an unique example of a consistent karyotypic abnormality 
since other malignant disorders, especially solid tumors, 
showed a great variability in karyotype (Sandberg, 1980). The 
introduction and constant refinement of chromosome banding 
techniques (Hagemeijer et al., 1979; Yunis, 1981; Testa, 1984) 
made it possible to identify and define tumor specific chromo-
somal aberrations. Combination of these sophisticated cytogene-
tic techniques with cytological, cytochemical and immunological 
studies revealed that the malignant cells of most human tumors 
have a clonal karyotypic defect (Yunis et al., 1982; Yunis, 
1983; Berger and Flandrin, 1984). Three major types of karyoty-
pic changes can be distinguished that occur in tumor cells, 
either alone or in combination. 1) Numerical changes such as 
monosomy or trisomy, 2) structural changes such as transloca-
tions, deletions and inversions and 3) manifestations of gene 
amplification such as homogeneously staining regions (HSR's) or 
double minutes (DM's). In less than 10% of the cytogenetic 
studies the material was derived from solid tumors, the largest 
tumor group in humans. The majority of the cytogenetic data 
came from cytogenetic studies of hematopoietic disorders and 
lymphomas (70% and 20% resp.; Mitelman, 1986). This is in part 
due to the relatively simple collection of leukemic cells from 
bone marrow, blood or lymph- nodes, the well-defined conditions 
for culturing these cells and the adapted chromosome banding 
techniques. In Table 1 a list is shown of consistent chromoso-
mal aberrations (primarily translocations), found in several 
types of leukemia and lymphoma • The list also contains a few 
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known recurring chromosomal abnormalities (primarily deletions) 
which can be observed in human solid tumors despite the techni-
cal difficulties (Yunis 1983; Trent, 1984). From the collected 
cytogenetic data (from over more than 5500 tumors; Mitelman, 
1985) it is apparent that breakpoints of structural karyotypic 
aberrations are clustered to specific chromosomal regions (Mi-
telman, 1984; Mitelman, 1986). Some structural aberrations are 
exclusively found in one specific tumor subtype e.g. the 
t(l5;17)(q22;q21) (for nomenclature see ISCN, 1985) is found 
solely in acute non-lymphocytic leukemia (ANLL-M3) (FAB classi-
fication for acute leukemias, Bennett et al., 1976)(Larson et 
al., 1984). However most of the chromosomal breakpoint regions 
are shared either by neoplastic disorders originating from 
different cell types or by related disorders. For example the 
chromosome 22qll region is involved in structural aberrations 
observed in a variety of unrelated tumors such as meningiomas, 
gliomas, Di-George syndrome (del(22)(qll-qter)), Burkitt lym-
phoma (BL), acute lymphoblastic leukemia (ALL-L3) 
(t(8;22)(q24;qll)), ALL-Ll,-L2, ANLL-Ml, CML 
(t(9;22) (q34;qll) (Berger et al., 1985; Cannizzaro and Emanuel, 
1985; Emanuel et al., 1986). Whereas the 14qll region is fre-
quently involved in structural aberrations (translocations and 
inversions) in T-cell leukemia/lymphoma (Hecht et al., 1984; 
Clare et al., 1986; Hecht et al., 1986) and s~milarly the 14q32 
region in B-cell leukemia/lymphoma (Croce and Nowell, 1985; 
Cleary and Sklar, 1985a). At these latter two regions cell type 
specific genes have been localized: the T-cell receptor ~-chain 
gene at 14qll (Collins et al., 1985; Croce et al., 1985a) and 
the immunoglobulin heavy chain (IgH) genes at 14q32 (Croce et 
al., 1979; Kirsch et al., 1982). Previously a similar concor-
dance has been notice between the localization of cell lineage 
specific, transcriptionally active genes and one of the trans-
location breakpoints in B-cell lymphomas, both in human and 
mouse (Klein, 1981). The author suggested that in analogy with 
the oncogene activation model in virally induced tumors (Hay-
ward et al., 1981), the accidental transposition of specific, 
oncogene like genes to transcriptionally active regions could 
10 
alter the exp(ession of these specific genes. Support for this 
hypothesis came from observations in BL cell lines with a 
characteristic t(8;14): the c-myc gene, normally located at 
chromosome 8 (q24)(Neel et al., 1982; Dalla-Favera et al., 
1982a, 1982b) was translocated into the IgH gene locus (Taub et 
al., 1982; Dalla-Favera et al., 1983). This translocation of c-
myc resulted in an aberrant and sometimes enhanced expression 
of the c-myc oncogene (Shen-Ong et al., 1982; Erikson et al., 
1983a). An other example emphasized the fact that oncogenes 
might be involved in tumor specific translocations. The c-abl 
oncogene was translocated from its normal position on chromo-
some 9 (Heisterkamp et al., 1982) to the 22q- chromosome in the 
CML specific t(9;22)(q34;qll) (De Klein et al., 1982: Appendix 
Paper I). 
1.2 Oncogenes 
Several independent lines of cancer research have led to 
the discovery of cellular genes with a potential transforming 
activity. The majority of these cellular oncogenes were identi-
fied because they represent the cellular homologues (c-one) of 
the transforming genes of acute RNA tumor viruses. In contrast 
to the slow transforming RNA tumor viruses these acute RNA 
tumor viruses contain an extra host cell derived sequence, v-
~, which is responsible for the acute form of transformation. 
Usually the v-oncogenes are truncated and/or mutated processed 
forms of normal cellular genes (Bishop, 1983; Bishop and 
Varmus, 1984). Slow transforming RNA tumor viruses cause malig-
nant transformation after a protracted latent period. They can 
activate a cellular gene by proviral insertion next to it, 
placing this gene under the control of the strong promoter or 
enhancer sequences present in the viral long terminal repeat 
(LTR) (Varmus, 1982). Besides previously identified c-oncogenes 
like c-myc (Hayward et al., 1981; Payne et a1., 1982; Corcoran 
et al., 1984), ~ (Rechavi et al., 1982; Cohen et al., 1983; 
Gattoni-Celli et al., 1983); c-myb (Shen-Ong et al., 1984; 
Rosson and Reddy, 1986) and c-erbB (Fung et al., 1983; Raines 
11 
et al., 1985), other cellular genes can serve as targets for 
activation by proviral or transposon like integration, like 
int-1 (Nusse and Varmus, 1982; Nusse et al., 1984); pim-1 
(Cuypers et al., 1984; Selten et al., 1985) or Mvli-1 (Tsichlis 
et al., 1983). Alternatively, rearrangements and/or mutations 
of cellular genes can be caused by chromosomal aberrations. 
They may affect known c-oncogenes as c-myc and c-abl in the BL 
and CML specific translocations respectively, or lead to the 
identification of new putative c-oncogenes as bel-l and bcl-2 
(Nowell et al., 1984; Cleary and Sklar, 1985b) or pvt-1 (Webb 
et al., 1984; Cory et al., 1985). Like c-myc, these latter 
genes are joined to the immunoglobulin genes in the respective 
translocations. Similarly, the investigation of amplified DNA 
sequences in tumor cells showed the involvement of previously 
identified oncogenes: c-myc (Alitalo et al., 1983a) and K-ras 
(Schwab et al., 1983a) or led to the discovery of new, related 
oncogenes: N-myc (Schwab et al., 1983b) or L-myc (Nau et al., 
1985). 
Another approach, DNA-mediated gene transfer, led to the 
characterization of transforming genes present in tumor cells, 
competent to transform appropriate recipient cultured cells, 
e.g. the mouse fibroblast cell line NIH-3T3 (Cooper et al., 
1980). One fifth of the DNA's extracted from various tumors and 
tumor cell lines were able to induce focus formation in 
cultures of this immortalized, rodent cell line. The isolated 
transforming genes are in most cases mutated-members of the ras 
gene family: H-ras, K-ras or N-ras (Cooper, 1982; Der et al., 
1982; Shimizu et al., 1983; Hall et al., 1983; Cooper and Lane, 
1984). Despite obvious limitation, probably due to the reci-
pient cell line used, occasionally new and often truncated 
transforming genes have been isolated like met (Cooper et al., 
1984; Dean et al., 1985, Park et al., 1986), trk (Martin-Zanca 
et al., 1986), ~-and T-lym (Lane et al. 1982) or neu 
(Schlechter et al., 1984, 1985; Bargmann et al., 1986a, 198Gb). 
The normal cellular counter parts (proto-oncogenes) of 
the transforming and activated oncogenes are a heterogeneous 
group of genes which have been highly conserved throughout 
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evolution (Shilo and Weinberg, 1981~ Bishop, 1983~ Land et al., 
1983a). The tissue and stage specific expression (Muller et 
al., 1982, 1983, 1984a; Gonda and Metcalf, 1984; Duprey and 
Boettiger, 1985; Sariban et al., 1985; Thompson et al., 1986 
and Zimmerman et al., 1986) and the rapid induction upon mito-
genic signals (Kelly et al., 1983; Kruyer et al., 1984; Muller 
et al., 1984b) of some of these proto-oncogenes suggests that 
they play a role in regulation of normal cell differentiation 
and proliferation. Proto-oncogene products located in the 
nucleus (e.g. c-myc, c-myb and c-fos) may modulate the tran-
scriptional activity of the cell, whereas cytoplasmic products 
(e.g. ras, c-abl, c-sis-, e-yes) could be related to the signal 
pathway in response to growth or differentiation signals. The 
identification of gene products of oncogenes as growth factors 
(Waterfield et al., 1983; Robbins et al., 1983) or growth 
factor receptors (Downward et al., 1984, Sherr et al., 1985; 
Yamamoto et al., 1986; Bargmann et al., 1986) provided strong 
support for such a role. Quantitative (enhanced or constitutive 
expression) and qualitative (mutations, truncations) alteration 
of these gene products will interfere with the normal cellular 
functions and could ultimately lead to transformation (see 
reviews by Varmus, 1984; Bishop, 1985; Weinberg, 1985). 
The chromosomal location of many proto-oncogenes has been 
determined, using somatic cell hybrids and in situ hybridiza-
tion (Table 2). The striking concordance between the position 
of proto-oncogenes and consistent chromosomal aberrations (Fi-
gure 1) (Rowley, 1983; Yunis, 1983; Pearson and Rowley, 1985) 
has led to numerous molecular and cytogenetic studies to verify 
this apparent association. Ample evidence has been provided for 
the involvement of the c-myc and c-abl oncogenes in BL and CML 
specific chromosomal translocations respectively. But also in 
other structural abnormalities, oncogenes which map closely to 
the respective chromosomal breakpoints, may prove to be direct-
ly involved. Alternatively, cloned sequences or genes located 
in the vicinity of chromosomal breakpoints may serve as tools 
for a further cytogenetic and molecular characterization of the 
abnormality. In particular when they are expressed in a cell 
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type or/and differentiation stage-dependent manner •. Eventually 
they can lead to the identification and isolation of new onco-
genes. Other types of karyotypic changes such as deletions or 
amplifications could create a gene dosage effect of a specific 
oncogene, either direct, as demonstrated by the amplification 
of N-myc in neuroblastomas (Schwab et al., 1983b) or indirect 
by the deletion of an inhibitory sequence or tumor suppressor 
genes (anti-oncogene hypothesis), (Comings, 19731 Klein and 
Klein, 198Sa). The following review will focus primarily on the 
involvement of oncogenes in chromosomal translocations consis-
tently found in several hematopoietic disorders and in parti-
cular on the role of the c-abl oncogene in CML, since this has 
been the main subject of the experimental work preceding the 
completion of this thesis. 
2. STRUCTURAL ABERRATIONS: TRANSLOCATIONS AND INVERSIONS 
Among the acquired karyotypic changes in tumor cells, the 
most characteristic are the translocations and inversions. 
These structural aberrations are predominantly found in leuke-
mia and lymphoma. Several morphological subtypes of these neo-
plasia are associated in varying degrees of specificity with a 
typical consistent translocation. Variant or complex forms of 
these consistent translocations can help to define the critical 
genetic rearrangement, such as the translocation products which 
are consistently found in the specific type of leukemia or 
lymphoma (Rowley, 1982, 1984). Apparently, these aberrations do 
not involve gain or loss of genetic material and point directly 
to the site of action: the genes or DNA sequences located at 
the critical chromosomal breakpoints. A number of oncogenes 
have been located near or at the chromosomal breakpoints, and 
cloned sequences of these genes were used as probe to analyse 
and characterize the consistent chromosomal abnormality in the 
respective neoplasia. 
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2.1 The Ph1 translocation in chronic myelocytic leukemia 
Chronic myelocytic leukemia (CML) is a pluripotent stem 
cell disease characterized by the presence of the Philadelphia 
(Phl) chromosome in the leukemic cells of 96% of all CML pa-
tients. Cytogenetic analysis revealed that this Phl (or 22q-) 
chromosome is the result of either a standard translocation, 
t(9;22)(Rowley, 1973) in 90% of the cases, or of a variant 
translocation (3-8%) involving other chromosomes as well (Heim 
et al., 1985). A minority (3-7%) of the CML cases is without a 
Phl chromosome (Phl negative CML)(Rowley and Testa, 1982). The 
presence of a Ph1 chromosome is regarded as a prognostic factor 
in CML: Ph1-negative CML patients, with normal karyotypes or 
other karyotypic changes have a worse prognosis than the Ph1 -
positive CML patients (Whang-Peng and Knutsen, 1982). 
Cytogenetic studies and isoenzyme analysis have demon-
strated that CML is a clonal disorder of pluripotent stem cells 
(Fialkow et al., 1977; Geurts van Kessel et al., 1982). The Ph1 
positive leukemic cells have a growth advantage over normal 
bone marrow cells and usually all nucleated cells in the 
marrow are Phl positive at the time of diagnosis. The 
bone 
Ph1 
negative, normal cells persist but their growth is apparently 
suppressed by the leukemic cells (Dube et al., l984a, l984b; 
Frassoni et al., 1986). Several reports (Lisker et al., 1980; 
Fialkow et al., 1981) suggest that the acquisition of the Ph1 
chromososome is not the initial abnormality in CML. This stage 
may be preceded by a clonal outgrowth of an abnormal hemato-
poietic stem cell without a marked proliferation advantage. 
This, in most cases clinically inapparent stage, is followed by 
the induction of the Ph1 chromosome, which leads to the in-
creased expansion 
characteristic of the 
of committed myeloid 
chronic phase of CML (see 
progenitors, 
reviews by 
Koeffler and Golde, 1981; Champlin and Golde, 1985). After this 
chronic phase, which lasts in general 3-4 years, most CML 
patients ultimately evolve to a lymphoid or myeloid acute phase 
(blast crisis). This latter stage is usuallly accompanied by 
additional non-random chromosomal aberrations like trisomy 8 or 
17 
19, isochromosome 17q, or a second Ph1 chromosome (Sandberg, 
1980; O'Malley and Garson, 1985; Sadamori et al., 1985a). 
2.1.1 Cytogenetic and molecular characterization of the Ph1 
translocation 
The Ph1 chromosome usually results from a reciprocal 
translocation between chromosome 9 and 22, t(9;22)(q34;qll). 
Using somatic cell hybrids and in situ hybridization c-onco-
genes have been assigned to both chromosomes: the c-abl onco-
gene to chromosome 9 (q34)(Heisterkamp et al., 1982; Jhanwar et 
al., 1984) and the c-sis oncogene to chromosome 22 (ql3)(Swan 
et al., 1982; Dalla-Favera et al., 1982c; Jhanwar et al., 1984; 
Bartram et al., 1984). Molecular cloning of the breakpoint 
regions of chromosome 22 resulted in the identification of a 
breakpoint cluster region (bcr) (Groffen et al., 1984: Appendix 
Paper III; see section 2.1.3). 
c-abl 
c-SiS 
22 sq+ 
W2l 
,=., IGL !S' L.J 5'bcr 
c- abl 
3' 
Figure 2. 1 Schematic representation of the standard Ph translocation t(9;22) (q34;q11). 
The localization and orientation of the marker genes are indicated. 
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As a result of the Ph1 translocation (Figure 2; Table 3), 
the c-abl oncogene is translocated from chromosome 9q34 to the 
proximal (5') bcr sequences on chromosome 22qll (De Klein et 
al., 1982: Appendix Paper I). The bcr is disrupted and the 
distal (3') bcr sequences are translocated with the c-sis 
oncogene to the 9q+ derivative chromosome (Groffen et al., 
1983a). Another genomic marker of the chromosome 22qll region, 
the A immunoglobulin light chain gene (IgL) (Erikson et al., 
1981; McBride et al., 1982) remains on chromosome 22q- (Goyns 
et al., 1984). Similar studies of cytogenetic variant Ph1 
translocations (Table 3) revealed in all cases breaks on chro-
mosome 22 within the bcr, and the c-abl oncogene was 
consistently translocated to the remaining bcr sequences on the 
Ph1 chromosome. The c-sis oncogene was found to be located on 
the derivative chromosomes carrying the distal part of chromo-
some 22 (Table 3), indicating that the translocation of c-abl 
to a specific region on chromosome 22 was the critical event in 
these Ph1 positive CML patients. 
Recently this view has been strongly buttressed by the 
demonstration of a juxtaposition of c-abl and bcr sequences in 
the leukemic cells of some Ph1 negative CML patients (Table 3; 
Bartram et al., 1985b; Morris et al., 1986). On the basis of 
molecular characteristics (bcr/c-abl rearrangement) these CML 
patients are identical to Phl positive CML patients and possess 
also clinical and hematological features indistinguishable from 
Phl positive CML patients. This in contrast to other Ph1 -
negative CML patients who lack the bcr/c-abl rearrangement and 
differ clinically from classic CML. It has been suggested that 
these latter Ph1-negative CML cases actually represent myelo-
dysplasias (MDS) and reactive conditions other than CML with a 
clearly poorer clinical prognosis (Pugh et al., 1985). There-
fore the detection of bcr/c-abl juxtaposition in CML may be of 
prognostic value. 
These results, summarized in Table 3, indicate that both 
c-abl and bcr sequences may play a pivotal role in the pathoge-
nesis of CML. The molecular characteristics of these two loci, 
the position of the breakpoints and the consequences of the 
19 
bcr/c-abl juxtaposition will be discussed in the following 
sections. 
TABLE 3. Ph 1- CHROMOSOME IN CML 
Karyotype Chromosomal Loca 1 i zat ion of Reference 
c-abl c-sis bcr 
A. Standard Ph 1 translocation 
t (9;22) 9,22q- 22; 9q+ + 1,2,3,4,5,6 
B. Variant Ph 1 translocation 
-simple t(*;22) 9;22q- 22, ;!( + 7,8,9 
-complex t(*;9;22) 9;22q- 22' ;!( + 7,8,9 
-masqued t (6;22) 9,22q+ n.d. + 2,10 
t(1 ;3;5;9;22) 9,22q+ n.d. + 2' 10 
c. Ph1-negative 
-with trans locations 
t (9; 12) 9' 12q- 22 + 11 '12 
t (9; 13; 15) n.d. n.d. + 13 
-without trans locations 
1) 9,22 22 + 14,15 
2)0 9 n.d. + 16 
3) 9 22 3 ,6,8, 14,15 
0
only one case; n.d. not done; * stands for other chromosome as 9 or 22 
References: 
1. De Klein et al., 1982 
2. De Klein and Hagemeijer, 1984 
3- Bartram et al., 1984 
4. Groffen et al ., 1983a 
5. Goyns et a 1., 1984 
6. Groffen et al., 1984 
7- Hagemeijer et al., 1984 
8. Bartram et.al., 1983 
9- Bartram et al ., 1985a 
10. Hagemeijer et al., 1985 
11. Bartram et al., 1985b 
12. Hagemeijer et al., 1986 
13. Hagemeijer et al., pers.comm. 
14. Morris et al., 1986 
15. Bartram and Carbonell, 1986 
16. Bartram, 1985 
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2.1.2 The human c-abl oncogene 
The proto-oncogene c-abl is the normal cellular homo-
logue of the transforming gene, v-abl, of Abelson murine Leuke-
'mia virus (A-MuLV). This retrovirus is a recombinant between 
Moloney MuLV and mouse cellular c-abl sequences (Goff et al., 
1980). It induces lymphoid tumors in vivo and transforms fibro-
blasts and hematopoietic cells in vitro (Rosenberg and Balti-
more, 1980~ Waneck and Rosenbergr 1981~ Prywes et al., 1983~ 
Waneck et al., 1986). Its transforming potential is tightly 
associated with the expression of a virus encoded protein 
pl60gag-abl exhibiting tyrosine specific kinase activity (Sef-
ton et al., 1981~ Srinivasan et al., 1982~ Reddy et al., 1983). 
The cellular c-abl gene is strongly conserved during 
evolution and c-abl specific sequences have been cloned from 
nematoda (Goddard et al., 1986), Drosophila (Shilo and Wein-
berg, 1981~ Hoffman-Falk et al., 1983), mouse (Goff et al., 
1980~ Goff and Baltimore, 1982~ Wang et al., 1984; Ben-Neriah 
et al., 1986a), cat (Schalken et al., 1985) and human DNA 
(Heisterkamp et al., 1983a~ 1983b~ Shtivelman et al., 1985; 
Grosveld et al., 1986~ Appendix Paper V). In human, v-abl 
homologous sequences are distributed discontinuously over a 
region of 32 kb and are dispersed over at least 9 exons (Figure 
3: exons 2-10). Cloning of human c-abl cDNAs (Shtivelman et 
al., 1985~ Grosveld et al., 1986: Appendix Paper V) allowed the 
identification of two additional exons 1 and A. Exon A is 
homologous to one of the four alternative first exons in mouse 
c-abl (Ben-Neriah et al., 1986a) and one other human first exon 
(exon B) is present 175 kb 5' of exon A. This exon can also be 
linked to the c-abl body exons 1-10 by alternative splicing 
(Figure 3)(A. Bernards pers. comm.). 
Southern blotting and the subsequent cloning and charac-
terization of chimeric breakpoint fragments have demonstrated 
the presence of chromosome 9 breakpoints within or in the 
vicinity of the c-abl gene. Some of these breakpoints occur 
within the large intron of 17 kb, separating the first exon A 
and the c-abl body exon 1 (Heisterkamp et al., 1983b~ Leibowitz 
c-abl 
+-----------175 kb 1-- v-abl homology ---1 
5' 
~~t~t~t========~F~~~~~~~~=m~~~ 
B 1 2 3 4 56 7 8 9 10 
21 
3' 
1-- c-abl body------{ 
Figure 3. 
The human c-abl gene. The two alternative first exons Band A and the c-abl 
body exons~ are indicated as hatched boxes. Distance between exon A and 
B and the position of the v-abl homologous part are shown above the map. 
The cloned and analysed breakpoints are indicated by arrow below the map. 
===if= represents a gap of unknown distance. 
et al., 1985a), whereas in other CML patients and the CML-
derived cell line K562 (Lozzio and Lozzio, 1975), the break-
points are located at variable distances, up to more than 80 kb 
upstream of exon A (Grosveld et al., 1986: Appendix Paper V; 
unpublished results). The localization of the K562 breakpoint 
is of particular interest because several reports (Heisterkamp, 
1983b; Collins and Groudine, 1983; Selden et al., 1983) have 
shown that c-abl and the AigL constant region (CA), but not 
the c-sis oncogene are amplified at least four fold in this 
cell line. The amplification of chromosome 9 sequences starts 
at the breakpoint on chromosome 9 and extends in the direction 
of the telomere of the chromosome, including all known c-abl 
sequences. However, exon B the human homologue of one of the 
alternative 5' exons of mouse c-abl (Ben Neriah et al., 1986) 
is not amplified in K562 DNA (A. Bernards, pers.comm.). This 
suggests that this 5' c-abl exon B is located upstream of the 
K562 breakpoint on chromosome 9 and implies that even break-
points, which map at a minimum of 80 kb s' of exon A, are still 
located within the c~abl gene. 
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2.1.3 The human bcr gene 
In contrast to the breakpoints on chromosome 9 which are 
scattered over a region of more than 100 kb, the chromosome 22 
breakpoints are all located within a small region of 5.0 kb 
termed the £reakpoint ~luster ~egion or bcr (Groffen et al., 
1984: Appendix Paper III). The isolation of bcr cDNAs establis-
hed that bcr is part of a larger protein encoding region: the 
'bcr' gene with an as yet unidentified cellular function 
(Heisterkamp et al., 1985: Appendix Paper IV). The bcr gene is 
orientated with its 5' end pointing towards the centromere of 
chromosome 22 and 2/3 of the coding regions, dispersed over a 
minimum of 18 exons encompassing 67 kb of genomic DNA, have 
been identified (Groffen et al., 1986). As shown in figure 4, 
three relatively small exons (designated 1-3), varying in size 
bcr 
-centromere 
5' 1 2 3 4 
1111 I 1~, Ill ,Ill ,II I 
Figure 4. 
.... 1, 
, ' 
, ' 
/ ' 
:1/ I I ', ':1 
1 2tlt3tt 4 
K562 
1----~" bcr '·.;..' ---! 
breakpoint cluster region 
Ill 
The human bcr gene. The 18 identified exons are indicated as solid boxes. 
The three exons (1-3) within the 5.0 kb bcr and an adjacent exon are num-
bered. The position of the breakpoints are-shown in the bottom part of the 
figure. 
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from 75 to 105 bases, are present within the bcr and all chro-
mosome 22 breakpoints are clustered in the non-coding regions 
between exon 2 and 3 or exon 3 and 4 of the bcr (Heisterkamp et 
al., 1985: Appendix Paper IV; Groffen et al., 1986; De Klein et 
al., l986a: Appendix Paper VI). Although all chromosome 22 
breakpoints are located within the bcr, these observations 
indicate that a small variation in the number of bcr exons 
remaining on the Ph1 chromosome occurs, some CML patients 
retain exon 3 and all sequences 5' of it on Ph1 , whereas in 
other CML patients this exon 3 is translocated, together with 
the 3' part of the bcr gene to the 9q+ derivative chromosome. 
In this respect the cell line K562 contains a genuine chromo-
some 22 breakpoint, located 3' of exon 3 (Figure 4). However, 
in contrast with the leukemic cells of CML patients, K562 
contains amplified remnants of the Ph1 chromosome (Grosveld et 
al., 1986: Appendix Paper V) present on an acrocentric marker 
chromosome (Selden et al., 1983). The amplified region may be 
relatively large since it encompasses CA, 5' bcr and at least 
150 kb of c-abl sequences. 
2.1.4 Analysis of CML breakpoints by DNA sequencing. 
In the Ph1 translocation, an illegitimate recombination 
takes place between sequences on chromosome 9 and 22. Sequence 
analysis and hybridization have indicated that the bcr gene has 
no homology to previously identified proteins sequences, in-
cluding the c-abl oncogene (Heisterkamp et al., 1985: Appendix 
Paper IV). Since the DNA sequence of the translocation junction 
regions could provide additional information about the possible 
mechanism of chromosomal translocation we determined the DNA 
sequence of several breakpoint regions (Heisterkamp et al., 
1985: Apppendix Paper IV ; Groffen et al., 1986; De Klein et 
al., l986a: Appendix Paper VI). The breakpoint sequence of one 
CML patient showed a perfect conservative break without loss or 
gain of chromosome 9 or 22 sequences (Heisterkamp et al., 1985: 
Appendix Paper IV). However, in other CML patients deletions of 
both chromosome 9 and 22 sequences were observed. 
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Usually the chromosome 22 deletions are small (100-500 bp) 
whereas the chromosome 9 deletions could encompass more than 70 
kb (De Klein et al., l986a: Appendix Paper VI). Comparison of 
the DNA sequence of several b~eakpoints suggests that homolo-
gous recombination is unlikely, since there is no apparent 
homology between the chromosome 9 and 22 breakpoint sequences. 
Nor is there any evidence for crossing over within a homologous 
oligonucleotide. Similar results have been obtained from 
sequence analysis of the t(8;l4) translocation in Burkitt lym-
phoma (Battey et al., 1983; Moulding et al., 1985). However, in 
CML there is some evidence that Alu-repetitive sequences are 
involved, since most of the breakpoint occur within Alu-repeats 
(Schmid and Jelinek, 1982) or Alu-repeat like sequences (Heis-
terkamp et al., 1985: Appendix Paper IV; Rogers et al., 1985; 
Groffen et al., 1986; De Klein et al., l986a: Appendix Paper 
VI). 
As illegitimate recombination within Alu-sequences has 
been reported in four independent cases of thalassemia (Vanin 
et al., 1983) and in one case of hypercholesterolemia (Lehrman 
et al., 1985), it is well conceivable that Alu-repetitive 
sequences are hot spots of recombination and play a role in the 
juxtaposition of 5' bcr and 3' c-abl sequences. 
2.1.5 Consequences of the Ph1 translocation 
As a result of the Ph1 translocation the bcr and c-
abl genes are located on the Ph1 chromosome; at the 5' (centro-
meric) side the 5' part of the bcr gene and at the 3' (telome-
ric) side, the translocated c-abl sequences, in the same tran-
scriptional orientation. 
Several investigators have addressed the question whether 
the Ph1 translocation influences the expression of these two 
genes. The c-abl mRNA transcripts of 6.0 and 7.0 kb are present 
in normal cells and tissues of both hematopoietic and non-
hematopoietic origin (Westin et al., 1982; Wang and Baltimore, 
1983; Gale and Canaani, 1984). In addition to these normal 
transcripts, a novel c-abl homologous mRNA of 8.5 kb is present 
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in the leukemic cells of CML patients and CML-derived cell 
lines (Canaani et al., 19841 Collins et al., 19841 Blick et 
al., 19841 Leibowitz et al., 1985b1 Starn et al., 1985). Similar 
results were obtained when the expression of the bcr gene was 
studied. In addition to the normal bcr rnRNAs of 7.5, 7.0 and 
4.5 kb a 8.5 kb bcr specific rnRNA transcript was present in the 
leukemic cells of Ph1 positive CML patients and CML derived 
cell lines (Starn et al., 19851 Grosveld et al., 1986: Appendix 
Paper V). This 8.5 kb bcr rnRNA migrated at the same position as 
the aberrant 8.5 kb c-abl rnRNA in agarose gels and contained 
only the 5' coding regions of the bcr. This aberrant 8.5 kb 
rnRNA seems to be specific for Ph1 positive cells, as it is not 
detected in either normal cells, tissues or other types of 
leukemia (Eva et al., 19821 Gale and Canaani, 19841 Romero et 
al., 19861 Grosveld et al., 1986: Appendix Paper V). However, 
the expression is not restricted to the myeloid cell lineage. 
Similar or often even enhanced expression of this 8.5 kb rnRNA 
has been reported in both the myeloid and lymphoid acute phase 
of CML (Romero et al., 1986) in erythroleukemia or lymphoid 
CML-derived cell lines (Collins et al., 19841 Konopka et al., 
1986) and in somatic cell hybrids between rodent fibroblasts 
and Ph1 positive leukemic cells (Kozbor et al., 1986). In these 
latter somatic cell hybrids the 8.5 kb rnRNA was only found in 
cell hybrids which retained the Ph1 chromosome. These results 
strongly suggested that the 8.5 kb rnRNA is a chimeric molecule 
that contains the 5' part of the bcr gene in addition to the c-
abl sequences. Direct proof of this hypothesis was achieved by 
the cloning of chimeric bcr/c-abl cDNAs (Shtivelman et al., 
19851 Grosveld et al., 1986: Appendix Paper V). These cDNAs 
contained part of the 5' coding regions of the bcr gene fused 
to the c-abl coding regions in a splice dependent manner 
following the GT-AG rules (Breathnach and Charnbon, 1981). Tran-
scription is likely to be initiated from the bcr promotor and 
probably stops at the 3' end of the c-abl gene (Figure 5). By 
splicing of the precursor RNA the 8.5 kb rnRNA is produced, in 
which the versatility of the splicing system accornodates for 
the large variation in intron size that links bcr and c-abl in 
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different patients. Depending on the chromosome 22 breakpoints, 
either bcr exon 2 or exon 3 will be spliced to the first 
available splice acceptor site of a c-abl exon: i.e. the second 
ex on 1, since the first c-abl exon A or exon B probably lack 
such a 3' splice acceptor site. Although DNA sequence data 
indicate that also other splices are compatible (e.g. between 
bcr ex on 1 and c-abl exon 1 or 2) until now these have not been 
encountered in CML. In cases were the bcr breakpoint is located 
3' of bcr exon 3 both mRNAs are made (Shtivelman, pers. 
comm.). This indicates that the 8.5 kb chimeric mRNA can differ 
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Figure 5. 
Schematic representation of the molecular consequence of the Ph1 transloca-
tion. The1topl ine shows the physically joined 5' bcr and 3 1 c-abl regions 
on the Ph chromosome. The exons are indicated by solid (bcr) or hatched 
(c-abl) boxes. This configuration allows the transcription-of chimeric mRNA 
(consisting of 5' bcr exons fused to the 3' c-abl body exons (middle line). 
This mRNA is translated into a chimeric fusion protein with a bcr aminoter-
minus and a c-abl carboxy terminus (bottom line). 
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in the presence or absence of one bcr exon (bcr exon 3; 75 
nucleotide in size). However, both mRNAs have one long open 
reading frame compatible with both the predicted bcr (Heister-
kamp et al., 1985: Appendix Paper IV) and known c-abl (Wang et 
al., 1984) reading frames. Translation of this 8.5 kb mRNA into 
protein seems certain, because both c-abl and bcr antisera 
precipitate the same aberrant p210 kD bcr/c-abl protein in 
several CML-derived cell lines and Ph1 positive CML patients 
(Konopka et al., 1984; 1985; Kloetzer et al., 1985, Naldini et 
al., 1986; Ben-Neriah et al., 1986b). This 210 kD bcr/abl 
protein is much larger than the normal 145kD c-abl protein and 
is like the viral protein pl60gag-abl a fusion protein in which 
theN-terminal aminoacids of c-abl have been replaced by the 5' 
bcr or ~ residues respectively. In the viral protein theN-
terminal ~ sequences, or other N-terminal sequences which can 
replace the ~ sequences, are required for protein stabiliza-
tion and hence transformation of lymphoid cells (Prywes et al., 
1985a; Matthey-Prevot and Baltimore, 1985). The bcr moiety of 
the p210bcr-abl fusion protein may serve a similar function, 
but whether the deletion of the c-abl N-terminus and/or its 
replacement by protein stabilizing sequences is the critical 
event for the conversion of the c-abl proto-oncogene into an 
oncogene is at the moment still unclear. However, the tyrosine 
kinase domain of v-abl is indispensable for transformation 
(Prywes et al., 1983, 1985b; Wang and Baltimore, 1985) and 
since this tyrosine kinase domain is also retained in the 
p210bcr-abl protein, it seems very likely that the tyrosine 
kinase activity of this protein plays an essential role in the 
altered growth pattern of the myeloid cells in CML. Initially 
it was suggested that the N-terminal substitutions could unmask 
the in vitro tyrosine kinase activity of the c-abl protein 
(Davis et al., 1985), but recent reports indicate that all c-
abl proteins have similar in vitro kinase activities although 
the viral pl60gag-abl and the p2lobcr-abl differ from their 
normal cellular counterparts in the way they utilize themselves 
as substrate (Konopka and Witte, 1985a, 1985b). Besides this 
difference in substrate specificity in vitro, which probably 
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also exists in vivo, the pl60gag-abl and the p210bcr-abl are 
phosphorylated on tyrosine in vivo. The normal mouse and human 
c-abl protein lack such a phosphorylation although they contain 
a tyrosine phosphorylation acceptor site with identical amino-
acid sequence as the v-abl protein (Groffen et al., l983b; Wang 
et al., 1984). The functional significance of in vivo phospho-
rylation is unclear but it often augments the catalytic activi-
ty of tyrosine kinases such as the EGF-receptor (Hunter and 
Cooper, 1985). Although c-abl lacks several characteristics of 
a receptor protein (e.g. membrane spanning sequence; extracel-
lulair domain, glycosylation) it is well conceivable that c-abl 
is part of a growth factor/receptor complex and plays a role in 
the signal transduction (Konopka and Witte, l985b). Hence the 
tyrosine kinase activity of the normal c-abl protein may be 
under strict control of such a growth factor/receptor complex. 
N-terminal substitution of the c-abl protein with ~ or bcr 
sequences could change the substrate specificity of the tyro-
sine kinase, or could enable the protein to escape such a 
regulation and would result in the delivery of a continuous 
proliferation signal to the cell even in the absence of the 
growth factor. Consistent with this model is the observation 
that normal hematopoietic cells become growth factor indepen-
dent in a non-autocrine manner, after infection with A-MulV 
(Cook et al., 1985; Pierce et al., 1985; Metcalf, 1986). The 
presence of the p210bcr-abl fusion protein may have similar 
stimulatory effects on the growth pattern of hematopoietic 
cells, or alternatively may help the neoplastic stem cell to 
ignore or override a negative regulatory signal produced by the 
normal adherent bone marrow cells (Eaves et al., 1986). 
2.1.6 Other oncogenes involved in CML 
There are several reports which indicate that other 
genes than the bcr or c-abl oncogene are involved in CML. By 
DNA mediated transfection of NIH3T3 cells it was shown, that 
some CML patients and CML derived cell lines contain an acti-
vated Nor K-ras gene (Eva et al., 1983, 1985; Hirai et al., 
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1985; H. Jansen, pers.comm.). Amplification and rearrangement 
of c-myc has been found in the acute phase of a CML patient 
(McCarthy et al., 1984). This may play a role in the progres-
sion of the disease. A similar role has been suggested for the 
expression of c-sis during accelerated/blast phase but not in 
the chronic phase of CML (Romero et al., 1986; Gale and Canaani 
1984, 1985). Several other, as yet unidentified genes, are 
expressed specifically in CML (Mars et al., 1985; Birnie et 
al., 1983; Calabretta et al., 1986) and may also play a role in 
the progression of the disease. Therefore, analysis of the 
effect of p210bcr-abl on normal hematopoietic cell prolifera-
tion by using gene transfer techniques or alternative inhibi-
tion of the translation of this protein with antisense bcrlc-
abl mRNA will help to define the precise role of this protein 
and hence the Phl translocation in the pathogenesis of CML. 
2.1.7 The Ph1 chromosome in ALL and AML 
The Ph1 chromosome has been reported in other non-CML 
hematopoietic disorders (Sandberg, 1980), including different 
subtypes of acute leukemia in which no preceeding chronic phase 
has been observed (Beard et al., 1976; Oshimura and Sandberg, 
1977; Bloomfield et al., 1977; 1978). The clinical distinction 
between blast crisis of CML and de ~ Ph1 positive ALL or AML 
is not always clear (Catovsky, 1979; Beard et al., 1976). 
Usually these latter cases have less than 100% Ph1 positive 
cells in the bone marrow during the acute phase, and clinical 
remission is accompanied by the elimination of the Ph1 chromo-
some from the bone marrow cells (Sandberg et al., 1980). The 
incidence of Ph1 positive AML is low (< 1%) and restricted to 
the Ml subtype (Abe and Sandberg, 1979; Bloomfield et al., 
1977; Yunis et al., 1984). A similar incidence (2-6%) has been 
reported for childhood ALL (Ll-L2) (Chessells et al., 1979; 
Priest et al., 1980). However, in adult ALL the Ph1 chromosome 
is the most frequent chromosomal abnormality with an incidence 
of 17-25% (Sandberg, 1980; LeBeau and Rowley, 1984b). 
As in CML, the P~ chromosome in ALL or AML is usually 
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the result of a t(9;22), although the incidence of variant 
translocations in ALL is higher than in CML or AML 
and Knutsen, 1982; De Klein et al., 1986b: Appendix 
Nevertheless, translocation of the c-abl oncogene 
(Whang-Peng 
Paper VII). 
to the Ph1 
chromosome was observed in all patients studied with Ph1 posi-
tive ALL (Erikson et al., 1986a; De Klein et al., 1986b: Appen-
dix Paper VII). However, molecular studies using bcr probes 
showed a hetereogeneous picture. In our own study (De Klein et 
al., 1986b: Appendix Paper VII), 6 Ph1 positive ALL patients 
showed bcr rearrangements as observed in CML, and 3 other 
patients did show recombinations involving 5' bcr sequences but 
the corresponding 3' bcr sequences were not detectable. A group 
of 5 ALL patients did not show any bcr rearrangement at all. 
The presence of the 8.5 kb bcr/c-abl mRNA was demonstrated only 
in the leukemic cells of those ALL patients with bcr rearrange-
ments. In patients without bcr rearrangements, only the normal 
bcr and c-abl mRNA species were present. Similar results were 
obtained by others (Rodenhuis et al., 1985; Erikson et al., 
1986a; Saglio et al., 1986). Using somatic cell hybrids it was 
shown that the 22qll breakpoint of one Ph1 positive ALL patient 
was located proximal to the bcr region (Erikson et al., 1986a), 
probably distal of the AigL locus. In another case in situ 
hybridization studies suggested a breakpoint within the A IgL 
region (Cannizzaro et al., 1985). 
In the limited number of Ph1 positive AML patients 
studied, a similar heterogeneity in bcr rearrangements was 
observed (Saglio et al., 1986; Erikson et al., 1986a; Bartram 
pers.comm.). These results indicate that, if c-abl is involved 
in the Ph1 positive ALL/AML patients without bcr rearrangem·ent 
the genetic mechanism of activation must be different from that 
reported in CML, whereas in Phl positive ALL and AML patients 
with bcr rearrangements probably the same or a similar p210bcr-
abl protein is present. The molecular aspects observed in these 
latter ALL/AML patients are indistinguishable from CML, rein-
forcing the possibility that some of the Ph1 positive ALL or 
AML patients may have a blast crisis, developed from subclini-
cal CML (Beard et al., 1976; Catovsky, 1979). 
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2.2 Structural aberrations in acute non-lymphocytic leukemia 
Concurrent with the constant refinement of cytogenetic 
techniques, clonal chromosomal abnormalities have been observed 
with increasing frequency (50-93%) in the bone marrow of pa-
tients with acute non-lymphocytic leukemia (ANLL)(Rowley and 
Potter, 1976; Yunis et al., 1981, 1984; Hagemeijer et al., 
1981; Larson et al., 1983). The most frequent abnormalities 
associated with ANLL are a non-random loss or gain of chromo-
somes (Rowley et al., 1982; Rowley, 1984). Furthermore a number 
of unique structural aberrations have been described which are 
associated with specific morphological subtypes of ANLL (FAB, 
Bennett et al., 1976; Table 1). Since several oncogenes (Fig.l) 
map closely to these chromosomal breakpoints, a number of these 
consistent aberrations have been assessed for a possible in-
volvement of these oncogenes. 
2.2.1 t(8;21) in acute myeloblastic leukemia 
The reciprocal translocation t(8;21) (q22;q22) is found 
in 18% of the karyotypic abnormal AML-M2 patients (acute myelo-
blastic leukemia with maturation)(Rowley, 1982; Rowley and 
Testa, 1982; LeBeau and Rowley, l984b). Cytogenetic studies of 
variant forms of the translocation indicated that translocation 
of 2lq material to the 8q- chromosome was the constant, and 
therefore probably critical event (Rowley 1982, 1984). At both 
breakpoints cellular oncogenes are located: the c-mos oncogene 
at chromosome 8q22 or 8qll (Prakash et al., 1982; Neel et al., 
1982; Caubet et al., 1985) and the c-ets-2 oncogene at chromo-
some 2lq22 (Watson et al., 1985, 1986)(Figure 1). 
Using in situ hybridization or somatic cell hybrids con-
taining the 8q- or 2lq+ recombinant chromosomes, it was esta-
blished that both oncogenes were located at the critical 8q-
chromosome, albeit without obvious DNA rearrangements (Drabkin 
et al., 1985; Sacchi et al., 1986). Translocation of c-ets-2 
was concordant with an altered expression of this oncogene in 
the AML-M2 leukemic cells, as compared with its expression in 
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normal lymphocytes and control cell lines (Sacchi et al., 1986; 
Watson et al., 1985). The c-ets-2 gene maps in the chromosome 
21 region that, when trisomic, confers the Down syndrome pheno-
type. This congenital aberration is associated with an in-
creased risk of acute leukemia, in particular AML (Alimena et 
al., 1985; Evans and Steward, 1972). These data might indicate 
that c-ets-2 is involved in the pathogenesis of AML-M2, al-
though its exact role remains to be established. Previous 
reports have demonstrated that c-mos can be activated by trans-
posen like insertions in mouse myeloma cell lines (Rechavi et 
al., 1982; Cohen et al., 1983; Gattoni Celli et al., 1983). 
However, its recent reassignment to band 8q11 (Caubet et al., 
1985) suggests that it could be located far more distant of the 
8q22 breakpoint than was assumed initially. In this case its 
involvement in t(8;21) AML-M2 is not very likely. 
2.2.2 t(15;17) in acute promyelocytic leukemia 
The translocation t(15;17)(q22;q21) is exclusively found 
in acute promyelocytic leukemia (APL) (ANLL-M3) and several 
investigators have suggested that this reciprocal translocation 
(or variants) can be found in every patient with APL, if opti-
mal cytogenetic techniques are used (Rowley et al., 1977; Kondo 
and Sasaki, 1982; Larson et al., 1984; De Braekelaar and Lin, 
1986; Misawa et al., 1986; Mitelman et al., 1986). The constant 
recombinant chromosome is the 15q+ chromosome. This suggests 
that translocation of the distal part of chromosome 17q to 
chromosome 15q results in a critical gene rearrangement which 
leads to malignant transformation of the promyelocytic cell 
(Rowley, 1982, 1984; Misawa et al., 1986). A number of 
interesting genes have been assigned to the chromosomes invol-
ved (Figure 1). The c-fes (or c-fps) oncogene at 15(q26) (Heis-
terkamp et al., 1982; Dalla Favera et al., 1982a; Harper et 
al., 1983; Jhanwar et al., 1984) is located at a great distance 
from the 15 q22 breakpoint and its translocation to the non-
critical 17q- chromosome seems fortuitous (Sheer et al., 1983). 
For the same reason it seems not very likely that the ~ or 
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the c-erbA-1 oncogenes are directly involved. These genes map 
proximal of the 17q21 breakpoint at 17pl3 and 17q21, respecti-
vely (Isobe et al., 1986; Miller et al., 1986; McBride et al., 
1986; Dayton et al., 1984; LeBeau et al., 1985a; Spurr et al., 
1984). However, some genes may be involved that map closely 
distal to the 17q21 breakpoint such as the nerve growth factor 
receptor gene (Huebner et al., 1986) or another growth factor 
receptor gene c-erbB-2 (or neu}(Schechter et al., 1985; 
Coussens et al., 1985; Stern et al., 1986). Both map at 17q21 
- l7q22. Using a mouse E2l eDNA probe, LeBeau et al. (1985a) 
have localized a E§l like sequence just distal to the 17q 
breakpoint and have proven its translocation to the critical 
15q+ chromosome. These sequences which are not coding for the 
human E2l gene (Lamb and Crawford, 1986) could represent an-
other as yet unidentified cellular gene which is possibly 
involved in the pathogenesis of promyelocytic leukemia. 
2.2.3 inv(l6) and t(l6;16) in acute myelomonocytic leukemia 
Recently, another cytogenetic-clinical association has 
been identified in acute myelomonocytic leukemia (AMMoL-M4) 
with abnormal eosinophils. Most of these AMMoL-M4 patients had 
an inv(l6) (pl3q22) or t(l6;16) (pl3;q22}(LeBeau et al., 1983; 
Arthur and Bloomfield, 1983; Testa et al., 1984). LeBeau et al. 
(1985b) have localized the metallothionin (MT) gene cluster to 
the l6q22 region and proved with the use of in situ hybridiza-
tion, that this MT gene cluster is split by the t(l6;16) or 
inv(l6). This could indicate, that either activation of an as 
yet unknown oncogene by association with the strong MT gene 
control elements, or abnormal MT gene expression itself is 
involved in the leukemogenesis of this specific AMMol-M4 with 
abnormal eosinophils. 
2.2.4 t(6;9) in acute non-lymphocytic leukemia 
The t(6;9) (p23;q34) is a relatively rare translocation 
in ANLL (< 0.5%) and is observed in AML-M2; AMMOl-M4 and AML-Ml 
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(Rowley, 1984; Vermaelen et al., 1983; Pearson et al., 1985; 
Carroll et al., 1985; Heim et al., 1986). This abnormality is 
interesting since, the chromosome 9 breakpoint is located in 
the same chromosomal band as in the t(9;22) (q34;q11) in CML and 
both CML and t(6;9) ANLL are associated with increased numbers 
of bone marrow basophils (Pearson et al., 1985). Recently, 
Westbrook et al. (1985) have demonstrated, that the chromosome 
9(q34) breakpoint is located at a unknown distance 3' of the 9= 
abl gene. Moreover, no abnormal or higher levels of c-abl 
transcripts or proteins are present in the few t(6;9) ANLL 
samples tested (Westbrook et al., 1985; Von Lindern 
pers.comm.). 
At chromosome 6(p21) the human homologue of pim-1 has 
been localized (Cuypers et al., 1986; Nagarajan et al., 1986). 
High levels of pim mRNA were observed in the cell line K562, 
which has an abnormal marker chromosome M2: t(6;6) (pter-.pll:: 
p21-+ qter)(Chen, 1985; Nagarajan et al., 1986) and in one 
t(6;9) ANLL patient (Von Lindern, pers.comm.). As yet it is not 
clear, whether the elevated pim mRNA levels are a consequence 
of the translocations, or represent the normal transcription 
levels in myeloid cells. Sofar, no rearrangements have been 
observed within the 30 kb genomic DNA surrounding the known 
human pim sequences. We are currently investigating the in-
volvement of the pim gene in the t(6;9) translocation and other 
malignancies associated with chromosome 6 aberrations (Miyamoto 
et al., 1984; Mecucci et al., 1985; Pedersen et al., 1986; Rey 
et al., 1985) using a human pim eDNA clone and proper control 
cells. 
2.2.5 Translocations involving 11q23 in ANLL and ALL 
Several investigators have noted the frequent involvement 
of chromosome band 1lq23 in specific translocations associated 
with childhood ANLL (Berger et al., 1982; Yunis, 1983; Rowley, 
l984; Hagemeijer et al., 1982, 1986a). Of the ANLL cases with a 
chromosome 11 translocation, 80% were classified as acute mono-
blastic leukemia (AMoL-M5) and 20% as AMMoL-M4 (FIWLC, 1984). 
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The t(9;11) (p2l;q23) is strongly associated with AMMol-M5 (Ha-
gemeijer et al., 1982), whereas other translocations such as 
t(ll;l7)(q23;q25), t{ll;l9)(q23;pl3), t(l0;ll}(pl5;q23) and 
t(6;11) (q27;q23) are found both in AMMoL-M4 and AMMoL-M5 (Yunis 
et al., 1984; Rowley, 1984; LeBeau, 1986). Moreover, all these 
translocations have also been associated with a poorly 
differentiated acute lymphoblastic leukemia (ALL-Ll)(Kaneko et 
al., 1986; Hayashi et al., 1985). The t(4;11) (q2l;q23) and 
t(l;ll) (p32:q23) are usually found in poorly differentiated 
ALL-Ll, often with some (inducible) myelo-monocytic morphology 
and markers and rarely associated with ANLL-M5 or M4 (Kaneko et 
al., 1986; Hagemeijer et al., 1986b; Mirro et al., 1986; Naga-
saka et al., 1983; Crist et al., 1985; Meyers et al., 1986). 
These data suggest that the llq23 translocation affects an 
early progenitor cell, capable of both lymphoid and myelo-
monocytic differentiation. It has been suggested (Crist et al., 
1985; Kaneko et al., 1986; Mirro et al., 1986) that due to the 
involvement of llq23 in the translocation, the differentiation 
pattern is blocked in an early stage and a gene on the reci-
pient chromosomes of the various translocations could influence 
the morphological and other clinical characteristics. In analo-
gy with the 14q32 and 14qll breakpoints in B or T-cell specific 
malignancies (sections 2.3) the llq23 region could bear the 
locus of a cell type specific gene and the breakpoint regions 
on the recipient chromosomes loci for growth promoting genes 
(Rowley, 1984; Yunis, 1983, et al., 1984). However, as yet 
there is no evidence for a somatically rearranged gene nor for 
a cell or stage specific gene located at the chromosome llq23 
region. Interesting in this respect is that at several of the 
recipient chromosomes or chromosome regions involved in these 
llq23 translocations, oncogenes or growth factor/receptor genes 
have been localized: At lp32 the L-myc and B-lym oncogenes 
(McBride et al., 1985; Morton et al., 1984), at 9p21-pl3 the 
interferon (IFN) a and B gene clusters (Trent et al., 1982), at 
10pl4-pl5 the interleukin-2 receptor gene (Leonard et al., 
1985) at 19pl3 the insulin receptor gene (Yang-Feng et al., 
1985), at chromosome 4 the c-raf-2 and c-kit oncogene (Bonner 
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et al., 1984; Besmer et al., 1986) and at chromosome 6 the c-
yes-2 oncogene (Semba et al., 1985). Other genes in this seg-
ment of chromosome 11 are myeloid specific antigens (Geurts van 
Kessel et al., 1984; Rettig et al., 1985) located at llql2-qter 
and four genes associated with cell-cell interactions located 
at llq23: Thy-1 (van Rys et al, 1985; Seki et al., 1985), NCAM 
(N'guyen et al. 1986; Rutishauer and Goridis, 1985), and proxi-
mal of the t(4;ll) breakpoint T0 and Tf genes of the T3-complex 
(Van den Elsen et al., 1986; Gold et al., 1986). All these 
genes may help to define and characterize the several llq23 
translocations in more detail. Another intriguing gene assigned 
to the llq23 region is the c-ets-1 oncogene (Detaisne et al., 
1984; Watson et al., 1985; 1986). The ets sequences were iden-
tified as a second cellular sequence transduced by the Avian 
acute leukemia virus E26 (Nunn et al., 1983; Leprince et al., 
1983). The presence of v-ets in the virus is associated with a 
block in differentiation capacity of the transformed cells 
(Beug et al., 1984). In contrast to the organization in chic-
ken, human c-ets sequences consist of two distinct domains 
located on different chromosomes. The 5' v-ets cellular homolo-
gue, c-ets-1 on chromosome llq23 and the 3' v-ets cellular 
homologue, c-ets-2 on chromosome 2lq22 (Watson et al., 1985; 
1986). The c-ets-1 gene is located distal of the llq23 break-
point and is translocated to the recipient chromosome involved 
in the (4;11) or (9;11) translocations (Diaz et al., 1986; 
Sacchi et al., 1986). Rovigatti et al., (1986a; 1986b) have 
reported that in almost all leukemia patients with llq23 abnor-
malities an alteration, often both amplification and rearran-
gement, of the c-ets-1 locus accompanied by an overall enhanced 
expression of c-ets-1 can be observed. Since other investiga-
tors (Sacchi et al., 1986; Diaz et al., 1986) report contradic-
tary results, the involvement of c-ets-1 in these leukemias is 
not unambiguously proven. 
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2.3 Translocations associated with lymphocytic leukemia and 
lymphoma 
As shown in Table 1, various characteristic structural 
aberrations have been described in patients with lymphocytic 
leukemia and lymphoma. The most frequently observed transloca-
tion in acute lymphoblastic leukemia (ALL), the t(9;22) trans-
location, is cytogenetically identical to the Ph1 chromosome 
and prompted molecular studies to explore the involvement of 
the c-abl and bcr genes (see section 2.1.6). The t(8;14) trans-
location, observed in some (B-cell) ALL-L3 patients and the 
variant t(2;8) and t(8;22) are strongly associated with 
Burkitt's lymphoma. In these specific translocations the direct 
involvement of the c-myc oncogene and the three immunoglobulin 
loci was proven. In other B cell specific leukemias and lympho-
mas consistent translocations involving chromosome band 14q32 
suggested a similar involvement of the IgH locus. An analogous 
situation is gradually emerging in T-cell specific malignan-
cies: The T-cell receptor a-chain gene locus is localized at 
chromosome 14qll ,and this 14qll region is frequently involved 
characteristic chromosomal aberrations of T-cell specific 
leukemias and lymphomas. 
2.3.1 The t(8;14) and variant (2;8) or (8;22) translocations in 
Burkitt's lymphoma 
Burkitt's lymphoma (BL) is a B-cell malignancy, which is 
characterized by three specific chromosomal translocations 
(Zech et al., 1976; Bernheim et al., 1981). In 80% of the BLs a 
t(8;14)(q24;q32) is found in which the human c-myc oncogene is 
translocated from its normal position at chromosome 8q24 (Neel 
et al., 1982; Dalla-Favera et al., 1982a, 1982b) to the Immuno-
globulin heavy chain (IgH) gene locus at chromosome 14q32 in a 
head to head orientation (Figure 6) (Kirsch et al., 1982; Taub 
et al., 1982; Dalla-Favera et al., 1983; Adams et al., 1983; 
Marcu et al. ,1983). In the variant t(2;8) (pl2;q24) and 
t(8;22) (q24;qll) translocations, the c-myc gene remains on 
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chromosome 8 and part of the immunoglobulin light chain (IgL) 
genes (located at chromosome 2pl2 and 22qll, respectively, 
Erikson et al., 1981; McBride et al., 1982) are translocated to 
the 3' site of the c-myc gene in a head to tail orientation (De 
la Chapelle et al., 1983; Erikson et al., 1983; Malcolm et al., 
1985)(Figure 6). A similar recombination between c-myc and the 
IgH or IgL genes has been observed in mouse plasmacytomas (mpc) 
bearing a t(l2;15) or variant (6;15) translocation (Klein, 
1981; 1983; Erikson et al., 1985a). 
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Figure 6. 
Schematic representation of the chromosomes involved in Burkitt lymphoma 
specific translocations: t(2;8) (p12;q24), t(8;14) (q24;q32) and t(8;22) 
(q24;q11). The position of the breakpoints and the transcriptional orien-
tation of the involved loci are indicated. 
The c-myc oncogene, 
forming gene v-myc of Avian 
tains 3 exons (Figure 7). 
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the cellular homologue of the trans-
myelocytomatosis virus MC29, con-
Only the exons 2 and 3, which are 
homologous to the v-myc gene, code for the nuclear c-myc pro-
tein (Alitalo et al., 1983b; Winquist et al., 1983; Eisenman et 
al., 1985). Transcription of the c-myc gene is initiated at two 
promoters (Pl and P2), located in the first untranslated exon 
and results in 2 mRNAs of 2.4 and 2.2 kb respectively (Taub et 
al., 1984; Zimmerman et al. 1986). The expression of c-myc is 
constant throughout the cell cycle in normal dividing cells and 
decreases rapidly during differentiation (Hann et al., 1985; 
Dony et al., 1985; Thompson et al., 1985). Conversely, the 
induction of cell proliferation by mitogens results in a dras-
tic increase of c-myc mRNA levels (Kelly et al., 1983; Lacy et 
al., 1986). The c-myc mRNA and protein have an extremely short 
half life (Dani et al., 1984; Rabbitts et al., 1985a, 1985b) 
and regulation of c-myc expression takes place both at the 
transcriptional level (Bently and Groudine, 1986) and at a 
post-transcriptional level by regulating the stability of the' 
mRNAs (Blanchard et al., 1985). In this latter post-transcrip-
tional control, the 5' untranslated exon seems to play an 
important role and loss of this exon results in a more stable 
+--centromere 
III 
Figure 7. 
II 
t(8; 14) 
Human c-myc 
5' t--------+ 3' 
t(8;22); t(2;8) 
The human c-myc gene. The three exons are indicated as boxes (hatched 
areas indicate protein coding regions). Transcriptional orientation (5'-+ 3') 
and the position of the alternative initiation sites for transcription (Pl 
and P2) are indicated. Below the map the position of the variant transloca-
tion t(8;22) and t(2,8) breakpoints as well as the position of the class 1, 
II and Ill t(8;14) breakpoints are shown. 
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c-myc mRNA (Piechaczyk et al., 1985; Eick et al. 1985; Rabbitts 
et al., 1985a). 
The t(8;14) BLs all have chromosome 8 breakpoints 5' of 
the two coding exons and can be divided in three classes: those 
with a breakpoint within the c-myc gene (class I; 50% of all 
BLs); those with a breakpoint immediately 5' of the gene (class 
II); and those with a breakpoint at an unknown distance 5' of 
the gene (class III). The variant t(2;8) or t(8;22) BL break-
points are located 3' of the c-myc gene (Cory, 1986; Figure 7). 
Although three breakpoints have been mapped in the vicinity of 
the gene (Hollis et al., 1984; Denny et al., 1985; Sun et al., 
1986), 
8 kb 
1986) 
the majority of these breakpoints are located more than 
3' of c-myc. Recent cytogenetic data (Manolov et al., 
suggest that some of the t(8;22) chromosome 8q24 break-
points are located at a different 8q24 subband than the t(8;14) 
or t(2;8) chromosome 8 breakpoints. In the mouse plasmacytoma 
variant t(6;15), these breakpoints 3' of c-myc cluster in a 
segment of DNA (pvt-1 locus), located at least 86 kb 3' of the 
c-myc gene (Webb et al., 1984; Cory et al., 1985; Banerjee et 
al., 1985). Proviral insertions found in this pvt-1 locus (in 
T-cell lymphomas) (Graham et al., 1985; Villeneuve et al., 
1986) result in comparable c-myc mRNA levels as in plasmacyto-
mas. This strongly suggests that a putative oncogene, involved 
in the regulation of c-myc expression is affected in both types 
of DNA rearrangements (Cory et al., 1985; Cough, 1985; Cory, 
1986). At the moment it is unclear whether the variant human 
BL translocations cluster in a similar region 3' of the c-myc 
gene. 
The breakpoints in the Ig loci showed a similar disperse 
pattern. In the IgL loci breakpoints were observed 5' of the CA 
or Ck genes or within the VL gene regions. In the IgH locus 
the switch (S) region is frequently involved, although other 
breakpoints have been located mores' close to the enhancer 
(EH) region or within the VH genes. The Ig genes undergo seve-
ral steps of somatic recombination during B-cell differentia-
tion (Tonegawa, 1983; Hood et al., 1985). There is no evidence 
that a similar joining mechanism is involved in the generation 
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of the c-myc/Ig recombinations, nor is there any evidence for 
homologous recombination or crossing over within a homologous 
oligonucleotide. Usually these Ig/c-myc recombinations separate 
the coding regions of the Ig genes and hence prevent the 
expression of a functional Ig molecule from the translocated 
chromosome (Erikson et al., 1982, 1983b; Croce et al., 1983). 
However, in one case expression of a Ig~ molecule was demon-
strated from the translocated 14q+ chromosome (Versnel et al., 
1986). Previously Lenoir et al. (1982) suggested that in the 
variant translocations, the expressed type of IgL chain is the 
same as the IgL locus involved in the variant translocation. 
However also AigL expressing t(2;8) BLand KigL expressing 
t(8;22) BLare reported (Magrath et al., 1983; Denny et al., 
1985; Hollis et al., 1984; A. Hagemeijer pers.comm.). Recently 
a striking correlation was observed between the breakpoints in 
the c-myc locus and the different stages of B-cell differentia-
tion (Pellici et al., 1986). Class III breakpoints were only 
found in the endemic (African-type) BLs, whereas class I and II 
breakpoints were only found in the more mature sporadic (Ameri-
can-type )BLs. Furthermore, breakpoints within the SH region 
are frequently found in either class I or II tumors, whereas 
class III tumors have only breakpoints 5' of the EH or in the 
VH regions (Cory, 1986). This could indicate a correlation 
between certain sites of recombination and the stage of B cell 
differentiation. Consistent with this possibility are the dif-
ferences in c-myc breakpoints in 4 (B-cell) ALL-L3 patients 
(all class I) and 2 (pre-B-cell) ALL patients (class 
(Peschle et al., 1984; Pegoraro et al., 1984; Blick et al., 
1986; Care et al., 1986). However, despite the enormous varia-
tion in myc/Ig recombination, all the translocations result in 
a constitutive expression of the c-myc gene involved in the 
translocation. The other, normal c-myc gene is usually not 
expressed (Stanton et al., 1983; Nishikura et al., 1983; Croce 
et al., 1983; Erikson et al., 1983a; 1983b). Since the c-myc 
genes 
(class 
involved were frequently altered, either by truncation 
I) or by mutations and/or deletions in the conserved s' 
region or in the first exon (class II and III) of the gene, it 
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was assumed that these structural changes play a role in the 
deregulation of c-myc (Battey et al., 1983~ Taub et al., 1984~ 
Rabbits et al., 1984~ Denny et al., 1985~ Pellici et al., 
1986). Several mechanisms are possible, both at the transcrip-
tional or posttranscriptional level. For example, in cases 
where the c-myc gene is truncated, transcription is initiated 
at cryptic promoters in the first intron. These truncated mRNAs 
have an increased stability as compared to the normal c-myc 
transcripts (Piechaczyk et al., 1985~ Eick et al., 1985~ Rab-
bitts et al., 1985a). Mutations in the first exon could have a 
similar effect or alternatively could prevent the binding of 
repressor molecules which regulate the transcription and/or 
elongation of the c-myc mRNAs (Leder et al., 1983~ Taub et al., 
1984~ Rabbitts et al., 1984~ Pellici et al., 1986~ Bentley and 
Groundine, 1986). In this respect an intriguing model has been 
proposed in which the constitutive expression of activated c-
myc genes would have a negative effect, either direct or in-
direct on the expression of the normal c-myc gene (Rabbitts et 
al., 1984~ Rapp et al., 1985~ Adams et al., 1985). However, 
several other investigators suggest that the lack of normal c-
myc expression is caused by normal regulation following the (B-
cell) differentiation of the tumors (Fe6 et al., 1985~ Croce et 
al., 1985b~ Cole, 1985). Another negative transcriptional con-
trol element with properties opposite to an enhancer sequence 
(dehancer) has been found in the well conserved region 5' of 
the c-myc gene (Remmers et al., 1986). Class II BL breakpoints 
(Fig.7) would result in the deletion or truncation of this 
dehancer element. 
Apparently, there are several mechanisms which can lead to 
deregulation of c-myc transcription (Klein and Klein, 1985a~ 
Rabbitts, 1985). However, from somatic cell hybrid experiments 
it is clear that the deregulation of the translocated BL c-myc 
gene requires a B-cell background (Nishikura et al., 1983~ 
1984) and that different genetic Ig elements play a role in the 
cis-activation of the c-myc gene (Croce et al., 1984~ Nishikura 
et al., 1985). Besides the normal IgH chain gene enhancer, 
located 5' of the s~-region, which can activate c-myc 
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transcription in both early and mature B-cell stages (Corcoran 
et al., 1985; Fahrlander et al., 1985; Feo et al., 1986) other 
sequences 3' of the SH (S~, Sy or Sa) regions have been pos-
tulated. These can activate c-myc transcription in BL over a 
long distance but only in a more mature stage of B cell dif-
ferentiation (Croce et al., 1985b; Croce and Nowell, 1985; Feo 
et al., 1986). Using transgenic mice bearing different c-myc 
genes, Adams et al. (1985) demonstrated, that enhancement and 
transcriptional activation of the c-myc gene is necessary to 
induce tumors in vivo, while neither truncation of the gene nor 
alteration of its normal chromosomal position are sufficient 
for activation. In their experiments, a c-myc gene driven by 
the IgH enhancer induced lymphoid tumors in 90% of the transge-
nic mice. Other enhancers, as those from SV40 or mouse mammary 
tumor virus (MMTV)-LTR are less effective (14-40% tumor in-
duction, (Stewart et al., 1984; Adams et al., 1985; Leder et 
al., 1986). In these latter experiments using a MMTV- LTR 
driven c-myc gene a variety of tumor 
the broad transforming potential of 
al., 1986). However, high expression 
illustrating 
(Leder et 
types arose, 
the c-myc gene 
of the c-myc is not suffi-
cient for tumor induction and the observation that most of the 
tumors were of clonal origin strongly suggested, that at least 
a second event was required to generate a fully transformed 
cell (Stewart et al., 1984; Adams et al., 1985; Cole, 1985; 
Leder et al., 1986). A similar situation exists in vitro, where 
an activated c-myc gene alone is not sufficient to cause trans-
formation, although it can abolish the need for certain growth 
factors and can block differentiation (Rapp et al., 1985; 
Kelly, 1985; Coppola and Cole, 1986). Several oncogenes (e.g. 
~; E1A) have been identified, that can complement the c-myc 
gene to transform primary embryonic fibroblasts in culture 
(Land et al., 1983a; 1983b; Ruley, 1983; Cooper and Lane, 
1984). Consistent with this second hit model is the isolation 
of B-lym from BL cell lines, using a NIH-3T3 transformation 
assay (Diamond et al., 1983; Neiman, 1985) and the detection of 
additional DNA rearrangements in other oncogenes in mouse plas-
macytoma cell lines (Cohen et al., 1983; Mushinski et al., 
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1983; Perlmutter et al., 1984; Klein and Klein, 1985a, 1985b). 
2.3.2 Translocations involving 14q32 in B cell leukemias and 
lymphomas 
Translocations involving band 14q32 are the most common 
non-random abnormalities found in a variety of B-cell lymphomas 
and leukemias (Table 1; Sandberg, 1980; Rowley and Testa, 1983; 
Yunis, 1983). Besides the already mentioned t(8;14) found in BL 
and ALL (section 2.3.1), other non-random translocations 
involving the IgH gene bearing 14q32 have been reported in 
different subtypes of lymphoma and chronic lymphocytic leukemia 
(CLL). Among these are the t(ll;l4)(ql3;q32), found in some 
patients with CLL and diffuse small or large cell lymphoma and 
the t(l4;18)(q32;q21), found in 90% of the patients with folli-
cular lymphoma (Yunis et al., 1982; 1984; Yunis, 1983; Nowell 
et al., 1986). Using IgH chain gene probes, cloning of the 
chromosomal breakpoints resulted in the identification of two 
B-cell lymphoma/leukemia breakpoint cluster regions: the 0.9 kb 
bel-l located at chromosome llql3 and the 2.1 kb bcl-2 located 
at chromosome 18q21, respectively (Erikson et al., 1984; Pego-
raro et al., 1984; Tsujimoto et al., 1984a, 1984b; Cleary and 
Sklar, 1985a). DNA sequence analysis of the breakpoint clones 
and normal chromosome 14 or 18 counterparts revealed that both 
types of translocations were the result of an aberrant V-D-J 
joining event (Tsujimoto et al., 1985b, 1985c; Cleary and 
Sklar, 1985b; Bakhshi et al., 1985). Since most 14q32 break-
points were located just 5' of the Ig enhancer, it was supposed 
that translocation to the proximity of the Ig enhancer could 
activate the expression of putative oncogenes located at the 
bel-l or bcl-2 breakpoint regions. Indeed a bcl-2 gene located 
at chromosome 18q21 has been identified. Translocation of this 
gene to the Ig Enhancer at chromosome 14q32 resulted in higher 
levels of transcription of a bcl-2 specific 6.0 kb mRNA (Tsuji-
moto et al., 1985a; Cleary and Sklar, 1985b). Recent results 
indicate that the t(l4;18) breakpoints are located in the 3' 
untranslated region of this gene. The translocation results in 
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the transcription of mRNAs of aberrant sizes but does not 
affect the bcl-2 protein coding sequences (Tsujimoto and Croce, 
1986). No such putative oncogene has been identified at the 
bel-l region until now. 
Fell et al. (1986) have recently analysed the 
t(2;14) (pl3;q32) translocation in two children with B-CLL (Son-
nier et al., 1983). Both the chromosome 14q32 breaks occurred 
just 5' of the Cy2 region of the IgH gene on the productive 
allele. Whether the chromosome 2pl3 breakpoints cluster in a 
limited DNA region is unclear. However, the paradigm of the 
t(8;14) in BL and the t(l4;18) in B-cell lymphomas justifies 
the assumption that the t(2;14) may have resulted in the soma-
tic mutation or activation of an as yet unidentified gene on 
chromosome 2pl3. 
In 30% of the childhood pre B-ALLs a non-random translo-
cation between chromosome 1 and 19 has been identified 
(t(l;l9) (q23;pl3.3), (Williams et al., 1984). The position of 
the chromosome 19 breakpoint coincides with the location of the 
insulin receptor gene (Yang-Feng et al., 1985). The insulin 
receptor is related to the tyrosine kinase family of oncogenes 
(Ullrich et al., 1985) and it will be interesting to see whe-
ther this gene is involved in the pre B-ALL specific (1;19) 
translocation. 
2.3.3 Translocations and inversions involving 14qll in T-cell 
leukemias and lymphomas 
T-lymphocytes have a special set of genes which are 
involved in the recognition of antigen. The most common T-cell 
antigen receptor (TCR) is a heterodimer comprised of an ~(TCR~) 
and ~(TCR~) gene chain. Recently a second TCR molecule has been 
identified and one of the chains of this heterodimer is encoded 
by the TCRy chain gene (Brenner et al., 1986; Bank et al., 
1986). Like the Ig genes in B-lymphocytes, these TCR genes are 
specifically rearranged and expressed during T-cell development 
(Hood et al., 1985; Goverman et al., 1986; Minden and Mak, 
1986). The TCR~ chain gene has been assigned to chromosome 
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14qll-ql3 (Croce et al., 1985a; Rabbitts et al., 1985c; Collins 
et al., 1985}. Since this 14qll-ql3 region is frequently invol-
ved in chromosomal abnormalities in T-cell leukemia and lympho-
ma, this strongly suggested, that by analogy of the involvement 
of the Ig genes in B-cell tumors, the TCRa locus was involved 
in T-cell leukemias and lymphomas (Hecht et al., 1984, 1985, 
Ueshima et al., 1984; Sadamori eta;., 1985b; Clare et al., 
1986; Dube et al., 1986}. 
The most common aberration in T-cell malignancies is an 
inversion of chromosome 14, inv(l4} (qllq32}, or the closely 
related t(l4;14}(qll;q32)(Zech et al., 1984; Hecht et al., 
1984; Sadamori et al., 1985b}. Croce et al. (1985a} suggested 
that a putative oncogene tel-l (!-cell !ymphoma/leukemia} was 
involved in these cases. However, molecular analysis revealed 
that the chromosome 14 inversion in a T-cell lymphoma cell line 
was caused by a site-specific recombination between IgH and 
TCRa loci (Baer et al., 1985; Denny et al., 1986}. This re-
sulted in the transcription of a chimeric Ig-TCR gene consist-
ing of a Ig VH gene segment and TCR Ja and Ca gene segments 
(Denny et al., 1986). A similar inv(l4} or t(l4;14) has also 
been observed in 'normal' lymphocytes and leukemic cells of 
Ataxia telangiectasia patients (Aurias et al., 1980, 1986}. As 
yet it is not cl~ar whether this chimeric Ig-TCR gene contri-
butes to the malignant transformation of T-cells. However, it 
is possible that the formation of an aberrant Ig-TCR cell 
surface receptor molecule results in the delivery of an inap-
propriate mitogenic stimulus. 
In T-ALL a specific t(ll;l4}(pl3;qll} has been reported 
(Williams et al., 1984} and in this type of translocation it 
was shown that the chromosome 14qll breakpoint occurred between 
the TCR Va and Ca gene segments (Lewis et al., 1985; Erikson et 
al., 1985b}. The chromosome llpl3 breakpoint coincides with the 
locus that is implied in Wilms tumor' (Riccardi et al., 1980; 
Van Heyningen et al., 1985). This suggested that either this 
Wilms tumor gene or a yet unknown gene, tcl-2, located in this 
region is involved in T-cell malignancies (Erikson et al., 
1985b}. In three cases of T-cell leukemia (2 cell lines and an 
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ALL patient with a t(8;14)(q24;qll)), it was demonstrated, that 
part of the TCRa chain locus was translocated to the 3' region 
of the c-myc gene (Mathieu-Mahul et al., 1985; Shima et al., 
1986; Erikson et al., 1986b). In the two cell lines the chromo-
some 8 breakpoint was located in the 3' flanking region of the 
c-myc gene, whereas in the T-ALL patients the breakpoint was 
located more than 38 kb downstream of the c-myc gene. Neverthe-
less, using somatic cell hybrids it was shown, that in this T-
ALL patient the translocation of the TCRa locus to the 3' c-myc 
region resulted in the deregulation of the transcription of 
this c-myc allele (Erikson et al., 1986b). This latter observa-
tion closely resembles the deregulation of the c-myc gene in 
the t(8;14)(q24;q32) in BLand B-ALL, described in section 
2.3.2. 
2.4. Chromosome translocations in solid tumors 
Cytogenetic studies of solid tumors have also led to the 
identification of structural abnormalities, although hampered 
by technical difficulties. With a few exceptions, most of 
these abnormalities are not specific for one tumor type (Trent, 
1984; Berger et al., 1985). Most of the structural abnormali-
ties are deletions, but also recurring chromosomal transloca-
tions have been described: t(2;13)(q37;ql4) in alveolar rhabdo-
myosarcoma (Turc-Carel et al., 1986), a t(3;8)(p2l;ql2) in 
salivary gland carcinoma (Market al., 1983), translocations 
involving 3pl4 (t(3;8) (pl4;q24) or t(3;11) (pl4;pl5)) in heredi-
tary renal cell carcinoma (Cohen et al., 1979; Pathak et al., 
1982; Yoshida et al., 1986), a t(6;14)(q2l;q24) in ovarian 
carcinoma (Wake et al., 1980), and the t(ll;22)(q24;ql2) in 
Ewing sarcoma (Aurias et al., 1983; Turc-Carel et al., 1983). 
Molecular analysis of somatic cell hybrids revealed that in a 
renal cell carcinoma t(3;8) the c-myc oncogene was translocated 
to the 3pl4 region (Drabkin et al., 1985). However, they could 
not detect any rearrangements in the 21 kb region surrounding 
the c-myc gene. Similar studies, using somatic cell hybrids 
between a Ewing sarcoma cell line and rodent cells, demon-
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strated the chromosome 22 breakpoint to be proximal to the c-
sis locus but distal to the bcr locus. Neither rearrangements 
nor an altered transcription of the c-sis gene were seen 
(Geurts van Kessel et al., 1985; Bechet et al., 1984). Recent 
experiments, using the chromosome llq23 c-ets-1 probe indicated 
that the chromosome ll breakpoint is distal to the c-ets-1 gene 
(Geurts van Kessel, pers.comm.). Since in all these experiments 
the same Ewing sarcoma cell line was used, further studies will 
be necessary to corroborate whether this is a common pattern 
among Ewing sarcomas. 
3. DELETIONS AND AMPLIFICATIONS 
A number of solid tumors and hematopoietic disorders are 
characterized by recurring deletions of part of a particular 
chromosome (Table l). In contrast to the rather specific chro-
mosomal breakpoints in recurring translocations, most of the 
breakpoints in the deletions are not consistent. Thus variable 
sizes of deleted fragments are observed among different pa-
tients. However, often a common deleted region can be deter-
mined which suggests, that the loss of genes located in that 
specific region is related to the particular tumor or disorder. 
In a number of myeloid disorders such a common region 
coincides with the position of a proto-oncogene. This could 
suggest, that loss or decreased expression of this oncogene is 
implied in the disturbed growth pattern. Another mechanism of 
tumorigenesis has recently been discovered in embryonal tumors 
as retinoblastoma and Wilms tumor. Experimental data strongly 
suggest, that concomittant loss or inactivation of both alleles 
of a specific regulatory or tumor suppressor gene is necessary. 
Preliminary data indicate, that the loss of this gene function 
can lead to enhanced levels of specific oncogenes. A more 
direct mechanism which could contribute to enhanced levels of 
oncogene expression is gene amplification. Cytogenetically 
these gene amplifications are manifested as homogeneously Stai-
ning Regions (HSR) or double minutes (DM). 
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3.1 Deletions associated with MD, RA and ANLL 
Abnormalities of the short arm of chromosome 12, predomi-
nantly deletions of 12p(pll-pl3qter), are frequently observed 
in patients with ANLL or myelodysplastic syndromes (MDS)(Berger 
et al., 1986; Web and Hossfeld, 1986). It has been suggested 
that this 12p- abnormality is a secondary event, although in 
some patients it is the only karyotypic abnormality (Berger et 
al., 1986). Two oncogenes, K-ras and int-1 have been localized 
in this 12p region(Jhanwar et al., 1983; Van 't Veer et al., 
1984). However as yet no studies exploring the fate of these 
genes in the 12p- abnormality have been reported. 
Loss of a whole chromosome 5 or loss of part of the long 
arm of chromosome 5(ql3-q33) has been observed in patients with 
ANLL and refractory anemia (RA) (Wisniewski and Hirschhorn, 
1983). At region 5q34, the c-fms oncogene is located (Groffen 
et al., 1983c). Recent data indicate that c-fms is related, if 
not identical to the mononuclear phagocyte growth factor recep-
tor of CSF-1 (Sherr et al., 1985; Sacca et al., 1986). Although 
this oncogene was deleted in 5 cases of RA (Nienhuis et al., 
1985; LeBeau et al., 1986), it was conserved in an ANLL patient 
with a 5q- deletion. A related gene, the human granulocyte 
macrophage colony stimulating factor (GM-CSF) located at 5q21-
q32 (Huebner et al., 1985) was consistently deleted in all 
patients studied with a 5q- chromosome (LeBeau et al., 1986). 
This suggests that deletion of one or both of these genes may 
be important in the pathogenesis of RA or ANLL although the 
involvement of other genes located at the critical 5q- region 
cannot be excluded. 
Another common abnormality in myeloid disorders is a 
deletion of chromosome 20q. LeBeau et al. (1985c) demonstrated, 
that these deletions were interstitial and that the ~ 
oncogene located at 20ql3 was consistently conserved. Although 
no rearrangements were detected in the c-src gene, this onco-
gene may be located close to the deletion breakpoint and its 
expression may be altered. 
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3.2 Deletions and recessive mutations in cancer 
Retinoblastoma (Rb) is an embryonal tumor which either 
occurs spontaneously (sporadic Rb), or to which predisposition 
can be inherited in an autosomal dominant manner. The inherited 
Rb is often bilateral and has in general an earlier onset than 
the unilateral sporadic form. Cytogenetic studies and isoenzyme 
segregation analysis revealed that both forms of Rb are asso-
ciated with a common deletion at chromosome 13ql4 (Vogel, 1979; 
Sparkes et al., 1983; Sparkes, 1984). Knudson (1971) suggested 
that Rb is caused by two mutational events. In the inherited 
form, one of these mutations is transmitted via the gerrnline 
and a second mutation occurs in a somatic cell. In sporadic Rb 
both mutations occur in the same somatic cell. Comings (1973) 
extended this hypothesis, by suggesting that in these types of 
tumors, which have both hereditary and sporadic appearance, the 
two mutations involved the two allelic copies of a regulatory 
or tumor suppressor gene (anti-oncogene). Loss of this suppres-
sor/regulatory function would result in the expression or acti-
vation of a transforming gene. Support for this hypothesis carne 
from studies using polymorphic enzyme markers and restriction 
fragment length polyrnorphisrns (RFLP)(Benedict et al., 1983; 
Cavenee et al., 1983, 1985; Dryja et al., 1984). These studies 
clearly demonstrated the development of herni or homozygosity of 
a mutated Rb allele in both hereditary and sporadic Rb. Since 
loss of both wild type Rb alleles is associated with tumor 
formation, this strongly suggests that the nature of the Rb 
mutation is recessive at the cellular level. (Gilbert, 1~83; 
Murphree and Benedict, 1984). 
Wilms tumor (WT), like retinoblastoma, is a childhood 
tumor which occurs usually sporadic, but to which predisposi-
tion can be inherited in an autosomal dominant trait. Cytogene-
tically WT is associated with a deletion of chromosome llpl3. 
Patients with a constitutional or congenital deletion in this 
llpl3 region often have aniridia, which suggests that both loci 
are closely linked on chromosome llpl3 (Slater, 1986; Kaneko et 
al., 1981; Orkin, 1984; Van Heyningen et al., 1985). Molecular 
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analysis with RFLPs indicate that the specific loss of hetero-
zygosity for the llp region was a common event in WT (Koufos et 
al., 1984; Orkin et al., 1984; Reeve et al., 1984; Fearon et 
al., 1984; Solomon, 1984). 
Patients, who have inherited the predisposition to either 
Rb or WT, have often an increased risk for the development of 
other specific tumors. These associated tumors can arise either 
simultaneously, or as a second primary tumor. For example, 
children with Beckwith-Wiedeman syndrome (BWS) have a predispo-
sition to develop WT, rhabdomyosarcoma and hepatoblastoma. 
Koufos et al. (1985) demonstrated that these three types of 
embryonal tumors share a common pathogenic mechanism: The spe-
cific development of chromosome llp homozygosity. In the BWS 
this predisposition is inherited as a single autosomal dominant 
mutation. This suggested that in each of these three embryonal 
tumors loss or inactivation of the same chromosomal region was 
involved. Whether they result from mutations in the same gene, 
or from an overlapping deficiency is as yet unknown. In addi-
tion, a specific loss of chromosome llp heterozygosity has been 
observed in 42% of the patients with bladder cancer (Fearon et 
al., 1985). Hereditary Rb patients have an increased risk for 
the development of osteosarcomas and Hansen et al. (1985) have 
provided evidence for the specific loss of heterozygosity for 
the chromosome 13ql4 region. 
A third example of clustered tumors, which probably share 
a common pathogenic mechanism, has recently been reported by 
Seizinger et al. (1986). They demonstrated a specific loss of 
chromosome 22 heterozygosity in acoustic neuroma. This neural 
tumor can arise spontaneously or in a heritable manner and 
this latter form is often bilateral and frequently associated 
with meningiomas. Since meningiomas are cytogenetically charac-
terized by a loss or deletion of chromosome 22 (Table 1), this 
strongly suggests that both neural tumors share a common mecha-
nism of tumorigenesis. A number of other human tumors such as 
familial renal carcinoma, neuroblastoma and small cell lung 
carcinomas (Table 1) fit also the Rb and WT model of tumorige-
nesis (Knudson 1971; Comings 1973). This could indicate that 
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the human genome contains a number of genes or loci at which 
mutations can lead to a predisposition for the development of a 
clusters of specific associated tumors. Loss of a tumor 
suppressor or regulatory gene by conversion to hemi or homozy-
gosity may therefore be a fundamental mechanism of tumorigene-
sis, especially in hereditary tumors (Murphree and Benedict, 
1984). The exact molecular nature of the mutated genes and/or 
sequences in these tumors as well as their target genes are as 
yet unresolved. However, in two embryonal tumors, Rb and WT, 
the oncogene N-myc has been implied as a possible target gene. 
In WT the levels of N-myc expression are significantly elevated 
as compared to normal adult or fetal kidney tissue (F. Alt. 
pers.comm.). Amplification of N-myc, accompanied by increased 
levels of expression have been reported in some Rb tumors and 
cell lines (Kohl et al., 1984; Lee et al., 1984; Squire et al., 
1985). In other Rb tumors, the expression of N-myc is similar 
to the expression observed in normal (8-12 week of gestation) 
fetal retina tissue (Squire et al., 1986). Based on this obser-
vation Squire et al. (1986) concluded, that the expression of 
N-myc in Rb is due to the embryonic origin of the tumor and not 
directly associated with the mutation in the Rb locus. However, 
this observation does not necessarily rule out a possible 
involvement of N-myc in Rb, since like the c-myc expression 
levels in BL (see section 2.3.1) constitutively expression of 
N-myc may be sufficient in the embryonic retina cells. It is 
even conceivable that this constitutive expression of N-myc 
prevents the differentiation of these cells, since recent re-
ports (Coppola and Cole, 1986; Dmitrovsky et al., 1986) showed, 
that the constitutive expression of a transfected c-myc gene 
resulted in the inhibition of differentiation of the recipient 
cell lines. 
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3.3 Amplification of oncogenes 
Chromosomal aberrations, as double minutes (DM) and homo-
geneously staining regions (HSR), are present in a variety of 
human tumors and tumor derived cell lines (Barker, 1982). These 
karyotypic abnormalities are cytogenetical markers for gene 
amplification (Hamlin, 1984; Schimke, 1984). It has been shown 
that in the tumor cells this amplified genetic material in-
cludes DNA sequences, that are identical or related to known 
cellular oncogenes. This amplification usually results in pro-
portionally enhanced rnRNA levels of the oncogene (reviews; 
Alitalo, 1984; Alitalo and Schwab, 1986). The reported examples 
of oncogene amplification in mammalian tumors can be divided in 
two types of appearance: A sporadic or tumor-specific type. 
Most cases of oncogene amplification in a variety of tumor 
derived cell lines, such as c-abl amplification in K562 cells 
(Collins and Groudine, 1983) belong to the first type since 
these are regarded as rare events in the respective tumor. 
Tumor specific oncogene amplification has been reported in four 
human malignancies. The c-erbB oncogene is amplified in several 
glioblastomas (Libermann et al., 1985), the c-myc oncogene is 
amplified in 32% of the breast carcinomas (Escot et al., 1986), 
the N-myc oncogene in neuroblastomas (Schwab et al., 1983b; 
Kohl et al., 1983; Schwab, 1985) and the c-myc, N-myc or L-myc 
oncogenes in small cell lung carcinomas (SCLC) (Nau et al., 
1985, 1986; Wong et al., 1986). Wong et al. (1986) studied the 
amplification of N-myc and c-myc oncogenes in human SCLC 
tumors. Their results indicated that the amplifications are not 
associated with the development of metastatic lesions. In con-
trast to previous studies (Little et al., 1983; Gazdar et al., 
1985) their results showed furthermore that the amplifications 
were not associated with the variant subclass of SCLC tumors 
in vivo. In neuroblastomas N-myc amplification is highly corre-
lated with a morphologically more advanced disease stage and 
rapid tumor progression (Brodeur et al., 1984; Seeger et al., 
1985). How these amplifications could contribute to the more 
agressive tumor type was recently suggested by the demon-
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stration of an inverse correlation between N-myc or c-myc 
oncogene expression and the expression of class I major histo-
compatibility antigens (R. Versteeg; R. Bernards, pers.comm.). 
As mentioned before in section 3.2, neuroblastomas and SCLC 
resemble in many respects the WT or Rb type of tumors. In 
addition to the enhanced or constitutive expression of myc 
oncogenes and the heriditary background of some neuroblastomas, 
both SCLC and neuroblastomas are associated with a recurring 
chromosomal deletion of chromosome 3 (pl4-p23) or chromosome 1 
(p36-p32), respectively (Whang-Peng et al., 1982; Brodeur et 
al., 1981). Furthermore all these tumors arise in organs/or 
tissues which showed a high expression of myc oncogenes in the 
embryonic counterparts (Zimmerman et al., 1986). However, whe-
ther the enhanced or constitutive expression of these myc genes 
contributes to tumorigenesis or reflect the embryonic nature of 
the tumor cells remains as yet unknown. 
4. CONCLUDING REMARKS 
The combined application of cytogenetic and molecular 
genetic techniques has elucidated the involvement of cellular 
oncogenes in tumor specific chromosomal abnormalities. Although 
these studies further underline the fundamental role of chromo-
somal abnormalities in tumor-development, as yet virtually 
nothing is known of the generation of these aberrations. DNA 
sequence analysis of BL and CML specific chromosomal breakpoint 
regions revealed no clue to a possible translocation mechanism. 
However, a report by Fialkow et al. (1981) indicates that in 
CML, the acquisition of the Ph1 chromosome is preceded by an 
initial phase of marked genetic instability. A similar phase of 
genetic instability of Ig or TCR loci may occur during the 
process of somatic rearrangements of these genes. During these 
phases, presumably various translocations occur and those with 
a selective growth advantage will eventually result in a clini-
cally apparent leukemia. 
It has been suggested that fragile sites may act as predis-
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posing factors for certain specific chromosomal rearrangements 
(Yunis and Soreng, 1984~ LeBeau and Rowley, 1984). The chromo-
somal location of a number of these fragile sites coincides 
with specific chromosomal breakpoint regions. Furthermore, 
leukemic patients were identified as carriers of a fragile site 
at the observed chromosomal breakpoint (Yunis, 1983~ LeBeau, 
1986). Although several genes, among which some oncogenes, have 
been mapped to an identical chromosomal region as a fragile 
site, at present the exact nature and function of the genes 
located at these sites remains an enigma. 
Molecular techniques as Southern blotting and chromosomal 
walking have demonstrated in a few tumor specific aberrations 
the localization of (putative) oncogenes in the direct vicinity 
of the chromosomal breakpoint region. However, in other tumor 
specific aberrations the exact nature of the association be-
tween cytogenetic changes and alterations at the DNA or gene 
level remains obscure. The application of new techniques as 
Pulsed Field Gradient (PFG) gel electrophoresis (Schwartz and 
Cantor, 1984~ Carle and Olson, 1984), which allows the separa-
tion of large (50-2000 kb) DNA fragments could help to corrobo-
rate a possible involvement of oncogenes in these cases. 
Furthermore, the use of PFG gels could lead to the detection of 
deletions which are not visible at the cytogenetic level. An 
example concerning deletions of part of chromosome lp32, which 
resulted in the activation of the trk oncogene in a human colon 
carcinoma has recently been reported (Martin-Zanca et al., 
1986). 
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SUMMARY 
Extensive cytogenetic studies revealed that a considerable 
number of human tumors, especially leukemias and lymphomas is 
associated with consistent, specific chromosomal aberrations. 
These observations suggested that at the specific breakpoint 
regions of these chromosomal abnormalities, genes are located, 
which could play a role in the malignant transformation of a 
normal cell into a tumor cell. Attractive candidates for such 
genes are the cellular oncogenes. Some of these oncogenes are 
located at the same region as the specific chromosomal break-
points. Recent data indicate that the protein products of these 
cellular proto-oncogenes are involved in the regulation of 
normal growth and differentiation. Disturbance of these 
functions (e.g. by chromosomal translocations) could result in 
an uncontrolled growth pattern. 
The Philadelphia (Ph1 ) translocation, present in about 96% of 
the patients with chronic myelocytic leukemia (CML), is one of 
the most typical and best documented examples of a consistent 
chromosomal aberration. Usually this translocation involves 
chromosome 9 and 22:t(9;22)(q34;qll) and results in two abnor-
mal chromosomes designated 9q+ and 22q- (or Phl chromosome). 
The human c-abl proto-oncogene has been localized at the long 
(q) arm of chromosome 9. By analysis of somatic cell hybrids, 
we have shown that this oncogene is translocated to the 22q-
chromosome. This proved unequivocally the reciprocal nature of 
the Ph1 translocation (Paper I). Study of variants forms of the 
Ph1 translocation demonstrated that the c-abl oncogene was 
consistently translocated to the 22q- chromosome even in cases 
where there was no visible involvement of chromosome 9. The 
location of the c-abl oncogene adjacent to the translocation 
breakpoint in CML was shown by the isolation of a DNA fragment 
from the 9q+ chromosome of a CML patient: this fragment con-
tained sequences of both chromosome 9 and 22. The breakpoint 
had occurred 14.5 Kb immediately s' of the v-abl homologous 
sequences and resulted in a 9q+ chromosome in which the tip of 
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chromosome 9, including the v-abl homologous sequences were re-
placed by sequences of chromosome 22 (Paper II). The isolated 
chromosome 22 sequences of this chimeric DNA fragment enabled 
us to clone the breakpoint region of chromosome 22 of this CML 
patient. A breakpoint cluster region (bcr) was identified on 
chromosome 22 and the DNAs of all Ph1 positive CML patients 
examined to date (over 30) have breakpoints in this 5.0 Kb 
chromosome 22 region. As a consequence of the Ph1 translocation 
part of bcr remains on the Ph1 chromosome and part is translo-
cated to the 9q+ chromosome (Paper III). Positive hybridization 
of bcr probes to eDNA or mRNA sequences suggested that this 
region contained protein encoding sequences. Part of this bcr 
gene has been characterized. However, as yet the bcr protein 
has an unknown cellular function. The 5.0 kb bcr, in which all 
the Ph1 positive CML breaks occur, is an internal part of this 
gene and contains three small coding regions. The chromosomal 
breakpoints are located in the non-coding region between these 
exons (Paper IV). In contrast to the limited region in which 
all the 22q- breakpoints are clustered, the breakpoints on 
chromosome 9 are scattered over a very large area which may 
vary from 5 kb up to more than 100 kb upstream of the v-abl 
homologous exons. However, in the leukemic cells of all Ph1 
positive CML patients a new, larger c-abl mRNA of 8.5 kb can be 
detected. This RNA is also present in the CML derived cell line 
K-562. Although this cell line has lost the Ph1 chromosome as 
such, it retained a Ph1 like bcr/c-abl construct. Hybridization 
of c-abl and different bcr probes revealed that c-abl and s' 
bcr probes hybridized to the same mRNA species. This could 
imply that K562 cells contain a chimeric bcr/c-abl mRNA. Direct 
proof of this supposition was achieved by the cloning of a eDNA 
that contained the chimeric part of this mRNA molecule. This 
chimeric eDNA has one long open reading frame, that is compati-
ble with both the predicted bcr and c-abl reading frames. Since 
this chimeric mRNA is also present in other Ph1 positive CML 
patients, probably the versatility of the splicing system acco-
modates for the large variation in intron size linking the bcr 
and c-abl genes (Paper V). 
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DNA sequence analysis of several chromosomal breakpoints 
revealed that homologous recombination between chromosome 9 and 
22 is unlikely. However, most of the breakpoints are located in 
Alu-repetitive sequences. This could suggest that these ALu-
repeats are hot spots of recombination (Papers IV, VI). 
The Ph1 translocation in CML and ALL patients is cytogeneti-
cally identical: in both cases the translocation is reciprocal 
and the c-abl oncogene is translocated to the 22q- chromosome. 
At the molecular level some of the Ph1 positive ALL patients 
differ from Ph1 positive CML patients. In 30% of the ALL pa-
tients the chromosome 22 breakpoint was located outside the 
bcr. In 70% of the patients, however, we could demonstrate a 
22q- breakpoint in the bcr region and the presence of a chime-
ric bcr/c-abl mRNA (Paper VII). 
In CML, this 8.5 Kb chimeric mRNA is translated into a p210 KD 
bcr/c-abl fusion protein. This fusion protein resembles in many 
aspects the Abelson murine leukemia virus v-abl protein. How-
ever, as yet it remains uncertain whether this p210 fusion 
protein contains indeed a transforming activity. 
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SAMENVATTING 
Uitgebreide cytogenetische studies hebben aangetoond dat een 
aanzienlijk aantal humane tumoren, vooral leukemie~n en lym-
fomen geassocieerd is met consistente, specifieke chromosomale 
afwijkingen. Verondersteld werd dat op de specifieke breukpunt-
regio's van deze chromosomale afwijkingen genen liggen, welke 
betrokken kunnen zijn bij de transformatie van een normale eel 
tot kankercel. Aantrekkelijke kandidaten voor dergelijke genen 
zijn de cellulaire oncogenen. Enkele van deze genen zijn reeds 
gelokaliseerd in gebieden waar ook specifieke chromosomale 
breukpunten zijn gevonden. Uit recent onderzoek is gebleken dat 
de genproducten van deze cellulaire oncogenen betrokken zijn 
bij de regulatie van de normale celvermeerdering en 
celdifferentiatie. Verstoring van deze functies (b.v. door 
chromosoom translokaties) zou kunnen leiden tot een ongecontro-
leerde celproliferatie. 
De Phildelphia (Ph1 ) translokatie, aanwezig in ongeveer 60% van 
de patienten met chronische myeloide leukemia (CML), is een van 
de meest karakteristieke en best gedokumenteerde voorbeelden 
van een tumor specifieke chromosomale afwijking. Gewoonlijk 
zijn bij deze translokatie de chromosomen 9 en 22 betrokken 
(t(9;22)(q34;qll)) en ontstaan hierbij twee abnormale chro-
mosomen, n.l. een 9q+ en een 22q- (Ph1 ) chromosoom. Het humane 
c-abl oncogen is gelokaliseerd op de lange (q) arm van chromo-
soom 9. Met behulp van somatische celhybriden, toonden wij aan 
dat dit oncogen verhuisde naar bet 22q- chromosoom. Dit leverde 
bet onweerlegbare bewijs op voor bet wederkerige karakter 
de Ph1 translokatie (Appendix Publikatie I). De studie 
variante vormen van de Phl translokatie toonde aan dat bet 
van 
van 
c-
abl oncogen ook daar verhuisde naar bet 22q- chromosoom, zelfs 
in gevallen waar chromosoom 9 niet zichtbaar betrokken leek in 
de translokatie. De ligging van bet c-abl oncogen op chromosoom 
9 dichtbij bet translokatie breukpunt in CML werd aangetoond 
door middel van de isolatie van een DNA fragment van bet 9q+ 
chromosoom van een CML patient. Dit fragment bevatte sequenties 
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van zowel chromosoom 9 als 22. De chromosomale breuk in de 
leukemische cellen van deze patient vond plaats 14,5 Kb 
"stroomopwaarts" van de v-abl homologe sequenties. Dit re-
sulteerde in een 9q+ chromosoom, waarvan de top van chromosoom 
9, inclusief de v-abl homologe sequenties was vervangen door 
chromosoom 22 sequenties (Appendix Publikatie II). De 
geisoleerde chromosoom 22 sequenties van dit chimaere DNA frag-
ment maakte het mogelijk om een breukpunt gebied van chromosoom 
22 te kloneren. Dit leidde tot de identificatie van een gebied 
op chromosoom 22 waarin de breukpunten van de verschillende CML 
patienten geklusterd voorkomen ~- De DNA's van alle tot nu 
toe onderzochte Ph1 positieve CML patienten bevatten een 
breukpunt in deze regio (Appendix Publikatie III). Ten gevolge 
van de Ph1 translokatie blijft een deel van de bcr achter op 
het 22q- chromosoom en een deel verhuist naar het 9q+ chro-
mosoom. Hybridisatie van bcr probes met eDNA en RNA sequenties 
toonde aan dat de bcr eiwit coderende sequenties bevatte. Een 
deel van dit bcr gen is gekarakteriseerd maar tot nu toe is de 
cellulaire functie van het bcr eiwit onbekend. Het 5.0 .kb bcr 
fragment, waarin alle CML specifieke chromosoom 22q- breuken 
plaatsvinden, is een intern gedeelte van dit gen en bevat drie 
kleine coderende regio's. De breuken vinden plaats in het niet 
coderende gebied tussen de exonen (Appendix Publikatie IV). 
In tegenstelling tot de situatie op chromosoom 22 zijn de 
breukpunten op chromosoom 9 verspreid over een groot gebied dat 
varieert van 5 kb tot meer dan 100 kb "stroomopwaarts" van de 
v-abl homologe exonen. Toch wordt in de leukemische cellen van 
alle Ph1 positieve CML patienten een nieuw, groter dan normaal 
c-abl mRNA molecuul aangetroffen. Dit RNA is ook aanwezig in de 
CML cellijn K562. Hoewel de K562 cellen geen Ph1 chromosoom 
bevatten, is in deze cellen ook een bcr/c-abl associaties 
opgetreden. Hybridizatie van K562 mRNA met c-abl en verschil-
lende bcr probes toonde aan dat zowel een c-abl als een s' bcr 
probe hybridiseerden met een groot, nieuw mRNA molecuul. Dit 
wijst erop dat de K562 cellen een chimaer bcr/c-abl mRNA bevat-
ten. Een direct bewijs van deze veronderstelling werd geleverd 
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door de klonering van een eDNA dat het chimaere gedeelte van 
dit RNA bevatte. Dit eDNA heeft een lang open leesraam dat 
overeenstemt met de voorspelde bcr en c-abl leesramen. Aan-
gezien dit chimere mRNA in alle Ph1 positieve CML patienten 
wordt gevonden, is het waarschijnlijk dat door de grote flexi-
biliteit, het splicing systeem geen moeite heeft met de grote 
variatie in intron grootte tussen de bcr en c-abl genen bij de 
verschillende patienten (Appendix Publikatie V). Uit DNA 
sequentie analyse van verschillende chromosomale breukpunten 
bleek dat homologe recombinatie tussen de chromosomen 9 en 22 
niet waarschijnlijk is. Aangezien de meeste breukpunten gesi-
tueerd zijn in zogenaamde repetitieve Alu sequenties lijkt het 
aannemelijk dat deze sequenties fungeren als "hot spots" voor 
recombinatie (Appendix Publikaties IV, VI). 
Het Ph1 wordt ook in patienten met acute lymfatische leukemie 
(ALL) aangetroffen. Cytogenetisch zijn de Ph1 translocaties in 
CML en ALL patienten identiek: in beide gevallen zijn de trans-
locaties reciprook en verhuist het c-abl oncogen naar chromo-
soom 22q-. Maar op moleculair niveau bleken sommige van de 
translocaties bij deze Ph1-positieve ALL patienten sterk te 
verschillen van die bij Ph1-positieve CML patienten. In circa 
30% van de Ph1 positieve ALL patienten vindt de breuk in chro-
mosoom 22 plaats buiten de bcr. In de overige 70% van de 
patienten konden we wel breuken in de bcr aantonen en bleek 
bovendien dat de leukemische cellen van deze patienten een 
chimaer bcr/c-abl) mRNA bevatte (Appendix Publikatie VII). In 
CML wordt dit chimaere mRNA molecuul vertaald in een p210 kD 
bcr/c-abl fusie eiwit. Dit fusie-eiwit lijkt in vele opzichten 
op het eiwit dat gecodeerd wordt door het v-abl gen van het 
Abelson muizen leukemie virus. Nog niet is aangetoond dat het 
p210 fusie-eiwit ook transformerende eigenschappen heeft. 
62 
REFERENCES 
Abe S, Sandberg A (1979) Chromosomes and causation of human cancer and 
leukemia XXXII. Cancer 43, 2352-2364. 
Adams JM, Gerondakis S,Webb E, Corcoran IM, Cory S (1983) Cellular .!!!Y£ 
oncogene is altered by chromosome translocation to an immunogloblin 
locus in murine plasmactomas and is rearranged similarly in human 
Burkitt lymphomas. Proc. Natl.Acad.Sci.USA 80, 1982-1986. 
Adams JM, Harris AW, Pinkert CA, Corcoran IM, Alexander WS, Cory S, 
Palmiter RD, Brinster RL (1985) The c-myc oncogene driven by immuno-
globulin enhancers induces lymphoid malignancy in transgenic mice. 
Nature 318, 533-538. 
Alimena G, Billstrom R, Casalone R, Gallo E, Mittelman F, Pasquali F 
(1985) Cytogenetic pattern in leukemic cells of patients with con-
stitutional chromosome anomalies. Cancer genet.Cytogenet. 16, 207-
218. 
Alitalo K, Schwab M, Linn CC, Varmus HE, Bishop JM (1983a) Homogeneously 
staining chromosomal regions contain amplified copies of an 
abundantly expressed cellular oncogene (c-rnyc) in malignant neuro-
endocrine cells from a human colon carcinoma. Proc.Natl.Acad.Sci USA 
80, 1707-1711. 
Alitalo K, Ramsay G, Bishop JM, Pfeifer S, Colby WW, Levinson AD (1983b) 
Identification of nuclear proteins encoded by viral and cellular .!!!Y£ 
oncogenes. Nature 306, 274-277. 
Alitalo K (1984) Amplification of cellular oncogenes in cancer cells. 
Med.Biol. 62, 304-317. 
Alitalo K, Schwab M (1986) Oncogene arrq;>lification in tumor cells. Adv. in 
Cancer Res. 47 (in press). 
Arthur D, Bloomfield C (1983) Partial deletion of the long arm of chromo-
some 16 and bone marrow eosino:E;tlilia in acute nonlymphocytic leuke-
mia: A new association. Blood 61, 994-998. 
Aurias A, Dutrillaux B, Buriot D, Lejeune J (1980) High frequencies of 
inversions and translocations of chromosomes 7 and 14 in Ataxia 
Telangiectasia. Mut.Res. 69, 369-374. 
Aurias A, Rimbaut C, Buffe D, Dubousset J, Mazabraud A (1983) Chromosomal 
translocations in Ewing's sarcoma. N.Eng.J.Med. 309, 496-497. 
Aurias A, Croquette MF, Nuyts JP, Griscelli C, Dutrillaux B (1986) New 
data on clonal anomalies of chromosome 14 in ataxia telangiectasia: 
tct (14;14) and inv(l4). Hum.Genet. 72, 22-24. 
Baer R, Chen K-c, Smith SD, Rabbitts TH (1985) Fusion of an immunoglo-
bulin variable gene and a T cell receptor constant gene in the 
chromosome 14 inversion associated with T cell tumors. Cell 43, 705-
713. 
Banerjee M, Wiener F, Spira J, Babonits M, Nilsson M-G, Sumegi J, Klein, 
G (1985) Mapping of the s:=!!!Y£, pvt-1 and immunoglobulin kappa genes 
in relation to the mouse plasmacytoma-associated variant (6;15) 
translocation breakpoint. EMBO J 4, 3183-3188. 
Bakhshi A, Jensen JP, Goldman P, Wright JJ, Me Bride OW, Epstein AL, 
Korsmeyer SJ (1985) Cloning the chromosomal breakpoint of t(l4;18) 
human lymphomas: clustering around JH on chromosome 14 and near a 
transcriptional unit on 18. Cell 41, 899-908. 
Bank I, De Pinho RA, Brenner MB, Cassimeris J, Alt FW, Chess L (1986) A 
functional T3 molecule associated with a novel heterodimer on the 
surface of immature human thymocytes. Nature 322, 179-181. 
63 
Bargmarm CI, Hung M-e, Weinberg RA (1986a) The neu oncogene encodes an 
epidermal growth factor receptor-related protein. Nature 319, 226-
230. 
Bargmann CI, Hung M-e, Weinberg RA (1986b) Multiple independent activa-
tions of the neu oncogene by a point mutation altering the transmem-
brane domain of pl85. Cell 45, 649-657. 
Barker PE (1982) Double minutes in human tumor cells. Cancer genet.Cyto-
genet. 5, 81-94. 
Bartram CR, de Klein A, Hagemeijer A, van Agthoven T, Geurts van Kessel 
A, Bootsma D, Grosveld G, Ferguson-Smith MA, Davies T, Stone M, 
Heisterkamp N, Stet:nenson JR, Groffen J (1983) Translocation of c-
abl oncogene correlates with the presence of a Philadelphia chromo-
some in chronic myelocytic leukaemia. Nature 306, 277-280. 
Bartram CR, de Klein A, Hagemeijer A, Grosveld G, Heisterkamp N, Groffen 
J (1981) Localization of the human c-sis oncogene in Ph1-positive 
and Ph -negative chronic myelocytic leukemia by in situ hybridiza-
tion. Blood 63, 223-225. 
Bartram CR (1985) bcr rearrangement without juxtaposition of c-abl in 
chronic myelocytic leukemia. J .Exp.Med. 162, 2175-2179. --
Bartram CR, Anger B, Carbonell F, Kleihauer E (1985a) Involvement of 
chromosome 9 in variant Ph translocation. Leuk.Res. 9, 1133-1137. 
Bartram CR, Kleihauer E, De Klein A, Grosveld GC, Teyssier JR, Heister-
k~ N, Groffen J (1985b) c-abl and bcr are rearranged in a 
Ph -negative CML patient. EMBO J. 4, 683-686. 
Bartram CR, Carbonell F (1986) bcr rearrangement in Ph-negative CML. 
Cancer genet.Cytogenet. in press. 
Battey J, Moulding C, Taub R, Murphy W, Stewart T, Potter H, Lenoir G, 
Leder P (1983) The human c-myc oncogene: structural consequences of 
translocation into the IgH locus in Burkitt lymphoma. Cell 34, 779-
787. 
Beard M, Durrant J, Catovsky D, Wiltshaw E, Amess J, Brearley R, Krik B, 
Wrigley P, Janossy G, Greaves M, Galton DAG (1976) Blast crisis of 
chronic myeloid leukaemia (CML) I. Presentation simulating acute 
lymphoid leukaemia (ALL). Br.J.Haematol. 34, 167-178. 
Bechet JM, Bornkamm G, Freese U-K, Lenoir GM (1984) The c-sis oncogene is 
not activated in Ewing's sarcoma. N.Eng.J.Med. 310, 393. 
Benedict WF, Murphree AL, Banerjee A, Spina CA, Sparkes M:, Sparkes RS 
(1983) Patient with 13 chromosome deletion: Evidence that the 
retinoblastoma gene is a recessive cancer gene. Science 219, 973-
975. 
Ben-Neriah Y, Bernards A, Paskin M, Daley GQ, Baltimore D (1986a) Alter-
native 5' exons in c-abl mRNA. Cell 44, 577-586. 
Ben-Neriah Y, Daley GQ, Mes-Masson A-M, Witte 00, Baltimore D (1986b) The 
chronic myelogenous leukemia-specific p210 protein is the product of 
the bcr/abl hybrid gene. Science 233, 212-214. 
Bennett JM, Catovsky D, Daniel MI', Flandrin G, Galton DAG, Gralnick HR, 
Sultan G. (1976) Proposals for the classification of acute leukae-
mias. Br.J.Haematol. 33, 451-458. 
Bentley DL, Groudine M (1986) A block to elongation is largely respons-
ible for decreased transcription of c-myc in differentiated HL60 
cells. Nature 321, 702-706. 
Berger R, Bernheim A, Sigaux F, Daniel M-T, Valensi F, Flandrin G (1982) 
Acute monocytic leukemia chromosome studies. Leuk.Res. 6, 17-26. 
64 
Berger R, Flandrin G (1984) Determining the nature of cells studied 
cytogenetically. Cancer Surveys 3, 423-438. 
Berger R, Bloomfield CD and Suther land GR (1985) Human Gene Mapping 8. 
Report of the committee on chromosome rearrangements in neOplasia 
and on fragil sites. Cytogenet.Cell Genet. 40, 490-535. 
Berger R, Bernheim A, Le Coniat M, Vecchione D, Pacot A, Daniel M-T, 
Flandrin G (1986) Abnormalities of the short arm of chromosome 12 in 
acute nonlyrnphocytic leukemia and Dysrnyelopoietic syndrome. Cancer 
genet.Cytogenet. 19, 281-189. 
Bernheim A, Berger R, Lenoir G (1981) Cytogenetic studies on African 
Burkitt's lymphoma cell lines t(8;14), t(2;8) and t(8;22) transloca-
tions. Cancer genet.Cytogenet. 3, 307-315. 
Besrner P, Murphy JE, George PC, Qiu F, Bergold PJ, Lederman L, Snyder HW, 
Brodeur D, Zuckerman EE, Hardy WD (1986). A new acute transfoming 
feline retrovirus and relationship of its oncogene v-kit with the 
protein kinase gene family. Nature 320, 415-421. --
Beug H, Leutz A, Kahn P, Graf T (1984) Ts mutants of E26 leukemia virus 
allow transformed rnyeloblasts but not erythroblasts or fibroblasts, 
to differentiate at the nonperrnissive temperature. Cell 39, 579-
588. 
Eigner SH, Mark J, Mahaley MS and Eigner DD (1984) Patterns of the early, 
gross chromosomal changes in malignant human gliomas. Hereditas 101: 
103-113. 
Birnie G, Burns J, Wiedemann J, Warnock A, Tindle R, Burnett A, Tansey P, 
Lucie N, Robertson M (1983) A new approach to the classification of 
human leukaemias: measurement of the relative abundance of a speci-
fic RNA sequence by means of molecular hybridization. Lancet i, 197-
200. 
Bishop JM (1983) Cellular oncogenes and retroviruses. Ann.Rev.Biochem. 
52, 301-354. 
Bishop JM, Varmus HE (1984) Functions and origins of retroviral transfor-
ming genes. In: molecular biology of tumor viruses. RNA Tumor Vi-
ruses ed. R. Weiss, N. Teich, H. Varrnus, J. Coffin rev .ed. Cold 
Spring Harbor Press, New York. 
Bishop JM (1985) Viral oncogenes. Cell 42, 23-38. 
Blanchard J-M, Piechaczyk M, Dani C, Charnbard J-c, Franchi A, Pouyssegur 
J, Jeanteur P (1985) c-.!!!YE_ gene is transcribed at high rate in Go-
arrested fibroblasts and is posttranscriptionally regulated in 
response to growth factors. Nature 317, 443-445. 
Blick M, Westin E, Gutterman J, Wong-Staal F, Gallo R, McCredie K, Kea-
ting M, Muqily E (1984) Oncogene expression in human leukemia. 
Blood 64, 1234-1239. 
Blick M, Westin E, Wong-Staal F, Gallo R, Me Credie K, Gutterman J (1986) 
Rearrangement and enhanced expression of c-~ oncogene fresh tumor 
cells obtained from a patient with acute lymphoblastic leukemia. 
Leuk.Res. 10, 381-387. 
Bloomfield C, Peterson L, Yunis J, Brunning R (1977) The Philadelphia 
chromosome (Ph1l in ad~ts presenting with acute leukemia: A 
comparison of Ph+ and Ph -patients. Br.J.Haernatol. 36, 347-358. 
Bloomfield C, Lindquist L, Brunning R, Yunis J, Coccia P (1978) The 
Philadelphia chromosome in acute leukemia. Virchows Arch.B Cell 
Path. 29, 81-91. 
65 
Bonner T, O'Brien SJ, Nash W3, Rapp UR, Morton CC, Leder P (1984) The 
htnnan homologs of the raf (mil) oncogene are located on htnnan chro-
mosomes 3 and 4. Science 223, 71-74. 
Boveri (1914) Zur frage der Entstehung Maligner Tumoren. Fisher, Jena. 
Breathnach R, Charnbon P (1981) Organization and expression of eukaryotic 
split genes coding for proteins. Ann.Rev.Biochem. 50, 349-383. 
Brenner MB, McLean J, Dialynas DP, Strominger JL, Smith JA, Owen FL, 
Seidman JG, Ip S, Rosen F, Krangel MS (1986) Identification of a 
putative second T-cell receptor. Nature 322, 145-149. 
Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA 
(1981) Cytogenetic features of human neuroblastomas and cell lines. 
Cancer Res. 41, 4678-4686. 
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplifica-
tion of N~ in untreated htnnan neuroblastomas correlates with 
advanced disease stage. Science 224, 1121-1124. 
Callabretta B, Venturelli D, Kaczmarek L, Narni F, Talpaz M, Anderson B, 
Beran M, Baserga R (1986) Altered expression of Gl-specific genes in 
human malignant myeloid cells. Proc.Natl.Acad.Sci. USA 83, 1495-
1498. 
Canaani E, Gale RP, Steiner-Saltz D, Berrebi A, Aghai E, Januszewicz E 
(1984) Altered transcription of an oncogene in chronic myeloid 
leukemia. Lancet i, 593-595. 
Cannizzaro LA, Emanuel BS (1985) In situ hybridization and translocation 
breakpoint mapping. Cytogenet.Cell Genet. 39, 179-183. 
Cannizzaro LA, Nowell PC, Belasco JB, Croce CM, Emanuel BS (1985) The 
breakpoint in 22qll in case of Ph-positive acute lymphocytic 
leukemia interrupts the immunoglobulin light chain gene cluster. 
Cancer Genet.Cytogenet. 18, 173-177. 
Care A, Cianetti L, Giampaolo A, Sposi NM, Zappavigna V, Mavilio F, 
Alimena G, Amadori S, Mandelli F, Peschle C (1986) Translocation of 
c-myc into the immunoglobulin heavy-chain locus in human acute B 
cell leukemia. A molecular analysis. EMBO J. 5, 905-911. 
Carle GF, Olson MV (1984) Separation of chromosomal DNA molecules from 
yeast by orthogonal-field-alternative electrophoresis. Nucl.Acids 
Res. 12, 5647-5664. 
Carroll AJ, Castleberry RP, Prchal JT, Finley WH (1985) Translocation 
(6;9) (p23;q34) in acute non-lymphocytic leukemia: Three new cases. 
Cancer Genet.Cyt£9enet. 18, 303-306. 
Catovsky D (1979) Ph positive acute leukaemia and chronic granulocytic 
leukaemia: one or two diseases. Br.J.Haematol. 42, 493-498. 
Caubet J, Matthieu-Mahul D, Bernheim A, Larsen CJ, Berger R (1985) Htnnan 
proto oncogen c-mos maps to 8qll. EMBO J. 4, 2245-2248. 
Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, 
Muq::hree AL, Strong LC, White RL (1983) Expression of recessive 
alleles by chromosomal mechanisms in retinoblastoma. Nature 305, 
779-784. 
Cavenee WK, Hansen MF, Nordenskjold M, Kock E, Maumenee I, Squire JA, 
Phillips RA, Gallie BL (1985) Genetic origin of mutations predis-
posing to retinoblastoma. Science 228, 501-503. 
Champlin RE, Golde DW (1985) Chronic myelogenous Leukemia: recent advan-
ces. Blood 65, 1039-1047. 
Chen T (1985) Modal karyotype of human leukemia cell line, K562 (ATCC 
CLL243). Cancer Genet.Cytogenet. 17, 55-60. 
66 
Chessels JM, Janossy G, Lawler SD, Seeker Walker IM (1979) The Ph1 chro-
mosome in childhood leukaemia. Br .J .Haematol. 41, 25-41. 
Clare N, Boldt D, Messerschmidt G, Zeltzer P, Hansen K, Manhoff L (1986) 
Lymphocyte malignancy and chromosome 14: structural aberrations 
involving band qll. Blood 67, 704-709. 
Cleary ML, Sklar J (1985a) DNA rearrangements in non-Hodgkin's lymphomas. 
Cancer Surveys 4, 331-348. 
Cleary ML, Sklar J (1985b) Nucleotide sequence of a t(l4;18) chromosomal 
breakpoint in follicular lymphoma and demonstration of a breakpoint 
cluster region near a transcriptionally active locus on chromosome 
18. Proc.Natl.Acad.Sci. USA 82, 7439-7443. 
Cohen AJ, Li FP, Berg S, Marchetto OJ, Tsai S, Jacobs SC, Brown RS (1979) 
Hereditary renal-cell carcinoma associated with a chromosomal 
translocation. N.Eng.J.Med. 301, 592-595. 
Cohen JB, Unger T, Rechavi G, Canaani E, Givol D (1983) Rearrangement of 
the oncogene c-mos in mouse myeloma NSI and hybridomas. Nature 306, 
797-799. --
Cole MD (1985) Regulation and activation of c-~. Nature 318, 510-511. 
Collins SJ, Groudine MI' (1983) Rearrangement and amplification of c-abl 
sequences in the human chronic myelogenous leukemia cell line K562. 
Proc.Natl.Acad.Sci.USA 80, 4813-4817. 
Collins SJ, Kubonishi I, Miyoshi I, Groudine MI' (1984) Altered transcrip-
tion of the c-abl oncogene in K562 and other chronic myelogenous 
leukemia cells. Science 225, 72-74. 
Collins MKL, Goodfellow PN, Spurr NK, Solomon E, Tanigawa G, Tonegawa S, 
Owen MJ (1985) The human T-cell receptor Cl-chain gene maps to 
chromosome 14. Nature 314, 273-274. 
Comings DE (1973) A general theory of carcinogenesis. Proc.Natl.Acad. 
Sci.USA 70, 3324-3328. 
Cook WD, Metcalf D, Nicola NA, Burgess NfJ, Walker F (1985) Malignant 
transformation of a growth factor-dependent myeloid cell line by 
Abelson virus without evidence of an autocrine mechanism. Cell 41, 
667-683. 
Cooper CS, Park M, Blair DG, Tainsky MA., Huebner K, Croce CM, van de 
Woude GF (1984) Molecular cloning of a new transforming gene from a 
chemically transformed human cell line. Nature 311, 29-33. 
Cooper GM, Okenquist S, Silverman L (1980) Transforming activity of DNA 
of chemically transformed and normal cells. Nature 284, 418-421. 
Cooper GM (1982) Cellular transforming genes. Scieoce 217, 801-806. 
Cooper GM, Lane MA. (1984) Cellular transforming genes and oncogenesis. 
Biochem.Biophys.Acta 738, 9-20. 
Coppola JA, Cole MD (1986) Constitutive c-~ oocogene expression blocks 
mouse erythroleukaemia cell differentiation but not commitment. 
Nature 320, 760-763. 
Corcoran IM, Adams JM, Dunn AR, Cory S (1984) Murine T lymphomas in which 
the cellular ~ oncogene has been activated by retroviral inser-
tion. Cell 37, 112-113. 
Corcoran IM, Cory S, Adams JM (1985) Transposition of the imnnoglobulin 
heavy chain enhancer to the ~ oncogene in a murine plasmacytoma. 
Cell 40, 71-79. 
Cory S, Graham M, Webb E, Corcoran L and Adams JM (1985) Variant (6;15) 
translocations in murine plasmacytomas involve a chromosome 15 locus 
at least 72 kb from the c-~ oncogene. EMBO J. 4, 675-681. 
67 
Cory S (1986) Activation of cellular oncogenes in hemopoietic cells by 
chromosome translocation. Adv.in Cancer Res. 37 in press. 
Cough N (1985) Chromosomal translocations and the c~ gene: paradigm 
lost? Trends Genet. 1, 63-64. 
Coussens L, Yang-Feng TL, Liao Y-c, Chen E, Gray A, McGraft J, Seeburg 
PH, Libermann TA, Schlessinger J, Francke U, Levinson A, Ullrich A 
(1985) Tyrosine kinase receptor with extensive homology to EGF 
receptor shares chromosomal localization with neu oncogene. Science 
230, 1132-1139. 
Crist W, Cleary M, Grossi C, Prasthofer E, Heggie G, Q:nura G, Carrol A, 
Link M, Sklar J (1985) Acute leukemias associated with the 4;11 
chromosome translocation have rearranged immunoglobulin heavy chain 
genes. Blood 66, 33-38. 
Croce CM, Shander M, Martinis J, Cicurel L, D'Ancona GG, Dolby 'IW, 
Koprowski H (1979) Chromosomal location of the genes for human 
immunoglobulin heavy chains. Proc.Natl.Acad.Sci.USA 76, 3416-3419. 
Croce CM, Thierfelder W, Erikson J, Nishikura K, Finan J, Lenoir GM and 
Nowell PC (1983) Transcriptional activation of an unrearranged and 
untranslocated c-IQY£ oncogene by translocation of a C Jc locus in 
Burkitt lymphoma cells. Proc.Natl.Acad.Sci USA 80, 6922-6926. 
Croce CM, Erikson J, ar-Rushdi A, Aden D, Nishikura (1984) Translocated 
c-rnyc oncogene of Burkitt lymphoma is transcribed in plasma cells 
and repressed in lymphoblastoid cells. Proc.Natl.Acad.Sci.USA 81, 
3170-3174. 
Croce CM, Nowell PC (1985) Molecular basis of human B cell neoplasia. 
Blood 65, 1-7. 
Croce CM, Isobe M, Palumbo A, Puck J, Ming J, Tweardy D, Erikson J, Davis 
M, Rovera G (1985a) Gene for a.-chain of human T-cell receptor: 
location on chromosome 14 region involved in T cell neoplasms. 
Science 227, 1044-1047. 
Croce CM, Erikson J, Huebner K, Nishikura K (1985b) Coexpression of 
translocated and normal c-IQY£ oncogenes in hybrids between Daudi and 
lymphoblastoid cells. Science 227, 1235-1238. 
Cuypers HI', Selten G, Quint W, Zijlstra M, Robanus Maandag ER, Boelens W, 
Van Wezenbeek P, Melief C, Berns A (1984) Murine leukemia virus-
induced T-cell lymphomagenesis: integration of proviruses in a dis-
tinct chromosomal region. Cell 37, 141-150. 
Cuypers HI', Selten G, Berns A, Geurts van Kessel AHM (1986) Assignment of 
the human homologue of pim-1 a mouse gene implicated in leukemogene-
sis to the pter-ql2 region of chromosome 6. Hum.Genet. 72, 262-265. 
Dani C, Blanchard JM, Peichaczyk M, El Sabouty S, Marty L, Jeanteur PH 
(1984) Extreme instability of !!!Y£ mRNA in normal and transformed 
human cells. Proc.Natl.Acad.Sci.USA 81, 7046-7050. 
Dalla-Favera R, Franchini G, Martinotti S, Wong-Staal F, Gallo RC, Croce 
CM (1982a) Chromosomal assignment of the human homologues of feline 
sarcoma virus and avaian myeloblastosis virus one genes. Proc.Natl 
Acad.Sci lEA 79: 4714-4717. -
Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM 
(1982) Human c-rnyc one gene is located on the region of chromosome 8 
that is translocated in Burkitt lymphoma cells. Proc.Natl.Acad.Sci. 
USA 79, 7824-7827. 
Dalla-Favera R, Gallo RC, Giallongo A, Croce CM (1982c) Chromosomal loca-
lization of the human homolog (c-sis) of the simian sarcoma virus 
one gene. Science 218, 686-688 • -
68 
Dalla-Favera R, Martinotti S, Gallo RC, Erikson J, Croce CM (1983) Trans-
location and rearrangements of the ~ oncogene locus in human 
undifferentiated B-cell lymphomas. Science 219, 963-967. 
Davis RL, Konopka JB, Witte CN (1985) Activation of the c-abl oncogene by 
viral transduction or chromosomal translocation generates altered c-
abl proteins with similar in vitro kinase properties. Mol.Cell.Biol. 
5, 204-213. 
Dayton AI, Selden JR, Laws G, Dorney 00, Finan J, Tripputi P, Emanuel BS, 
Rovera G, Nowell PC, Croce CM (1984) A human c-erb A oncogene homo-
logue is closely proximal to the chromosome 17 breakpoint in acute 
promyelocytic leukemia. Proc.Natl.Acad.Sci.USA 81, 4495-4499. 
Dean M, Park M, LeBeau MM, Robins TS, Diaz M:>, Rowley JD, Blair DG, Van 
de Woude GF (1985) The human met oncogene is related to the tyrosine 
kinase oncogenes. Nature 318,~5-388. 
De Braekeleer M, Lin CC (1986) The occurrence of the 15~17 translocation 
in acute promyelocytic leukemia. Cancer Genet.Cytogenet. 19, 311-
319. 
De Klein A, Geurts van Kessel A, Grosveld G, Bartram CR, Hagemeijer A, 
Bootsma D, Spurr NK, Heisterkarnp N, Groffen J, Stephenson JR (1982) 
A cellular oncogene is translocated to the Philadelphia chromosome 
in chronic myelocytic leukaemia. Nature 300, 765-767. 
De Klei£ A, Hagemeijer A (1984) Cytogenetic and molecular analysis of the 
Ph translocation in chronic myeloid leukemia. Cancer Surveys 3, 
515-529. 
De Klein A, van Agthoven T, Groffen C, Heisterkarnp N, Groffen J, Gros-
veld G (l986a). Molecular analysis of both translocation products of 
a Philadelphia positive CML patient. Nucl.Acid Res. 14, 7071-7081. 
De Klein A, Hagemeijer A, Bartram CR, Houwen R, Hoefsloot L, Carbonell F, 
Chan L, Barnett M, Greaves M, Kleihauer E, Heisterkarnp N, Groffen J, 
Grosveld G (1986b) bcr rearrangement and translocations of the c-abl 
oncogene in Philadelphia positive acute lymphoblastic leukemia. 
Blood, in press. 
De la Chapelle A, Lenoir G, Boue J, Boue A, Galano P, Huerre C, Szajnert 
M-F, Jeanpierre M, Lalouel J-M, Kaplan J-c (1983) Lambda Ig constant 
region genes are translocated to chromosome 8 in Burkitt's lymphoma 
with t(8~22). Nucl.Acids Res. 11, 1133-1142 
Denny cr, Hollis GF, Magrath IT and Kirch IR (1985) Burkitt lymphoma cell 
line carrying a variant translocation creates new DNA at the break-
point and violates the hierachy of immunoglobulin gene rearrange-
ment. Mol.Cell.Biol. 5, 3199-3207. 
Denny cr, Yoshikai Y, Mak 'IW, Smith SD, Hollis GF, Kirsch IR (1986) A 
chromosome 14 inversion in a T-cell lymphoma is caused by site-
specific recombination between immunoglobulin and T-cell receptor 
loci. Nature 320, 549-551. 
Der GJ, Krontiris TG, Cooper GM (1982) Transforming genes of human 
bladder and lung carcinoma cell lines are homologous to the ras 
genes of Harvey and Kirsten sarcoma viruses. Proc.Natl.Acad.Sci. 
USA 79, 3637-3640. 
De Taisne C, Gegonne A, Stehelin D, Bernheim A, Berger R (1984) Chromo-
somal localization of the human proto-oncogene c-ets. Nature 310, 
581-583. 
Diamond A, Cooper GM, Ritz J, Lane M-A (1983) Identification and mole-
cular cloning of the human Blym transforming gene activated in 
Burkitt's lymphomas. Nature 305, 112-116. 
69 
Diaz MO, LeBeau MM, Pitha P, Rowley JD (1986) Interferon and c-ets-1 
genes in the translocation (9:ll)(p22:q23) in human acute monocytic 
leukemia. Science 231, 265-267. 
Dmitrovsky E, Kuehl WM, Hollis GF, Kirsch IR, Bender TP, Segal S (1986) 
Expression of a transfected human ~ oncogene inhibits differen-
tiation of a mouse erythroleukaemia cell line. Nature 322, 748-750. 
Dony C, Kessel M, Gruss P (1985) Post-transcriptional control of ~ and 
p53 expression during differentiation of the embryonal carcinoma 
cell line F9. Nature 317, 636-639. 
Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, 
Schlessinger J, Waterfield MD (1984) Close similarity of epidermal 
growth factor receptor and v-erb ~ oncogene protein sequences. 
Nature 307, 521-527. 
Drabkin HA, Bradley C, Hart I, Bleskan J, Li FP, Patterson D (1985a) 
Translocation of ~ in the hereditary renal cell carcinoma asso-
ciated with a t(3:8) (pl4.2:q24.13) chromosomal translocation. Proc. 
Natl.Acad.Sci.USA 82, 6980-6984. 
Drabkin HA, Diaz M, Bradley CM, LeBeau MM, Rowley JD, Patterson D (1985b) 
Isolation and analysis of the 2lq+ chromosome in the acute myeloge-
nous leukemia 8:21 translocation: Evidence that c-mos is not trans-
located. Proc.Natl.Acad.Sci.USA 82, 464-468. --
Dryja TP, Cavenee WK, White R, Rapaport JM, Petersen R, Albert IM, Bruns 
GAP (1984) Homozygosity of chromosome 13 in retinoblastoma. 
N.Eng.J.Med. 310, 550-553. 
Dube ID, Gupta CM, Kalousek DK, Eaves CJ, Eaves AC (1984a) Cyt£9enetic 
studies of early myeloid progenitor compartments in Ph -positive 
chronic myeloid leukemia (CML). Br.J.Haematol. 56, 633-644. 
Dube ID, Kalousek DK, Coulombel L, Gupta CM, Eaves CJ, Eaves AC (1984bl 
Cytogenetic studies of early myeloid progenitor compartment in Ph 
positive chronic ~eloid leukemia. II. Long-term culture reveals the 
persistence of Ph -negative progenitors in treated as well as newly 
diagnosed patients. Blood 63, 1172-1177. Dube ID, Raimondi SC, Pi D, Kalousek DK (1986) A new translocation, 
t(l0:14)(q24:qll) in T cell neoplasia. Blood 67, 1181-1184. 
Duprey SP, Boettiger D (1985) Developnental regulation of c-rnyb in normal 
myeloid progenitor cells. Proc.Natl.Acad.Sci.USA 82, 6937-6941. 
Eaves AC, Cashman JD, Gaboury LA, Kalousek DK, Eaves CJ (1986) Unregu-
lated proliferation of primitive chronic myeloid leukemia progeni-
tors in the presence of normal marrow adherent cells. Proc. 
Natl.Acad.Sci.USA 83, 5306-5310. 
Eick D, Piechaczyk M, Henglein B, Blanchard J~, Traub B, Kofler E, Wiest 
S, Lenoir GM, Bornkamm GW (1985) Aberrant c~ RNAs of Burkitt's 
lymphoma cells have longer half-lives. EMBO J. 4, 3717-3725. 
Eisenman RN, Tachibana CY, Abrams HD, Hann SR (1985) V~ and c~ 
encoded proteins are associated with the nuclear matrix. Mol.Cell. 
Biol. 5, 114-126. 
Emanuel BS, Nowell PC, McKeon C, Croce CM, Israel MA (1986) Translocation 
breakpoint mapping: molecular and cytogenetic studies of chromosome 
22. Cancer Genet.Cytogenet. 19, 81-92. 
Erikson J, Martinis J, Croce CM (1981) Assignment of the genes for human 
Aimmunogloblin chains to chromosome 22. Nature 294, 173-175. 
Erikson J, Finan J, Nowell PC, Croce CM (1982) Translocation of immuno-
globulin VH genes in Burkitt lymphoma. Proc.Natl.Acad.Sci USA 79, 
5611-5615. 
70 
Erikson J, Ar-Rushdi A, Drwinga HL, Nowell PC, Groce CM (1983a) Tran-
scriptional activation of the translocated c~ oncogene in Burkitt 
lymphoma. Proc.Natl.Acad.Sci.USA 80, 820-824. 
Erikson J, Nishikura K, Ar-Rushdi A, Finan J, Emanuel BS, Lenoir G, 
Nowell PG, Croce CM (1983b) Translocation of an imnunoglobulkin k 
locus to a region 3' of an unrearranged c~ oncogene enhances c-
!!!Y£ transcription. Proc.Natl.Acad.Sci.USA 80, 7581-7585. 
Erikson J, Finan J, Tsujimoto Y, Nowell PC, Croce CM (1984) The chromo-
some 14 breakpoint in neoplastic B cells with the t(ll;l4) translo-
cation involves the irmnunoglobulin heavy chain locus. Proc.Natl. 
Acad.Sci. USA 81, 4144-4148. 
Erikson J, Miller DA, Miller ill, Abcarian PW, Skurla RM, Mushinski JF, 
Croce CM (1985a) The c~ oncogene is translocated to the involved 
chromosome 12 in mouse plasmacytomas. Proc.Natl.Acad.Sci.USA 82, 
4212-4216. 
Erikson J, Williams DL, Finan J, Nowell PC, Croce CM (1985b) Locus of the 
a. chain of the T-cell receptor is split by chromosome translocation 
in T cell leukemias. Science 229, 784-786. 
Erikson J, Griffin CA, Ar-Rushdi A, Valtieri M, Hoxie J, Finan J, Emanuel 
BS, Rovera G, Nowell PC, Groce CM (1986a) Heterogeneity of chromo-
some 22 breakpoints in Philadelphia positive (Ph+) acute lymphocytic 
leukemia. Proc.Natl.Acad.Sci.USA 83, 1807-1811. 
Erikson J, Finger L, Sun L, Ar-Rushdi A, Nishikura K, Minowada J, Finan 
J, Emanuel BS, Nowell PC, Croce CM (1986b) Deregulation of c-!!!Y£ by 
translocation of the a.-locus of the T-cell receptor in T-cell leuke-
mias. Science 232, 884-886. 
Escot C, Theillet C, Lidereau R, Spyratos F, Champeme M-H, Gest J, Calla-
han R (1986) Genetic alteration of the c~ proto-oncogene in human 
primary breast carcinomas. Proc.Natl.Acad.Sci.USA 83, 4834-4838. 
Eva A, Robbins KC, Andersen PR, Srinivasan A, Tronick SR, Reddy EP, 
Ellmore NW, Galen AT, Lautenberg JA, Papas TS, Westin EH, Wong-Staal 
F, Gallo OC, Aaronson SA (1982) Cellular genes analogous to retro-
viral one genes are transcribed in human tumour cells. Nature 295, 
116-119. 
Eva A, Tronick SR, Gol RA, Pierce JH, Aaronson SA (1983) Transforming 
genes of human hematopoietic tumors: Frequent detection of ras-
related oncogenes whose activation appears to be independent of tumor 
phenotype. Proc.Natl.Acad.Sci.USA 80, 4926-4930. 
Eva A, Pierce J, Aaronson SA (1985) Interactions of oncogenes with herna-
poietic cells. In Leukemia: Recent Advances in Biology and Treatment 
p.3-15 Alan R Liss Inc. 
Evans D, Steward J (1972) Down's syndrome and leukaemia. Lancet ii-1322. 
Fahrlander PD, Sfunegi J, Yang J-Q, Wiener F, Marcu KB, Klein G (1985) 
Activation of the c-myc oncogene by the imnunoglobulin heavy-chain 
gene enhancer after multiple switch region-mediated chromosome 
rearrangements in a murine plasmacytoma. Proc.Natl.Acad.Sci.USA 82, 
3746-3750. 
Fearon ER, Vogelstein B, Feinberg AP (1984) Somatic deletions and dupli-
cation of genes on chromosome 11 in Wilm' s tumours. Nature 309, 
176-178. 
Fearon ER, Feinberg AP. Hamilton SH, Vogelstein B (1985) Loss of genes on 
the short arm of chromosome 11 in bladder cancer. Nature 318, 377-
380. 
71 
Fell HP, Smith RG, Tucker PW (1986) Molecular analysis of the t(2;14) 
translocation of childhood chronic lymphocytic leukemia. Science 
232, 491-494. 
Feo s, Ar-Rushdi A, Huebner K, Finan J, Nowell PC, Clarkson B, Croce CM 
(1985) Suppression of the normal mouse ~ oncogene in human 
lymphoma cells. Nature 313, 493-495. 
Feo S, Harvey R, Showe L, Croce CM (1986) Regulation of translocated c-
!!!Y£ genes transfected into plasmacytoma cells. Proc.Natl.Acad.Sci~ 
USA 83, 706-709. 
Fialkow PJ, Jacobson RJ, Papayannopoulou T (1977) Chronic myelocytic 
leukemia: Clonal origin in a stem cell canmon to the granulocyte, 
erythrocyte, platelet and monocyte/macrofhage. Am.J .Med. 63, 125-
130. 
Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA 
(1981) Evidence for a multistep pathogenesis of chronic myelogenous 
leukemia. Blood 58, 158-163. 
Frassoni F, Repetto M, Podesta M, Piaggio G, Raffo MR, Sassarego M, 
Bacigalupo A, ~rmont AM (1986) Competitive survival/proliferation 
of normal and Ph -positive haemopoietic cells. Br .J .Haematol. 63, 
135-141. 
Fung YKT, Lewis ~, Crittenden LB, Kung ID (1983) Activation of the 
cellular oncogene c-erbB by LTR insertion: molecular basis for 
induction of erythroblastosis by avain leukosis virus. Cell 33, 
357-368. 
Gale RP, Canaani E (1984) An 8-kilobase abl RNA transcript in chronic 
myelogenous leukemia. Proc.Natl.Acad.Sci.USA 81, 5648-5652 
Gale RP, Cannani E (1985) The molecular biology of chronic myelogenous 
leukemia. Br.J.Haematol. 60, 395-408. 
Gattoni-celli s, Hsiao w-L, Weinstein IB (1983) Rearranged c-mos locus in 
a MOPC-21 murine myeloma cell line and its persistence in hybrido-
mas. Nature 306, 795-797. 
Gazdar AF, Carney DN, Nau MM, Minna JD (1985) Characterization of variant 
subclasses of cell lines derived from small cell lung cancer having 
distinctive biochemical, morfhological, and growth properties. Can-
cer Res. 45, 2924-2930. 
Geurts van Kessel AHM, van Agthoven AJ, Hagemeijer A (1982) Clonal origin 
of the Philadelfhia translocation in chronic myeloid leukemia de-
monstrated in somatic cell hybrids using an adenylate kinase-1 
polymorfhism Cancer Genet.Cytogenet. 6, 55-58. 
Geurts van Kessel A, Tetteroo P, van Agthoven T, Paulussen R, van Dongen 
J, Hagemeijer A, von dem Borne A (1984) Localization of human mye-
loid-associated surface antigen detected by a panel of 20 monoclo-
nal antibodies to the ql2-qter region of chromosome-H. J. Immunol. 
133, 1265-1269. 
Geurts van Kessel A, Turc-carel C, De Klein A, Grosveld G, Lenoir G, 
Bootsma D. (1985) Translocation of oncogene c-sis from chromosome 
22 to chromosome 11 in a Ewing sarcoma-derived cell line. Mol.Cell 
Biol. 5, 427-429. 
Gibas Z, Prout GR, Pontes JE, Sandberg M (1986) Chromosome changes in 
germ cell tumors of the testis. Cancer Genet.Cytogenet. 19, 245-
252. 
Gilbert F (1983) Retinoblastoma and recessive alleles in tumorigenesis. 
Nature 305, 761-762. 
72 
Goddard JM, Weiland JJ, Capecchi MR (1986)... Isolation and characterization 
of caenorhabditis elegans D~ sequences homologous to the v-abl 
gene. Proc.Natl.Acad.Sci.USA 83, 2172-2176. --
Goff SP, Gilboa E, Witte CN, Baltimore D (1980) Structure of the Abelson 
murine leukemia virus genome and the homologous cellular gene: 
studies with cloned viral ~. Cell 22, 777-785. 
Goff SP, Baltimore D (1982) The cellular oncogene of the Abelson murine 
leukemia virus genome. Adv .in Viral Oncol. 1, (ed. G. Klein) Raven 
Press, N.Y. p.l27-139. 
Gold DP, Van Dongen JJM, Morton CC, Bruns G, van den Elsen P, Geurts van 
Kessel AHM, Terhorst C (1986) The gene encoding the subunit of the 
T3/T-cell receptor complex maps to chromosome ll in humans and to 
chromosome 9 in mice. Submitted. 
Gonda TJ, Metcalf D (1984) Expression of !!!Y!2r !!lY£ and fos proto-oncogenes 
during the differentiation of a murine myeloid leukemia. Nature 310, 
249-251. 
Goverman J, Hunkapiller T, Hood L (1986) A speculative view of the multi-
component nature of the T-cell antigen recognition. Cell 45, 475-
484. 
Goyns MH, Young BD, Geurts van Kessel A, De Klein A, Grosveld G, Bartram 
CR, Bootsma D (1984) Regional mapping of the human immunoglobulin 
lambda light chain to the Philadelphia chromosome in chronic myeloid 
leukemia. Leuk.Res. 8, 547-553. 
Graham M, Adams JM, Cory S (1985) Murine T lymphomas with retroviral 
inserts in the chromosomal 15 locus for plasmacytoma variant trans-
location (1985) Nature 314, 740-743. 
Groffen J, Heisterkamp N, Stephenson JR, Geurts van Kessel AG, de Klein 
A, Grosveld G, Bootsma D (1983a) c-sis is translocated from chromo-
some 22 to chromosome 9 in chronic myelocytic leukemia. J .Exp.Med. 
158: 9-15. 
Groffen J, Heisterkamp N, Reynolds FH, Stephenson JR (1983b) Homology 
between phosphotyrosine acceptor site of human c-abl and viral 
oncogene prodcts. Nature 304, 167-169. --
Groffen J, Heisterkamp N, Spurr N, Dana S, Wasmuth JJ, Stephenson JR 
(1983c) Chromosomal localization of the human c-fms oncogene. 
Nucl.Acid Res. ll, 6331-6341. --
Groffen J, Stephenson JR, Heisterkamp N, De Klein A, Bartram CR, Grosveld 
G (1984) Philadelphia chromosomal breakpoints are clustered within a 
limited region, bcr, on chromosome 22. Cell 36, 93-99. 
Groffen J, Heisterkamp H, Starn K, De Krein A, Grosveld G (1986) Activa-
tion of c-abl as a result of the Ph translocation in chronic myelo-
cytic leukemia. Adv .in Viral Oncology (in press). 
Grosveld G, Verwoerd T, van Agthoven T, de Klein A, Ramachandran KL, 
Heisterkamp N, Starn K, Groffen J (1986) The chronic myelocytic cell 
line K562 contains a breakpoint in bcr and produces a chimeric 
bcr/c-abl transcript. M::ll.Cell.Biol. 6: 607-616. 
Hagemeijer A, Smit EME, Bootsma, D (1979) Improved identification of 
chromosomes of chromosomes of leukemic cells in methotrexate-treated 
cultures. Cytogenet. Cell Genet. 23, 208-212. 
Hagemeijer A, Hahlen K, Abels J (1981) Cytogenetic follow-up of patients 
with non-lymphocytic leukemia II. Acute non-lymphocytic leukemia. 
Cancer Genet.Cytogent. 3, 109-124. 
73 
Hagerneijer A, Hillllen K, Sizoo W, Abels J (1982) Translocation 
(9;ll)(p2l:q23) in three cases of acute monoblastic leukemia. Cancer 
Genet.Cytogenet. 5, 95-105. 
Hagerneijer A, Bartram CR, Smit EME, van Agthoven J!J, Bootsrna D (1984) If 
the chromoscmal region 9q34 always involved in variants of the Ph 
translocation? Cancer Genet.Cytogenet. 13, 1-16. 
Hagemeijer A, de Klein A, GOdde-Salz E, Turc-Carel C, Smit EME, van 
Agthoven T, Grosveld G (1985) Translocation of c-abl to masked Ph in 
chronic myeloid leukemia. Cancer Genet. Cytogenet. 18, 95-104. 
Hagerneijer A, Adriaansen HJ, Bartram CR (1986a) New possibilities for 
cytogenetic analysis of leukemic cells. In: Minimal Residual Disease 
in Acute Leukemia (ed. Hagenbeek, LOwenberg) Martinus Nijhoff Publ., 
Dordrecht p.l-11. 
Hagerneijer A, Van Dongen J, Slater R, van 't Veer M, Behrendt H, lliihlen 
K, Sizoo W, Abels J (1986b) Characterization of the blast cells in 
acute leukemia with translocation (4;11). Submitted. 
Hall A, Marshall CJ, Spurr N, Weiss RA (1983) Identification of transfor-
ming gene in two human sarcoma cell lines as a new member of the ras 
gene family located on chromosome one. Nature 303, 396-400. ---
Hamlin JL, Milbrandt JD, Heintz NH, Azizkhan JC (1984) rNA sequence 
amplification in mammalian cells. Int.Rev.Cytol. 90, 31-83. 
Hann SR, Thompson CB, Eisenman RN (1985) c-_!!!Y£ oncogene protein synthesis 
is independent of the cell cycle in human and avian cells. Nature 
314, 366-369. 
Hansen MF, Koufos A, Gallie BL, Phillips RA, Fodstad 0, Brogger A, Gedde-
Dahl T, Cavenee WK (1985) Osteosarcoma and retinoblastoma: A shared 
chromosomal mechanism revealing recessive predisposition. Proc.Natl 
Acad.Sci. USA 82, 6216-6220. 
Harper ME, Franchini G, Love J, Simon MI, Gallo RC, Wong-Staal F (1983) 
Chromoscmal sublocalization of human c~ and c-fes cellular one 
genes. Nature 304, 169-171. 
Hayashi Y, Sakurai M, Kaneko Y, AbeT, Mori T, Nakazawa (1985) ll;l9 
Translocation in a congenital leukemia with two cell populations of 
lymphoblasts and rnonoblasts. Leuk.Res. 9, 1467-1473. 
Hayward WS, Neel BC, Astrin SM (1981) Activation of a cellular one gene 
by promoter insertion in ALV-induced lymphoid leukosis. Nature 290, 
475-480. 
Hecht F, Morgan R, Kaiser-McCaw Hecht B, Smith SD (1984) Common region on 
chromosome 14 in T-cell leukemia and lymphoma. Science 226, 1445-
1447. 
Hecht F, Morgan R, Gemmill RM, Kaiser-M::: Caw Hecht B, Smith SD (1985) 
Translocations in T-cell leukemia and lymphoma. N.Engl.J .Med. 313, 
758. 
Hecht F, Kaiser-McCaw Hecht B, Morgan R (1986) T-cell cancer breakpoints 
at genes for T-cell receptor on chromosomes 7 and 14. Cancer Genet. 
Cytogenet 20: 181-183. 
Heim s, Billstrom R, Kristoffersson U, Mandahl, Strombeck B, Mitelman F 
(1985) Variant Ph translocations in chronic myeloid leukemia. Cancer 
Genet.Cytogenet. 18, 215-227. 
Heirn S, Kristoffersson U, Mandahl N, Mitelman F, Bekassy AN, Garwicz S, 
Wiebe T (1986) High resolution banding analysis of the reciprocal 
translocation t(6;9) in acte non-lymphocytic leukemia. Cancer Genet 
Cytogenet. 22, 195-201. 
74 
Heisterkamp N, Groffen J, Stefbenson JR, Spurr NK, Goodfellow PN, Solanon 
E, Carritt B, Bodmer WF (1982) Chromosanal lcx::alization of human 
cellular homologues of two viral oncogenes. Nature 299, 747-749. 
Heisterkamp N, Groffen J, Stefbenson JR (l983a) The human v-abl cellular 
homolog. J .Mol.App.Genet.2, 57-68. 
Heisterkamp N, Stefhenson JR, Groffen J, Hansen PF, de Klein A, Bartram 
CR, Grosveld G (l983b) Localization of the c-abl oncogene adjacent 
to a translcx::ation breakpoint in chronic myelocytic leukemia. Na-
ture 306, 239-242. 
Heisterkamp N, Starn K, Groffen J, de Klein A, Groffen G (1985) Structural 
organization of the bcr gene and its role in the Ph translcx::ation. 
Nature 315, 758-761.---
Hirai H, Tanaka s, Azuma M, Anraku Y, Kobayashi Y, Fujisawa M, Okabe T, 
Urabe A, Takaku F (1985) Transforming genes in human leukemia 
cells. Blood 66, 1371-1378. 
Hoffmann-Falk H, Einat D, Shilo, B-Z., Hoffman FM (1983) Drosofbila 
melanogaster DNA clones homologous to vertebrate oncogenes: eviden-
ce for a common ancestor to the src and abl cellular genes. Cell 
32, 589-598. --- ---
Hollis G, Mitchell K, Battey J, Potter H, Taub R, Lenoir G, Leder P 
(1984) A variant translcx::ation places the ..:t immunoglobulin genes 3' 
to the c-~ oncogene in Burkitt's lymphoma. Nature 307, 752-755. 
Hood L, Kronenberg M, Hunkapiller T (1985) T-cell antigen receptors and 
the irrrounoglooolin supergene family. Cell 40, 225-229. 
Huebner K, Isobe M, Crcx::e CM, Golde DW, Kaufman SE, Gasson JC (1985) The 
human gene encoding GM-<:SF is at 5q21-q32, the chranosome region 
deleted in the Sq- anomaly. Science 230, 1282-1285. 
Huebner K, Isobe M, Chao M, Bothwell M, Ros AH, Finan J, Hoxie JA, Sehgal 
A, Buck CR, Lanahan A, Nowell PC, Koprowski H, Crcx::e CM (1986) The 
nerve growth factor receptor gene is at human chromosome region 
17ql2 - 17q22, distal to the chromosome 17 breakpoint in acute 
leukemias. Prcx::.Natl.Acad.Sci.USA 83, 1403-1407. 
Hunter T, Cooper JA (1985) Protein-tyrosine kinase. Ann.Rev.Bicx::hem. 54, 
897-930. 
ISCN (1985) An international system for human cytogenetic nomenclature. 
Harden rx:;, Klinger HP (eds) Published in collaboration with Cytoge-
net.Cell genet. (Karger, Basel 1985). 
Isobe M, Emanuel BS, Givol D, Oren M, Crcx::e CM (1986) Lcx::alization of a 
gene for human p53 tumor antigen to band 17pl3. Nature 320, 84-85. 
Jhanwar SC, Neel BG, Hayward WS, Chaganti RSK (1983) Lcx::alization of e-
ras oncogene family on human germline chromosomes. Prcx:: .Natl.Acad. 
Sci. USA 80, 4794-4797. · 
Jhanwar SC, Neel BG, Hayward WS, Chaganti RSK (1984) Localization of the 
cellular oncogenes abl, sis, and fes on human germline chromosomes. 
Cytogenet.Cell Genet. 38, 73-75. 
Kaneko Y, Egues MC, Rowley JD (1981) Interstitial deletion of short arm 
of chromosome 11 limited to Wilms' tumors cells in a patient with-
out aniridia. Cancer Res 41, 4577-4578. 
Kaneko Y, Maseki N, Takasaki N, Sakurai M, Hayashi Y, Nakazawa S, Mori T, 
Sakurai M, Takeda T, Shikano T, Hiyoshi Y (1986) Clinical and hema-
tologic characteristicts in acute leukemia with llq23 translcx::a-
tions. Blood 67, 484-491. 
75 
Kelly K, Cochran BH, Stiles ill, Leder P (1983) Cell-specific regulation 
of the c-myc gene by lymphocyte mitogenes and platelet-derived 
growth factor. Cell 35, 603-610. 
Kelly K (1985) Growth factors short-circuited. Nature 317, 390. 
Kirsch IR, Morton C::C, Nakahara K, Leder P (1982) Human inmunoglooolin 
heavy chain genes map to a region of translocation in malignant B 
lymphocytes. Science 216, 301-303. 
Klein G (1981) The role of gene dosage and genetic transpositions in 
carcinogenesis. Nature 294, 313-318. 
Klein G (1983) Specific chromosomal translocations and the genesis of B-
cell-derived tumors in mice and men. Cell 32, 311-315. 
Klein G, Klein E (1985a) Evolution of tumours and the impact of molecular 
oncology. Nature 315, 190-195. 
Klein G, Klein E (1985b) ~Ig juxtaposition by chromosomal transloca-
tions some new insights, puzzles and paradoxes. Immunology Today 6, 
208-215. 
Kloetzer W, Kurzrock R, Smith L, Talpaz M, Spiller M, Gutterman J, Ar-
linghaus R (1985) The human cellular abl gene product in the chro-
nic myelogenous leukemia cell line K562 has an associated tyrosine 
protein kinase activity. Virology 140, 230-238. 
Knudson AG (1971) Mutation and Cancer: Statistical study of retinoblasto-
ma. Proc.Natl.Acad.Sci USA 68, 820-823. 
Koeffler HP, Golde DW (1981) Chronic myelogenous leukemia- new concepts. 
N.Engl.J.Med 304, 1201-1209: 1269-1274. 
Kohl NE, Kanda N, Schrek RR, Bruns G, Latt SA, Gilbert F, Alt FW (1983) 
Transposition and amplification of oncogene related sequences in 
human neuroblastomas. Cell 35, 359-367. 
Kohl NE, Gee CE, Alt FW (1984) Activated expression of the N-myc gene in 
human neuroblastomas and related tumors. Science 226, 1335-1337. 
Kondo K, Sasaki M (1982) Further cytogenetic studies on acute promyelocy-
tic leukemia. Cancer Genet.Cytogenet 6, 39-46. 
Konopka JB, Watanabe SM, Witte CN (1984) An alteration of the human c-abl 
protein in K562 leukemia cells unmasks associated tyrosine kinase 
activity. Cell 37, 1035-1042. 
Konopka JB, Watanabe SM, Singer JW, Collins SJ, Witte Oil (1985) Cell 
lines and clinical isolates derived from Phl-positive chronic mye-
logenous leukemia patients express c-abl proteins with a common 
structural alteration. Proc.Natl.Acad.Sci USA 82, 1810-1814. 
Konopka JB, Witte Oil (1985a) Detection of c-abl tyrosine kinase activity 
in vitro permits direct comparison of normal and altered abl gene 
products. Mol.Cell.Biol. 5, 3116-3123. 
Konopka JB, Witte Oil (1985b) Activation of the abl oncogene in murine and 
human leukemias. Biochemica et Bio:E=hysica Acta 823, 1-17 • 
Konopka J, ClarkS, Me Laughlin, Nitta M, Kato Y, Strife A, Clarkson B, 
Witte 0 (1986) Variable expression of the translocated c-abl onco-
gene in Philadel:E=hia chromosome positive B-lymphoid cell lines from 
chronic myelogenous leukemia patients. Proc.Natl.Acad.Sci USA 83, 
4049-4052. 
Koufos A, Hansen MF, Lampkin BC, Workman ML, Copeland NG, Jenkins A, 
Cavenee WK (1984) Loss of alleles at loci on human chromosome 11 
during genesis of Wilms' tumour. Nature 309, 170-172. 
Koufos A, Hansen MF, Copeland NG, Jenkins NA., Lampkin BC, Cavenee WK 
(1985) Loss of heterozygosity in three embryonal tumors suggests a 
common pathogenetic mechanism. Nature 316, 330-334. 
76 
Kozbor D, Giallonga A, Sierzega ME, Konopka JB, Witte 00, Showe LC, Croce 
CM (1986) Expression of a translocated c-abl gene in hybrids of 
mouse fibroblasts and chronic myelogenous leukaemia cells. Nature 
319, 331-333. 
Kruyer W, Cooper JA, Hunter T, Verma I (1984) Platelet derived growth 
factor induces rapid but transient expression of the c-fos gene and 
protein. Nature 312, 711-716. 
Lacy J, Sarkar SN, Sumners W::: (1986) Induction of c-myc expression in 
human B lymphocytes by B-cell growth factor and anti-immunogloblin. 
Proc.Natl.Acad.Sci USA 83, 1458-1462. 
Lamb P. Crawford L (1986) Characterization of the human p53 gene. Mol. 
Cell Biol. 6, 1379-1385. 
Land H, Parada LF, Weinberg RA (1983a) Tumorigenic conversion of primary 
embryo fibroblasts requires at least two cooperating oncogenes. 
Nature 304, 596-602. 
Land H, Parada LF, Weinberg RA (1983b) Cellular oncogenes and multistep 
carcinogenesis. Science 222, 771-778. 
Lane MA, Sainten A, Cooper GM (1982) Stage-specific transforming genes of 
human and mouse B- and T-lymphocyte neoplaSllls. Cell 28: 873-880. 
Larson R, LeBeau M, Vardiman J, Testa J, Golanb H, Rowley J (1983) The 
predictive value of initial cytogenetic studies in 148 adults with 
acute nonlymphocytic leukemia: a 12-year study (1970-1982). Cancer 
Genet.Cytogenet. 10, 219-236. 
Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD (1984) 
Evidence for a 15;17 translocation in every patient with acute 
promyelocytic leukemia. Am.J.Med. 76, 827-841. 
LeBeau MM, Larson RA, Bitter MA, Vardiman JW, Golomb HM, Rowley JD (1983) 
Association of an inversion of chromosome 16 with abnormal marrow 
eosinophils in acute myelomonocytoic leukemia. N.Engl.J .Med. 309, 
630-636. 
LeBeau MM, Rowley JD (1984a) Heritable fragile sites in cancer. Nature 
308, 607-608. 
LeBeau MM, Rowley JR (1984b) Recurring chromosomal abnormalities in leu-
kemia and lymphoma. Cancer Surveys 3, 371-394. 
LeBeau MM, Westbrook LA, Diaz MO, Rowley JD, Oren M (1985a) Translocation 
of the p53 gene in t(l5;17) in acute promyelocytic leukemia. Nature 
316, 826-828. 
LeBeau MM, Diaz MO, Karin M, Rowley JD (1985b) Metallothionein gene 
cluster is split by chromosome 16 rearrangements in myelomonocytic 
leukemia. Nature 313, 709-711. 
LeBeau MM, Westbrook Cl\, Diaz MO, Rowley JD (l985c) ~ is consistently 
conserved in the chromosomal deletions (20q) observed in myeloid 
disorders. Proc.Natl.Acad.Sci.USA 82, 6692-6696. 
LeBeau MM (1986) Chromosomal fragile sites and cancer-specific rearrange-
ments. Blood 67, 849-858. 
LeBeau MM, Westbrook Cl\, Diaz MO, Larson RA, Rowley JD, Gasson JC, Golde 
IM, Sherr CJ (1986) Evideoc:e for the involvement of GM-CSF and FMS 
in the deletion (5q) in myeloid disorders. Science 231, 984-987. 
Leder P, Battey J, Lenoir G, Moulding C, Murphhy W, Potter H, Stewart T, 
Taub R (1983) Translocations among antibody genes in human cancer. 
Science 222: 765-761. 
Leder A, Pattengale P, Kuo A, Stewart T, Leder P (1986) Consequences of 
wild spread deregulation of the c-myc gene in transgenic mice: 
multiple neoplaslllS and normal development. Cell 45, 485-495. 
77 
Lee w-H, Murphee AL, Benedict WF (1984) Expression and amplification of 
the N-myc gene in primary retinoblastoma. Nature 309, 458-459. 
Lehrman M, Schneider W, Slidhof T, Brown M, Goldstein J, Russel D (1985) 
Mutation in LDL receptor: Alu-Alu recombination deletes exons enco-
ding transmembrane and cytoplasmic danains. Science 227, 140-145. 
Leibowitz D, Schaefer-Rego K, Popenoe DW, Mears JG, Bank A (1985a) Varia-
ble breakpoints on the Philadelphia chromosome in chronic myeloge-
nous leukemia. Blood 66, 243-245. 
Leibowitz D, Cubbon R, Bank A (1985b) Increased expression of a novel c-
abl-related RNA in K562 cells. Blood 65, 526-529. -
Lenoir GM, Preud 'hanrne JL, Bernheim A, Berger R (1982) Correlation be-
tween immunoglobulin light chain expression and variant transloca-
tion in Burkitt's lymphoma. Nature 298, 474-476. 
Leonard W, Donlon T, Lebo R, Greene W (1985) Localization of the gene 
encoding the human interleukin-2 receptor on chromosome 10. Science 
2281 1547-1549 • 
Leprince D, Gegonne A, Coll J, de Taisne C, Schneeberger A, Lagrou C, 
Stehelin D (1983) A putative second cell-derived oncogene of the 
avian leukaemia retrovirus E26. Nature 306, 395-397. 
Lewis WH, Michalopoulos EE, Williams DL, Minden MD, Mak 'IW (1985) Break-
points in the human T-cell antigen receptor a.-chain locus in two T-
·cell leukaemia patients with chromosanal translocations. Nature 
317, 544-546. 
Libermann TA, Nusbaum HR, Razon N, Kris R, Lax I, Soreq H, Whittle N, 
Waterfield MD, Ullrich A, Schlessinger J (1985) Amplification, 
enhanced expression and possible rearrangement of EGF receptor gene 
in primary human brain tumours of glial origin. Nature 313, 144-
147. 
Lisker R, Casas L, Mutchinick o, Perez-chavez F, Labardini J (1980) Late-
appearing Philadelphia chromosome in two patients with chronic mye-
logenous leukemia. Blood 56, 812-814. 
Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD (1983) Amplification 
and expression of the c-myc oncogene in human lung cancer cell 
lines. Nature 306, 194-196. 
Lozzio CB, Lozzio BB (1975) Human chronic myelogenous leukemia cell line 
with positive Philadelphia chromosome. Blood 45, 321-334. 
Magrath I, Erikson J, Whang-Peng J, Sieverts H, Amstrong G, Benjamin D, 
Triche T, Alabaster O, Groce CM (1983) Synthesis of kappa light 
chains by cell lines containing an 8;22 chromosomal translocation 
derived from a male homosexual with Burkitt's lymphoma. Science 
222, 1094-1098. 
Malcolm S, Davis M, Rabbitts TH (1985) Breakage on chromosome 2 brings 
the Ck gene to a region 3' of c-myc in a Burkitt's lymphoma line 
carrying a (2;8) translocation. Cytogenet. Cell Genet. 39, 168-172. 
Manolov G, Manolova Y, Klein G, Lenoir G, Levan A (1986) Aternative 
involvement of two cytogenetically distinguishable breakpoints on 
chromosome 8 in Burkitt's lymphoma associated translocations. Can-
cer Genet. Cell Genet. 20, 95-99. 
Marcu KB, Hrris LJ, Stanton LW, Erikson J, Watt R, Croce CM (1983) Trans-
criptionally active c-myc oncogene is contained within N~, a DNA 
sequence associated with chromosome translocations in B-cell neo-
plasia. Proc.Natl.Acad.Sci.USA 80, 519-125. 
Mark J, Dahlenfors R, Ekedahl C (1983) Cytogenetics of the human benign 
mixed salivary gland tumour. Hereditas 99, 115-129. 
78 
Mars W, Florine D, Talpaz M, Saunders G (1985) Preferentially expressed 
genes in chronic myelogenous leukemia. Blood 65, 1218-1225. 
Martin-Zaca D, Hughes SH, Barbacid M (1986) A human oncogene formed by 
the fusion of truncated tropomyosin and protein tyrosine kinase 
sequences. Nature 319, 743-748. 
Mathey-Prevot B, Baltimore D (1985) Specific transforming potential of 
oncogenes encoding protein tyrosine kinases. EMBO J. 4, 1769-1774. 
Mathieu-Mahul D, caubert JF I Bernheim A, Mauchauffe, Palmer E, Berger R, 
Larsen C-J (1985) M::>lecular cloning of a DNA fragment from human 
chromosome 14 (14qll) involved in T-cell malignancies. EMBO J. 4, 
3427-3433. 
M:::Bride OW, Hieter PA, Hollis GF, Swan D, Otey MC, Leder P (1982) Chromo-
somal location of human kappa and lambda linmunoglobulin light chain 
constant region genes. J .Exp.Med. 155, 1480-1490. 
M:::Bride ow, Kirsch I, Hollis G, Nau M, Battey J, Minna J (1985) Human c-
~ proto oncogene on chromosome lp32. Cytogent.Cell Genet. 40, 
p.694 (abstract). 
McBride OW, Merry D, Givol D (1986) The gene for human p53 cellular tUiliOr 
antigen is located on chromosane 17 short arm (17pl3). Proc.Natl. 
Acad.Sci USA 83, 130-134. 
McCarthy D, Rassool F, Goldman J, Graham S, Birnie G (1984) Genomic 
alterations involving the ~proto-oncogene locus during the 
evolution of a case of chronic granulocytic leukaemia. Lancet ii, 
1362-1365. 
Mecucci C, Michaux JL, Tricot G, Louwagie A, Van den Berghe H (1985) 
Rearrangements of the short arm of chromosane 6 in T-cell lympho-
mas. Leuk.Res. 9, 1139-1148. 
Metcalf D (1986) The molecular biology and functions of the granulocyte-
macrophage colony-stimulating factors. Blood 67, 257-267. 
Meyers L, Michalski K, Miles J, Hakami N (1986) Translocation (4;11) in 
acute myelogenous leukemia. cancer Genet.Cytogenet 22, 143-148. 
Miller C, Mohandes T, WOlf D, Prokocirner M, Rotter V, Koeffler HP (1986) 
Human p53 gene localized to short arm of chromosome 17. Nature 319, 
783-784. 
Minden MD, Mak 'lW (1986) The structure of the T-cell antigen receptor 
genes in normal and malignant T cells. Blood 68, 327-336. 
Mirro J I Kitchingman G, Williams D, Lauzon GJ I Lin c-c, callihan T, Zipf 
T (1986) Clinical and laboratory characteristics of acute leukemia 
with the 4;11 translocation. Blood 67, 689-697. 
Misawa S, Lee E, Schiffer CA, Liu Z, Testa JR (1986) Association of the 
translocation (15;17) with malignant proliferation of promyelocytes 
in acute leukemia and chronic myelogenous leukemia at blastic 
crisis. Blood 67, 270-274. 
Mitelman F (1984) Restricted number of chromosomal regions inplicated in 
aertiology of human cancer and leukaemia. Nature 310, 325-327. 
Mitelman F (1985) catalog of chromosome aberrations in cancer. In: Pro-
gress and Topic in Cytogenetics. vol. 5 ed. AA Sandberg 
Mitelman F (1986) Clustering of chromosomal breakpoints in neoplasia. 
cancer Genet. Cytogenet. 19' 67-71. 
Mitelman, F, Manolov G, Manolova Y, Billstr0m R, Heim S, Kristoffersson 
U, Mandahl N, Ferro MI', Roman CS (1986) High resolution chromosane 
analysis of constitutional and acquired t(l5;17) maps c-er~ to 
subband 17qll.2. cancer Genet.Cytogenet. 22, 95-98. ---
79 
Miyamoto K, Tomita N, Ishii A, Nonaka H, Kondo T, Tanaka T, Kitajima K 
(1984) Chromosome abnormalities of leukemia cells in adult patients 
with T-cell leukemia. Jl.Natl.Canc.Inst. 73, 353-362. 
Morris CM, Reeve AE, Fritzgerald PH, Hollings PE, Beard MEJ, Heaton OC 
(1986) Genomic diversity correlates with clinical variation in Ph1-
negative chronic myeloid leukaemia. Nature 330, 281-283. 
Morton C, Taub R, Diamond A, Lane M-A, Cooper G, Leder P (1984) Mapping 
of the human Blym-1 transforming gene activated in Burkitt lympho-
mas to chromosome 1. Science 223, 173-175. 
Moulding C, Rapoport A, Goldman P, Battey J, Lenoir G, Leder P (1985) 
Structural analysis of both products of a reciprocal translocation 
between c-myc and immunoglobulin loci in Burkitt lymphcma. Nucl. 
Acids Res. 13, 2141-2152. 
MUller R, Slamon DJ, Tremblay JM, Cline MJ, Verma IM (1982) Differential 
expression of cellular oncogenes during pre and postnatal develop-
ment of the mouse. Nature 299, 640-644. 
MUller R, Tremblay JM, Adamson ED, Verma IM (1983) Tissue and cell 
type-specific expression of two human c-one genes. Nature 304, 454-
456. 
MUller R, MUller D, Guilbert L (1984a) Differential expression of c-
fos in hematopoietic cells: correlation with differentiation- of 
rnonomyelocytic cells in vitro. EMBO 3, 1887-1890. 
MUller R, Bravo R, Burckhardt J, Curran J (1984b) Induction of c-fos gene 
and protein by growth factors precedes activation of c-myc. Nature 
312, 716-720. 
Muqhree AL, Benedict WF (1984) Retinoblastoma: clues to human oncogene-
sis. Science 223, 1028-1033. 
Mushinski JF, Potter M, Bauer SR, Reddy EP (1983) rNA rearrangement and 
altered RNA expression of the c-myb oncogene in mouse plasmacytoid 
lymphosarcomas. Science 220, 795-798. 
Ngarajan L, Louie E, Tsujimoto Y, Ar-Rushdi A, Huebner K, Groce CM (1986) 
Localization of the human pim oncogene (Pim) to a region of chromo-
some 6 involved in translocations in acute leukemias. Proc.Natl. 
Acad.Sci USA 83, 2556-2560. 
Nagasaka M, Maeda S, Maeda H, Chen H-L, Kita K, Mabuchi 0, Misu H, Matsuo 
T, Sugiyama T (1983) Four cases of t(4;11) acute leukemia and its 
myelcmonocytic nature in infants. Blood 61, 1174-1181. 
Naldini L, Stacchini A, Cirillo IM, Aglietta M, Gavosto F, Comoglio PM 
(1986) Phosphotyrosine antibodies identify the p210c-abl tyrosine 
kinase and protein phosphorylated on tyrosine in human chronic 
myelogenous leukemia cells. Mol.Cell.Biol. 6, 1803-1811. 
Nau MM, Brooks BJ, Battey J, Sausville E, Gazdar AF, Kirsch IR, McBride 
00, Bertness V, Hollis GF, Minna JD (1985) L-myc, a new myc-related 
gene amplified and expressed in human small cell lung cancer. 
Nature 318, 69-73. 
Nau MM, Brooks BJ, Carney DN, Gazdar AF, Battey JF, Sausville EA, Minna 
JD (1986) Human small-cell lung cancers show amplification and 
expression of the N-myc gene. Proc.Natl.Acad.Sci.USA 83, 1092-1096. 
Neel BG, Jhanwar SC, Chaganti RSK, Hayward WS (1982) Two human c-one 
genes are located on the long arm of chromosome 8 • Proc .Natl.Acad. 
Sci.USA 79, 7842-7846. 
Neiman P (1985) The~ oncogenes. Adv.Cancer Res. 36, 107-123. 
80 
Nguyen C, Mattei ~, Mattei JF, Santoni M-J, Goridis C, Jordan B (1986) 
Localization of the human N~ gene to band q23 of chromosome 11: 
The third gene coding for a cell interaction oolecule mapped to the 
distal portion of the long arm of chromosome 11. J.of Cell Biol. 
102, 711-715. 
Nienhuis I>JN, Bunn HF, Turner PH, Gopal TV, Nash ViG, O'Brien SJ, Sherr CJ 
(1985) Expression of the human c-fms proto-oncogene in hematopoie-
tic cells and its deletion in the 5q- syndrome. Cell 42, 421-428. 
Nishikura K, Ar-Rushdi A, Erickson J, Watt R, Rovera G, Croce CM (1983) 
Differential expression of the normal and of the translocated human 
c-myc oncogene in B cells. Proc.Natl.Acad.Sci.USA 80, 4822-4826. 
Nishikura K, Ar-Rushdi A, Erikson J, de Jesus E, Dugan D, Croce CM (1984) 
Repression of rearranged ~ gene and translocated c-myc in mouse 3T3 
cells x Burkitt lymphoma cell hybrids. Science 224, 399-402. 
Nishikura K, Erikson J, Ar-Rushdi A, Huebner K, Croce CM (1985) The 
translocated c-myc oncogene of Raji Burkitt lymphoma cells is not 
expressed in human lymphoblastoid cells. Proc.Natl.Acad.Sci.USA 82, 
2900-2904. 
Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic 
granulocytic leukemia. Science 132, 1497. 
Nowell PC, Erikson J, Finan J, Emanuel B, Croce CM (1984) Chromosomal 
translocations, immunoglobulin genes and oncogenes in human B-cell 
tUI!K>urs. Cancer Surv. 3, 531-542. 
Nowell PC, Vonderheid EC, Besa E, Hoxie JA, Moreau L, Finan JB (1986) The 
most common chromosome change in 86 chronic B cell or T cell 
tumors: a 14q32 translocation. Cancer Genet.Cytogenet. 19, 219-227. 
Nunn MF, Seeburg PH, Moscovici C, Duesberg PH (1983) Tripartite structure 
of the avian erythroblastosis virus E26 transforming gene. Nature 
306, 391-395. 
Nusse R, Varmus HE (1982) Many tumors indeed by the mouse mammary tumor 
virus contain a provirus integrated in the same region of the host 
genome. Cell 31, 99-109. 
Nusse R, van Ooyen A, Cox D, Fung Yicr', Varmus H (1984) Mode of proviral 
activation of a putative mammary oncogene (int-1) on mouse chromo-
some 15. Nature 307, 131-136. 
O'Malley FM, Garson OM (1985) Chronic granulocytic leukemia: correlation 
of blastic transformation type with karyotypic evolution. Am.J.Hae-
matol. 20, 313-323. 
Orkin SH (1984) Wilms' tumor: molecular evidence for the role of chromo-
some 11. Cancer Surv. 3, 4665-478. 
Orkin SH, Goldman DS, Sallan SE (1984) Developnent of hooozygosity for 
chromosome 11p markers in Wilms' tumour. Nature 309, 172-174. 
Oshimura M, Sandberg A (1977) Chromosomes and causation of human cancer 
and leukemia XYN. Cancer 40, 1149-1160. 
Park M, Dean M, Cooper C, Schmidt M, O'Brien SJ, Blair rx;, Van de Woude ? 
(1986) Mechanism of met oncogene activation. Cell 45, 895-904. 
Pathak S, Strong LL, Ferrell FE, Trindade A (1982) Familial renal cell 
carcinoma with a 3;11 chromosome translocation limited to tllllK>r 
cells. Science 217, 939-941. 
Payne GS, Bishop JM, Varmus HE (1982) Multiple arrangements of viral DNA 
and an activated host oncogene in bursal lymphomas. Nature 295, 
209-217. 
Pearson M, Rowley JD (1985) The relation of oncogenesis and cytogenetics 
in leukemia and lymphoma. Ann.rev.Med. 36, 471-483. 
81 
Pearson MG, Vardiman JW, LeBeau MM, Rowley JD, Schwartz S, Kerman SL, 
Cohen M-1, Fleischman EW, Prigogina EL (1985) Increased number of 
marrow baso];tlils may be associated with a t(6;9) in ANLL. Am.J.He-
matol. 18, 393-403. 
Pedersen MF, Bennett JW, Wang N (1986) Nonrandom chromosome structural 
aberrations and oncogene loci in human malignant melanana. Carx::er 
Genet.Cytogenet. 20, 11-27. 
Pegoraro L, Palumbo A, Erikson J, Falda M, Giovanazzo B, Emanuel BS, 
Rovera G, Nowell PC, Croce CM (1984) A 14;18 and an 8;14 chromosane 
translocation in a cell line derived from an acute B-cell leukemia. 
Proc.Natl.Acad.Sci.USA 81, 7166-7170. 
Pelicci P-{3, Knowles IM, Magrath I, Dalla-Favera R (1986) Chromosomal 
breakpoints and structural alterations of the c-rnyc locus differ in 
endemic and sporadic forms ofBurkitt lymphoma. Proc.Natl.Acad.Sci. 
USA 83, 2984-2988. 
Perlmutter RM, Klotz JL, Pravtcheva D, Ruddle F, Hood L (1984) A novel 
6;10 chromosanal translocation in the murine plasmacytoma NS-1. 
Nature 307, 473-475. 
Peschle C, Mavilio F, Sposi N, Giampaolo A, Care A, Bottero L, Bruno M, 
Mastroberardino G, Gastaldi R, Testa M, Alimena G, Amadori S, 
Mandelli F (1984) Translocation and rearrangement of c-rnyc into 
immunoglobulin a heavy chain locus in primary cells from acute 
lymphocytic leukemia. Proc.Natl.Acad.Sci.USA. 81, 5514-5518. 
Piechaczyk M, Yang J-Q, Blanchard J-M, Jeanteur P, Marau KB (1985) Post 
transcriptional mechanisms are responsible for accumulation of 
trurx::ated c-rnyc RNAs in murine plasma cell tumors. Cell 42, 589-
597. 
Pierce JH, DiFiori PP, Aaronson SA, Potter M, Pumphrey J, Scott A, Ihle 
JN (1985) Neoplastic transformation of mast cells by Abelson-MuLV: 
abrogation of IL-3 dependence by a non-autocrine mechanism. Cell 
41, 685-693. 
Prakash K, McBride OW, Swan DC, Devares SF, Tronick SR, Aaronson SA 
(1982) Molecular cloning and chromosomal mapping of a human locus 
related to the transforming gene of Moloney murine sarcoma virus. 
Proc. Natl.Acad.Sci USA 79, 5210-5214. 
Priest JR, Robison LL, McKenna RW, Lindquist LL, Warkentin PI, leBien 'IW, 
Woods WJ, Kersey JH, Coccia PF, Nesbit ME (1980) Philadel];tlia 
chromosome positive childhood acute lymphoblastic leukemia. Blood 
56, 15-22. 
Prywes R, Foulkes JG, Rosenberg N, Baltimore D (1983) Sequences of the A-
MuLV protein needed for fibroblast and lymphoid cell transforma-
tion. Cell 34, 569-579. 
Prywes R, Hoag J, Rosenberg N, Baltimore D (1985a) Protein stabilization 
explains the ~ requirement for transformation of lymphoid cells 
by Abelson murine leukemia virus. J.Virology 54, 123-132. 
Prywes R, Foulkes JG, Baltimore D (1985b) The minimum transforming region 
of v-abl is the segment encoding protein-tyrosine kinase. J .Virol. 
54, 114-122. 
Pugh W:::, Pearson M, Vardiman JW, Rowley JD (1985) Philadelphia chromo-
some-negative chronic myelogenous leukemia: a morphological reas-
sesment. Br.J.Haematol. 60, 457-467. 
Rabbitts T, Forster A, Harnlyn P, Baer R (1984) Effect of somatic mutation 
within translocated c-myc genes in Burkitt's lymphoma. Nature 309, 
592-597. 
82 
Rabbitts TH (1985) The c-rnyc oncogene: involvement in chromosomal abnor-
malities. Trends.Genet. 1, 327-331. 
Rabbitts PH, Forster A, Stinson MA., Rabbitts TH (1985a) Truncation of 
exon 1 from the c-myc gene results in prolonged~ mRNA stabili-
ty. EMBO J. 4, 3727-3733. 
Rabbitts PH, Watson JV, Lam'>nd A, Forster A, Stinson MA., Evan G, Fischer 
W, Atherton E, Sheppard R, Rabbitts TH (1985b) Metabolism of c-myc 
gene products: ~ mRNA and protein expression in the cell cycle. 
EMBO J. 4, 2009-2015. 
Rabbitts TH, Lefranc MP, Stinson MA., Sims JE, Schroder J, Steinmetz M, 
Spurr NL, Solomon E, Goodfellow PN (1985c) The chromosomal location 
of T-cell receptor genes and a T-cell rearranging gene: possible 
correlation with specific translocations in human T cell leukemia. 
EMBO J. 4, 1461-1465. 
Raines MA., Lewis WG, Grittenden LB, Kung H--J (1985) c-ert:B activation in 
avian leukosis virus induced erythroblastosis: clustered integra-
tion sites and the arrangement of provirus in the c-ert:B alleles. 
Proc. Natl.Acad.Sci.USA 82, 2287-2291. ---
Rapp UR, Cleveland JL, Brightman K, Scott A, Ihle JN (1985) Abrogation of 
IL-3 and IL-2 dependence by recombinant murine retroviruses expres-
sing v-myc oncogenes. Nature 317, 434-438. 
Rechavi G, Givol D, Canaani E (1982) Activation of a cellular oncogene by 
INA rearrangement: Possible involvement of an IS-like element. Na-
ture 300, 607-610. 
Reddy EP, Smith MJ, Srinavasan A (1983) Nucleotide sequence of Abelson 
murine leukemia virus genome: Structural similarity of its trans-
forming gene product to other one gene products with tyrosine-
specific kinase activity. Proc.Natl.Acad.Sci.USA 80, 3623-3627. 
Reeve AE, Housiaux PJ, Gardner RJM, Chewings WE, Grindley RM, Mil low LJ 
(1984) Loss of a Harvey ras allele in sporadic Wilms' tumour. 
Nature 309, 174-176. 
Renmers EF, Yang J-Q, Marcu KB (1986) A negative transcriptional control 
element located upstream of the murine ~ gene. EMBO J. 5, 899-
904. 
Rettig WJ, Dracopoli NC, Chesa PG, Sprengler BA, Beresford HR, Davies P, 
Biedler JL, Old LJ (1985) Role of human chromosome ll in determi-
ning surface antigenic phenotype of normal and malignant cells. 
J.Exp.Med. 162, 1603-1619. 
Rey JA, Bello MJ, de Carrpos JM, Ramos MC, Benitez J (1985) Cytogenetic 
findings in a human malignant melanoma metastatic to the brain. 
Cancer Genet .Cytogenet. 16, 179-183 • 
Riccardi VM, Hittner HM, Francke U, Yunis JJ, Ledbetter D, Borges W 
(1980). The aniridia~ilms tumor association: The critical role of 
chromosome band llpl3. Cancer genet.Cytogenet. 2, 131-137. 
Robbins KC, Antoniades HN, Devare SG, Hunkapiller J.VW, Aaronson SA (1983): 
Structural an immunological similarities between simian sarcoma 
virus gene product( s) and human platelet-derived growth factor. Na-
ture 305, 605-608. 
Rodenhuis S, Smets LA, Slater RM, Behrendt H, Veerman AJP (1985) Distin-
guishing the Philadelphia chromosome of acute lymphoblastic leuke-
mia from its counterpart in chronic myelogenous leukemia. 
N.Engl.J.Med. 313, 51-52. 
Rogers JH, Heisterkamp N, Groffen J (1985) Oncogene chrornosoe breakpoints 
and Alu-sequeoces and reply. Nature 317 , 559. 
83 
Romero P, Blick M, Talpaz M, Muqtly E, Hester J, Gutterman J (1986) c-sis 
and c-abl expression in chronic myelogenous leukemia and other 
hematologic malignancies. Blood 67, 839-841. 
Rosenberg N, Baltimore D (1980) Abelson virus. In: Viral Oncology ed. G. 
Klein (New York, Raven Press) p. 187-203. 
Rosson D, Reddy EP (1986) Nucleotide sequence of chicken~ complemen-
tary DNA and implications for~ oncogene activation. Nature 319, 
604-606. 
Rovigatti U, Watson DK Yunis JJ (1986a) Amplification and rearrangement 
of Hu-ets-1 in leukemia and lymphoma with involvement of llq23. 
Science 232, 398-400. 
Rovigatti U, Carroll M, Sacher R, Jacobson R, Gallie B, Yunis J (1986b) 
Alteration of c-ets oncogenes in human hemopoietic neoplasias. 
abstr. International Symposiuni Normal and neoplastic blood cells: 
from genes to therapy, Rome 1986. 
Rowley JD (1973) A new consistent chromosomal abnormality in chronic 
myelogenous leukaemia identified by quinacrine fluorescence and 
Giemsa staining. Nature 243, 290-293. 
Rowley JD, Potter D (1976) Chromosomal banding patterns in acute non-
lymphocytic leukemia. Blood 47, 705-721. 
Rowley JD, Golomb H, Dougherty C (1977) 15/17 translocation, a consistent 
chromosomal change in acute promye1ocytic leukaemia. Lancet i, 549-
550. 
Rowley JD (1982) Identification of the constant chromosome regions invol-
ved in human hematologic malignant disease. Science 216, 749-751. 
Rowley JD, Testa JR (1982) Chromosome abnormalities in malignant hematc:r-
logic diseases. Adv.Canc.Res. 36, 103-148. 
Rowley J, Alimena G, Garson o, Hagemeijer A, Mittelman F, Prigogina E 
(1982) A collaborative study of the relationship of the morphologi-
cal type of acute nonlymphocytic leukemia with patient age and 
karyotype. Blood 59, 1013-1022. 
Rowley JD (1983) Human oncogene locations and chromosome aberrations. 
Nature 301, 290-291. 
Rowley J (1984) Biological implications of consistent chromosome rearran-
gements in leukemia and lymphoma. Cancer Res. 44, 3159-3168. 
Ruley HE (1983) Adenovirus early region 1A enables viral and cellular 
transforming genes to transform primary cells in culture. Nature 
304, 602-606. 
Rutishauser u, Goridis C (1986) NCAM: the molecule and its genetics. 
Trends in Genet. 2, 72-76. 
Sacca R, Stanley ER, Sherr CJ, Rettenmier CW (1986) Specific binding of 
the mononuclear phagocyte colony-stimulating factor CSF-1 to the 
product of the v-fms oncogene. Proc.Natl.Acad.Sci.USA 83, 3331-
3335. --
Sacchi N, Watson DK, Geurts van Kessel AHM, Hagemeijer A, Kersey J, 
Drabkin liD, Patterson D, Papas TS (1986) Hu-ets-1 and Hu-ets-2 
genes are transposed in acute leukemias with (4;11) and (8;21) 
translocations. Science 231, 379-382. 
Sadamori N, Matsunaga M, Yao E-I, Ichimaru M, Sandberg AA (1985a) Chromo-
somal characteristics of chronic and blastic phases of Ph-positive 
chronic myeloid leukemia. Cancer Genet.Cytogenet. 15, 17-24. 
84 
Sadanori N, Kusano M, Nishino K, Tagawa M, Yao E-I, Yamada Y, Amagasaki 
T, Kinoshita K-I, Ichimaru M (1985b) Abnormalities of chromosome 14 
at band 14qll in Japanese patients with adult T-cell leukemia. 
Cancer Genet.Cytogenet. 17, 279-282. 
Saglio G, Pegoraro L, Avanzi G, Giovinazzo B, Locatelli F, Falda M, 
Zaccaria A, Attadia V, Guerrasio A, Serra A, Spinelli P, Gavosto F 
(1986). Abstract: Normal and neoplastic blood cells: from genes to 
therapy. Rome June 10-13, 1986. 
Sandberg AA (1980) The chromosomes in human cancer and leukemia. Elsevier 
/North Holland, New York. 
Sandberg A, Kohno S-I, Wake N, Minowada (1980) Chromosomes and causation 
of human cancer and leukemia. XLII. Cancer Genet.Cytogenet. 2, 145-
174. 
Sandberg AA (1986) Chromosome changes in bladder cancer: Clinical and 
other correlations. Cancer Genet.Cytogenet. 19, 163-175. 
Sariban E, Mitchell T, Kufe D (1985) Expression of the c-fms proto-
oncogene during human monocytic differentiation. Nature 316, 64-66. 
Schalk en JA, van den Ouweland N!W, Bloemers HPJ, van de Ven JWM (1985) 
Characterization of the feline c-abl proto-oncogene. Biochemica et 
Bio};tlysica Acta 824, 104-ll2. --
Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, 
Weinberg RA (1984) The neu oncogene: a erb-B related gene encoding 
a 185.000-Mr tumour antigen. Nature 312, 513-516. 
Schechter AL, Hung M-e, Vaidyanathan L, Weinberg RA, Yang-Feng T, Francke 
u, Ullrich A, Coussens L (1985) The neu gene: an erb-B homologous 
gene distinct from and unlinked to the gene encoding the EGF recep-
tor. Science 229: 976-978. 
Schimke RI' (1984) Gene amplification in cultured animal cells. Cell 37, 
705-713. 
Schmid CW, Jelinek WR (1982) The Alu family of dispersed repetitive 
sequences. Science 216, 1065-1070. 
Schwab M, Alitalo K, Varmus HE, Bishop JM, George D (1983a) A cellular 
oncogene (c-Ki-ras) is amplified, overexpressed, and located within 
karyotypic abnormalities in mouse adrenocortical tumour cells. Na-
ture 303, 497-501. 
Schwab M, Ali talo K, Klempnauer KH, Varmus HE, Bishop JM, Gilbert F, 
Brodeur G, ·Goldstein M, Trent J (1983b) Amplified DNA with limited 
homology to ~ cellular oncogene is shared by human neuroblastoma 
cell lines and a neuroblastoma tumour. Nature 305, 245-248. 
Schwab M (1985) Amplification of N-myc in human neuroblastomas. Trends 
Genet. 1, 271-275. 
Schwartz OC, Cantor CR (1984) Separation of yeast chromosomes-sized DNAs 
by pulsed field gradient gel electrophoresis. Cell 37, 67-75. 
Seeger RC, Brodeur GM, Sather H, Dalton A, Siegel SE, Wong KY, Harmrond D 
(1985) Association of multiple copies of the N-myc oncogene with 
rapid progression of neuroblastomas. N.Eng.J.Med. 313, ll-116. 
Sefton BM, Hunter T, Raschke W: (1981) Evidence that the Abelson virus 
protein functions in vivo as a protein kinase that phos};tlorylates 
tyrosine. Proc.Natl.Acad.Sci.USA 78, 1552-1556. 
Seki T, Spurr N, Obata F, Goyert S, Goodfellow P, Silver J (1985) The 
human Thy-1 gene: structure and chromosomal location. Proc.Natl. 
Acad.Sci.USA 82, 6657-6661. 
Seizinger BR, Martuza RL, Gusella JF (1986) Loss of genes on chromosome 
22 in tumorigenesis of human acoustic neuroma. Nature 322, 644-647. 
85 
Selden JR, Emanuel BS, Wang E, Cannizzaro L, Palumbo A, Erikson J., 
Nowell PC, Rovera G, Croce CM (1983) Amplified C.A and c-abl genes 
are on the same marker chromosome in K562 leukemia cells. Proc.Natl 
Acad.Sci.USA 80, 7289-7292. 
Selten G, Cuypers HI', Berns A (1985) Proviral activation of the putative 
oncogene Pim-1 in MulV induced T-cell lymphanas. EMBO J. 4, 1793-
1798. --
Semba K, Yamanishi Y, Nishizawa M, Sukegawa J, Yoshida M, Sasaki M, 
Yamamoto T, Toyoshima K (1985) Location of the e-yes gene on the 
human chromosome and its expression in various tissues. Science 
227, 1038-1040. 
Sheer D, Hiorns LR, Stanley KF, Goodfellow PN, Swallow J:M, Poveys S, 
Heisterkamp N, Groffen J, Stephenson JR, Solomon E (1983) Genetic 
analysis of the 15~17 chromosome translocation associated with 
acute promyelocytic leukemia. Proc.Natl.Acad.Sci.USA. 80, 5007-
5011. 
Shen-0ng GL, Keath EJ, Piccoli SP, Cole MD (1982) Novel_!!!¥£ oncogene RNA 
from abortive immunoglobulin-gene recombination in mouse plasmacy-
tomas. Cell 31, 443-452. 
Shen-Dng GLC, Potter M, Mushinski JF, Lavu S, Reddy EP (1984) Activation 
of the ~ locus by viral insertional mutagenesis in plasmacytoid 
lymphosarcomas. Science 226, 1077-1080. 
Sherr CJ, Rettemier QiJ, Sacca R, Rousel MF, Look AT, Stanley ER (1985) 
The c-fms proto-oncogene product is related to the receptor for the 
mononuclear phagocyte growth factor, CSF-1. Cell 41, 665-676. 
Shilo B.-Z, Weinberg RA (1981) DNA sequences homologous to vertebrate 
oncogenes are conserved in Drosophila melanogaster. Proc.Natl.Acad. 
Sci.USA 78, 6789-6792. 
Shima E, Lebeau M, McKeithan T, Minowada J, Showe L, Mak T, Minden M, 
Rowley J, Diaz M (1986) Gene encoding the a-chain of the T cell 
receptor in moved immediately downstream of c-rnyc in a chromosomal 
8~14 translocation in a cell line from a human T-cell leukemia. 
Proc.Natl.Acad.Sci USA 83, 3439-3443. 
Shimizu K, Goldfarb M, Suard Y, Perucho M, Li Y, et al. (1983) Three 
human transforming genes are related to the viral ras oncogenes. 
Proc.Natl.Acad.Sci USA 80, 2112-2116. -
Shtivelman E, Lifshitz. B, Gale RP and Canaani E (1985) Fused transcript 
of abl and bcr genes in chronic myelogenous leukaemia. Nature 315, 
550-554. -
Slater RM (1986) The cytogenetics of Wilms' tumor. Cancer Genet.Cytoge-
net. 19, 37-41. 
Solomon E (1984) Recessive mutation in aetiology of Wilms' tumour. Nature 
309, 111-112. 
Sonnier JA, Buchanan GR, Howar-Peebles PN, Rutledge J, Smith RG (1983) 
Chromosomal translocation involving the immunoglobulin kappa-chain 
and heavy chain loci in a child with chronic lymphocytic leukemia. 
N.Engl.J.Med. 309, 590-594. 
Sparkes RS, Murphree AL, Lingua RW, Sparkes M:, Field LL, Funderburk SJ, 
Benedict WF (1983) Gene for hereditary retionoblastoma assigned to 
human chromosome 13 by linkage to esterase D. Science 219, 971-973. 
Sparkes RS (1984) Cytogenetics of retinoblastana. Cancer Surveys 3, 479-
496. 
86 
Spurr NK, Solomon E, Jansson M, Sheer D, Goodfellow PN, Boehner WG.F, 
Vennstrom B (1984) Chromosomal localization of the human hom::>logues 
to the oncogenes erbi\ and B. EMBO J. 3, 159-164. 
Squire J, Gallie Bl, Philips RA (1985) A detailed analysis of chromosomal 
chnages in heritable and non-heritable retinoblastoma. Hum.Genet. 
70, 291-301. 
Squire J, Goddard AD, canton M, Becker A, Phillips RA, Gallie BL (1986) 
Tumour induction by the retinoblastoma mutation is independent of 
N-myc expression. Nature 322, 555-557. 
Srinivasan A, Dunn C'f., Yuasa Y, Devare SG, Reddy EP, Aaronson SA (1982) 
Abelson murine leukemia virus:_ structural requirements for trans-
forming gene function. Proc.Natl.Acad.Sci USA 79, 5508-5512. 
Starn K, Heisterkarrp N, Grossveld G, de Klein A, Verma RS, Coleman M, 
Dosik H, Groffen J (1985) Evidence of a new chimeric bcr/c-abl mRNA 
in patients with chronic myelocytic leukemia and the Philadelphia 
chromosome. N.Engl.J.Med. 313, 1429-1433. 
Stanton LW, Watt R, Marcu KB (1983) Translocation, breakage and truncated 
transcripts of c-myc oncogene in murine plasmacytomas. Nature 303, 
401-406. 
Stern DF, Hefferman PA, Weinberg RA (1986) pl85 a product of the neu 
proto-oncogene, is a receptorlike protein associated with tyrosine 
kinase activity. MolCell.Biol. 6, 1729-1740. 
Stewart TA, Pattengale PK, Leder P (1984) Spontaneous mammary adenocarci-
nomas in transgenic mice that carry and express mtv/rnyc fusion 
genes. Cell 38, 627-637. 
Sun LK, Showe LC, Croce G1 (1986) Analysis of the 3' fanking region of 
the human c-myc gene in lymphomas with the t(8;22) and t(2;8) chro-
mosomal translocations. Nucl.Acids Res. 14, 4037-4050. 
Swan DC, McBride 00, Robbins KC, Keithley DA, Reddy EP, Aaronson SA 
(1982) Chromosomal mapping of the Simian sarcoma virus one gene 
analogue in human cells. Proc.Natl.Acad.Sci.USA 79, 4691-4695. 
Taub R, Kirsch I, Morton C, Lenoir G, Swan D, Tronick S, Aaronson S, 
Leder P (1982) Translocation of the c-myc gene into immunoglobulin 
heavy chain locus in human Burkitt lymphoma and murine plasmacytoma 
cells. Proc.Natl.Acad.Sci.USA 79, 7837-7841. 
Taub R, Moulding C, Battey J, Murphy W, Vasicek T, Lenoir GM, Leder P 
(1984) Activation and somatic mutation of the translocated c-myc 
gene in Burkitt lymphoma cells. Cell 36, 339-348. 
Testa JR (1984) High resolution chromosomal analysis of acute leukemia: 
current assessment. cancer Surveys 3, 359-370. 
Testa J, Hogge D, Misawa S, Zandparsa N (1984) Chromosome 16 rearrange-
ments in acute myelornonocytic leukemia with abnormal eosinophils. 
N.Eng.J.Med. 310, 468-469. 
Thompson CB, Challoner PB, Neiman PE, Groudine M (1985) Levels of c-myc 
oncogene mRNA are invariant throughout the cell cycle. Nature 314, 
363-366. 
Thompson CB, Challoner PB, Neiman PE, Groudine M (1986) Expression of the 
~oncogene during cellular proliferation. Nature 319, 374-380. 
Tonegawa S (1983) Somatic generation of antibody diversity. Nature 302, 
575-581. 
Trent J, Olson S, Lawn R (1982) Chromosomal localization of human leuko-
cyte, fibroblast, and immune interferon genes by means of in situ 
hybridization. Proc .Natl.Acad .Sci. USA 79, 7809-7813. - --
87 
Trent JM (1984) Chromosomal alterations in hmnan solid tl.l!IDrs: implica-
tions of the stem cell model to cancer cytogenetics. Cancer Surveys 
3, 395-422. 
Tsichlis PN, Strauss PG, Hu LF (1983) A common region for proviral rnA 
integration in Mo-MuLV-induced rat thymic lymphomas. Nature 302, 
445-449. 
Tsujimoto Y, Yunis J, Onorato-Showe L, Erikson J, Nowell PC, Croce CM 
(1984a) Molecular cloning of the chromosomal breakpoint of B-cell 
lymphomas and leukemias with the t(ll;l4) chromosome translocation. 
Science 224, 1403-1406. 
Tsujimoto Y, Finger LR, Yunis J, Nowell PC, Croce CM (l984b) Cloning of 
the chromosome breakpoint of neoplastic B cells with the t(l4;18) 
chromosome translocation. Science 226, 1097-1099. 
Tsujimoto Y, Cossman J, Jaffe E, Croce CM (1985a) Involvement of the 
bcl-2 gene in human follicular lymphoma. Science 228, 1440-1443. 
Tsujimoto Y, Gorham J, Cossman J, JaffeE, Groce CM (1985b) The t(l4;18) 
chromosome translocations involved in B-cell neoplasms result from 
mistakes in VDJ joining. Science 229, 1390-1393. 
Tsujirnoto Y, Jaffe E, Cossman J, Gorham J, Nowell PC, Croce CM (1985c) 
Clustering of breakpoints on chromosome 11 in human B-cell neo-
plasms with the t(ll;l4) chromosome translocation. Nature 315, 340-
343. 
Tsujimoto Y, Croce CM (1986) Analysis of the structure, transcripts and 
protein products of bcl-2 the gene involved in human follicular 
lymphoma. Proc.Natl.Acad.Sci.USA 83, 5214-5218. 
Turc-Carel C, Philip I, Berger M-P, Philip T, Lenoir GM (1983) Chromoso-
mal translocations in Ewing sarcoma. N.Eng.J.Med. 309, 497-498. 
Turc-Carel C, Lizard-Nacol S, Justrabo E, Favrot M, Philip T, Tabone E 
(1986) Consistent chromosomal translocation in alveolar rhabdomyo 
sarcoma. Cancer Genet.Cytogenet. 19, 361-362. 
Ueshima Y, Rowley JD, Variakojis D, Winter J, Gordon L (1984) Cytogenetic 
studies on patients with chronic T cell leukemia/lymphoma. Blood 
63, 1028-1038. 
Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, 
Coussens L, Liao Y.-u, Tsubokawa M, Mason A, Seeburg PH, Grunfeld 
C, Rosen CM, Ramachandran J (1985) Human insulin receptor and its 
relationship to the tyrosine kinase family of oncogenes. Nature 
313, 756-761. 
Van den Elsen P, Bruns G, Gerhard D, Pravtcheva D, Jones C, Housman D, 
Ruddle F, Orkin S, Terhorst C (1985) Assignment of the gene coding 
for the T38 subunit of the T3-T cell receptor complex to the long 
arm of human chromosome 11 and to mouse chromosome 9. Proc.Natl. 
Acad.Sci.USA 82, 2920-2924. 
Van Heyningen V, Boyd PA, Seawright A, Fletcher JM, Fantes JA, Buck ton 
KE, Spowart G, Porteous IlJ, Hill RE, Newton MS, Hastie ND (1985) 
Molecular analysis of chromosome 11 deletions in aniridia~ilms' 
tl.l!IDr syndrome. Proc.Natl.Acad.Sci.USA 82, 8592-8596. 
Vanin E, Henthorn P, Kioussis D, Grosveld F, Smithies 0 (1983) Unexpected 
relationships between four large deletions in the human_ ~-globin 
gene cluster. Cell 35, 701-709. 
Van Rys J, Giguere V, Hurst J, van Agthoven T, Geurts van Kessel A, 
Govert S, Grosveld F (1985) Chromosomal localization of the human 
Thu-1 gene. Proc.Natl.Acad.Sci.USA 82, 5832-5835. 
88 
Van 't Veer L, Geurts van Kessel A, Heerikhuizen H, Ooyen A, Nusse R 
(1984) Molecular cloning and chromosomal assignment of the human 
homolog of int-1, a mouse gene implicated in mammary tumorigenesis. 
Mol.Cell.Biol. 4, 2532-2534. 
Varmus HE (1982) Recent evidence for oncogenesis by insertion mutagene-
sis and gene activation. Cancer Surv. 2, 309-319. 
Varmus HE (1984) The molecular genetics of cellular oncogenes. Ann.Rev. 
Genet.l8, 553-612. 
Vernaelen K, Michaux J, Louwagie A, Van den Berghe H (1983) Reciprocal 
translocation t(6;9) (p2l;q33): A new characteristic chromosome ano-
maly in myeloid leukemias. Cancer Genet.Cytogenet. 10, 125-131. 
Versnel MA, Van Dongen JJM, Geurts van Kessel AHM, De Klein A, Bos NA., 
Hagerneijer A (1986) Expression of the human irrmunoglobulin heavy 
chain gene of the 14q+ chromosome in a t(8;14) positive Burkitt 
lymphoma cell line demonstrated in somatic cell hybrids. Cancer 
Genet.Cytogenet. 19, 321-330. 
Villeneuve L, Rassart E, Jolicoeur P, Graham M, Adams JM (1986) Proviral 
integration site mis-1 in rat thymomas corresponds to the pvt-1 
translocation breakpoint in murine plasmacytomas. Mol.Cell.Biol. 6, 
1834-1837. 
Vogel F (1979) Genetics of retinoblastoma. Hurn.Genet. 52, 1-54. 
Von Hansernann D (1890) Uber asyrnrnetrische zellteilung in epithel krebsen 
und der biologische bedeutung. Virchows Archiv fur Path.Anatorni und 
Physiologie 119, 299-326. 
WakeN, Hreschchyshyn MM, Piver SM, Matsui S, Sandberg AA (1980) Specific 
cytogenetic changes in ovarian cancer involving chromosomes 6 and 
14. Cancer Res. 40, 4512-4518. 
Waneck GL, Rosenberg N (1981) Abelson leukemia virus induces lymphoid and 
erythroid colonies in infected fetal cell cultures. Cell 26, 79-89. 
Waneck GL, Keyes L, Rosenberg M (1986) Abelson virus drives the differen-
tiation of Harvey virus-infected erythroid cells. Cell 44, 337-344. 
Wang JYJ, Baltimore D (1983) Cellular RNA homologous to the Abelson 
murine leukemia virus transforming gene: Expression and relation-
ship to the viral sequence. Mol.Cell.Biol. 3, 773-779. 
Wang JYJ, Ledley F, Goff S, LeeR, Groner Y, Baltimore D (1984) The mouse 
c-abl locus: molecular cloning and characterization. Cell 36, 349-
356. 
Wang JYJ, Baltimore D (1985) Localization of tyrosine kinase-coding 
region in v-abl oncogene by the expression of v-abl encoded pro-
teins in bacteria. J.Biol.Chem. 260, 64-71. 
Waterfield MD, Scrace GI', Whittle N, Stroobant P, Johnsson A, Wasteson A, 
Westermark B, Heldin CH, Huang JS, Deuel TF (1983) Platelet-derived 
growth factor is structurally related to the putative transforming 
protein p28s1 s of simian sarcoma virus. Nature 304, 35-39. 
Watson DK, McWilliarns-Smith ID, Nunn MF, Duesberg PH, O'Brien SJ, Papas 
TS (1985) The ets sequence from the transforming gene of avian 
erythroblastosis virus, E36, has unique domains on human chromo-
somes 11 and 21: both loci are transcriptionally active. Proc.Natl 
Acad.Sci.USA 82, 7294-7298. 
Watson DK, McWilliarns-Smith MJ, Kozak C, Reeves R, Gearhart J, Nunn MF, 
Nash W, Fowle JR, Duesberg P, Papas TS and O'Brien SJ (1986) Con-
cerved chromosomal position of dual domains of the ets protoonco-
gene in cats, mice and humans. Proc.Natl.Acad.Sci.USA 83, 1792-
1796. 
89 
Webb E, Adams JM, Cory S (1984) Variant (6;15) translocation in a murine 
plasmacytoma occurs near an immunoglobulin K gene but far from the 
~oncogene. Nature 312, 777-779. 
Web HJ, Hossfeld DK (1986) 12p- Chromosome in patients with acute myelo-
cytic leukemia or myelodysplastic syndromes following exposure to 
mutagenic agents. Cancer Genet.Cytogenet. 19, 355-356. 
Weinberg RA (1985) The action of oncogenes in the cytoplasm and nucleus. 
Science 230, 770-776. 
Westbrook CA, LeBeau MM., Diaz MO, Groffen J, Rowley JD (1985) Chromosomal 
localization and characterization of c-abl in the t(6;9) of acute 
nonlymphocytic leukemia. Proc.Natl.Acad.Sci .USA 82, 8742-8746. 
Westin EH, Wong-Staal F, Gelmann EP, Dalla Favera R, Papas TS, Lautenberg 
JA, Eva A, Reddy EP, Tronick SR, Aaronson SA, Gallo RC (1982) 
Expression of cellular homologues of retroviral one genes in human 
hematopietic cells. Proc.Natl.Acad.Sci.USA 79, 2490-2494. 
Whang-Peng J, Kao-Shan CS, Lee EC, Bunn DA, Carney IN, Gazdar AF, Minna 
JD (1982) Specific chromosome defect associated with human small-
cell lung cancer: deletion 3p (14-23). Science 215, 181-182. 
Whang-Peng J, Knutsen T (1982) Chromosomal abnormalities. In: Shaw, M.T. 
(ed) Chronic granulocytic leukemia East.Sussex. UK Praeger p. 49-
92. 
Williams DL, Look AT, Melvin SL, Roberson PK, Dahl G, Flake T, Stass S 
(1984) New chromosomal translocations correlate with specific im-
munophenotypes of childhood acute lymphoblastic leukemia. Cell 36, 
101-109. 
Wingvist R, Saksela K, Alitalo K (1984) The _!!!Y£ proteins are not asso-
ciated with chromatin in mitotic cells. EMBO J. 3, 2947-2950. 
Wisniewski LP, Hirschhorn K (1983) Acquired partial deletions on the long 
arm of chromosome 5 in hematologic disorders. Am.J.Hemat. 15, 295-
310. 
Wong AJ, Ruppert JM, Eggleston J, Hamilton SR, Bay lin SB, Vogelstein B 
(1986) Gene amplification of ~ and N-myc in small cell carcino-
ma of the lung. Science 233, 461-464. 
Yamamoto K, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, 
Toyoshima K (1986) Similarity of protein encoded by the human c-
erbB-2 gene to epidermal growth factor receptor. Nature 319, 230-
~
Yang-Feng TL, Francke U, Ullrich A (1985) Gene for human insulin recep-
tor: localization to site on chromosome 19 involved in pre-B-cell 
leukemia. Science 228, 728-731. 
Yoshida MA, Ohyashiki K, Ochi H, Gibas Z, Prout GR, Pontes EJ, Huben R, 
Sandberg AA (1986) Rearrangements of chromosome 3 in renal cell 
carcinoma. Cancer Genet.Cytogenet. 19, 35l-354. 
Yunis JJ, Bloomfield CD, Ensrud K (1981) All patients with acute non-
lymphocytic leukemia may have a chromosomal defect. N .Eng .J .Med. 
305' 135-139. 
Yunis JJ (1981) New chromosome techniques in the study of human neopla-
sia. Human Path. 12, 540-549. 
Yunis JJ, Oken MM., Kaplan ME, Ensrud KM, Howe RR, Theologides A (1982) 
Distinctive chromosomal abnormalities in histologic subtypes of 
non-Hodgkin's lymphoma. N.Engl.J.Med. 307, 1231-1236. 
Yunis JJ, Soreng AL (1984) Constitutive fragile sites and cancer. Science 
226, 1199-1204. 
90 
Yunis JJ (1983) The chromosomal basis of human neoplasia. Scieoce 221, 
227-236. 
Yunis JJ, Brunning RD, Howe RB, Lobell A (1984) High-resolution chromo-
somes as an independent prognostic indicator in adult acute nonlym-
phocytic leukemia. N.Engl.J.Med. 311, 812-818. 
Zech L, Haglund U, Nilsson K, Klein G (1976) Characteristic chromosomal 
abnormalities in biopsies and lymphoid-cell lines from patients 
with Burkitt and non-Burkitt lymphanas. Int.J .Caocer 17, 47-56. 
Zech L, Gahrton G, Hamnarstr5m L, Juliusson G, Mellstedt H, Robert KH, 
Smith CIE (1984) Inversion of chromosome 14 marks human T-cell 
chronic lymphocytic leukaemia. Nature 308, 858-860. 
Zimmerman KA, Yancopoulos GD, Collum RG, Smith RK, Kohl NE, Denis KA, Nau 
MM, Witte CN, Toran-Allerand D, Gee CE, Minna JD, Alt EW (1986). 
Differential expression of ~ family genes during murine develop-
ment. Nature 319, 780-783. 
19 juni 1956 
mei 1974 
september 1974 
september 1978 
mei 1982 
april 1982 
juni 1986 
CURRICULUM VITAE 
Geboren te Lent 
Eindexamen Atheneum B aan bet 
Canisius College te Nijmegen 
Aanvang studie Biologie aan de 
Katholieke Universiteit Nijmegen 
Kandidaatsexamen Biologie (Blw) 
Doctoraalexamen Wiskunde en Natuur-
wetenschappen aan de Katholieke 
Universiteit te Nijmegen 
91 
Hoofdvak: Chemische Cytologie o.l.v. 
Dr. F. Wanka en Dr. P. Dijkwel, 
Faculteit der Wis- en Natuurkunde, 
Nijmegen. 
Bijvakken: Nefrologie o.l.v. 
Dr. P. Capel, Faculteit der 
Geneeskuunde, Nijmegen. 
Moleculaire Biologie: o.l.v. 
Dr. R. Flavell en Dr. F. Grosveld, 
M.R.C., Londen. 
Aanvang promotieonderzoek op de 
afdeling Celbiologie en Genetica van 
de Erasmus Universiteit o.l.v. 
Prof.Dr. D. Bootsma en 
Dr. G.C. Grosveld met financiele 
steun van bet Koningin Wilhelmina 
Fonds en bet fonds Geven voor Leven 
ten behoeve van de Kinderoncologie. 
Toekenning van een ZWO stipendium 
om een postdoctoraal onderzoek te 
verrichten aan bet National Cancer 
Institute, Federick, U.S.A. in 1987. 

93 
PAPER I 
NATURE 300: 765-767 (1982) 

A cellular oncogene is translocated to 
the Philadelphia chromosome 
in chronic myelocytic leukaemia 
Annelies de Klein*, Ad Geurts van Kessel*, 
Gerard Grosveld*, Claus R. Bartram*, 
Anne Hagemeijer*, Dirk Bootsma*, 
Nigel K. Spurrt, Nora Heisterkamp:j:, 
John Groffen:j: & John R. Stephenson:j: 
*Department of Cell Biology and Genetics, Erasmus University, 
PO Box 1738-3000 DR Rotterdam, The Netherlands 
t Imperial Cancer Research Fund, Lincoln's Inn Fields, 
London WC2A 3PX, UK 
:j: Laboratory of Viral Carcinogenesis, National Cancer 
Institute-FCRF, Frederick, Maryland 21701, USA 
The transforming genes of oncogenic retroviruses are 
homologous to a group of evolutionary conserved cellular one 
genes'. The human cellular homologue (c-ab/) ofthetransform-
ing sequence of Abelson murine leukaemia virus (A-MuLV) 
was recently shown2 to be located on chromosome 9. The long 
arm of this chromosome is involved in a specific translocation 
with chromosome 22, the Philadelphia translocation (Ph1), t(9; 
22) ( q34, qll), which occurs in patients with chronic myelocytic 
leukaemia (CML)3-5. Here we investigate whether the c-ab/ 
gene is included in this translocation. Using c-abl and v-abl 
hybridization probes on blots of somatic cell hybrids, positive 
hybridization is found when the 22q- (the Philadelphia chromo-
some), and not the 9q+ derivative of the translocation, is present 
in the cell hybrids. From this we conclude that in CML, c-abl 
sequences are translocated from chromosome 9 to chromosome 
22q-. This finding is a direct demonstration of a reciprocal 
exchange between the two chromosomes6 and suggests a role 
for the c-abl gene in the generation of CML. 
The human c-ab/ sequences represent a cellular homologue 
of the transforming component of A-MuLV. This retrovirus is 
a recombinant between Moloney MuL V and mouse cellular 
c-abl sequences7 and induces lymphoid tumours on in vivo 
inoculation of the mouse8 •9 • The major A-MuLV translational 
product has been identified as a poly-protein, Pl20'"•·•bt, con-
sisting of amino-terminal structural proteins encoded by the 
Abelson- MuLV 
v-abl probe 
v-nbl hybnd1z1ng 
sequences 
c-ab! probes 
s1zes of c-ab! 
EcoR! fragments 
c- abl 
p 1.7 
B B 
w 
2.9 
-p 1.7 
7.2 
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M-MuLV gag gene, linked to an acquired cellular sequence 
encoded carboxy-terminal componene0' 1 1 • This protein is one 
of several virus-encoded transforming proteins with tyrosine-
specific protein kinase activity12- 15• Similar oncogenic sequences 
of Harvey and Kirsten sarcoma virus are homologous to trans-
forming sequences (c-Ha-ras, c-Ka-ras) isolated from human 
bladder and lung carcinoma cell lines 1~18• Both these sequences 
induce transformation of mouse NIH 3T3 cells after transfec-
tion, establishing that the human genes have potential trans-
forming activity. Recently, the human c-ab/ gene has been 
cloned in cosmids19 • Usingv-ahl DNA as a probe, several clones 
containing overlapping sequences representing the entire c-abl 
gene were isolated from a human lung carcinoma cosmid library. 
The restriction enzyme map of the human v-abl cellular 
homologue, presented in Fig. 1, identifies areas of the gene 
which hybridize to v-abl sequences. The gene is distributed 
over a region of 40 kilobases (kb) of human DNA and contains 
multiple intervt!ning sequences. On transfection of Rat-2 cells 
with the c-abl cosmids, no transforming activity was detected, 
not unexpectedly, as none of the cosmid clOnes tested contained 
the entire c-ab[ gene19• 
By Southern blot analysis of a series of somatic cell hybrids, 
the human c-abl gene has been localized on chromosome 92 • 
This finding is of interest because of the involvement of the 
long arm of chromosome 22 (band 22qll) in a specific translo-
cation with the long arm of chromosome 9 (band 9q34 ), the 
Philadelphia translocation (Ph1), occurring in human CML3 ... 
The abnormal chromosomes are designated 9q• and 22q-; of 
these, the 22q- chromosome is observed in 92% ofCML cases5 • 
We investigated the chromosomal location of the human c-ab/ 
gene in cases of CML, where the Philadelphia translocation is 
present. Southern blot analyses with c-ab/ and v-abl probes 
were performed on EcoRI-digested DNAs from somatic cell 
hybrids segregating the 9q• and 22q- chromosomes. 
The cell hybrids used here contain a full complement of 
mouse or Chinese hamster chromosomes and a limited number 
of human chromosomes. The hybrid cell lines have been 
obtained by fusion of cells from mouse (Pg 19 and WEHI-3B) 
or Chinese hamster (E36 and a3) origin with leukocytes from 
different CML patients and from a normal donor6 ' 20• The human 
chromosome content of these cells is summarized in Table 1 
and is based on chromosome analysis. In addition, the hybrid 
cells were tested for the expression of human adenylate kinase-1 
(AK1) enzyme activity, a marker localized proximal in band 
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Fig.l Restriction enzyme map of the human c-ab! region19• The upper line of the figure shows the BamHI subclone of A-MuLV; the hatched 
box presents the long terminal repeat, the solid bar. the acquired celiular :;;equences. Directly beneath the A-MuLV genome, a subgenomic Pst 
1. 7-kb fragment, used as a probe in this study, is shown. Human c-ab[ DNA restriction fragments homologous to v·abl sequences are indicated 
as black boxes and those that show homology to the 1.7 -kb Pst v-abl fragments are designated by P 1.7. The third line shows the human c-ab! 
0.6-kb BamHI and 2.2-kb Hindiii-EcoRI probes, which hybridize to 5' and 3' c-ab[ EcoRI fragments, respectively. The sizes of all EcoRI 
c-ab! fragments are indicated on the fourth line. The bottom line represents the restriction enzyme map of the human c-ab! gene. Restriction 
enzymes include BamHI (B), Hindiii (H) and EcoRI (E). A ~~;::e:~j~ed characterization of the hum~n c-ab! locus will be published 
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Fig. 2 · Localization of human c-ab! sequences on the Philadelphia chromosome, using hybrid cell lines and human c-abl probes. A. detection 
of the human 5' end 2.9-kb EcoRI c-ab{ fragment in DNA from a, human placenta; h, 1DCB-23B (chromosome 9); c, PgMe-25NU (chromosome 
22q): d. 14CB-21A (chromosome 9q.): e. 1CN-17aNU (chromosome 22q-): f. WESP-2A (chromosome 22q-): g. mouse Pg19: h. Chinese 
hamster E36: i, mouse WEHI-3B; j, Chinese hamster a3. B, detection of the 3'-end 5.0-kb EcoRI c-abl fragment in DNAs as indicatec. m 
A(a-j). The derivations of all these cell lines and their complements of human chromosomes are summarized in Table 1. 
Methods: All cell lines used in this experiment were grown in large batches (107-108 cells) and DNA was prepared as described by Jeffreys 
and Flavel128• £caRl-restricted DNAs (10 ~g per lane) from human placenta. hybrid cell lines. mouse and Chinese hamster fusion partners 
were electrophoresed on 0.7% agarose gels. Hindiii and Hindiii-EcoRI-digested A DNAs were included as molecular weight markers {not 
shown). Afterblottingto nitrocellulose, the filters were hybridized to the 0.6-kbBamHI c-ab[ (A) or 1.1-kb Hindiii-EcoRic-abl {B) restriction 
fragments described in Fig. 1. Hybridization and washing procedures (to 0.1xSSC at 65o.C) were carried out according to the method of 
Bernards and FlaveiJ23 . 
9q34 (ref. 21). This latter test was necessary to exclude the 
possibility of hidden (broken or rearranged) chromosome 9 
fragments in the 22 and 22q- cell lines. 
Detection of the human c-ab! restriction fragments in hybrid 
cell DNAs is often inconclusive using v-abl probes, because 
the human sequences are present in submolar amounts (20-
50%) and also because many of the human c-ab! restriction 
fragments electrophorese in close proximity with strongly 
hybridizing mouse or Chinese hamster fragments. To obtain 
molecular probes with specificity for human c-ab! sequences, 
two restriction fragments were isolated from subclones of c-aM-
containing cosmids, with homology to the presumptive 5' and 
3' proximal EcoRI fragments of c-ab!. These are 2.9 and 5.0 kb, 
respectively. in size (Fig. 1). After hybridization and washing 
to high stringency (0.1 x SSC) 12• the 5'-terminal 0.6-kb BamHI 
probe and the 3'-terminal1.1-kb Hindiii-EcoRI probe cross-
hybridize to a very low extent with mouse or hamster c-ab! 
sequences. Figure 2A shows an example of a hybridization 
experiment with the 0.6-kb BamHI probe. This Southern blot 
illustrates hybridization of EcoRI-restricted DNAs of hybrid 
cell lines containing chromosomes 22, 9, 9q+ or 22q·. As 
controls, hybridization of the probe with human placenta DNA 
and DNA from the mouse and Chinese hamster fusion partners 
is shown. It is clear that the 2.9-kb EcoRI fragment, detected 
in human placenta DNA, is also present in the lanes containing 
DNA from the hybrid cell lines 10 CB-23B (chromosome 9). 
1CB-17a NU and WESP-2A (both containing chromosome 
22q-). The band is not detected in lanes containing DNA from 
Table 1 Human chromosome content of human-mouse and human-Chinese hamster somatic cell hybrids 
Hybrid 
PgMe-25NU 
10CB-23B 
14CB-21A 
1CB-17aNU 
WESP-2A 
Human chromosomes 
4 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y 9q• 22q· 
- - - - - - - - + -
- + - + - + + -
- + - - + + - - - - + - - + - -
- + - - + - + + - - - + - + -
- + + - + - - + -
+ 
+ 
Human 
isoenzyme 
AKJ 
+ 
Ref. 
26 
6 
20 
6 
The origin and details of the initial characterization of the somatic cell hybrids are described in the references listed in the last column. PgMe-25NU 
and WESP-2A are hybrids obtained from fusions with mouse Pg19 and WEHI-3B cells, respectively. Chinese hamster cell line E36 was used to 
produce hybrid clones 10CB-23B and 14CB-21A, while Chinese hamster cell line a3 was used to obtain 1CB-17aNU. Chromosome analysis was 
done using reverse (R) banding with acridine orange, after heat denaturation. At least 16 metaphases were analysed per cell line. The presence 
of human AKI activity was assayed by cellulose acetate (Cellogel) electrophoresis27 • This test is inconclusive for the WESP-2A cell line (x), 
because the expression of AKI was found to be repressed in hybrids derived from fusion with WEHI-3B cells {A.H.M., G.v.K., unpublished 
results). Chromosome and isoenzyme analyses22 were performed on the same batches of hybrid cells that were used for the isolation of DNA. 
a b c 
kb 
' 
11- t 
7.2-
4.0-. \ 
3.4- • 2.9-
2.5- • 
, .. 
Fig. 3 Localization of human c-ab! sequences on the Philadelphia 
chromosome, using a 22q- somatic cell hybrid and a v-abl probe. 
£caRl-digested DNAs (10 IJ.g) from human placenta (a), hybrid 
WESP-2A (b) and mouse WEHI-3B cells (c) were hybridized 
with the 1.7-kb Pst v-abl fragment (Fig. 1), as described in Fig. 
2 legend. After hybridization, the filters were washed to 1 X sse 
at 65 "C. Molecular weights of human c-ab! fragments were 
deduced from co-electrophoresed Hindlll and Hindiii-EcoRI-
digested A DNA markers. 
PgMe-25Nu (chromosome 22), 14CB-21A (chromosome 9q+), 
Pg19 and WEHI-3B (mouse controls) or E36 and a3 (Chinese 
hamster controls). Analogous results are obtained when the 
same £caRl-digested DNAs are hybridized to the 3'-terminal 
1.1-kb Hindiii-EcoRI probe (Fig. 2B). The 5.0-kb EcoRI 
fragment is detected only in DNA from human placenta and 
from hybrid cell lines containing chromosome 22q- or 9. 
The above results show that both the 5' and 3' ends of the 
c-ab{ gene are translocated to chromosome 22q-. Because all 
other c-ab! EcoRI fragments, which hybridize to v-abi sequen-
ces, are flanked by the 2.9-kb and 5.0-kb EcoRI fragments, it 
seems highly probable that these fragments are also included 
in the translocation to the Philadelphia chromosome. To test 
this possibility directly, hybridization was performed using a 
1.7-kb Pst v-abl probe (Fig. 1). Because of the problems with 
v-abl probes indicated above, only WESP-2A, the hybrid con-
taining the most 22q- sequences (50% of the molar amount), 
was tested. As shown in Fig. 3, the viral probe detects human 
EcoRI c-ab! fragments of 11, 7.2, 4.0, 3,.4, 2.9 and 2.5 kb 
(weakly). Of these fragments, the 11-kb band has been shown 
to map outside the main human c~abl locus19 and will not be 
considered here. The human 2.9-, 3.4-, and 4.0-kb c-ab! frag-
ments are readily detected in the WESP-2A DNA. In contrast, 
the 7.2-kb EcoRI fragment can only be seen in a short exposure 
of this filter (not shown), due to spill-over of radiation from 
strongly hybridizing mouse c-ab! fragments in this area. The 
2.5-kb EcoRI human c-ab! fragment co-migrates with a mouse 
fragment of similar size and thus cannot be identified in this 
analysis. 
The hybrid cell lines containing the 9q+ and 22q- chromo-
somes examined in the present study, were obtained from fusion 
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experiments with CML cells from three different individuals. 
Therefore, we conclude that in the Philadelphia translocation 
a fragment of chromosome 9 is translocated to chromosome 
22q- and that this fragment includes the human c-ab! sequen-
ces. This finding establishes that the translocation is reciprocal, 
a general assumption which is now demonstrated unequivocally. 
Moreover, the data map the human c-ab! sequences distal to 
AK1 (not translocated to 22q·, 6, 20) on chromosome 9. The 
most interesting aspect is that it raises the possibility of involve~ 
ment of the human c-ab! gene in the generation of CML. 
In principle, the chromosomal translocation associated with 
CML could lead to elevated levels of c-ab! expression which, 
by analogy to the c~Ha-ras gene in bladder carcinoma, would 
induce malignant transformation24• Elevated levels of c-ab{ 
expression could be the result of coupling of the gene to an 
enhancer sequence present on chromosome 22 or, alternatively, 
the gene could be linked to a strong promoter of another gene. 
To test these possibilities, we have initiated studies to clone 
the c-ab! gene from the 22q- chromosome using WESP-2A 
DNA and a cosmid vector system. Finally, it is of interest that 
in some CML patients variant Ph 1 translocations are observed, 
in which the participation of chromosome 9 cannot be detected 
by classical cytogenetic analysis3'5 • In another group of CML 
patients the Ph 1 translocation appears to be completely 
absent25• We are now investigating whether the c-ab! gene is 
translocated to chromosome 22 in these cases also. 
These studies were initiated as part of a collaborative effort 
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Boucke for help with the preparation of the manuscript. The 
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(Koningin Wilhelmina Fonds) and under NCI PHS contract 
NOI-C0-75380. C.R.B. is a recipient of a fellowship from the 
Deutsche Forschungsgemeinschaft. 
Received 12 November; accepted 25 November 1982, 
1. Coffin, J. M, ct a/, J. Virol. 40, 953-957 (1981). 
2, Heisterknmp, N. eta/, Nature 299, 747-750 (1982), 
3, Rowley, J.D. Nature 243, 290-293 {1973), 
4. Lawler, S.D. Clin. Haemat. 6, 55-75 (1977), 
5, Rowley, J.D. Clin. Haemat, 9, 55-86 (1980). 
6. Geurts van Kessell, A, H. M. eta/. Cytogenet. Cd/ Genet. 30, 83-91 (1981), 
7. Goff, S, P .. Gilboa, E., Witte, 0. M. & Baltimore, D. Cel/22, 777 785 (1980}, 
8. Potter, M., Sklar, M, D. & Rowe, W. P. Science 182, 592-594 (1973), 
9, Premkumar, E., Potter, M., Singer, P. A. & Sklar, M. D, Ctl/6, 149-159 (1975). 
10. Witte, 0. N., Rosenberg, N., Pnskind, M .. Shields, A. & Baltimore, D. Proc:. natn. Ac:ad. 
Sc:i, U.S.A. 15, 2488-2492 (1978). , 
11. Reynolds, F. H. Jr, Sacks, T. L, Deobagkar, D. N, & Stephenson,], R. Proc:. natn, Ac:ad. 
Sc:i. U.S.A. 75, 3974-3978 (1978), 
12. Van de Yen, W. J, M., Reynolds, F. H. Jr & Stephenson, 1. R. Virology 101, 185-197 
(1980), 
13, Witte, 0, N., Dasgupta, A. & Baltimore, D. Nature 283,826-831 (1980}. 
14. Blomberg, J., Reynolds, F. H. Jr, Van de Yen, W. J. M, & Stephenson, J. R. Nature 286, 
504-507 (1980). 
15, Sefton, B. M., Hunter, T. & Raschke, W. C. Proc. natn. Acad. Sci. U.S.A. 18, 1552-1556 
(1981). 
16, Der, C. J,, Krontiris, T. C. & Cooper, G, M. Proc. natn. Acad. Sci. U.S.A. 19,3637-3640 
{1982). 
17. Paradn, L. F •• Tabin, C., Shih, C. & Weinberg, R. A. Nature 297,474-478 (1982). 
18. Santos, E., Tronick, S. R., Aaronson, S. A., Pulcinni, S. & Barbncid, M. Nature 298, 
343-347 (1982). 
19. Heisterknmp, N., Groffen, J. & Stephenson, J. R. f. molec, appl. Genet. (in the press). 
20, Geurts vnn Kessel. A. H. M., vnn Agthoven, A. J, & Hngemeijer, A. Canctr Gt>net, 
Cytogenet, 6, 55-58 (1981). 
21. Ferguson-Smith, M.A. & Aitken, D. A. Cytog.-net, Cdl Genet. 22,49-451 (l978l. 
22. Povey, S., Boyd, Y., Duncan, M. E., Jeremiah, S. J, & Carritt, B. Cytogenet. Cell G.-net, 
22, 461-464 (1978). 
23, Bernards, R. & Flavell, R. A. Nucleic: Acids Res. 8, 1421-1533 (1980), 
24. Chnng, E. H., Furth, M. E., Scolnick, E. M. & Lowy, D. R. Natuu 297,479-483 (1982). 
25. Sandberg, A. A. Canc:a Genet. Cytogenet, 1, 217-228 {1980), 
26, Geurts van Kessel, A. H. M., den Boer, W. C., van Agthoven, A. J, & Hagemeijer, A, 
Somatic Oil Genet. 1, 645-656 (1981), 
27. Mcera Khan, P. Archs. Biochcm. Biophys. 145,470-483 (1971), 
28, Jeffreys, A. J, & Flavell, R. A, Cd/12, 429-439 (1977), 

99 
PAPER II 
CANCER SURVEYS 3: 515-529 (1984) 

Cytogenetic and molecular analysis of the Ph 1 
translocation in chronic myeloid leukaemia 
A. DE KLEIN and A. HAGEMEIJER 
Department of Cell Biology and Genetics, Erasmus University, Rotterdam 
I Introduction 
ll Standard Ph 1 translocation 
1 Cytogenetic studies 
2 Somatic-cell genetic studies 
3 Cellular oncogenes c-abl and c-sis as genetic markers 
ill Cytogenetic variants of the Ph 1 translocation in chronic myeloid leukaemia 
1 Introduction 
2 c-sis in standard and variant Ph 1 translocations 
3 c-abl in variant Ph 1 translocations 
4 Conclusions 
IV Molecular analysis of the Ph 1 translocation 
1 Cloning of the breakpoints 
2 Characterization of the breakpoint regions on chromosomes 22 and 9 
3 Transcription of c-abl in chronic myeloid leukaemia 
4 Conclusions 
V Prospects 
Keywords: Chronic myeloid leukaemia, Philadelphia chromosome, Ph 1 
translocation, Ph1 variants, cellular oncogenes, c-sis, c-ab!, breakpoint 
cluster region. 
Summary 
The Ph 1 translocation is a consistent chromosomal abnormality associated 
with chronic myeloid leukaemia. Usually the Ph 1 results from a translocation 
(9;22)(q34;qll), but in a small percentage of cases variant forms are 
observed where other chromosomes are also involved. Analysis of the 
standard Ph1 translocation using somatic-cell hybridization and recombinant 
DNA techniques showed that two cellular oncogenes c-ab! and c-sis were 
translocated from chromosome 9 to 22q- and from chromosome 22 to the 
9q+ derivative, respectively. Study of variant forms of the Ph1 using the 
in-situ hybridization technique of single-copy DNA probes derived from these 
two cellular oncogenes revealed that c-sis was translocated from chromosome 
22 to different chromosomes involved in the variant Ph 1 translocations, 
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concomitantly with the visible part of 22q. In contrast, c-ab! was consistently 
translocated to the 22q- or Ph 1 chromosome even in cases where at first sight 
chromosome 9 was not involved. 
Molecular analysis of breakpoint regions on the 9q+ and the 22q-
derivatives was undertaken, trying to delineate further the molecular 
structure of the Ph 1 rearrangement and the possible mechanism for activation 
of the c-abl oncogene. A region of 5.8 kb (breakpoint cluster region) was 
cloned from chromosome 22 and all the breakpoints analysed so far from 
patients with chronic myeloid leukaemia were found to cluster within this 
region. At this point, it seems that the conjunction of the breakpoint cluster 
region, i.e. a specific region of chromosome 22, and the c-ab! translocation 
constitute a rearrangement which could play a fundamental role in the 
pathogenesis of chronic myeloid leukaemia. 
I Introduction 
In 1960, Nowell and Hungerford described for the first time an abnormal 
small chromosome in the leukaemic cells of two patients with chronic myeloid 
leukaemia (CML). This abnormal chromosome was called Philadelphia (Ph1) 
chromosome according to the location of the laboratory of discovery and was 
thought to be a deletion of one of the small acrocentrics. 
In 1973, using banding techniques, Rowley showed that the Ph 1 did not 
result from a simple deletion of chromosome 22 but from a translocation: the 
deleted part of chromosome 22 is translocated to the long arm of 
chromosome 9. The rearrangement was described as t(9q+;22q-) or 
t(9;22)(q34;qll) using the International System for Cytogenetic 
Nomenclature (ISCN, 1978). 
Cytogenetic analysis of chromosomal abnormalities in CML and other 
haematopoietic diseases revealed that: (1) The Ph1 chromosome (22q-) is 
consistently found in more than 90% of the CML cases, where it appears as an 
acquired stem-cell abnormality observed in the majority of bone-marrow 
cells. (2) Cytogenetic variants of the Ph 1 translocation have been reported in 
about 3-8% of the Ph1+ CML cases. These variants show a 22q-
chromosome, with translocation of the distal part of 22 to a chromosome other 
than 9, although chromosome 9 also appears to be involved in complex 
variants. (3) A small percentage (3-7%) of CML cases are without a Ph 1 
chromosome (Ph 1-negative); they tend to show much more rapid clinical 
deterioration and shorter survival than the Ph1+ cases. (4) The Ph 1 
chromosome is sometimes found in other haematopoietic disorders, 
particularly in the adult type of acute lymphoblastic leukaemia (ALL). 
These cytogenetic findings in CML and their relevance for clinical diagnosis 
and prognosis have been discussed in a number of reviews (Lawler, 1977; 
Hagemeijer et al., 1980; Rowley, 1980; Sandberg, 1980). In summary, the 
Ph 1 translocation still appears as the paradigm of the consistent chromosomal 
change associated with a specific type of malignancy, i.e. CML. The role 
played by the specific translocation in the pathogenesis of the disease remains 
to be established. The recent discovery of cellular oncogenes (Cooper, 1982) 
and their localization near the breakpoints in several specific chromosomal 
rearrangements in various forms of cancer suggest a key role of these genes in 
the development of these neoplasms (Rowley, 1983). Of interest here are the 
c-ab! and c-sis oncogenes which have been assigned to chromosomes 9 and 
22, respectively (Heisterkamp eta/., 1982; Dalla-Favera eta/., 1982). The 
involvement of these cellular oncogenes in the standard and variants forms of 
the Ph 1 translocation have been studied by molecular techniques and by 
in-situ hybridization directly on metaphase chromosomes using cloned 
fragments of the genes as probes. We found that the c-ab! oncogene was 
consistently involved in the Ph 1 rearrangement(s). Furthermore, molecular 
cloning of the breakpoint regions on chromosomes 9 and 22 was undertaken 
and was facilitated by the close proximity of the c-ab! oncogene and the 
presumed breakpoints. 
II The standard Ph 1 translocation 
1 Cytogenetic studies 
Using the methotrexate synchronization method (Hagemeijer eta!., 1979) a 
precise cytogenetic definition is obtained of the standard Ph 1 translocation, 
t(9;22), associated with CML (Fig. 1). The breakpoints are localized in bands 
9q34 and 22q11 following the ISCN (1978) nomenclature. Translocation of 
the deleted part of chromosome 22 to the 9q+ derivative is clearly visible, but 
it is less obvious that a small segment of chromosome 9 is translocated to 
the 22q- derivative. Several studies using cytophotometric and cyto-
densitometric measurements gave indications in favour of a reciprocal 
translocation but failed to produce unequivocal evidence (Mayall eta!., 1977; 
Watt and Page, 1978; Wayne and Sharp, 1982). 
2 Somatic-cell genetic studies 
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Somatic-cell hybrids were obtained by fusion of rodent cells of Chinese 
hamster or mouse origin with blood or bone-marrow cells of patients with 
Ph 1+ CML. In these interspecies hybrid cell lines, random segregation of 
Fig. 1. Chromosomal pairs 9 and 22 from a bone-marrow metaphase of a CML patient 
illustrating the standard t(9;22)(q34;q 11) (R-bands with acridine orange) 
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Fig. 2. Diagram showing the Ph 1 translocation (9;22)(q34;qll) and the location of the marker 
genes relative to the breakpoints 
chromosomes of human origin takes place and it is possible to isolate a panel 
of hybrid clones containing, in addition to the rodent genome, only one of the 
human chromosomes involved in the Ph 1 translocation, i.e. either the 9q+ or 
the 22q- or their normal counterparts, 9 or 22. A panel of hybrid clones 
segregating these chromosomes have been isolated, originating from eight 
different CML patients carrying the standard t(9;22). These clones were 
assayed simultaneously for human chromosomal content and for the 
expression of genes known to be located on chromosome 22 or on the distal 
part of chromosome 9. A number of enzyme markers were assayed: adenylate 
kinase-1 (AK1) assigned to 9q34 (Mohandas et al., 1978), the band involved 
in the Ph 1 translocation, and three markers of chromosome 22, i.e. 
mitochondrial aconitase (AC02), arylsulphatase-A (ARSA) and 
N-acetyl-a-D-galactosaminidase (NAGA) (Geurts van Kessel eta!., 1980). 
These four enzyme markers segregated together, with the 9q+ derivative 
confirming the translocation of 22q to 9 but failing to demonstrate reciprocity 
(Fig. 2) (Geurts van Kessel eta!., 1981a). 
3 Cellular oncogenes c-abl and c-sis as genetic markers 
The localization of two human cellular oncogenes, c-ab! and c-sis on 
chromosomes 9 and 22, respectively, stimulated an investigation of the fate of 
these oncogenes in the (9;22) translocation. The cellular homologue (c-ab!) 
of the transforming gene (v-abl) of Abelson murine leukaemia virus is highly 
conserved in evolution. As for other cellular oncogenes, sequences 
homologous to c-ab! have been found in several vertebrate genomes (Goff et 
a!., 1980) and in Drosophila melanogaster (Shilo and Weinberg, 1981; 
Hoffman-Falk eta/., 1983). The human c-ab/ sequences homologous to the 
v-abl gene have been cloned (Heisterkamp et a/., 1983a). These c-ab/ 
sequences are distributed over a region of 40 kb of genomic DNA and contain 
several intervening sequences. The precise 5' and 3' boundaries of the human 
c-ab/ gene still remain to be determined. Experimental data obtained from 
the mouse c-ab/ gene indicate that the v-abl homologous sequences represent 
an internal part of the mouse c-ab/ gene (Wang, 1983; Wang eta/., 1984). 
The human c-ab/ sequences have been localized to the long arm of 
chromosome 9 (Heisterkamp et al., 1982) at position 9q34 (Jhanwar eta/., 
1984). Analysis of DNA from a panel of rodent-human somatic-cell hybrids 
already mentioned, containing either the 9q+ or the 22q- chromosome 
demonstrated the translocation of human c-ab/ from chromosome 9 to the Ph 1 
chromosome (De Klein eta/., 1982). 
c-sis represents the cellular homologue of the transforming gene (v-sis) of 
simian sarcoma virus (Josephs eta!., 1983). The human c-sis gene is localized 
on chromosome 22 (Dalla-Favera et al., 1982) at position 22ql3.1 (Jhanwar 
eta/., 1984). Hybridization of a c-sis probe to DNA of somatic-cell hybrids 
revealed that this gene is translocated to the 9q+ derivative chromosome in 
the Ph1 translocation (Groffen et al., 1983). 
Another genomic marker of chromosome 22 is the 1 light-chain 
immunoglobulin gene. The constant part of this gene (C 1) has been localized 
to the same band 22qll as the Ph1 breakpoint on chromosome 22 (McBride 
eta/., 1982). Hybridization of this probe (C1) to DNA of a selected panel 
of hybrid cells indicated that this gene remains on the Ph 1 chromosome 
(Goyns eta/., 1984). 
In summary, although involving Ph1 derivatives of different patients, all 
experiments showed the same segregation pattern of the markers tested 
which suggested that, in all patients studied, the breakpoints were consistent, 
at least relative to the markers tested. On chromosome 9 the breakpoint is 
distal to AK1 and proximal to c-ab/, while on chromosome 22 the breakpoint 
is distal to C 1 and proximal to A C02 (Fig. 2). Furthermore, the translocation 
of the c-ab/ oncogene from chromsome 9 to 22q- constitutes. the first 
unequivocal evidence that the standard Ph 1 translocation is a reciprocal 
exchange between chromosomes 9 and 22. 
Ill Cytogenetic variants of the Ph 1 translocation in chronic myeloid 
leukaemia 
1 Introduction 
The demonstration that two cellular oncogenes were translocated in the 
standard Ph I translocation, t(9;22), suggested that one or both of these 
oncogenes could play a role in the pathogenesis of the disease. In order to 
study the specificity of the translocation of these oncogenes, we analysed their 
position in the cytogenetic variants of Ph\ in CML. 
Three forms of cytogenetic variants have been reported: firstly, 'simple' 
translocations between chromosome 22 and another chromosome, without 
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Table 1. Mapping of cellular oncogenes c-ab/ and. c-sis to the derivative chromosomes observed in standard and variant forms of the Ph 1 
translocation in CML 
Number 
of cases pf11 translocation 
A. Control with normal karyotype 
3 None 
B. Standard Ph 1 translocation in CML 
5 t(9;22) ( q34;q II) 
2 t(9;22) 
1 ~9;22) 
C. Complex translocation variantsh 
1 t(l ;9;22) (p32;q34;q11) 
I t(9;11;22) (q34;q12;qll) 
D. Apparently 'simple' translocation variantsc 
1 t(4;9;22) (p16;q34;ql1) 
1 t(9;12;22) (q34;p13;qll) 
I t(7;9;22) (p22;q34;qll)d 
I t(4;9;22) (p!6;q34;q11)c 
I t(9; II ;22) (q34;q23;qll)f 
1 t(9;19;22) (q34;p13;qll) 
E. Masked Phi 
1 t( 6;22) (p21 ;q 11 )g 
F. Phi-negative CML 
I None 
3 Noneh 
1 None 
Derivative chromosomes 
None 
9q+, 22q-
9q+, 22q-
9q+, 22q-
9q+, 22q-, lp-
9q+, 22q-, llq-
9q-, 22q-, 4p+ 
9q-, 22q-, 12p+ 
9q-, 22q-, 7p+ 
9q-, 22q-, 4p+ 
9q-, 22q-, llq+ 
9q-, 22q-, 19p+ 
None 
None 
N<'me 
22q+, 6q-
Chromosomal localization of 
c-ab! c-sis 
9q34 
9, 22q-
9, 22q-
9, 22q-
9, 22q-
9, 22q-
9, 22q-
9, 22q-
9, 22q+ 
9 
9 
22ql3.1 
22, 9q+ 
22, 9q+ 
22, lp-
22, llq-
22 
22 
Techniques used8 
S,H 
s 
H 
H 
s 
S,H 
H,B 
H,B 
H,B 
B 
B 
B 
H,B 
s 
H 
H 
as. segregation analysis in somatic cell hybrids; H, in-situ hybridization technique using radioactive probes; B, high-resolution banding techniques 
hThree additional cases were studied by banding only and were consistent with breakpoints in 9q34 and 22qll resulting in clear 9q+ and 22q-
derivatives: i.e. t(9;10;22) (q34;q24;qll), t(9;14;22) (q34;q32;q11) and t(9;16;22) (q34;p112;q11) 
cstudy of these cases with high-resolution banding showed involvement of one chromosome 9 resulting in a 9q- derivative undetectable when only 
standard cytogenetic techniques are used 
dRefcrred by J. Fraisse, St. Etienne, France 
<Referred by H. Van Den Berghe, Leuven, Belgium 
fReferred by C. Turc-Carel, Dijon, France 
gReferred by E. Godde-Salz, Kiel, West Germany 
hTwo of the cases were referred by M. F. Turchini, Clermont-Ferrand, France 
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apparent involvement of chromosome 9; secondly, complex translocations 
involving 9, 22 and at least one other chromosome (in these cases the third 
chromosome is recipient of the deleted part of 22q-, while 9 is recipient of 
the deleted part of the third chromosome); thirdly, a rare type of variant 
called 'masked Ph 1' where the Ph 1 is the recipient of a part of another 
chromosome (Tanzer et al., 1977; Pasquali et al., 1979; Sandberg, 1980; 
Oshimura et al., 1982). 
Examples of these variants were studied using high-resolution banding, 
segregation analysis of chromosomes and chromosomal markers in 
somatic-cell hybrids and in-situ hybridization of radioactive DNA probes. 
Chromosomal in-situ hybridization of radioactive probes allows the mapping 
of a gene to a chromosomal region, often restricted to one band. This 
technique is based on the property of single-stranded DNA to hybridize 
specifically to complementary sequences to form double-stranded structures. 
In these experiments we used single-copy DNA probes, tritiated by 
nick~translation: a 1.7-kb BamHI fragment of c-sis (Groffen et al., 1983) and 
a 0.6-kb BamHI fragment and a 1.1-kb Hindiii EcoRI fragment of c-abl 
(Heisterkamp eta!., 1983a). Results of these studies (Geurts van Kessel eta!., 
1981b; De Klein et al., 1982; Bartram et al., 1983, 1984; Groffen et al., 
1983; Hagemeijer et a!., 1984; A. Hagemeijer et a!., unpublished 
observations) are summarized in Table 1. 
2 c-sis in standard and variant Ph 1 translocations 
By in-situ hybridization, c-sis was mapped on chromosome 22 at the junction 
between band q12 and q13 or at 22q13.1, far away from the breakpoint on 
22qll involved in the Ph1 translocations. Consequently, in Ph 1+ CML c-sis 
was found to be located on the derivative chromosome carrying the visibly 
deleted part of 22q, i.e. the 9q+ in standard Ph 1 and another chromosome in 
the complex variants studied. Therefore, at first sight c-sis translocation in 
CML appeared as a trivial event associated with the translocation of the 
chromosomal part carrying the gene, and located at a relatively large distance 
from the critical breakpoint on 22q11. 
3 c-abl in variant Ph 1 translocations 
The c-ab! oncogene maps consistently to the 22q- derivative or Ph 1 
chromosome, in all cases of Ph 1+ CML, with either a standard or a variant 
translocation. In cases of complex translocations, all clearly involving 
chromosome 9, this finding was to be expected. In the so-called 'simple' 
translocation variants, the finding of the c-ab! gene on the 22q-
demonstrated the participation of the distal part of chromosome 9 in these 
variants as well (Fig. 3). Cytogenetic studies of these cases by high-resolution 
banding also showed a small deletion of one of the two chromosomes 9, 
confirming that all variants are complex translocations, involving 
chromosomes 22 and 9 and at least one other chromosome. In the so-called 
simple translocations, the breakpoint is in the telomeric region of the third 
chromosome and as a result subsequent translocation of this fragment to 9q34 
is barely visible. In two cases of masked Ph 1 that we studied , c-ab! maps on 
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Fig. 3. Diagram illustrating the regional localization of labelling sites in a variant Ph 1 
t(9; 12;22), after in-situ hybridization of c-ab/ sequences. Only one chromosome 9 has been 
marked because distinction between 9 and 9q- is elusive in most metaphases. The accumulation 
of grains on the 22q- demonstrates the participation of chromosome 9 in this rearrangement 
the 22q+ (masked Ph 1) at an interstitial site, adjacent to the 22qll 
breakpoint; in one particular case, cytogenetic changes of chromosome 9 
were not visible. 
4 Conclusions 
From these experiments we concluded that translocation of c-ab! to 
chromosome 22 was a constant feature and therefore probably relevant to the 
genesis of Ph1+ CML. In Ph1- CML, translocation of c-ab! or c-sis oncogenes 
was not observed. This is in agreement with the absence of chromosomal 
rearrangements in these patients and also in accordance with the view that 
CML without a Ph 1 chromosome is a different clinical entity with different 
origin, prognosis and survival. 
IV Molecular analysis of the Ph 1 translocation 
1 Cloning of the breakpoints 
The localization of the breakpoint at the most telomeric band of chromosome 
9 (band 9q34) and the consistent translocation to chromosome 22q- of a 
relatively small fragment of less than 5000 kb containing v-abl homologous 
sequences suggest that the breakpoint on chromosome 9 is located near or 
within the c-ab/locus. We investigated the position of c-ab! sequences relative 
to the breakpoint on chromosome 9 by cloning DNA fragments upstream to 
the known c-ab! sequences from the leukaemic cells of a CML patient and by 
identification of chimeric fragments containing sequences from 
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Fig. 4. Cloning strategy and analysis of the breakpoints in the Ph 1 translocation. The bars 
represent DNA fragments: solid bars indicate sequences from chromosome 9 and open bars 
sequences from chromosome 22. Restriction sites are indicated by: E, EcoRI; B, BamHI; Bg, 
Bg!II; H, Hindiii. Probes isolated from the DNA fragments are indicated by hatched boxes 
beneath the bars at the appropriate sites. A: Restriction enzyme analysis of the c-ab! region on 
chromosome 9. The hatched boxes indicate the v-abl homologous sequences. The EcoRI sites are 
indicated with small vertical lines. B: Enlargement of the 14.5-kb BamHI fragment of 
chromosome 9, situated in front of the known c-ab! sequences, of which single copy DNA probes 
were isolated. C: Restriction-enzyme analysis of the two Bg1II fragments detected by the probes 
indicated in (B). The 11-kb fragment shows complete homology with sequences of chromosome 
9, the 6-kb fragment shows homology with chromosome 9 and chromosome 22 sequences and 
therefore contained the breakpoint on 9 in this particular CML patient. A probe was made from 
the 22 part of the fragment. D: Restriction-enzyme analysis of a region of chromosome 22 
containing the 5.0-kb Bg!II fragment that hybridizes to the probe indicated in C. From this 
fragment new probes were isolated, among others the Bg!II-Hindiii probe represented in (D). 
E: Restriction-enzyme analysis of the two Bg!II fragments hybridizing to the probe indicated in 
(D). The 5.0-kb fragment is the chromosome 22 sequence illustrated in (D), while the 9.5-kb 
fragment shows only partial homology with chromosome 22 and partial homology with 
chromosome 9 sequences. The latter appears as the fragment carrying the breakpoint on 
chromosome 22 in this particular patient 
chromosomes 9 and 22 (Heisterkamp et al., 1983b). The strategy of cloning 
and analysis of the chimeric and normal DNA fragments is summarized in 
Fig. 4. From a region approximately 14.5 kb upstream (Fig. 4A) of the v-abl 
hybridizing sequences, two single-copy fragments were isolated. These probes 
(Fig. 4B) identify an 11-kb hybridizing Bglii fragment in Bglii-digested DNA 
of normal human cells and several CML patients. In the DNA of one CML 
patient an extra hybridizing Bg!II fragment of 6.0 kb was found. Analysis of 
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this fragment revealed that the 5' part was colinear with the former cloned 
chromosome 9 sequences located at the 5' side of the c-ab! gene. The 3' end 
of this fragment appeared to be derived from chromosome 22 sequences (Fig. 
4C) and we concluded that this 6.0-kb Bglii chimeric fragment represents the 
breakpoint at the 9q+ chromosome. Probes made from these chromosome 22 
sequences only hybridized to a 5.0-kb Bglii fragment in normal human DNA 
(Fig. 4D). With a probe made of the 5' side of this 5.0-kb Bglii fragment, we 
were able to detect an extra 9.5-kb Bglii fragment in the DNA of this 
particular CML case. This fragment contained chromosome 22 sequences at 
the 5' end, and chromosome 9 sequences at the 3' end. Therefore it contained 
the breakpoint on chromosome 22q- (Fig. 4E). The presence of a breakpoint 
located 14.5 kb immediately upstream of the human v-abl homologous 
sequences seems to be unique for the DNA of this particular CML patient. 
Using the same probes from the c-ab! locus, we were not able to localize other 
chromosome 9 breakpoints in the DNA of several other CML patients. 
Analysis of the chimeric fragments, however, suggests that the breakpoints on 
chromosomes 9 and 22 exhibit a perfect reciprocal exchange, at least at the 
level of detection by restriction-enzyme analysis. 
2 Characterization of the breakpoint regions on chromosomes 22 and 9 
To investigate and characterize further the location of the breakpoints on 
chromosome 22 in various Ph 1+ CML patients, a cosmid library of non-CML 
human DNA was screened and a region of 46 kb of human chromosome 22 
DNA was cloned. The 5.0-kb Bglii fragment cloned in the previous 
experiments (Fig. 4D) was situated in the centre of this region. Southern blot 
analyses of DNA from more than 20 CML patients, who were shown to be 
Ph1-positive by cytogenetic techniques, was performed using probes specific 
for this 5.0-kb Bglii fragment (Fig. 4C and 4D). In each case, in 
BglU-digested CML DNA, the expected 5.0-kb fragment originating from the 
normal chromosome 22 was found and in addition one or two fragments of 
different lengths. These fragments were shown by restriction-enzyme analysis 
to be the result of a break on chromosome 22 in the 5.0 kb region analysed by 
the specific probes for this region (Fig. 4C and 4D). The breakpoints on 
chromosome 22 are not situated at an identical site but they cluster in a 
specific region, the breakpoint cluster region (bcr), of up to 5.8 kb (Groffen et 
al., 1984). 
The bcr region was found to be normal in DNA isolated from other 
neoplastic tissues or cell lines tested, and in the DNA from Ph 1 - CML 
patients or fibroblasts from Ph 1+ CML patients. These results indicate that 
the involvement of the bcr region is specific for the leukaemic cells in Ph 1+ 
CML patients. Up to now we have not been able to identify the function of 
the chromosome 22 region in which the breakpoints are situated. This region 
is a part of band 22q11 which also contains the A. light-chain constant region 
(CA.) (McBride et al., 1982). However, no cross-homology was observed 
between our cosmid clones and C A. At present we are investigating whether 
this region contains protein coding, or transcription-regulating sequences 
which, in combination with the translocated c-abl sequences, might be 
responsible for the neoplastic transformation of the cell. 
The probes from the bcr region provided the tools for cloning several 9q+ 
and 22q- breakpoint fragments of different CML patients. The pieces of 
chromosome 9 present in these fragments showed no cross-homology either 
with each other or with the cloned c-abl locus. Since they cover a region of 
about 100 kb of chromosome 9, we assume that location of the breakpoints in 
chromosome 9 may vary from less than 14.5 kb to more than 100 kb in front 
(5') of the v-abl homologous sequences. We do not know whether these 
breakpoints actually occur within the human c-abl locus because the most 5' 
exon of human c-abl has not been identified yet. However, the possibility 
must be considered that the human c-abl oncogene extends over a much 
larger region than that characterized by homology to the viral oncogene v-abl 
(Wang and Baltimore, 1983). 
3 Transcription of c-abl in chronic myeloid leukaemia 
Gale and Canaani (1984) investigated the expression of c-abl in cells of 
patients with a Ph 1+ CML, with Ph 1- CML, healthy controls, and patients 
with other types of leukaemia. In Ph I+ CML, enhanced c-abl expression was 
not observed. However, a new RNA transcript of 8 kb was found which 
sometimes replaced one of the normal 6 kb or 7 kb transcripts. We have 
studied c-ab! expression in the K562 cell line which has been established from 
the leukaemic cells of a Ph 1+ CML patient in blast crisis. Although a typical 
Ph 1 chromosome is not visible in this cell line, the c-ab! oncogene and C A. 
gene sequences are amplified and map on one of the newly formed marker 
chromosomes (Collins and Groudine, 1983; Selden et al., 1983). In this cell 
line we found the new 8-kb RNA transcript replacing the 6-kb transcript. 
Both breakpoint fragments from chromosomes 9 and 22 in this cell line 
have been cloned (Heisterkamp et al., 1983b). The breakpoint on 
chromosome 9 is located about 100 kb in front of the known sequences of 
c-abl. As a consequence, the distance between the bcr and the v-abl 
hybridizing sequences must be over 100 kb. Nevertheless, this translocation 
resulted in a new c-abl RNA transcript. Experiments aimed at the cloning of 
the eDNA of this new c-abl RNA are in progress. This eDNA will enable us to 
investigate whether the altered gene product has transforming properties. 
Furthermore, it will help us to identify the origin of the new"sequences in the 
enlarged c-abl transcripts. These new sequences could be either the result of 
alternative splicing of the c-abl RNA or derived from chromosome 22 
sequences upstream of the breakpoint on chromosome 22. 
4 Conclusions 
The specificity of the bcr in chromosome 22 in Ph 1 positive CML suggests that 
rearrangements in this region may be involved in the pathogenesis of CML. 
Although the breakpoints on chromosome 9 are distributed over a large 
region 5' to the v-abl hybridizing sequences, the translocation of the c-ab! 
oncogene results in an altered RNA transcript of 8 kb. These observations 
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strongly suggest that human c-ab! and bcr together may play a role in the 
generation of the neoplasm. 
V Prospects 
Molecular analysis of the CML-specific chromosomal translocation has 
revealed that both the bcr and the transposition of the c-ab! oncogene in the 
vicinity of this region of chromosome 22 play an essential role in the 
pathogenesis of CML. These findings open new ways for investigations. 
Further molecular characterization of the bcr and of the eDNA coding for the 
new c-ab! transcript may give information on the specific function of the bcr 
and on the role of the c-ab! in the malignant transformation of the cells in 
CML. Using c-ab! probes in in-situ hybridization experiments, we were able 
to demonstrate the translocation of this oncogene to the Ph 1 chromosome in 
all types of cytogenetic variants in CML. It is essential now to use bcr probes 
either in Southern blot analysis or by in-situ hybridization to study the 
eventual participation of chromosome 22 in cases which are atypical either 
clinically or cytogenetically. We have indications in some cases of ALL, 
carrying a Ph 1 chromosome, that the breakpoint on chromosome 22 is located 
outside the bcr. So far these are the only exceptions of Ph 1+ leukaemia 
showing breakpoints outside this region. These preliminary observations 
indicate that molecular analysis of this type may discriminate between true 
Ph1+ ALL and CML presenting with a lymphoblastic blast crisis (Sandberg et 
al., 1980). We have studied the DNA of CML patients in lymphoblastic and 
myeloblastic blast crisis with bcr probes. The hybridization pattern in 
Southern blot analysis was similar to that observed during the chronic phase 
in the same patients. Similar studies should be carried out on true Ph 1+ acute 
myeloblastic leukaemia (AML). Recently we had the opportunity to study the 
DNA from two patients with CML showing cytogenetically a translocation 
involving chromosome 9q34 and a chromosome other than 22: t(9;12) 
(referred by J. R. Teyssier, Reims) and t(9;13;15) (referred by M. R. 
Riviere, Brest). In both cases the cytogenetic picture of chromosome 22 
appeared normal. Results obtained by Southern blot analysis with the bcr 
probes suggest that rearrangements did occur. These observations encourage 
further investigations into the molecular basis of Ph 1- CML. Clinically, 
these cases constitute a heterogeneous group. Many patients show rapid 
clinical deterioration and transformation in blast crisis, while others present 
with a rather typical CML chronic phase of 3-4 years. We have found that, 
in agreement with the cytogenetic absence of translocation, the position of 
the c-ab! and c-sis oncogenes in this case is unaltered. It now becomes 
essential to analyse also the structural integrity of the bcr in these cases. In 
some patients a bcr-c-abl conjunction may have happened at chromosomal 
locations other than 22q-. The observation of normal c-ab! RNA transcripts 
in the leukaemic cells of a Ph 1- CML patient (Canaani et al., 1984; Gale and 
Canaani, 1984) suggests that, in at least some Ph 1- CML patients, c-ab! is not 
rearranged either cytogenetically of molecularly. It is expected that further 
investigations along these lines would result in a better definition of CML, and 
also of other Ph 1+ leukaemias where the classification on morphological 
grounds, as ALL, AML or blast crisis of CML has been regularly disputed. 
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Summary 
We have identified and molecularly cloned 46 kb of 
human DNA from chromosome 22 using a probe 
specific for the Philadelphia (Ph') translocation 
breakpoint domain of one chronic myelocytic leu-
kemia (CML) patient. The DNAs of 19 CML patients 
were examined for rearrangements on chromosome 
22 with probes isolated from this cloned region. In 
17 patients, chromosomal breakpoints \Xere found 
within a limited region of up to 5.8 kb, for which we 
propose the term "breakpoint cluster region" (bcr). 
The two patients having no rearrangements within 
bcr lacked the Ph' chromosome. The highly specific 
presence of a chromosomal breakpoint within bcr in 
Ph' -positive CML patients strongly suggests the in-
volvement of bcr in this type of leukemia. 
Introduction 
Chronic myelocytic leukemia (CML) is characterized by the 
presence of the Philadelphia (Ph') chromosome in the 
leukemic cells of 96% of all CML patients. The Ph' chro-
mosome is the result of a translocation between chromo-
some 22 and chromosome 9 (Rowley, 1973, 1982; Sand-
berg, 1980); its presence has important prognostic and 
diagnostic value. Previously we described the localization 
of the human c-ab/ oncogene (Heisterkamp et al., 1983a), 
to chromosome 9 (Heisterkamp et al., 1982) and demon-
strated its translocation to the Philadelphia (22q-) chro-
mosome in CML (de Klein et al., 1982). This demonstrated 
unequivocally that the t(9;22) is reciprocal. As the break-
point on chromosome 9 is at the most telomeric band on 
this chromosome, q34, human c-ab/ must be translocated 
on a relatively small fragment of less than 5000 kb to 
chromosome 22, suggesting a potential role for the c-ab/ 
oncogene in CML. This hypothesis was strengthened by 
the isolation of a chimeric DNA fragment from one CML 
patient containing sequences from chromosome 9 and 22 
and located 14 kb immediately 5' of human v-abl homol-
ogous sequences (Heisterkamp et al., 1983b ). In the 
present study, we have used the chromosome 22-specific 
sequences of the chimeric DNA fragment to isolate a 
second chimeric chromosome 9/22 (9q+) fragment from a 
:j: Present address: Oncogene Science, Inc., 222 Station Plaza N., Mineola, 
NY 11501. 
different CML patient. The chromosome 9-specific se-
quences in this fragment must be localized at a minimal 
distance of 40 kb from the human v-abl homologous 
sequences. Using the same probe, we have isolated an 
extended region on chromosome 22 from non-CML human 
DNA. In contrast to the situation on chromosome 9, the 
breakpoints on chromosome 22 in the DNAs of these two 
CML patients had occurred in the same region, although 
not at an identical site. Subsequently, we investigated the 
genomic organization of this area in a number of other 
Ph' -positive CML patients: all exhibited abnormal restric-
tion enzyme patterns, indicating that in Ph+-positive CML 
a breakpoint occurs in a single well defined region of 
chromosome 22. 
Results 
Isolation of a 9q+ Chimeric Fragment 
Previously we have isolated a chimeric DNA fragment 
containing sequences originating from chromosomes 9 
and 22 (Figure 18) from a CML patient, 0319129. On 
chromosome 9, the breakpoint was located immediately 
to the 5' of hurnan v-ab/ homologous sequences (Figure 
1 A) and may even be within the human c-ab/ oncogene. 
However, the DNAs of two other CML patients did not 
contain rearrangements in this region; furthermore, we 
have molecularly cloned an additional 11 kb of DNA to the 
5' and have found no rearrangements in this area for these 
two DNAs (results not shown). Therefore, we decided to 
investigate whether we could localize the Ph' translocation 
breakpoint to a specific site on chromosome 22. Using a 
1.2 kb Hind 111-Bgl II fragment (1.2 HBg, see Figure 1 B) 
containing chromosome 22 sequences from the break-
point region of CML patient 0319129 as a probe, we 
examined the DNA of the leukemic cells of a second 
patient (02120185). As shown in Figure 2A, this probe 
detects a normal 5.0 kb Bgl II fragment in control DNA 
(lane 1), in DNA of patient 0319129 (lane 2) and in DNA 
of patient 02120185 (lane 3). As expected, it also detects 
the breakpoint fragment of DNA 0319129 (Figure 1B and 
Figure 2, lane 2). In DNA of patient 02120185, an extra 
Bgl II fragment of 6.6 kb is visible (Figure 2, lane 3). 
Similarly, this probe hybridizes to a norrnal 3.3 kb Bam HI 
fragrnent in all three DNAs (Figure 2B), but detects an 
additional abnormal 11.3 kb Bam HI fragrnent in DNA 
02120185 (lane 3). As we could detect additional restriction 
enzyme fragments with other restriction enzymes in DNA 
02120185 (data not shown), we decided to examine 
whether these abnormal fragments were the result of the 
presence of a chromosomal breakpoint. Using the 1 .2 kb 
HBg fragment as a probe, we molecularly cloned the 11.3 
kb Bam HI fragment in charon 30. In this fragment only 1.2 
kb of DNA, homologous to the probe, was defined as 
originating from chromosome 22; to determine all chro-
mosome 22-specific sequences in the 11.3 kb Bam HI 
fragment, it was necessary to isolate the homologous 
region on chromosome 22 from non-CML DNA. For this 
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Figure 1. Position of the 9q+ Chromosomal Breakpoint in Spleen DNA of 
Patient 0319129 in Relation to Human v-ab/ Homologous Sequences 
(A) The human v-ab/ homologous regions are designated I through VII and 
are indicated by solid bars: Eco AI sites are marked by small vertical lines. 
The vertical arrow points to the breakpoint in the DNA of CML patient 
0319129. (B) The molecularly cloned region ot DNA ot patient 0319129 
that contains a breakpoint The solid bar indicates sequences from chro-
mosome 9, while the open bar represents sequences from chromosome 
22. The 1.2 kb HBg probe is indicated as a hatched box. Restriction 
enzymes include: Bam HI (B), Bglll (Bg), Hind Ill (H), Sst I (S), Xba I (Xb), 
Xho I (Xh) and Eco AI (E). 
purpose, a previously described (Groffen et al., 1982) 
human lung carcinoma cosmid library was screened with 
the 1.2 kb HBg probe. Three cosmid clones were isolated, 
which contained overlapping portions of the same region. 
Molecular Cloning of Ph' Breakpoint Region of 
Normal Chromosome 22 
As shown in Figure 3A, a region of approximately 46 kb 
was molecularly cloned; the 1.2 kb HBg probe hybridizes 
to a Bgl II fragment of 5.0 kb, located centrally in the 
cloned region. No homology is apparent between the 
restriction map of this region and that of human c-sis 
(Dalla-Favera et al., 1981), an oncogene situated on chro-
mosome 22 but translocated to chromosome 9 in the Ph' 
translocation (Groffen et al., 1983a). This confirms earlier 
reports that indicated that c-sis is not located in the 
immediate proximity of the Ph' breakpoint (Bartram et al., 
1983a). In vanant Burkitt lymphoma, a t(8;22) has been 
described in which the immunoglobulin light chain was 
found to be involved (de Ia Chapelle et al., 1983). The 
light-chain constant region (CI\) and the Ph' chromosomal 
breakpoint have been localized to chromosome 22 band 
qll (Rowley, 1973; McBride et al., 1982; Yunis, 1983): this 
suggests that c-ab/ could be translocated into Cl\ in 
patients with CML. However, a probe isolated from the A 
constant region showed no cross-homology with the above 
described chromosome 22 sequences. Additionally, no 
hybridization to a murine ;>.,-variable region probe (Miller et 
al., 1981) was observed (results not shown). 
To facilitate comparison of the 11 .3 kb Bam HI fragment 
with homologous sequences on chromosome 22, the 5.0 
kb Bgl II fragfTlent was subcloned into pSV2-neo (Figure 
3B). In concordance with our previous results (Heisterkamp 
et al., 1983b), in the 6.0 kb Bglll breakpoint fragment from 
CML patient 0319129, restriction enzyme sites 3' to the 
most 3' Eco Rl site originate from chromosome 22 (Figure 
3C). In the 11.3 kb Bam HI fragment (F1gure 3D) approxi-
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Figure 2, Restnction Enzyme Analysis of CML DNAs 
Ten m1crogram of h1gh molecular we1ght DNA was digested w1th Bgl !1 (A) 
or Bam HI (B), electrophoresed on 0. 75% agarose gels, and blotted. DNAs 
analyzed were from human cell !ine GM3314 (lane 1 ), CML pat1ent 0319129 
(lane 2), and CML pat1ent 02120185 (lane 3). Frozen spleen tissues. 
1nclud1ng those used as a source for the Isolation of DNAs shown 1n Figure 
5, were obtained through the 81olog1cal Carcinogenesis Branch, DCCP. 
Hybr1dlzat1on was W1th the 1.2 kb HBg probe (see Figure 1 ); filters were 
washed to 0.3 X SSC at 65°C. Molecu~r weights at fragments hybndiz1ng 
to the probe are 1nd1cated tn ktlobases. 
mately 2.5 kb of DNA, including the 3' Bam HI site and 
extending to the 3' Xho I site, originates from chromosome 
22. 
The 11.3 kb Bam HI Fragment Also Contains a 
Breakpoint 
To establish conclusively that the 11.3 kb Bam HI fragment 
represents a chimeric fragment of chromosomes 22 and 
9, we isolated a 1.3 kb Eco Rl fragment from the chro-
mosome 22 nonhomologous region. Using this fragment 
as a probe, homologous sequences were detected in Bgl 
11-digested mouse DNA (Figure 4, lane 1) and Chinese 
hamster DNA (not shown). These bands, however, were 
clearly resolved from the Bgl II fragment visible in human 
DNA (lane 2). No human sequences homologous to the 
probe were detected in rodent -human somatic cell hybrids 
PgMe-25Nu, having human chromosome 22 as its only 
human component (lane 4) or in WESP-2A, (lane 3) con-
taining a Ph' chromosome but not chromosome 9 or 9q+ 
(de Klein et al., 1982). In the rodent-human somatic cell 
hybrids 1 OCB-23B (lane 5), containing human chromo-
some 9 and in 14CB-21A, containing a 9q+ chromosome 
(not shown), a Bglll fragment of human origin homologous 
to the probe clearly was present. The only human DNA 
sequences these two hybrids have in common are those 
originating from chromosome 9. Therefore, the 11.3 kb 
Bam HI fragment possesses a breakpoint and represents 
a chimeric fragment containing chromosome 9- and 22-
specific sequences isolated from a second CML patient. 
Clustering of Ph' Breakpoints on Chromosome 22 
in CML Patients 
S1nce in each of the above two CML DNAs the breakpoint 
in the t(9;22) on chromosome 22 was localized w1thin a 
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Figure 3. Comparative Restriction Enzyme Analysis of the Breakpoint 
Region on Chromosome 22 with Two 9q+ Breakpoint Regions 
A restriction enzyme map of the cloned region in which chromosomal 
breaks occur on chromosome 22 is shown in (A); a subclone containing 
the 5.0 kb Bglll fragment in (B) is compared with the 6.0 kb Bglll and 11.3 
kb Bam HI restriction enzyme fragments of the 9q+ chromosomes in (C) 
and (0); heavy lines indicate sequences from chromosome 22, whereas 
light lines Indicate sequences originating from chromosome 9. B = Bam 
HI; Bg = Bglll; Bs = BstE II; E = Eco Rl; H = Hind Ill; K = Kpn I; S = Sst 
I; X= Xba I; Xh = Xho I. 
common region, we decided to investigate this area in 
other CML DNAs. As the 1.2 HBg probe had detected 
abnormal (9q+) Bgl II restriction fragments in DNAs 
0319129 and 02120185, we subjected 17 additional in· 
dependent CML DNAs to similar analysis; six of these were 
from spleen tissue, nine were from patient blood, and two 
were from bone marrow. As shown in Figure 5, lanes 1-
13, CML DNAs from spleen, blood, and bone marrow all 
contained additional Bglll fragments hybridizing to the 1.2 
HBg probe; the DNAs of the patients shown in lanes 14-
17 did not exhibit abnormal Bgl II fragments. Two of these 
(H81-258, lane 14 and COSO, lane 15) showed deviant 
restriction enzyme patterns with other restriction enzymes 
(this will be discussed below). 
To confirm that the 1.2 HBg probe detected chromo· 
somal rearrangements and not merely DNA polymor-
phisms for the restriction enzyme Bgl II, all DNAs were 
subjected to digestion with at least one, but in most cases 
two or more different restriction enzymes. After hybridiza· 
lion with the 1.2 HBg probe, abnormal restriction enzyme 
fragments were detected in all Ph' ·positive CML DNAs 
(also see below). Thereiore, a polymorphism for Bgl II 
seems an unlikely explanation for the abnormal fragments 
shown in Figure 5; moreover, in the DNAs of most patients, 
abnormal fragments of different molecular weights are 
detected with the 1.2 HBg probe. 
No extra Bgl II fragments were found in DNA isolated 
frorn cultured fibroblasts of patient H80-251 (lane 18) 
although an extra Bgl II fragment is clearly visible in DNA 
isolated frorn the leukemic cells of this patient (lane 7). 
Moreover, DNA isolated from the fibroblast cell line, AG 
1732, established from a Ph' ·positive CML patient, also 
lacked abnormalities (lane 19) in this region. Finally, in DNA 
isolated from leukemic cells of a Ph' -negative CML patient 
(lane 17) and of a two-year-old child with juvenile Ph'. 
negative CML, no visible rearrangements were found (lane 
16), confirming our results of previous experiments (Bar-
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Figu_re 4. Origin of the 5' Sequences of the 11.3 kb Bam HI Fragment 
High molecular weight DNAs, including mouse (lane 1 ), human cell line 
A204 (lane 2), WESP·2A (chromosome 22q-, lane 3), PgMe·25Nu (chro· 
mosome 22, lane 4), and 10CB-23B (chromosome 9, lane 5) yvere digested 
w1th Bgl Jl, electrophoresed On an 0.75% agarose gel, blotted, and hybrid-
IZed to a 1 .3 kb Eco Rl probe isolated from the 11.3 kb Bam HI fragment. 
tram et al., 1983b) in which no translocations concerning 
c-ab/ to chromosome 22 or c-sis to chromosome 9 were 
found in Ph' -negative CML. 
Sublocalization of Ph' Breakpoints on Chromosome 
22 
As is apparent from the detailed restriction enzyme analysis 
of the breakpoint fragments· of the DNAs of patients 
0319129 and 02120185, the exact breakpoints are not 
localized at. identical sites on chromosome 22. To sublo· 
calize the breakpoints in the DNAs of the other CML 
patients more precisely, we arbitrarily divided the 5.0 kb 
Bgl II fragment into segments bordered by restriction en· 
zyme sites for Bgl II, Bam HI, and Hind Ill (see F-igure 6, 
bottom). Region 0 thus extends from the 5' Bgl II site to 
the first 5' Hind Ill site, region 1, a 0.6 kb Hind Ill-Bam HI 
fragment, is bordered by the same Hind Ill site at the 5' 
and a Bam HI site.3' to it. Region 2 is delineated by this 
Bam HI site at the 5' and a Hind 1111 site 3' to it; region 3 is 
the 1 .2 kb Hind 111-Bgl II fragment ( 1.2 HBg) used as a 
probe in the experiments described above. Region 4 is 
outside the 5.0 kb Bgl II fragment and is bordered at the 
5' by the Bglll site and at the 3' by a Barn HI site. 
As is evident from the restriction enzyme map of the 6.0 
kb breakpoint fragment of CML DNA 0319129 (Figure 3C), 
the Bam HI site from chromosome 22 in region 1 is found 
on the 9q+ chromosome, whereas the Hind Ill site 5' to it 
is missing; therefore, a break must have occurred between 
these two restriction enzyme sites in region 1. In accord· 
ance with this, only a (normal) 3.3 kb Bam HI fragment is 
detected with the 1.2 HBg probe, which originates from a 
region 3' to the Bam HI site (Figure 2B, lane 2). In DNA 
02120185, however, this Bam HI site is missing on the 9q+ 
chromosome (Figure 3D) and, therefore, the 1.2 HBg probe 
detects, in addition to the normal 3.3 kb Barn HI fragment, 
the 11.3 chimeric Bam HI fragment. As the 3' Hind Ill site 
at region 2 is present in this 9q+ fragment, the breakpoint 
in this DNA is in region 2. 
In DNA 0311068, as in DNA 0319129, only a normal3.3 
kb Bam HI fragment is detected with the 1.2 HBg probe, 
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Figure 5. Analysis of ONAs from CML Patients 
DNAs analyzed include isolates from CML pabent 0311068 (lane 1 ), 7701 C (lane 2), C999 (lane 3), C481 (lane 4), 879·1 00 (lane 5), 879·216 (lane 6), HB(). 
251 (lane 7), CML 0 (lane 8), HB1-164 (lane 9), H81-122 (lane 1 0), H81-118 (lane 11 ), H79-179 (lane 12), H77-94 (lane 13), HB1·25B (lane 14), COSO (lane 15), 
C011 (lane 16), and H79-147 (lane 17). Also shown are DNAs isolated from fibroblasts of patient HB0-251 (lane 18) and from the fibroblast cell hne AG 1732 
(lane 19). 
DNAs in lanes 1-4 and 15-16 were 1solated from the frozen spleens of CML patients; those from CML patients 0311068 and 7701 C conta1ned a very high 
percentage of leukemic cells; the percentage of leukemic cells in the other spleen tissues IS not known. There are no data concerning the presence of a Ph' 
chromosome in cells of these spleens. DNAs 1n lanes 7-14 and 17 were isolated from blood and those in lanes 5-6 from bone marrow. Cells from whrch 
DNA was isolated were examined for the presence of the Ph' chromosomal marker: bone marrow a(ld blood cells of a!\ pat1ents except patient H79 147 were 
Ph' -positive. The human fibroblast cell line AG 1732, obtained from the Human Genetic Mutant Cell Repository (Camden, New Jersey) was established from 
a CML patrent carryrng the Ph' chromosome in her leukemic cells. DNA (1 0 ,ug) was drgested wrth Bg! II, electrophoresed on an agarose gel, blotted, and 
hybridrzed to the 1.2 kb HBg probe. 
indicating that no break has occurred within this fragment 
(Figure 6, lane 1). When the 0.6 kb Hind Ill-Bam HI 
fragment encompassing region 1 is used as a molecular 
probe, a normal 5.0 kb and two abnormal Bgl II fragments 
of 4.0 and 3.2 kb are visible. The 3.2 i<b Bgl II fragment 
represents a 9q+ chimeric fragment containing the 3' Bgl 
II site from the 5.0 kb Bgl II fragment on chromosome 22, 
as it is also detected with the 1.2 HBg probe (Figure 5, 
lane 1). The 4.0 kb Bgl II fragment is a 22q- chimeric 
fragment with the 5' Bgl II site originating from chromo· 
some 22; it is not detected by the 1.2 HBg probe. The 
breakpoint in DNA 0311068 must be located in region 1. 
The 1.2 HBg probe detects, in addition to a normal 3.3 
kb Bam HI fragment, an abnormal 6.2 kb Bam HI fragment 
in CML DNA 7701C (Figure 6, lane 3). The Bam HI site 
bordering region 2 at the 5' must, therefore, be absent 
from the 9q+ chromosome. The Hind Ill site at the 3' of 
region 2 has been retained, as only one normal 4.5 kb 
Hind Ill fragment is visible after hybridization to 1.2 HBg 
(Figure 6, lane 4 ). This CML DNA must contain a breakpoint 
in region 2. 
Patient C481 and H77·92 apparently have a breakpoint 
in region 3, encompassing the 1.2 HBg probe. For exam-
ple, in DNA of patient C481 the 1.2 HBg probe hybridizes 
to three restriction enzyme fragments in every restriction 
enzyme digest: abnormal Bgl II fragments of 6.0 and 2.8 
kb and a normal one of 5.0 kb (Figure 5, lane 4), abnormal 
Hind Ill fragments of 7.0 and 3.5 kb in addition to a normal 
4.5 kb fragment (Figure 6, lane 7), abnormal Bam HI 
fragments of 7.5 and 5.2 kb and a normal3.3 kb fragment 
(Figure 6, lane 8). Therefore, in this CML DNA, the 1.2 HBg 
probe detects both the 22q- and 9q+ br~akpoint frag-
ments. 
The situation in the DNA of patient COSO is less clear. 
As only one normal 5.0 kb Bgl II fragment is visible after 
hybridization to 1.2 HBg (Figure 5, lane 15), a chromosomal 
breakpoint most likely has occurred outside the Bgl II 
fragment. As the 1.2 HBg probe detects an abnormal 5.0 
kb Hind Ill fragment in addition to the normal 4.5 kb Hind 
Ill fragment (Figure 6, lane 6), a chromosomal breakpoint 
may be situated immediately 3' of the 5.0 kb Bgl II 
fragment. This is supported by the hybridization of the 
same probe to an abnormal 13 kb Bam HI fragment (and 
the normal 3.3 kb fragment, Figure 6, lane 5). The break-
point has therefore been tentatively placed in region 4; in 
DNA of this patient, the 1.2 HBg probe would detect only 
22q- restriction enzyme fragments. 
Using different restriction enzymes and probes from the 
5.0 kb Bgl II fragment, we have analyzel:l the location of 
the breakpoint in all CML DNAs shown in Figure 5, lane 
1-15. These results are summarized in Table 1 . 
Discussion 
In the present studies we have identified and cloned a 
breakpoint cluster region (bcr) on chromosome 22, in· 
valved in the chromosomal translocation, t(9;22), of Ph'· 
positive CML. In total we have studied 19 CML patients; 
ten of these were shown to be Ph' -positive by cytogenet· 
ical analysis. All of the patients of this latter group pas· 
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Figure 6. Analysis of Ph' Translocation Breakpoints on Chromosome 22 
Top: DNA of patients was digested with Bam HI (lanes 1, 3, 5, 7), Bgl II 
(lane 2), or Hind Ill (lanes 4, 6, 8). Hybridization was with the 1.2 kb HBg 
probe; Jane 2 is hybridized with a 0.6 kb HB probe indicated in the bottom 
of the figure. Molecular weights of marker fragments in kilobases are 
indicated in the left of the figure. Bottom: bcr, the region within the cloned 
chromosome 22 sequences containing Ph' translocation breakpoints iden-
tified in this study, is shown schematically. The numbers refer to the 
subregions mentioned in the text; the probes used are indicated above the 
figure. 
sessed a chromosomal break within bcr. Of the remaining 
nine patients, one was cytogenetically characterized as 
Ph' ·negative and a second patient has Ph' -negative juve· 
nile CML; as expected, they did not exhibit a breakpoint 
in this region. Seven of seven nonkaryotyped patients 
were Ph' ·positive because a chromosomal break could be 
identified within bcr. The involvement of bcr in the Ph' 
translocation is highly specific for CML, as analogous 
rearrangements were not found in DNAs isolated from 
other neoplastic tissues or cell lines, including DNAs from 
four acute myeloid leukemia patients, one acute myelo· 
monocytic leukemia patient, glioblastoma, melanoma, mul· 
tiple myeloma, and teratocarcinoma cell lines (data not 
shown). Since abnormalities were not seen in a fibroblast 
cell line established from a Ph' ·positive CML patient, in 
cultured fibroblasts of a Ph' ·positive CML patient, or in 
leukemic cells of two Ph'·negative CML patients, we be· 
lieve these rearrangements to be highly specific for the 
leukemic cells in Ph' -positive CML patients. In two [Jatients 
these rearrangements were rigorously analyzed and shown 
to represent chromosomal breakpoints. Probes, isolated 
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Table 1. Breakpoint Location within bcr of Ph' -positive CML Patients 
CML Breakpoint CML Breakpoint 
Patient Location Patient Location 
0311068 H81-122 2, 3 
7701C H81-118 2, 3 
C999 H79·179 
C481 H77·94 
B79-100 H81·258 1. 2 
B79·216 0, 1, 2 coso 4 
H80·251 0,1 0319129 
CML·O 02120185 
H81-164 2, 3 
The different breakpoint subreg1ons (0-4) are as indicated in Figure 6, 
bottom. For some patients, the exact breakpoint subregion has not yet 
been determined: more than one subregion is indicated 1or these patients 
1n the table. 
from the bcr, in particular the 1.2 kb HBg probe, are highly 
specific tools for the identification of the Ph' translocation 
in leukemic DNA and as such, may be of diagnostic value, 
in particular when no metaphase chromosome spread can 
be obtained. 
We have molecularly cloned a region of chromosome 
22 from non·CML DNA that contains the Ph' breakpoints 
in CML DNA. The orientation of the chromosome 22· 
specific sequences in the two 9q+ breakpoint fragments 
determines the orientation of the breakpoint cluster region 
on the chromosome: the most 5' end will remain on 
chromosome 22 (Figure 7) and, depending on the exact 
position of a breakpoint, a smaller or larger region of bcr 
will be translocated to chromosome 9. Although the break· 
poinrbn the Ph' chromosome is in band q11 (Rowley, 
1973; Yunis, 1983) and the A light-chain constant region 
has been localized to the same band (McBride et al., 1982; 
our unpublished results) no cross-homology was observed 
between the chromosome 22 cosmid clones and CA. As 
of yet, these clones contain unidentified sequences. Ex· 
periments to determine if this region of chromosome 22 
contains protein coding regions and/or enhancer se-
quences are in progress. 
Previously we have reported the isolation of a Ph' 
breakpoint fragment containing chromosome 9 sequences 
originating approximately 14 kb 5' of human v-ab/ homo!· 
ogous sequences (Heisterkamp et al., 1983b). However, 
we were unable to detect chromosomal breakpoints in 
other CML DNAs up to 11 kb 5' of this breakpoint. The 
9q+ breakpoint fragment from a second CML patient, 
isolated in the present study, contains 9 kb of DNA 
originating from chromosome 9. Preliminary results sug· 
gest that these sequences must be separated by, at 
minimum, 27 kb of DNA 5' of the previously reported 
breakpoint. Therefore, the breakpoint on chromosome 9 
appears to be variable in different Ph' -positive CML pa· 
tients and may be found within a relatively large but limited 
region on chromosome 9; the region of chromosome 9 
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Figure 7. DiagrammatiC Representation of the Ph' Translocation 
The horizontal arrows indicate the chromosomal breakpoint in chromosome 
22. Mapping of c-sis to the region of chromosome 22 (q12.3 to q13.1) 
translocated to chromosome 9 is as previously described (Groffen et al., 
1983a: Bartram et al., 1983a). Localization of c-ab/to the terminal portion 
of chromosome 9 (q34), wh1ch IS translocated to chromosome 22 in the 
Ph' translocation, is as described in the text. The maximum size of bcr, 
from the 5' Bglll to the 3' Bam HI site, is 5.8 kb. 
containing human c-ab/ ( q34-qter) that is translocated to 
chromosome 22 is too small to be visualized by cytoge-
netic analysis and does not exceed 5000 kb (Heisterkamp 
et al., 1983b; de Klein et al., 1982). 
At present, we do not know whether the two breakpoints 
we have identified actually occur within human c-ab/ coding 
sequences: the most 5' ex on of human c-ab/ has not yet 
been determined. However, the possibility must be consid-
ered that the human c-ab/ oncogene extends over a much 
larger region than that characterized by homology to the 
viral oncogene v-ab/; whereas the v-ab/ oncogene is 3.5 
kb in length (Goff et al., 1980). Homologous RNA species 
ranging in size from 5-7 kb (Ozanne et al., 1982; Westin 
et al., 1982), have been reported in humans. In contrast to 
the situation on chromosome 9, the breakpoints on chro-
mosome 22 seem to be clustered in a very limited region. 
It is evident, however, even at the restriction enzyme level, 
that the breakpoints have not occurred in one specific site 
but rather are distributed over a region of up to 5.8 kb. 
Analogous to the t(9;22) in Ph'-positive CML, a t(8;14) 
is found in many patients with Burkitt lymphoma: in the 
latter case, the human oncogene c-myc, located on chro-
mosome 8, (Dalla-Favera et al., 1982; Taub et al., 1982) is 
often translocated into the immunoglobulin heavy-chain 
locus on chromosome 14 (Taub et al., 1982; Dalla-Favera 
et al., 1983; Adams et al., 1983; Erikson et al., 1983; 
Hamlyn and Rabbits, 1983). The breakpoints on chromo-
some 8 may be distributed over a relatively large region 5' 
of human c-myc (Dalla-Favera et al., 1983; Adams et al., 
1983; Erikson et al., 1983), a situation analogous to that 
of human c-ab/ on chromosome 9. On chromosome 14, 
breakpoints in the variable (Erikson et al., 1982) and in the 
constant region of the heavy-chain locus have been re-
ported in Burkitt lymphoma, indicating that neither the 
breakpoints on chromosome 8 nor those 14 can be found 
within a breakpoint cluster region as discussed in the 
present study. The bcr on chromosome 22 seems as of 
yet to be unique in human. However, the existence of bcrs 
on other human chromosomes is not unlikely taking into 
consideration the increasing number of reports of other 
highly specific translocations in neoplastic diseases (for a 
review, see Yunis, 1983). 
The specificity of the presence of a chromosomal break-
point on chromosome 22 within bcr in Ph' ,positive CML 
indicates that this region may be involved in CML. Addi-
tionally, a human oncogene, c-ab/, is consistently translo-
cated to chromosome 22, even in patients with complex 
Ph' translocations (Bartram et al., 1983b) and is amplified 
in a CML cell line, K562, (Heisterkamp et al., 1983b). 
Although the breakpoints on chromosome 9 are distributed 
over a relatively large region of DNA 5' to human v-ab/ 
homologous sequences, the specific translocation of this 
oncogene in the t(9;22) must be of functional significance. 
Therefore, we believe that both human c-ab/ and bcr may 
be associated with Ph' -positive CML. 
Experimental Procedures 
Somatic Cell Hybrids 
PgME-25 Nu IS a human-mouse somatic cell hybrid obtained from fusion 
w1th mouse Pg19 cells; it contains as its only human component chromo-
some 22. Chinese hamster cell line E36 was used to obtain hybrids 1 OCB-
238 and 14CB-21A. The hybrid 10CB-238 contains human chromosomes 
5, 9, 11, and 19, whereas 14CB-21A has retained chromosomes 4, 7, 8, 
14, 20, and 9q+ (Geurts van Kessel et al., 1981b: Geurts van Kessel et al., 
1981C; de Klein et al., 1983). WESP 2A was obtained by fusion of mouse 
WEHI-38 cells with leukocytes of a Ph'-positive CML patient and contains 
human chromosomes 7, 8, and 14 1n addttion to the Ph' chromosome (de 
Klein et al., 1983). 
Southern Blot Analysis 
Htgh molecular weight DNAs were isolated as descnbed (Jeffreys and 
Flavell, 1977), digested with restriction enzymes, and electrophoresed on 
agarose gels. Blotting was according to Southern (1975) on nitrocellulose 
(Schleicher and Schuell, pH 7 .9). Nick translation of probes and filter 
hybridizations were as described (Flavell et al., 1978: Bernards and Flavell, 
1980). Spectfic activity of the probes were 2-5 x 108 cpmfJ.Lg. Filters were 
exposed to XAR-2 ftlm (Kodak) at -70°C with Dupont Lightning Plus 
intenstfying screens. 
Isolation of Probes 
DNA probes were prepared by digestion with appropriate restrictton en-
zymes, followed by electrophoresis through low-melting-point agarose gels. 
Desired bands were cut from the gel and brought into solution by heating 
at 65°C for 30 min. Agarose was removed by two extractions with phenol 
equilibrated with 0.3 M NaOAc (pH 5.0), and one extraction with phenol/· 
chloroformjisoamylalcoho\ (25:24:1 ). DNA was precipitated with ethanol 
and 0.2 M NaOAc (pH 4.8) in the presence of 20 J.Lgfml Dextran T-500 as 
earner. Restnctton enzymes and low-melting-point agarose were purchased 
from Bethesda Research Laboratories and were used according to the 
supplier's specifications. 
Molecular Cloning 
Subcloning of the 5.0 kb Bglll fragment and cloning of the 11.3 kb Bam HI 
fragment was according to published procedures (Groffen et al., 1983b), 
A previously described {Grotten et al., 1982) human lung carcinomacosmtd 
library was screened with the 1.2 HBg probe according to the method of 
Grosveld et al. (1981). Three positive cosmid clones were isolated and 
mapped independently by d1gest1on of individual restriction enzyme frag-
ments isolated from low-melting-point agarose gels. 
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The Philadelphia (Ph') chromosome. an abnormal chromosome 
22 (ref. 1), is one of the best-known examples of a specific human 
chromosomal abnormality strongly associated with one form of 
human leukaemia, chronic myelocytic leukaemia (CML). The 
finding2 that a small region of chromosome 9 which includes the 
c-ab[ oncogene is translocated to chromosome 22 prompted studies 
to elucidate the molecular mechanisms involved in this disease. 
We have demonstrated previously that the chromosome 9 of one 
patient with CML contains a breakpoint 14 kilobases (kb) 5' of 
the most 5' v-ahl-homologous exon3 • These data suggest a role for 
c-abl in CML, a theory supported by the presence of an abnormally 
sized ahl messenger RNA4•5 and protein6 in the CML cell line 
K562. The region involved in the translocation on chromosome 22 
has also been identified: all Ph'-positive patients examined to date 
have a breakpoint within a 5.8-kb region, for which we have 
proposed the name 'breakpoint cluster region' (berf. To determine 
whether her contains protein-encoding regions, probes from her 
were tested for their ability to hybridize to complementary DNA 
sequences. A 0.6-kb Hindlll/ Bam HI her restriction enzyme frag-
ment proved suitable for isolating several eDNA clones from a 
human fibroblast eDNA Iibrary8 • Using her eDNA sequences, we 
obtained data strongly suggesting the presence of a chimaeric 
her/ahl mRNA in the leukaemic cells of Ph'-positive CML 
patients. The recent isolation of eDNA clones containing her and 
abl sequences confirms this finding 12• Because the her part of the 
chimaeric mRNA could be required to induce the transforming 
activity of the human c-abl oncogene, we have now initiated studies 
to characterize the normal ~her gene and to determine the effect 
of a translocation within its coding domain. We demonstrate that 
as a result of the Ph' translocation, a variable number of bcr exons 
are included in the chimaeric bcrl abl mRNA. The her gene sequen-
ces in this mRNA could be responsible for the transition of the 
abl cellular proto-oncogene into an oncogene.· 
The largest eDNA, V1-3, containing an insert of 2.2 kb, was 
characterized in detail by restriction enzyme mapping (Fig. 1a) 
and sequence analysis (Fig. 1b). The eDNA contains one long 
open reading frame, starting at the poly(G) tail at the 5' end 
and continuing to nucleotide 1,770, where a stop codon is 
encountered. All other reading frames have many stop codons 
within the entire region. The long open reading frame has the 
coding capacity for 589 amino-acid residues, corresponding to 
a protein of relative molecular mass (Mr) -65,000; at the 31 
end, a polyadenylation signal occurs at nucleotide 2,182 fol-
lowed by a poly( A) tail beginning at base 2,208 indicating that 
the eDNA contains the complete 3' end of the gene. Although 
translational start sequences are encountered at the 51 end, it is 
unlikely that this eDNA contains a complete copy of the mRNA, 
as N orthem blot hybridizations indicate the presence of bcr 
mRNAs of -4.0 and -6.5 kb. Computer searches of newly 
isolated protein sequences derived directly from proteins or 
deduced from eDNA nucleotide sequences frequently result in 
the identification of proteins with partial homology. Such infor-
mation is valuable, frequently allowing the assignment of a 
preliminary function to an unknown protein. Therefore, the PIR 
FASTP program 10 was used to search for her-homologous pro-
teins; no proteins with significant homology were found, indica!-
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ing that the bcr protein exhibits an as yet unidentified cellular 
function. 
To determine the orientation of the bcr gene on chromosome 
22, 5' and 3' probes were prepared from the V1-3 eDNA and 
hybridized to cosmids7 containing human chromosome 22 
sequences. This established that the 5' end of the bcr gene is 
towards the centromere of chromosome 22 and is retained after 
the Ph' translocation; the 3' end of the bcr gene lies in the 
direction of the telomere and is translocated to chromosome 9 
in the t(9; 22) translocation. The eDNA hybridizes to restriction 
enzyme fragments distributed over a region of up to 45 kb of 
chromosome 22 DNA (Fig. 2a). Within this region, a minimum 
of 13 exons are present. To determine the exact position and 
number of exons within the breakpoint cluster region, all 
hybridizing regions in bcr were sequenced and compared with 
the V1-3 eDNA. Four relatively small exons, designated 1-4, 
were present within bcr, varying in size from 76 to 105 base 
pairs (bp) (Fig. 2b): in the eDNA, these exons correspond to 
nucleotides 483-836 (Fig.1b). As bcr was defined as the area 
on chromosome 22 in which the Ph1 breakpoints are found, we 
conclude that the breakpoints occur within a gene. 
Having determined the position of the exons within bcr, we 
investigated whether the breakpoints occur in exon or intron 
regions. For CML DNA such as that ofCML patient C481, this 
was readily determined. We had previously demo~strated7 a 
breakpoint within a 1.2-kb H/Bg bcr fragment in several CML 
DNA samples, including that of patient C481. As no coding 
sequences are located within this region (see Fig. 2), patients 
such as C481 must have a chromosomal breakpoint in the intron 
between the exons designated 3 and 4. 
A less simple situation was encountered in the DNA of· 
patients 0311068 and 7701C. Nonetheless, cloning of9q+ break-
point fragments from these DNAs (data not shown) and restric-
tion enzyme analysis followed by Southern hybridization 
enabled us to locate the breakpoints between exons 2 and 3 (see 
Fig. 2). The breakpoints in the previously cloned'·' 9q+ break-
point fragments of patients 0319129 and 02120185 were analysed 
by DNA sequencing. In addition, we cloned the 22q- breakpoint 
fragments of patient 0319129 (unpublished results) and of the 
cell line K562. DNA sequence analysis of the breakpoint regions 
of these fragments and that of the sequence of the corresponding 
chromosome 22 regions enabled us to define the point of translo-
cation for these DNAs (see Fig. 2). None of the breakpoints 
analysed here could be located within an exon, indicating that 
in the Ph' translocation, breakpoints occur within intron regions 
of her. For four of the six DNA samples analysed, the transloca-
tion would result in the transcription of a mRNA that includes 
bcr exons I and 2 {see Fig. 2); in two CML DNAs the third 
ex on would be additionally incorporated in the chimaeric her I c-
ab! mRNA. Exon 3 encodes only 25 amino acids, not substan-
tially increasing the size of the chimaeric protein. 
A knowledge of the DNA sequence of the translocation junc-
tion point may provide additional information about the 
mechanism of chromosomal translocation. Figure 3 a shows the 
sequence of the region containing the crossover point for translo-
cation in the DNA of patient 0319129 and compares this with 
normal chromosome 22 and 9 DNA sequences. In 0319129 
DNA, the chromosomal break has occurred in a rather 'precise' 
manner, leading to the generation of a 22q- and 9q+ sequence 
exactly reflecting the sequence of the normal chromosome 22 
and 9 DNA sequences. However, at the breakpoint, a C nucleo-
tide is found in both the 9q+ and 22q- sequences, whereas the 
chromosome 22 sequence contains a G at that position. Note 
that both chromosomes 9 and 22 contain limited stretches of 
homology near the break (Fig. 3a underlined); a DNA search 
revealed homology of this region to human Alu repetitive 
sequences. 
No such similar stretches of homologous sequences between 
chromosomes 9 and 22 occur at the breakpoint in the DNA of 
patient 0212015 (Fig. 3b) or in that of K562 DNA (data not 
shown). In the 9q+ DNA of patient 0212015, sequences are 
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Fie. 1 bcr eDNA V!-3 .. a, Restric· 
tion enzyme map of Vl-3. The black 
bar indicates the open reading frame 
sequences, the thin line non-trans-
lated sequences. The 3' end of the 
eDNA containing the poly( A) tail is 
depicted as An- Restriction enzymes 
include: A, Ava!; Ap, Apa!; B, 
B&lll; Bs, BstEII; H; Hindlll; HI, 
Hinfl; P, Pst!; PII, Pvull; S, Sau3A. 
b, DNA sequence and translation of 
Vl-3 sequence. Amino-acid residues 
are indicated with a one-letter sym-
bol below the sequence. The exact 
position of exons designated 1-6 (see 
Fig. 2a) within Vl-3 bcr eDNA is 
shown by the numbers above the 
sequence. DNA sequencing was per-
formed using the dideoxy-chain 
termination method14 on restriction 
enzyme fragments of the eDNA sub-
cloned into M13 phage1!5. All regions 
were sequenced on both strands. 
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Fig. 2 Genomic organization of the bcr gene. 
a, Restriction enzyme map of chromosome 22 
sequences encompassing bcr. Exons are indi-
cated by black boxes below the restriction 
enzyme map. The position of the numbered 
exons has been determined by sequencing; all 
other exom; were located by hybridization to 
the VlM3 eDNA The asterisk indicates a polyM 
morphic Bglii restriction enzyme site. b, 
Restriction enzyme map of the breakpoint 
cluster region, with the exons as indicated in a. 
Below the map, the approximate positions of 
the breakpoints in different CML DNAs are 
indicated by horizontal or vertical arrows. 
Restriction enzymes include: A, Ava!; B, 
BamH!; Bg, Bglll; E, EcoRI, H, Hindiii; P, 
Pst!; S, Smai; Ss, Sst!; X, Xhoi. The break· 
point of the 22q- chromosome from DNA 
0319129 was cloned as a 9.5-kb Bglll fragment 
in Charon 30 according to previously described 
methods16• 9q+ fragments were isolated by clon~ 
ing a 7.2Mkb BamHI fragment and a 7.7~kb 
Eco RI fragment into Charon 30 and A gtwes, 
respectively. 
found between the breakpoints on chromosomes 9 and 22 
(Fig. 3b) which are not present in the sequenced region of the 
normal chromosomes 9 and 22. This suggests that in the 9q + 
chromosome a secondary event has taken place; it is possible 
that after translocation of chromosome 22 sequences to chromo· 
some 9 ~ a deletion affecting chromosome 9 sequences occurred. 
The arrow indicating the breakpoint on chromosome 9 (see 
Fig. 3b) would then represent the point of deletion. In addition, 
compared with the normal chromosome 9 sequences, the 
chromosome 9 sequences ofthe 9q+ fragment contain 13 nucleo-
tide changes within an 81-bp stretch. These changes may reflect 
differences between individuals (the control chromosome 9 
sequences were isolated from a human lung carcinoma cosmid 
library); however, the number of nucleotide substitutions would 
be very high in such an event. Moreover, the chromosome 22 
part of the 9q+ fragment contains no nucleotide changes in 
either intron or exon sequences, favouring the explanation of 
inefficient DNA repair on deletion of chromosome 9 sequences. 
These results indicate that bcr is part of a gene oriented with 
its 5' end towards the centromere of chromosome 22. In the 
Philadelphia translocation, a break occurs within bcr, and 
sequences from chromosome 9 which contain the human c-abl 
oncogene in all Ph'-positive cases examined7•9 are translocated 
to the 3' of the truncated bcr gene. The joining of bcr and c-abl 
sequences is highly specific for CML, as this configuration has 
been found in complex translocations9 and even in the leukaemic 
cells of one CML patient cytogenetically lacking the Ph' chromo-
some11. Because the orientation of c~abl on chromosome 9 is 
also centromere-5'-3'-telomere~ her and c-abl are joined in a 
head-to-tail fashion on the Ph' chromosome. Although the dist-
ance between the most 5' v~abl homologous to v-abl and the 
physical breakpoint may vary from 14 kb (patient 0319129) to 
> 100 kb (K562), the effect of the translocation on the expression 
of the her gene and c-abl seems to be very similar in different 
patients: in K562 and in Ph'-positive CML patients, abnormal 
RNA transcripts of -8.5 kb are detected, which hybridize to 
both c-abl and 5' bcr exon probes. The molecular cloning of a 
chimaeric eDNA from K562 cells has provided definitive proof 
for the existence of chimaeric mRNA 12• The chimaeric mRNAs 
must be the result of transcription initiating at the promoter of 
the bcr gene; depending on the exact location of the breakpoint, 
the transcript will include all 5' exons in addition to either exons 
1 and 2 or exons 1~ 2 and 3 of bcr. Recent sequence analysis of 
K562 bcr/ abl eDNA confirms the variable presence of the third 
exon. In K562 we found that, as predicted, the third exon is 
present in the eDNA, immediately preceding c-abl sequences. 
In contrast, Southern blot analysis of the molecularly cloned 
22q- genomic DNA fragment of, for example, patient 0319129 
unambiguously demonstrates that in this patient exon 3 has 
been removed from the Ph' chromosome and will not be included 
in a chimaeric her I abl transcript. Transcriptiq~ continues into 
the c-ab! oncogene~ including, as a minimum, the most 5' v-ab/-
homologous exon and all exons 3' of it, including the phos-
photyrosine acceptor site13• We do not know whether the 
inclusion of exon 3 in the chimaeric mRNA has an effect on 
the progression of the disease. 
Chromosomal aberrations may be generated by specific events 
involving recombination-prone DNA sequences. Alternatively, 
such recombination events could occur almost at random. In 
either case, a very limited number of translocations will result 
in gene alterations leading to the disruption of normal growth 
and differentiation. In the Ph' translocation, we have found that 
breakpoints on chromosome 9 are spread over a region of up 
to 100 kb. The breakpoints on chomosome 22 occur within a 
smaller region of around 5.0 kb. Nonetheless, no sequence 
homology can be found between breakpoint regions of different 
CML patients or coding regions of c-abl and bcr genes. There-
fore, we may conclude that the processes underlying the Ph' 
translocation are random recombination events. Once such re-
combinations result in a genomic configuration that allows the 
transcription of chimaeric bcr/ abl mRNA, malignant prolifer-
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a o3a129 1 9 TTGTTGCTTTTGGAGA~CTCTGTCA..££fillCTGGACTGCAGTGGCACAATCACAGCTCAC 
2~~: nn~~~I~g~i~~~i~~~~I~n~~~~~~~~~~~~¢~~~~~~¢~~~~n~ng~~i~~~x~~i2~~ 
22 GT~CCTCTTGTCTCCTCCi::AGGAG!fillAAGGTGGGtAGGA§1lliTTCTCCCTGAGTGGCTGC 
b 02120185 
9 cCCGGGTTCA.i.GCGATfcrcCrcccrcAGCCrti-TGAGrAGCTGG.i.ACTACAGGCACGi-GccACCATGcc 
9q + CC CGGGTT CAC GT GAT ACTCTTGC CT CAG CTT CCTG CAT AGCTG GGACT A CAGGCACC CACCACCACGCC 
Z2 TGACACTGGCTTACCTTGTGCCAGGCAGATGGCAGCCACACAGTGTCCACCGGATGGTTGATTTTGAAGC 
9 CAG CT AA TTTATTGTTT GTTTGTTTGTTT GTTTTCCTGAGAC GGAGTCTCACTGT CACCCAGGCTGGAG 
9 q + CAGCT AA TTTrtTGT A TGTTT AGT AGAGACGAG GTTT ¢lt~CAGAAGCTGACCTCTTTGGT CT CTTGCGCAG 
Z2 AGAGTT AGCTT GTCACCT GCCTTCCCTTT CC CGGGACAACAGAAG CT GA CCT CTTT GATCT CTTGCGCAG 
I 
9 TGCAGTGGCGTAATCTTGGCTCACTGCAACCTCCACCTCCCGGG 
9q+ ATGATGAGTCTCCGGGGCTCTATGGGTTTCTGAATGTCATCGTC 
22 ~;~~~~TCTCCGGGGCTCTATGGGTTTCTGAATGTCATCGTC 
Fig. 3 Breakpoint sequences of the DNAs of two CML patients. 
a, Sequence of0319129 DNA; the sequences are in a 5'-3' orienta-
tion. Normal chromosome 9 sequences (first line) are from non-
CML DNA; the 9q+ and 22q- sequences (second and third lines) 
are from DNA of patient 0319129. Normal chromosome 22 sequen-
ces (fourth line) are from non-CML DNA. An arrow indicates the 
breakpoint on chromosomes 9 and 22; the nucleotide C found in 
both the 9q + and 22q- sequences at the breakpoint is boxed. 
Limited regions of homology between the normal chromosome 9 
and 22 sequences are underlined. b, Breakpoint sequence of 
02120185 DNA; normal chromosome 9 and 22 sequences (first and 
third lines in each set) were from non-CML DNA. The 9q+ 
sequence on the second line contains an area boxed to indicate 
that it does not originate from the normal chromosomes 9 or 22 
sequenced in the present experiments. Dots above the chromosome 
9 sequences indicate nucleotide differences at those positions from 
the 9q+ chromosome. The beginning of exon 3 (see Fig. 2b) in the 
9q + and 22 sequence is indicated in the figure. Small restriction 
enzyme fragments containing the breakpoints were chosen for 
sequence analysis, based on restriction enzyme mapping data and 
comparison with normal chromosome 9 and 22 maps. 
ation of specific cell types may occur. It seems highly likely that 
this chimaeric mRNA is translated into protein because an 
abnormally sized 210,000-M, c-ab/ protein was detected in K562 
cells. In contrast to the normal c-ab/ protein, the P210 has 
tyrosine kinase activity6 • 
It is tempting to speculate that the bcr moiety of the fusion 
protein is responsible for this effect. However, although the 
consequences of the Ph1 translocation on a molecular level are 
becoming evident, it remains to be established whether this 
phenomenon is actually the cause or merely one of the steps 
that eventually result in CML. 
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The Chronic Myelocytic Cell Line K562 Contains a Breakpoint in 
bcr and Produces a Chimeric bcrlc-abl Transcript 
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In the DNAs of all Ph1-positive chronic myelocytic leukemia patients studied to date, a breakpoint on 
chromosome 22 (the Ph1 chromosome) can be demonstrated with a probe from the her (breakpoint cluster 
region). Although the K562 cell line was established from cells of a chronic myelocytic leukemia patient, we 
have been unable to detect the Ph1 chromosome by cytogenetic means. Employing a probe from the 5' region 
of her, we have cloned an amplified Ph1 breakpoint fragment from K562. This demonstrates that K562 contains 
multiple remnants of a Ph1 chromosome with a breakpoint within her and thus may serve as a model system 
for the study of Ph1-positive chronic myelocytic leukemia at a molecular level. The isolation of her eDNA 
sequences shows that parts of her encode a protein. Employing K562, we demonstrate the presence of an 
abnormally sized mRNA species hybridizing to c-ab/ and to a her eDNA probe, indicating the possible 
consequence of the Ph1 translocation on a transcriptional level in chronic myelocytic leukemia. The isolation 
and sequencing of a eDNA containing the breakpoint area of this mRNA provide further evidence for its 
chimeric structure. Cloning of large stretches of chromosomal DNA flanking her and c-abl sequences in K562 
and identification of the exons participating in the formation of the chimeric mRNA shows that a splice of at 
least 99 kilobases is made to fuse the 3' her exon to the 5' c-abl exon. Furthermore two chimeric cDNAs were 
isolated containing chromosome 9 sequences that map 43.5 kilobases downstream from the K562 breakpoint. 
These chromosome 9 sequences neither hybridize to the 8.5-kilobase chimeric c-abl mRNA nor to normal c-abl 
mRNAs in Hela cells and probably represent incorrect splicing products present in the K562 cell line. 
Chronic myelocytic leukemia (CML) is a pluripotent stem 
cell disease characterized by the presence of the Philadel-
phia (Ph1) chromosome in the leukemic cells of 96% of all 
CML patients. The Ph1 chromosome is the result of a 
translocation between chromosomes 22 and 9 (31). The 
human c-ab/ oncogene (17) has been mapped to the long (q) 
arm of chromosome 9 (18). By analysis of somatic cell 
hybrids, we have shown that this oncogene is translocated to 
the Ph1 (22q-) chromosome in Ph1-positive CML. demon-
strating that c-ab/ is involved in the translocation between 
chromosomes 9 and 22 (8). The location of the c-ab/ 
oncogene adjacent to the translocation breakpoint in CML 
was shown by the isolation of a DNA fragment from the 9q+ 
chromosome of a CML patient: this fragment contained 
sequences of both chromosomes 9 and 22. The breakpoint 
had occurred 14 kilobases (kb) immediately 5' of the v-abl 
homologous sequences and resulted in a 9q + chromosome in 
which the tip of chromosome 9. including the v-abl homol-
ogous sequences. was replaced by sequences of chromo-
some 22 (20). The isolated chromosome 22 sequences of this 
chimeric DNA fragment enabled us to study their role in the 
Ph1 translocation in greater detail. A breakpoint cluster 
region (her) was identified on chromosome '22: the DNAs of 
all (over 30) Ph1-positive CML patients examined to date 
have breakpoints in this region of up to 5.8 kb. As a result. 
c-ab/ is linked to the same chromosome 22 sequences on the 
Ph1 chromosome in all patients. oriented with its 5' end 
toward and its 3' end away from bcr (14). 
In 1975. Lozzio and Lozzio (25) reported the isolation of a 
cell line, K562. from the pleural effusion of an adult patient 
* Corresponding author. 
with CML. This cell line expresses phenotypic markers of 
eythroid lineage and displays induced and spontaneous 
globin synthesis (23). We and others (5. 20. 33) have shown 
that the c-ab/ oncogene and the 1\ immunoglobulin light chain 
constant region (CI\) are amplified at least fourfold in this cell 
line. In contrast. another human oncogene. c-sis. is not 
amplified (20) and is normally located on chromosome 22 but 
transposed to chromosome 9 in the Ph1 translocation (13). 
These data suggest that K562 contains part of a Ph 1 chro-
mosome which is at least fourfold amplified. However, 
cytogenetic data are not confirmative, because we cannot 
detect a Ph 1 chromosome in different pedigrees of this cell 
line and others (25) have suggested the presence of a single 
Ph1 chromosome. Such findings leave the question unre-
solved as to whether K562 cells may serve as a model system 
for the study of Ph1-positive CML at the molecular level. In 
the present study we demonstrate the presence of a Ph1 
chromosomal breakpoint in the DNA of K562. The 
breakpoint has occurred in her. confirming our previous 
results that a breakpoint in her is highly specific for CML. In 
addition. we have established that her is part of a protein-
encoding region (19). Shtivelman et al. (34) have described 
the existence of a chimeric her/c-ab/ mRNA in the CML 
derived cell lines K562 and EM-2, by cloning partial cDNAs 
for these molecules. From sequence analysis of the chimeric 
cDNAs the authors show that the mRNA can code for a 
bcr/c-abl fusion protein. In the present paper we provide 
independent confirmation for the presence of the chimeric 
bcrlc-abl mRNA in K562. We identify and sequence the 
chromosomal exons of her and c-ab/ that participate in the 
formation of the chimeric mRNA and show that they are at 
minimum 97 kb apart in K562. Furthermore we provide 
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evidence that probably alternative splicing products can be 
formed from the berlc-abl precursor mRNA in K562. 
MATERIALS AND METHODS 
Southern blotting and hybridization. High-molecular-
weight DNAs were isolated as described previously (22), 
digested with restriction enzymes, and electrophoresed on 
agarose gels. Blotting was as described by Southern (35) on 
nitrocellulose (Schleicher & Schnell Co.: ph 79). Nick 
translation of probes and filter hybridizations were as 
described previously (2, 10). The specific activity of the 
probes was 2 x 108 to 5 x 108 cpm/f.Lg. Filters were exposed 
to XAR-2 film (Eastman Kodak Co.) at -70'C with DuPont 
Lightning Plus intensifying screens. 
Isolation of probes. DNA probes were prepared by diges-
tion with appropriate restriction enzymes, followed by elec-
trophoresis through low-melting-point agarose gels. Desired 
bands were cut from the gel and brought into solution by 
heating at 65'C for 30 min. Agarose was removed by two 
extractions with phenol equilibrated with 0.3 M sodium 
acetate (pH 5.0) and one extraction with phenol-chloroform-
isoamyl alcohol (25:24:1). DNA was precipitated with 
ethanol and 0.2 M sodium acetate (pH 5.6) in the presence of 
20 1-"g of Dextran T-500 per ml as a carrier. Restriction 
enzymes and low-melting-point agarose were purchased 
from Bethesda Research Laboratories. Inc., and were used 
according to the supplier's specifications. 
Molecular cloning. A cosmid library was constructed of 
size-fractionated K562 DNA partially digested with Mba! by 
previously published procedures (12) and screened with the 
0.6-kb Hindiii-BamH! her probe (see Fig. 2) by the method 
of Grosveld et al. (15). Three positive cosmid clones were 
isolated and mapped independently by digestion of individ· 
ual restriction enzyme fragments isolated from low-melting-
point agarose gels. 
Construction of k562 eDNA libraries. Total polyadenylated 
[poly(A)+] RNA (50 f.Lg) was denatured with 1 mM 
methylmercuric hydroxide before eDNA synthesis (26). 
First-strand synthesis was primed with oligo(dT) or 120 ng of 
c-ab/ 27-mer primer. eDNA synthesis was performed as 
described by Gubler and Hoffman (16). The double-stranded 
eDNA was treated with 10 U of T4 polymerase (Bethesda 
Research Laboratories) for 10 min at 37'C before EeoRI 
methylation and EeoRI linker addition. After EcoRI diges-
tion. excess linkers were removed by passage of the eDNA 
over Sepharose 2B-CL (Pharmacia Fine Chemicals). The 
eDNA was ligated to ;l.gtlO DNA cut with EcoRI. essentially 
as described by Huynh et al. (21). For the total library 4 x 
106 plaques were screened. and for the c-ab/ primed library 
2 x 105 plaques were screened. EeoRI inserts from positive 
plaques were subcloned into the EeoRI site of pUC18 or 
pUC19. 
RNA analysis. Total RNA was isolated by the LiCI-urea 
method (1). Poly(A)+ RNA was obtained after two passages 
of the RNA over oligo(dT)-cellulose, and 20 f.Lg of poly(A)+ 
RNA of K562 was electrophoresed on a 1% agarose gel in 
the presence of formaldehyde (26). After blotting, nitrocel-
lulose filters were hybridized to the probes indicated in the 
legends to Fig. 3 and Fig. 8. 
RESULTS 
Identification of K562 chimeric DNA fragments. In the 
DNAs of all Ph 1-positive CML patients examined to date, 
the presence of a bn:akpoint on chromosome 22 can be 
demonstrated for the majority of the DNAs by using a 1.2-kb 
Hindiii-Bg/11 probe (14) (Fig. 1A); for example, abnormal 
EeoRI restriction enzyme fragments are clearly present in 
the DNAs of CML patients 02120185, 0319129, and 0311068 
(Fig. 2A). Restriction enzyme fragments containing these 
breakpoints have been molecularly cloned (14, 20; unpub-
lished results) and shown to represent 9q+ fragments. In the 
K562 cell line abnormal fragments could not be detected 
either with EeoRI (Fig. 2A, lane 4) or with each of several 
other restriction enzymes tested (data not shown) after 
hybridization to the 1.2-kb Hindiii-Bg/11 probe. This could 
indicate that K56Z does not contain a breakpoint on chr6· 
mosome 22 within ber. To examine this more thoroughly, a 
probe more to the 5' (0.6-kb Hindiii-BamHI probe: Fig. 1A) 
within her was prepared and hybridized to the DNA of K562 
digested with different enzymes. This probe detects, in 
addition to the normal 5.0-kb Bg/11 fragment (Fig. 2B, lanes 
3 and 4), abnormal Bg/11 fragments in K562 DNA (Fig. 2B, 
lane 2). Moreover, one of these fragments is amplified at 
least fourfold. Abnormal amplified restriction enzyme frag· 
ments in K562 could also be detected by using other en-
zymes (Fig. 2B, lane 1). Since the 0.6-kb Hindiii-BamHI 
probe has detected 22q- fragments in the DNAs of a number 
of CML patients (14), it seemed likely that the abnormal 
amplified fragments in K562 represent amplified sequences 
on the 22q- chromosome. 
Molecular cloning of the K562 22q- breakpoint fragment. 
To analyze the abnormal amplified fragments in more detail, 
a cosmid library was constructed from K562 DNA partially 
digested with Mba! (12, 15). Numerous colonies of the 
approximately 100,000 recombinants hybridized with the 
0.6-kb Hindlll-BamHI probe; three such positive colonies 
containing overlapping portions of the same region were 
selected for further restriction enzyme analysis (Fig. 1D). It 
is evident from a comparison of the detailed restriction 
enzyme maps of normal chromosome 22 sequences (Fig. 1B) 
and K562 DNA (Fig. 1C) that the homology between the two 
terminates 3' to the most 5' Ava] site. 
A 1.0-kb EcoRI probe prepared from K562 DNA immedi-
ately 3' to the breakpoint (Fig. 1D) hybridizes to DNA 
isolated from somatic cell hybrids containing human chro-
mosome 9 in the absence of chromosome 22, but not to DNA 
isolated from hybrids containing chromosome 22 (data not 
shown). This indicates that the sequences isolated from 
K562 DNA are chimeric and contain the breakpoint of the 
22q- chromosome. The entire region is amplified at least 
fourfold; the chromosome 9-specific sequences are also 
amplified, as can be demonstrated by the strong hybridiza-
tion of the 1.0-kb EcoRI probe to K562 DNA in comparison 
with control DNA (Fig. 2C). Thus the amplification of 
chromosome 9 sequences begins at the point where the 
breakpoint has occurred on chromosome 9 in the Ph1 
translocation and extends in the direction of the telomere of 
the chromosome, including the c-ab/ oncogene. The ampli-
fied region may be relatively large. since the distance be-
tween the breakpoint on chromosome 9 and the most 5' v-abl 
homologous exon is, at minimum 99 kb (this paper). 
bcr is part of a gene. These results indicate that all 
Ph1-positive CML DNAs, including that from the cell lme 
K562 established almost a decade ago and propagated m 
tissue culture, contain a common genetic defect. a break on 
chromosome 22 within a very narrowly defined region. This 
region was found to code for part of a gene of unknown 
function on chromosome 22 (19). Normal her eDNA clones 
isolated with the 0.6-kb Hindiii-BamHI probe (Fig. 1A), 
such as pVl-3. were characterized by restriction enzyme 
mapping (Fig. 3) and hybridization to the genomic DNA of 
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FIG. 1. Restriction enzyme map of the K562 breakpoint region on chromosome 22. A, Restriction enzyme map of human chromosome 22 
sequences; the 5.8-kb BgUl-BamHl (bcr) region encompasses the 0.6-kb Hindlll-BamHl and 1.2-kb Hindlll-BgUl probes. D. Restriction 
enzyme map of the Ph1 chromosome in K562; the Ph1 chromosomal breakpoint is indicated with an arrow. Band C represent more detailed 
restriction enzyme maps of the indicated regions of A and D', respectively. The solid bars represent chromosome 22 sequences, whereas the 
open bars indicate sequences originating from chromosome 9. Probes used in the study are shown above A and below D. Abbreviations: A, 
A val; B, BamHl; Bg, BgUl; E, EcoRl; H, Hindlll; K, Kpnl; P, Pstl; S, Sstl; Xh, Xhol. 
chromosome 22. DNA sequence analysis of the eDNA and 
homologous genomic bcr sequences .showed exact concor-
dance (19). 
Since the eDNA cloning procedure orients the eDNA in 
the vector (29), the transcriptional orientation of the bcr gene 
could be established; it points toward the telomere of chro-
mosome 22. This implies that bcr and the linked c-ab/ gene 
are transcribed in the same direction on the Ph1 chromosome 
(5' end centromeric, 3' end telomeric). 
Consequence of the Ph1 translocation on bcr and c-abl 
expression. Since the bcr gene is oriented in the same 
transcriptional direction as the c-ab/ oncogene, we next 
examined the influence of the Ph1 translocation on the 
transcription of these genes in K562. 
For the detection of c-ab/ mRNA we used a human c-ab/ 
riboprobe containing a 0.6-kb EcoRI-BamHI fragment in 
pSP64 (28). This fragment contains the most 5' human v-abl 
hybridizing exon as identified by DNA sequencing (see Fig. 
5 and 6). This exon is homologous tci the mouse c-ab/ exon 
containing the v-ab/-gag-abl junction identified and se-
quenced by Wang et a!. (37). To examine the effect of the 
amplification and translocation of the human c-ab/ oncogene 
on its expression, poly(A)+ RNA was isolated from K562 
and control Hela cells. In concordance with results obtained 
by others (6, 11), the c-abl-specific probe detects 6.0- and 
7.0-kb mRNAs both in Hela cells and in K562. In addition, a 
novel c-ab/ homologous mRNA of8.5 kb is detected in K562 
(Fig. 3, left lane). An extra band of approximately 11 kb is 
also visible and may represent c-ab/ precursor RNA, which 
has not been studied in further detail. The abnormally sized 
mRNA seems to be characteristic of Ph1-positive cells, as it 
is not detected in either normal control cells or cells of other 
types of leukemia (4, 11). 
For experiments involving bcr gene expression, the fol-
lowing two probes were subcloned from the normal bcr 
eDNA pV1-3: probe A, Pvuii-Psti. containing sequences 5' 
of the K562 breakpoint, and probe B, Psti-Pvuii, 3' of the 
breakpoint (Fig. 3). The relative position of the breakpoint 
within the eDNA was determined by Southern hybridiza-
tion; c[)NA sequences 5' of the breakpoint hybridize with 
the K562 and normal chromosome 22 cosmid clones, 
whereas sequences 3' of it only hybridize with normal cloned 
chromosome 22 DNA sequences (Fig. 1). Both probes were 
cloned in reversed orientation in pSP64 and pSP65, respec-
tively. Hybridization of the Northern blot with bcr probe A 
shows a strongly hybridizing band of 8.5 kb that migrates at 
the same position as the 8.5-kb c-abl-hybridizing RNA (Fig. 
4). Vague bands of around 7.0 and 4.5 kb are also detected 
and could represent the normal bcr transcripts; however the 
nature and structure of these transcripts has not been 
analyzed in detail (35a). Because the c-ab/ and bcr probes do 
not cross-hybridize, the nature of the 8.5-kb RNA can be 
explained in two ways: either this new RNA is a hybrid RNA 
consisting in pan of bcr and in part of c-ab/ sequences. or 
alternatively K562 contains a new ab/ and a bcr RNA that 
happen to be of the same size. When the K562 poly(A) + 
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FIG. 2. Ph1 chromosomal breakpoint in K562. A. EcoRI digest 
oflO ILg of DNA from eML patients 02120185 (lane 1), 0319129 (lane 
2), and 0311068 (lane 3) and from the cell line K562 (lane 4). B, K562 
DNA digested with Sst! (lane 1) and Bglll_(lane 2); DNAs of human 
cell lines AG1732 (lane 3) and AG2655 (lane 4) digested with Bglll. 
e, EcoRl digest of K562 DNA (lane 1) and ONA of human cell line 
GM3344 (lane 2). A, B, and e were hybridized with different 
molecular probes as shown at the bottom of the figures; the origin of 
the probes is as indicated in Fig. L 31P-labeled Hindlll-digested A 
DNA is included in the left lane of each panel as a molecular weight 
marker. 
RNA blot is hybridized to probe B (3' of the K562 
breakpoint) no hybridization to the 8.5-kb RNA can be 
detected (Fig. 4). In longer exposures of this Northern blot, 
only faint hybridization can be seen with the normal her 
RNAs. This experiment suggests that the 8.5-kb mRNA is 
indeed a chimera and contains, in addition to c-ab/ se-
quences, the 5' region of the her gene. 
Cloning of a eDNA containing the chimeric part of the 
8.5-kb mRNA. To investigate the structure of the 8.5-kb 
mRNA in more detail, a K562 eDNA library was constructed 
in t..gtlO (21) by using a 27-mer c-ab/ oligonucleotide to prime 
the first-srrand eDNA synthesis. The primer was derived 
from the 5' side of the human v-ab/ homologous region 
(designated exon a2 in Fig. 5), and its sequence is shown in 
Fig. 6A. After screening of this library with a combined c-ab/ 
0.3-kb EeoRI-Kpn! probe (specific for the 5' side of exon a2, 
Fig. 5) and her probe A (Fig. 3) several hybridizing plaques 
were found; one, ba 4.1, was subcloned in pUC19 and 
analyzed in detail.- This eDNA contains a insert of 468 bp 
flanked by synthetic EeoR! linkers. The restriction map ofba 
4.1 is given in Fig. 5. Hybridization of the ba 4.1 insert to a 
Southern blot containing EeoRI-digested K562 DNA and 
non-CML DNA (GM3344) results in the detection of three 
amplified EeoR! fragments of 16.0, 7 .0, and 2.9 kb in K562 
and single-copy fragments of 17.0 kb in K562 and 17.0, 7.0, 
and 2.9 kb in GM3344 (Fig. 7). These bands could be 
identified by hybridization of the eDNA probe to cloned 
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FJG. 3. Restriction enzyme map of the normal bcr eDNA, 
pVl-3. Three normal bcr eDNA clones were isolated from a 
fibroblast eDNA library (29) after screening with the 0.6-kb Hindlll-
BamHl probe (Fig. 1A). Of the largest eDNA, pV1-3, only the 
2.2-kb eDNA insert is shown flanked by poly( G) and poly(A) tails. A 
restriction enzyme map was deduced with the following enzymes: 
Pv, Pvu!I; Bg, Bg!II; H, Hindlll; Ps, Pstl; and A, Ava!. The arrow 
indicates the position of the her breakpoint in the cell line K562. 
Sequences to the left are linked to c-abl and are amplified in K562; 
sequences to the right are not amplified. Probe A represents a 0.5-kb 
Pvu!I-Pstl fragment, and probe B a 0.56-kb Pstl-Pvu!I fragment, 
both cloned in reversed orientation into pSP65 and pSP65, 
respectively. 
c-ab/ and her sequences (data not shown). The 17.0-kb 
single-copy fragment in both DNAs represents the normal 
EeoRI fragment on chromosome 22. whereas the amplified 
16.0-kb band represents the her gene containing the Ph1 
breakpoint (Fig. 1D). The 2.9-kb band contains c-ab/ exon a2 
(Fig. 5), and the 7 .0-kb band could be mapped directly 5' to 
tbe 2.9-kb c-ab/ fragment. The exon sequences present in 
Kb 
8.5-
7.0-
6.0-
probe 
c-abl 
probe 
A 
probe 
B 
-28s 
FIG. 4. Hybridization of K562 Northern blot with c-ab/ and her 
probes. Poly(A)+ RNA (20 IJ-g) ofK562 was run on a 1% agarose gel 
and transferred to nitrocellulose. As probes we used a 0.6-kb 
EcoRl-BamHl c-ab/ fragment (8), a 0.5-kb Pvull-Pstl 5' bcr frag· 
ment (probe A) and a 0.56-kb Pstl-Pvu!I 3' her fragment (probe B) 
cloned in pSP64, pSP65, and pSP64, respectively. The probes were 
labeled and hybridized as described in the supplier's manual 
(Promega Biotec). After hybridization the filters were washed under 
stringent conditions (0.03X SSe [1X SSe in 0.15 M Nael plus 0.015 
M sodium citrate], 65°C). 
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b2 b3 xl 
FIG. 5. Restriction enzyme maps of two chimeric cDNAs and the positions of the exon sequences in the K562 breakpoint region. The 
upper line represents the restriction map of the Ph1 chromosome in K562. The chromosomal breakpoint is indicated by an arrow above 'the 
map, as is the region of c-ab/ that is homologous to v-abl sequences. Blocks represent exon sequences of which b2 and b3 are bcr exons and 
al and a2 c-ab! exons. xl represents a chromosome 9-specific exon not homologous to c-ab!. Symbols: 1\ , mapped and cloned chromosome 
9 sequences (at the 3' side of exon xl another 10 kb of chromosome 9 sequences have been cloned and mapped, but this has been omitted 
from the figure);-=/ f:-, gap of unknown size. The middle line represents the restriction map of the chimeric K562 eDNA ba 4.1. The relative 
positions of the ba 4.1 exon sequences on K562 chromosomal DNA are indicated by the dashed lines. The lower line represents the restriction 
map of chimeric K562 eDNA SE. The relative positions of the SE exon sequences on K562 chromosoinal DNA are again indicated by dashed 
lines. Only the bcr exons of interest in SE have been indicated. The arrows under both cDNAs and chromosomal exon sequences indicate 
the sequence strategies. All sequences were done by the method of Maxam and Gilbert (27). Dots indicate the positions of the end labels. The 
arrows indicate directions and lengths of the sequences; an exception on this was the chromosomal exon xl, of which the 1.6-kb 
EcoRI-BamHI and 0.3-kb BamHI-EcoRI fragments were cloned in M13 and sequenced by the dideoxy method (32). All sequences were 
determined from both strands, except for the 1.6-kb chromosomal EcoRl-BamHI fragments of exon xl, which was sequenced from one 
strand. Solid bars represent chromosome 22 sequences, whereas open bars indicate sequences from chromosome 9. -Abbreviations: B, 
BamHI; Bg, Bg/II; E. EcoRI; H. Hindl!l; Hill. Hindlll; K, Kpnl; S. Sail; Sa, Saul. 
these fragments are located within one 2.7-kb Bg!II frag-
ment, indicated in Fig. 5. From these two experiments we 
concluded that eDNA ba 4.1 contains previously identified 
bcr and c-ab/ coding sequences complemented with as yet 
unidentified c-ab/ hybridizing DNA. To determine the exact 
nature ofba 4.1, the eDNA was sequenced (27) as designated 
in Fig. 5; the sequence is shown in Fig. 6A. Comparison of 
the 5' side of the clone to the pV1-3 bcr eDNA sequence 
revealed exact concordance with the 3' part of bcr exon 2 
and the entire bcr ex on 3 (here designated b2 and b3; Fig. 5) 
(19). The bcr sequence in ba4.1 is immediately flanked at the 
3' side by an unknown non-bcr sequence. The 3' end of the 
clone is identical to the sequence of c-ab/ exon a2 (Fig. 6A) 
and ends with the sequence of the 27-mer c-ab/ primer. The 
unknown middle part of ba 4.1 contains an Saul site (posi-
tion 147; Fig. 6A) that also seemed to be present in the 
genomic 2.7-kb Bg/II c-ab/ fragment (Fig. 5)_ Sequencing of 
the genomic DNA around the Saul site (Fig. 5) identified the 
c-ab/ exon a1 coding for the unknown ba 4.1 eDNA se-
quence (Fig. 6A). Mapping of the Saul site localizes c-ab/ 
exon a1 0.56 kb upstream from c-ab/ exon a2. The genomic 
0.3-kb Saul-Sail fragment containing exon a1 (Fig. 5) detects 
the c-ab/ mRNAs of6.0 and 7.0 kb in HeLa cells and of6.0, 
7.0, and 8.5 kb in K562 cells (data not shown). This proves 
that ex on a1 is part of the c-ab/ gene. Comparison of the ba 
4.1 eDNA sequence to the sequence of Shtivelman et al. (34) 
shows exact concordance. 
The sequence of the genomic bcr-exon b3, as defined by 
the bcr eDNA sequence, is followed by a splice donor-site (3) 
(Fig. 6A); the K562 breakpoint has been localized to 3' of 
this splice site in the intron between bcr exons b3 and b4 
(19). The genomic sequence of c-ab/ exon al is immediately 
preceded by a splice acceptor and followed by a splice donor 
(Fig. 6A), and c-ab/ exon a2 again is preceded by a splice 
acceptor. Therefore in eDNA ba 4.1 these three exons are 
linked following the GT-AG rule, resulting in the open 
reading frame (Fig. 6A). This frame is in phase with the 
predicted bcr (19), v-abl, 'and mouse c-ab/ (37) reading 
frames. 
Minimal distance between her exon b3 and c-abl exon al in 
K562. By chromosomal walking experiments with genomic 
K562 cosmid and A. libraries, we cloned and mapped 54 kb of 
chromosome 9 DNA downstream of bcr ex on b3 and 45 kb of 
DNA upstream of c-ab/ exon a1 as indicated in Fig. 5. Still, 
the overlap between the two has not been found. This 
implies that in K562 a splice of at minimum 99 kb has to be 
performed to link bcr ex on b3 and c-ab/ exon a1. An obvious 
question is how the splice system deals with an intron of this 
size and whether alternative splices are made. Screening 
with bcr probe A (Fig. 3) of an oligo(dT)-primed K562 eDNA 
library in A.gtlO produced two clones that contained bcr 
sequences linked to DNA that did not cross-hybridize to 
eDNA ba 4.1. One of these clones, 8E, is shown in Fig. 5. 
Due to incomplete EcoRl methylation of the eDNA during 
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eDNA ba 4.1 
b2 ~ 
bcr- Va!HisSerl leProleuThrlleAsnlysG\IpAspGluSerProGlyLeuTyrGlyPheleuAsnVallleValHi sSerAlaThr GTCCACAGCATTCCGCTGAC'CATCAATAAGGA~GATGAGTCTCCGGGGCTCTATGGGTTTCTGAATGTCATCGTCCACTCAGCCACT -90-
,, 
v-src- amino acid 48 --s erArgSerPheGlyThr~~!tt!GluProlysleuPhelll:iGlyPhcAsnThrSerAspThrVal._, 
bcr /c-<Jb 1- G 1 yPhclysGl nSerSerl ysAl aleuGl nArgProV<~IAI aSerAspPheG\ uProGlnG I yleuScrG 1 uAI<JA laArgTrpAsnSer 
GGATTT AAG CAGAGTT CAA AAG CCCTTCAG C GG C CAGT AG CATCTGAC TTTGAG CCT CAGGGT CTGAGT GAAG C C GC TC GTTGGAACT C C -1 8 0-
v-src- ThrSerProG\nArg~lliAlaLeuAli'!G\yGlyVJIThrThr~~~~!x.!:-~TyrGluSerArgThrGluThrAsp~ 
c-ab 1- L ysG I uAsnLeuleuA 1 aG 1 yProSerG 1 uAsnAspProAsnleuPhe\h:Jl A 1 alcuTyrAspPheVal A 1 aSe rG 1 yAspAsnThrleu 
AAGGAAAACCTTCTCGCTGGACCCAGTGAAAATGACCCCAACCTTITCGTTGCACTGTATGATTTTGTGGCCAGTGGAGATAACACTCTA -270-
,, 
* v-src- ~Phelys~G lyGluArg~Glnlle~~lAsnAsnThrG!yGlyAspTrp!.!:ELeuAlaHisScrleuThrThr~~lli~ 
c-ab 1- Ser lleThrlysG TYGTULysLeuArgVa 1 LeuG 1 yTyrAsnH i sAsnG1 yG 1 uTrpCysGI uA laG! nThrlysAsnG 1 yGl nG l yTrp 
AG CAT AACT AAAG GTGAAAAG CTC CG G GT CTT AGG CT AT AA T CACM TG GGGAATGGTGT GAAG C C CAAAC CAAAAATGG C CAAG G CT GG - 3 6 0 -
v-src- Leu~~~I:t.!:Y~lAlaProSerAsp~E~GinA!aGluGiui.!J:!!Y.!:PhelliLYS!l~I~!:~ArgG!uSer~Arg~ 
c-abl- Va 1 ProSerAsnTyr t \eThrhoV<Jl AsnSerleuGlulysH i sSerTrpTyrH i sG !yProV<J! SerArgAsnAlaAI aG 1 uTyrleu 
GT C C CAAGCAACT ACATCACG C CAGTCAACAGT CTGGAGAAACACTC CTG GT ACCATGGG C CTGT GTC C C GCAAT G C CG C TGAGT AT CT G - 4 S 0-
~--
v-src- LculeuAsnProGluAsn 
c-abl- c;userSerGlylleA;;; 
CTGAGCAGCGGGATCAAT -468-
primer + 
bcr exon b3 
~GATGAGT CTC CGGGGCTCTATGGGTTTCTGAATGTCATCGTCCACTCAG CCACTGGATTT AAGCAGAGTTC~ g t.J.Jgtac tggt t tg -90-
gggaggagggttgg -101!-
c-ab\ exon al 
c t t t t t tctg t tcccccct t tc tct tccag EGCCCTTCAGCGGCCAGTAGCATCTGACTTTGAGCCTCAGGGTCTGAGTGAAG CCGCTC -90-
G TTG G AACTC CAAG GAAAAC CTTCT CG CTG GAC C CAGTGAAAATGAC C C CAAC C TTTT CGTTG CACTG T AlGA TTTT G TGG C CAG TG GAG -1 80-
AT AACACTCTAAGCAT AACT AA~ gtaaaagggt tg tgggcagc tag tggtggt -234-
c-abl cxon <l2 
a ta tgtc tgat t tggt teet t tc t tc tcag ~GAAAAGCTCCGGGTCTT AGG CT ATAATCACAATGGGGAATGGTTTGAAGCCCAAACCA -90-
AAAA TG G C CAAG G CTG GG TC C CAAG CAACT ACATCACG C CAGTCAACAG T CTG G AGAAA CACT C CTG G T AC CA TGG G C CTGTG T CCC G CA -1 3 0-
AT G CCG CTGAGT AT C T G CTGAG CAG CG GGAT CAAT -232-
the construction of the library, both clones have been 
truncated at their 3' end at an endogenous EcoRl site. The 
0.3-kb BamHl-EcoRl fragment of 8E (Fig. 5) is amplified in 
K562 DNA (data not shown) and hybridizes to cloned 
genomic DNA sequences mapping 43.5 kb downstream from 
the K562 Ph1 breakpoint (Fig. 5). DNA sequence analysis of 
the chimeric 3' part of the 8E eDNA (strategy indicated in 
Fig. 5) and the homologous genomic exon (designated xl; 
Fig. 5) shows exact splicing of bcr exon b3 to exon xl 
following the GT-AG rule. because xl is preceded by a splice 
acceptor site (Fig. 6B). However this mRNA cannot code for 
a chimeric bcrlc-abl protein since exon xl contains transla-
eDNA BE 
cxon x1 
bl b2 
G 1 uG 1 nG 1 nlysLy~PheArgScr~heSerleuThrScrVa 1 G 1 uleuG 1 nMetleuThrAsnSerCy5Vo1l L ys LeuG I nThrVlll 
GAGCAGCAGAAGAA~TTCAGAAGCTTCTCCCTGACATCCGTGGAGCTGCAGATGCTGACCAACTCGTGT.GTGAAACTCCAGACTGTC -90-
bl 
HisSer t leProLeuThr r 1 eAsnlysGI IeAspGluSerProGI yleuTyrGI yPheLeuAsnVa I I leV;J 1 Hi sSerAlaThrGly 
CACAGCATTCCGCTGACCATCAATAAGGA~GATGAGTCTCCGGGGCTCTATGGGTTTCTGAATGTCATCGTCCACTCAGCCACTGGA -180-
xl 
PhelysGl nSerSe~ArgSerH i sThrVa 1 AsnGlnVa 1 MetleuArgLeuSerG IySerArgProCysArgiStOPJ 
TTTAAGCAGAGTTC~AGAAGCCATACGGTGAACCAGGTGATGCTGAGGTTATCTGGATCCAGGCCATGCAG~GCCATATTTAC -270-
CTTTGTGAT A TTG G GG CTGATCTTG GAG CTGTCTGGATCTGAC CAGTCTC CAGGTTGAAAACTCTTGCAACTTTCGTTTTTGGAT AGTG C -3 60-
T CACCTCGT ATCTGT ACTCGT AACTG CT A TTTCT AG G C GAA TTGTCC C CTTTCTC CTCC CTCTTC C CTCATCTC CCTCTCTC CTCTG C CT -4 SO-
GGCTGACACCAGGAAGGAGGAGTTTTCTTTTATTTAGATAAAAAAAAGTTGAGAGGAGGCAGCTCCAGAAATGTGGGATACTCAGCACTG -540-
GAGACATTTGGGCTGGAATTC -561-
.:Jeil t t t tee tetgge t t t tgge tg t t t tag EAGAAGCCATACGGTGAACCAGGTGATGCTGAGGTTATCTGGATCCAGGCCATGCAGAT -90-
GAAG C CAT A TTT AC CTTTG TGAT A TTG G GG CTGATCTTG GAG CTG TCTG GATCTGAC CAGTCT C CAGGTTGAAAACT CTTG CAACTTTCG -1 8 0-
TTTTTGGATAGTGCTCACCTCGTATCTGTACTCGTAACTGCTATTTCTAGGCGAATTGTCCCCTTTCTCCTCCCTCTTCCCTCATCTCCC -270-
TC TCT <;CTCTG C CTGG CTGACAC CAGGAAGGAG GAGTTTTCTTTT ATTT AGAT AAAAAAAAGTTGAGAGGAG G CAGCTC CAGAAATGT GG -3 60-
GAT ACTCAG CACTG GAGACATTTGGG CTGGAA TTC -395-
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FIG. 6. DNA sequence analysis of eDNA ba 4.1 and eDNA SE and the corresponding chromosomal exons. Sequence strategies and 
methods are as indicated in the legend to Fig. 4. A. (i) The nucleotide sequence of the 468-base-pair EcoRl fragment of eDNA ba 4.1; b2, b3, 
a1, and a2 indicate the bcr and c-ab! exons included in ba 4.1; brackets mark the boundaries of the exons. The synthetic c-ab! primer used 
for the eDNA synthesis is underlined and indicated by arrows. The amino acids encoded by the eDNA sequence are shown. The v-abl 
homologous sequences start at position 373. The amino acid sequence of c-ab! is aligned with that of v-src amino acids (36). Symbols: *.the 
position and.number of amino acids deleted from v-src; ·-·,gap in v-src to align the sequences. A solid underJine indicates an exact match 
between v-src and c-ab[ amino acids, a dashed underline indicates a match between v-src and c-ab[ amino acids with similar structure or 
identical charge. (ii) The nucleotide sequence of bcr exon b3 (19), followed by the 3' intron sequence. Brackets indicate the boundaries of 
the exon. as defined by the eDNA sequence. (iii) The nucleotide sequence of c-ab! exon a1, preceded and followed by intron sequences. 
Brackets indicate the boundaries of the exon as defined by the ba 4.1 eDNA sequence. (iv) The nucleotide sequence of the 5' half of c-ab! 
exon a2. preceded by intron sequences. Bracket indicates the boundary of the exon as defined by the ba 4.1 eDNA sequence. B; (i) The 
nucleotide sequence of the chimeric 3' end of eDNA 8E~ bl, b2, b3, and xl indicate the bcrand chromosome 9 exons included in SE. Brackes 
mark exon boundaries. The amino acid sequence encoded by this eDNA is shown~ 21 codons 3' of the breakpoint a stopcodon are 
encountered. (ii) The nucleotide sequence of the exon x1 preceded by the intron sequence. Bracket indicates the 5' exon boundary as defined 
by the SE eDNA sequence. 
tion termination signals in all reading frames including the 
frame predicted by the bcr sequence (Fig. 6B). Hybridiza-
tion of the exon xl BE probe to Northern blots containing 
poly(A)+ RNA of K562 and Hela cells showed two hybrid-
izing bands of 9.5 and 5.5 kb in K562 RNA (Fig. SA), 
whereas no signal could be detected in HeLa RNA (Fig. 8B). 
Since the sizes of the RNAs detected by this 0.3-kb BamHI-
EcoRI probe in K562 differ from those of the normal c-ab/ 
transcripts, we conclude that 8E represents the product of an 
alternatively spliced precursor mRNA, resulting in a chi-
meric nonfunctional mRNA that contains chromosome 9 
sequences not belonging to the c-ab/ gene. 
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FIG. 7. Hybridization of eDNA ba 4.1 to chromosomal DNA ol 
K562 and GM3344 cells. Southern blot of EcoRI digests of 10 f1g ol 
DNA from the cell line K562 and cell line GM3344. Both lanes were 
hybridized to the 32P-labeled EcoRI insert of eDNA ba 4.1. Molec-
ular masses are indicated at the side of the gel. 
DISCUSSION 
The present findings demonstrate that the CML cell line 
K562, like all Ph1-positive CML patient material examined 
to date, contains a breakpoint on chromosome 22 within the 
breakpoint cluster region on chromosome 22. However, in 
contrast with the leukemic cells of patients, the K562 cell 
line contains amplified remnants of the Ph1 chromosome. 
including Ct.., a part of bcr, and c-ab/. These amplified 
regions do not represent multiple copies of intact Ph1 chro-
mosomes. but rather are present on one acrocentric marker 
chromosome (33). Most probably, the regions originate from 
a multiplication of a large region of DNA from the original 
Ph1 chromosome: all copies of the bcr breakpoint region 
contain identically sized breakpoint fragments with the re-
striction enzymes tested. 
K562 cells also differ from other CML cells in that the 9q + 
chromosome cannot be detected by Southern blot analysis, 
in concordance with results of cytogenetical analysis in 
which the 9q+ chromosome was found to be absent from 
K562 (33); the absence of the 9q+ chromosome strengthens 
the hypothesis that the 22q- chromosome is critical to the 
malignant proliferation of these leukemic cells. 
The breakpoint cluster region on chromosome 22 was 
found to be part of a gene: in K562. the chromosomal break 
leading to the formation of the Ph1 chromosome has oc-
curred within an intron of this gene; exons 5' of this point 
remain on the Ph1 chromosome, whereas exons to the 3' side 
most probably were translocated to the 9q + chromosome in 
the original recombination event in the patient from whose 
cells K562 was established. 
K562 contains an increased level of the abnormal 8.5-kb 
c-ab/ mRNA as compared with other CML cell lines (6). 
Since c-ab/ is amplified in K562, it is likely that this higher 
expression is caused by the higher copy number of the 
oncogene. In addition, 5' bcr, located on the same amplifi-
cation unit and present in approximately the same copy 
number, exhibits high expression of an abnormal 8.5-kb 
mRNA. 
Direct proof that both probes hybridize to the same 
molecule was given by Shtivelman et al. (34) and by cloning 
of eDNA ba 4.1 containing the chimeric portion of the 
bcr/c-abl mRNA. 
Translation of the chimeric eDNA sequence of ba 4.1 into 
protein shows one open reading frame (Fig. 6A) that is 
compatible with both the predicted bcr and the known v-abl 
reading frames (3 7). Comparison of the human c-ab/ amino 
acid sequence of ba 4.1 with the protein sequence of homol-
ogous regions in v-abl and mouse c-ab/ shows complete 
amino acid conservation between exon a2 and v-abl and one 
difference with mouse c-ab/ (Fig. 6A). Amino acid 117 ofba 
4.1 is a tyrosine, and in mouse c-ab/ it is a cystine. Extensive 
amino acid sequence homology has been described between 
v-src (36), v-abl, and mouse c-ab/ (37). The homology 
between v-src and human c-ab/ does not stop at the 5' side of 
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FIG. 8. Hybridization of exon xl probe to Northern blots of 
K562 and HeLa poly(A)+ RNA. Northern blots with K562 and 
HeLa poly(A)+ RNA were prepared as described in the legend of 
Fig. 3. A, In the left lane, K562 RNA was hybridized with a 0.6-kb 
EcoRI-BamHI c-ab/ probe (Fig. 5); in the right lane, K562 RNA was 
hybridized with a 0.3-kb BamHI-EcoRI exon x1 probe (Fig. 5). B, 
K562 RNA (left lane) and HeLa RNA (right lane) were hybridized 
with the 0.3-kb BamHI-EcoRI x1 probe. The probe was labeled with 
32P by the oligo-labeling method of Feinberg and Vogel stein (9). The 
molecular masses and the position of the 28S rRNA are indicated at 
the side of the gel. 
c-ab/ exon a2 (Wang et al. [37] have compared the homolo-
gous mouse c-ab/ exon to v-src), but extends further 5' into 
c-ab/ exon a1 (Fig. 6A); 15 of the 57 amino acids of a1 are 
homologous with v-src. Although ex on a1 is absent in the 
v-abl gene it apparently belongs to part of the protein that is 
as conserved between v-src and c-ab/ as the 3' adjoining 
kinase domains (as defined by v-abl [30]). These results 
further underline the supposition that c-src and c-ab/ have a 
common ancestor. 
From the ba 4.1 sequence (Fig. 6A), it is clear that bcr 
exon b3 and c-ab/ exon a1 are compatible, although the 
splice takes place within a codon. Mapping experiments and 
sequencing of several Ph1 breakpoint clones from different 
patients indicated that breakpoints occur in introns between 
bcr exons b2 and b3 or b3 and b4 (19; unpublished results). 
Since these two exons have the 3' splice donor site after the 
first nucleotide of the codon, both can be spliced to c-ab/ 
exon a1, resulting in mRNAs that can differ in the presence 
or absence of one bcr exon, i.e .. 75 nucleotides in size. 
dependent on the position of the Ph1 breakpoint in bcr. 
Whether the proteins encoded by these two mRNAs will 
have different characteristics remains to be elucidated. This 
splicing pattern would also explain why the same 8.5-kb 
mRNA.is detected in different patients (4, 11, 35a) although 
the distance between the Ph1 breakpoint and v-abl hybridiz-
ing sequences varies from 14 to at least 101 kb. 
As shown by Shtivelman et a!. (34), we have strong 
evidence that exon a1 does not represent the 5' end of the 
c-ab/ gene. Moreover we have also isolated a normal c-ab/ 
eDNA clone that contains sequences further 5' of c-ab/ exon 
a1 (unpublished results). So at least one or more c-ab/ exons 
must be located further 5' of exon al. Whether these exons 
can also be included in the K562 splicing event is unknown 
and leaves the possibility that ba 4.1 represents only one of 
several translatable chimeric mRNAs that could be pro-
duced in K562. However, if this indeed is the case then it 
seems unlikely that the 5' end of the c-ab/ gene can be 
included in a protein-coding chimeric mRNA, since no splice 
acceptor site will be available and frameshift mutations and 
stop codons are probably introduced by the nontranslated 
region of the 5' end of the gene. 
Splices over large and varied distances such as those 
found between bcr and c-ab/ on the Ph1 chromosome open 
the possibility that exons from other genes not belonging to 
c-ab/ could be included in the pre-mRNA and therefore end 
up in a mature mRNA. In fact, eDNA 8E represents an 
example of this possibility. Although the chromosome 9-
specific exon x1 was spliced to bcr exon b3 following the 
GT-AG rule (Fig. 6B), it does not contain an open reading 
frame. Employing the bcr reading frame, a protein termina-
tion signal in 8E is encountered at 21 codons 3' of the 
breakpoint. Hybridization of exon x1 to Northern blots of 
K562 and HeLa RNA results in the detection of two RNAs 
of different size than the c-ab/ RNAs for K562, whereas in 
HeLa cells no RNA at all could be detected. This strongly 
suggests that exon x1 does not belong to the c-ab/ gene. 
Because 8E is clearly a chimeric eDNA, hybridization of bcr 
probe A (Fig. 3) to K562 Northern ·blots should show up the 
same 9.5 and 5.5 kb RNAs as probe xl. For reasons we do 
not understand, this does not seem to be the case, but we are 
confident that 8E represents an aberrant chimeric RNA 
because a second. independently picked eDNA clone has the 
same chimeric structure. Unfortunately, both clones have 
been truncated at their 3'-end EcoRI site, so no information 
is available concerning the nature of the 3' region of these 
mRNAs. The possibility remains that x1 is spliced at its 3' 
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side to c-ab/ sequences, although hybridization of c-ab/ 
probes to K562 Northern blots does not show up the 9.5- and 
5.5-kb mRNAs. Why this differential splice occurs in the 
K562 bcr!c-abl pre-mRNA remains an open question. 
The implications of the translocation of c-ab/ to the 3' side 
of bcr on the Ph1 chromosome are as follows. Transcription 
is likely to be initiated from the bcr promoter and probably 
stops at the 3' enc! of the c-ab/ gene. By splicing of the 
precursor RNA the 8.5-kb mRNA is produced, in which the 
versatility of the splicing system accomodates for the large 
variation in intron size that links bcr and c-ab/ in different 
patients. From the data now available, we know that the 
variation in this chimeric 8.5-kb mRNA can comprise one 
bcr exon, i.e., 75 nucleotides (19). Translation of the 8.5-kb 
mRNA into protein seems almost certain, since the chimeric 
part of the molecule contains an open reading frame that 
links the predicted bcr and c-ab/ reading frames. A likely 
candidate for such a protein is the abnormally sized 210-
kilodalton c-ab/ protein found in K562 cells, which in con-
trast to normal c-ab/ has in vitro tyrosine kinase activity (24), 
very similar to that of the v-abl gene product (7). The bcr 
moiety of this hybrid molecule could unmask the c-ab/ 
tyrosine kinase activity, raising the question whether bcr is 
sufficient or necessary for this effect. The bcrlc-abl hybrid 
protein may have transforming activity; since the chimeric 
8.5-kb mRNA is also found in Ph1-positive CML patients 
(35a), the protein is likely to be present in all cases of 
Ph1-positive CML, but it remains to be established whether 
this plays an essential role in the generation or maintenance 
ofCML. 
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ABSTRACT 
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The breakpoint regions of both translocation products of 
the (9;22) Philadelphia translocation of CML patient 83-H84 
and their normal chromosome 9 and 22 counterparts have been 
cloned and analysed. Southern blotting with bcr probes and 
DNA sequencing revealed that the breaks on chromosome 22 
occurred 3' of bcr exon b3 and that the 88 nucleotides be-
tween the breakpoints in the chromosome 22 bcr region were 
deleted. Besides this small deletion of chromosome 22 sequen-
ces a large deletion of chromosome 9 sequences (>70kb) was 
observed. The chromosome 9 sequences remaining on the 9q+ 
chromosome (9q+ breakpoint) are located at least 100 kb 
upstream of the v-abl homologous c-abl exons whereas the 
translocated chromosome 9 sequences-{22q- breakpoint) could 
be mapped 30 kb upstream of these c-abl sequences. The break-
points were situated in Alu-repetitive sequences either on 
chromosome 22 or on chromosome 9, strengthening the hypothe-
sis that Alu-repetitive sequences can be hot spots for recom-
bination. 
INTRODUCTION 
Chronic myelocytic leukemia (CML), a pluripotent stem 
cell disease is characterized by the presence of a Phila-
delphia (Ph1 ) chromosome in the leukemic cells of more than 
90% of all CML patients (1). This Ph1 chromosome is the 
result of a reciprocal translocation between chromosomes 9 
and 22 (2,3). Previous studies indicated that in all Ph1 (+) 
CML patients a human oncogene c-abl, normally located on 
9q34, was translocated to a specific, limited area on chromo-
some 22, the breakpoint cluster region (bcr)(4,5.) The 5.0 kb 
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bcr contains 4 small coding regions (6) and is an internal 
part of a large 'bcr' gene. Thusfar all chromosome 22 break-
points (>30) 
breakpoints 
area, which 
map within two introns of this bcr. However, 
on chromosome 9 are scattered over a very large 
may vary from 14 kb (7) up to more than 100 kb 
(8) upstream of the v-abl homologous sequences of the c-abl 
gene. As a result of the translocation, the c-abl sequences 
are linked in a head-to-tail fashion to the 5' bcr sequences 
on the Ph1 chromosome. Recent studies indicated, (8,9,10) by 
demonstration of the presence of a chimeric bcr/c-abl mRNA, 
that this region is transcriptionally active. The s' bcr and 
c-abl coding sequences are linked by RNA splicing, apparently 
independent from the distance between the two genes on the 
Ph1 chromosome. The detection of an abnormally sized c-abl 
protein (11) supports this hypothesis and is the presumable 
translation product of this chimeric mRNA found in the leuke-
mic cells of Ph1 (+) CML patients and CML-derived cell lines. 
Virtually nothing is known about the mechanism of chromosomal 
translocation in CML. Sequence data from the breakpoints of 
two CML patients suggest that Alu-repetitive sequences may 
play a role (6,12). Here we report the cloning of the break-
point regions of both translocation products of a CML patient 
with a t(9;22). Mapping and sequencing of the chromosomal 
breakpoint regions and their normal counterparts revealed 
that the translocation did not occur in a conservative man-
ner: both chromosome 9 and 22 sequences were deleted. 
Furthermore Alu-repetitive sequences were located near or at 
the breakpoint in this CML patient. 
MATERIALS AND METHODS 
CML patient and cell lines 
CML patient 83-H84 is an 18-year old male. In this study 
leukophoresis material from the chronic phase of CML (karyo-
type t(9;22) (q34;qll) prior to treatment was obtained. The 
cell line K562 (13) and Hela cells were used as controls. 
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Southern blotting and hybridization 
High-molecular weight DNA's, isolated as described (14) 
were digested with restriction enzymes, electrophoresed on 
0.7% Agarose gels and blotted according to Southern (15). 
Isolated DNA fragments (8) were labeled with 3 2p as described 
by Feinberg and Vogelstein (16). Probes containing repetitive 
sequences were preincubated with sonicated human DNA to Cot=l 
(lO.pa mg/ml, 0.6M sodium phosphate buffer pH7, 3 hr at 
65°C). Hybridization and washing conditions were as described 
in previous publications (3,5). 
Genomic cloning 
To isolate the breakpoint regions a genomic library of 
patient 83-H84 DNA was constructed in A-EMBL-3 (17). Normal 
chromosome 9 counterpart of phage EMBL-3a (9q+) was isolated 
from another CML-EMBL-3 library. The normal chromosome 22 or 
chromosome 9 sequences were previously cloned from human 
cosmid or phage libraries (5,7,8). 
DNA sequencing 
Subcloned fragments of the breakpoint areas in pUC9 were 
sequenced according the methods of Maxam and Gilbert (18). In 
those cases where no suitable sites were available, a series 
of Bal 31 deleted subclones were generated and sequenced 
using end labeled sites of the pUC9 poly linker. 
RESULTS 
Identification and cloning of the chimeric DNA fragments 
To identify the chimeric DNA fragments, Bglii digested 
DNA of CML 83-H84 and control cell lines were hybridized to 
bcr probes. The 5' bcr probe (2.2 kb Bg-H, Fig. lC) detects 
an abnormal fragment of 5.7 kb (Fig. 2D) besides the normal 
5.0 kb Bglii fragment. This 5.7 kb fragment is not present in 
Hela or K562 DNA and represents the 22q- breakpoint Bglii 
fragment of CML 83-H84. In a similar manner we identified the 
9q+ Bglii fragment of 2.4 kb (Fig. 2A) using the 3' bcr probe 
(1.2 kb H-Bg, Fig. lC). To analyse the aberrant fragments in 
more detail, a A-EMBL-3 library was constructed of size-
fractionated, partially Mboi digested CML 83-H84 DNA. This 
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library (lxl06 ph} was screened with both the 5' and 3' bcr 
probe. Positive phages, hybridizing only to either the 5' or 
the 3' bcr probe, were isolated and mapped by double diges-
tion of individually isolated restriction enzyme fragments 
from low-melting point agarose gels (Fig. lB, lD). The phages 
hybridizing to the 5' or 3' bcr probe contained the expected 
abnormal Bglii fragments of 5.7 and 2.4 kb resp. The 5' end 
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Fig. 1. Restriction enzyme map of the 9q+ (B) and 22q-
(D) breakpoint regions and their normal chromosome 9 (A and 
E) and chromosome 22 (C) counterparts. Solid bars rep~esent 
chromosome 9 sequences, whereas the open bars indicate 
sequences originating from chromosome 22 DNA fragments cloned 
in phage and probes used in the study are indicated below the 
relevant maps. A* marks the 0.7 kb Ba-H fragments in map C 
in which both chromosome 22 breakpoints are located. The 
restriction enzyme sites on the 3' end of map A (indicated by 
a dot) are deduced from Southern blots. Ba 
Bglii, E = EcoRI, H = Hindiii, S = Sali. 
BamHI, Bg 
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of the 5.7 kb fragment was colinear with bcr sequences 5' of 
the 0.7 BamHI- Hindi!! fragment (Fig.lC), whereas the 3' end 
of the 5.7 kb fragment was identical to previously cloned 
chromosome 9 sequences (Fig. lD,lE).These sequences, and as a 
consequence the 22q- breakpoint on chromosome 9, were located 
30 kb at the 5' side of the known c-abl exons (3,7). The 3' 
end of the 2.4 kb chimeric fragment was colinear with the 3' 
bcr sequences, confirming a breakpoint in the 0.7 kb BamHI-
Hindiii segment of the bcr. The chromosome 9 origin of the 5' 
end of this 2.4 kb fragment was demonstrated using somatic 
cell hybrids containing either chromosome 9 or 22 (data not 
shown). We used two small Bglii fragments of 0.9 and 0.6 kb 
as probes (Fig. lB) to isolate recombinant phages that con-
tained the normal chromosome 9 counterpart of this chimeric 
fragment. Although the CML 83-H84 EMBL-3 library contained 
several positive phages, restriction enzyme ~nalysis revealed 
that these did not cover the 9q+ breakpoint. Therefore a 
positive phage ( Agr.9) extending 0.6 kb 3' of the 9q+ break-
point was isolated from a CML-EMBL-3 library of another 
patient (gr)(Fig. lA). To exclude the possibility of cloning 
artefacts we made chromosome 9 probes from the chimeric 
fragments and hybridized them to Southern blots of CML 83-H84 
DNA and control cell lines. As shown in Fig. 2B the 0.5 kb, 
Bg-E probe (Fig. lB) hybridizes to a normal 2.0 kb Bglii 
fragment in all DNAs and only in the CML 83-H84 DNA the 2.4 
kb 9q+ chimeric fragment is present. A 0.9 kb Ba-Bg probe 
(Fig. lD) detects the 5.7 kb 22q- chimeric Bglii fragment in 
the CML 83-H84 DNA (Fig. 2E). The normal 7.2 kb Bglii frag-
ment present in Hela and CML 83-H84 DNA is amplified at least 
4 fold in K562 DNA. 
Minimal distance between the two chromosome 9 breakpoints 
In a recent report (8) we have demonstrated that in K562 
the 22q- breakpoint is located at a distance of at least 100 
kb upstream of the known c-abl sequences. This entire region, 
including the 5' bcr (Fig. 2D, 8.0 kb Bglii fragment), the 
more than 100 kb of chromosome 9 sequences upstream of the 
known c-abl sequences and c-abl sequences, is amplified at 
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(lane 1}, 
2. Southern blots of Bglii digested DNA of K562 
CML 83-H84 (lane 2} and Hela (lane 3} hybridized 
with bcr probes (A,D}; chromosome 9 probes (B,C,E,F}. 
A: 1.2 kb Hindiii- Bglii (3' bcr, lC}, B: 0.5 kb Bglii-
EcoRI (from.A3a}, C: 1.2 kb EcoRI- Sali (from .Agr.9}, D: 
2.2 kb Bglii- Hindiii (5' bcr, lC}, E: 0.9 kb BamHI Bglii 
(from .A 814} and F: 8 kb BamHI(from pK9-l}. The used probes 
are indicated in figure 1 below the relevant restriction 
enzyme maps. 
least four fold in K562. The amplification of the chromosome 
9 sequences in K562 starts at the 22q- breakpoint and extends 
towards the telomere of chromosome 9. The 22q- breakpoint of 
CML 83-H84 maps 30 kb upstream the known c-abl sequences, and 
therefore the chromosome 9 sequences of the 22q- chimeric 
fragment of CML 83-H84 are also amplified in K562 (Fig. 2E, 
lane 1}. The 2.0 kb normal Bglii fragment containing the 9q+ 
breakpoint of CML 83-H84 is not amplified in K562 and there-
fore must map to the 5' side of the K562 Phl-breakpoint (Fig. 
2B, lane 1} and thus is located at a distance of more than 
100 kb upstream of the known c-abl sequences. This indicates 
that the distance between the two chromosome 9 sequences is 
at least 70 kb. 
We were not able to detect any additional 
Bglii fragments using either a 1.2 kb E-S probe 
spanning the 9q+ breakpoint or a 8.0 kb Ba probe 
hybridizing 
(Fig. lA} 
(Fig. lE. 
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Fig. 3. Restriction enzyme maps of the subcloned break-
point (B,D) and corresponding normal chromosome 9 (A,E) and 
22 (C) fragments. Solid bars indicate chromosome 9 sequences 
and open bars indicate chromosome 22 sequences.The arrows 
below the relevant maps indicate the sequence strategies. All 
sequences were done by the method of Maxam and Gilbert (18) 
and dots indicate the position of the end label. Only the 
restriction enzyme maps and Alu-repetitive sequences around 
the breakpoints are shown -< >- indicates known DNA 
ornrnitted from the figure). The hatched bar below the figure 
indicates the position of the 300 bases shown in figure 4. 
The position and orientation of Alu-repetitive sequences are 
indicated in the maps using the Alu-consenses symbol shown at 
the bottom. The 300 bp Alu-consensus (19) consist of two 
nearly homologous halves (arrows) each followed by an A-rich 
tract (zigzags) (12). The used subclone (see also figure 1): 
A: 1.2 kb EcoRI - Sali, B: 2.4 kb Bglii, C:5.0 kb Bglii, D: 
5.7 kb Bglii, E: 8.0 kb BamHI, restriction enzymes: Ba 
BamHI, Bg = Bglii, Bs = Bstii, E = EcoRI, H = Hindiii, Sa 
Sali, Sm = Smai, Ss = Sstl, T = Taql, X = Xhoi. 
154 
spanning the 22q- breakpoint (Fig. 2C and 2F). The previously 
identified 9q+ and 22q- breakpoint Bglii fragments of 2.4 kb 
and 5.7 kb, resp. hybridize only very faintly to these probes 
because these parts of the probes contained several repeti-
tive sequences which where competed out with human cot-1 DNA 
during hybridization. 
kb E-S or 8.0 kb Ba 
However the remaining parts of the 1.2 
probes, which were able to detect the 
normal hybridizing 2.0 and 7.2 kb Bglii fragments did not 
detect any additional hybridizing fragments. Probably ~e 
chromosome 9 sequences between the two breakpoints are de-
leted although we cannot exclude the possibility that these 
sequences are present somewhere else in the genome. 
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Fig. 4. DNA sequence analysis of the breakpoint subclones 
and their normal chromosome 9 and 22 counterparts. Sequence 
strategy and methods are indicated in figure 3. Only 300 
nucleotides (indicated in figure 3) of the determined sequen-
ce is shown in this figure (other seqences are available on 
request from publisher). Sequence 9 represents the sequence 
of subclone A in figure 3, 9q+; the sequence of subclone B 
etc. Homology is indicated by vertical bars and the boxed 
sequences in the 22 sequence are the deleted chromosome 22 
bcr sequences. A 9q+ breakpoint, A: 22q- breakpoint of 
CML 83-H84. 
155 
DNA sequences of breakpoints and normal counterparts 
In order to determine the exact recombination site, 
subcloned breakpoint fragments (Fig. 3B, 3D) and correspond-
ing normal chromosome 9 (Fig. 3A, 3E) and 22 (Fig. 3C) frag-
ments were sequenced (18) as designated in Figure 3. The 
comparison of the breakpoint sequences with their normal 
counterparts is shown in Figure 4. At the breakpoints no 
nucleotides are inserted, but the boxed chromosome 22 sequen-
ces between the 22q- and 9q+ breakpoint (position 105, 193, 
resp.) are deleted. Comparison of the sequences with a human 
Alu repeat consensus sequence (19) revealed that both the 
breakpoints 
breakpoint 
occurred in a Alu-repetitive sequence: the 9q+ 
in a chromosome 22 Alu repeat and the 22q- break-
point in a chromosome 9 Alu repeat. 
The orientation and exact localization of the Alu repeats and 
other Alu related sequences in the vicinity of the break-
points i·s shown in Figure 3. 
DISCUSSION 
Using a 5' and 3' bcr probe, we were able to identify 
the 22q- and 9q+ breakpoint fragments of a Ph1 -positive CML 
patient (CML 83-H84). The same bcr probes were-used-to screen 
a CML 83-H84 EMBL-3 phage library and positive phages 
containing the aberrant fragments were isolated and analysed. 
The chromosome 9 sequences present in the 22q- subclone were 
identical to previously cloned chromosome 9 sequences and map 
30 kb upstream of c-abl exon a2 (8)(the first v-abl homolo-
gous exon of c-abl). These sequences were amplified in K562, 
a CML-derived cell line. The chromosome 9 sequences of the 
9q+ breakpoint subclone were not amplified in K562. The 
amplification of chromosome 9 sequences in K562 starts with 
the chromosome 9 sequences located at the 22q- breakpoint of 
K562 and this whole area, including the 5' part of the bcr 
gene and the c-abl oncogene is amplified. The 22q- breakpoint 
of this cell line maps at a distance of more than 100 kb 5' 
of the c-abl exon a2 (8). Since the chromosome 9 sequences in 
the 9q+ breakpoint segment of CML 83-H84 are not amplified in 
i56 
K562, these must be located at the 5' side of the K562 
breakpoint on chromosome 9, at a distance of >70 kb (>100-30) 
5' of the 22q- breakpoint of CML 83-H84. The chromosome 9 
sequences inbetween these two breakpoints are probably de-
leted since no extra aberrant fragments were detectable when 
we used chimeric fragments as probes in a Southern blot of 
CML 83-H84 DNA and control lines DNA. However we cannot 
exclude the possibility that these sequences are present 
somewhere else in the genome. Sequencing confirmed that the 
breakpoints in the bcr of chromosome 22 were located 3' of 
bcr exon b3 (6), but not at an identical site. The 88 nucleo-
tides of bcr between the two chromosome 22 breakpoints a~e 
also deleted. Probably these deletions are the results of 
secondary recombination events, occurring at either the ori-
ginal Ph1 or 9q+ chromosome (Fig. 5). Although we have no 
direct proof we favor the explanation that the second recom-
bination event took place at the Phl chromosome (Fig. 5, IIA) 
This would result in a shorter Ph1 chromosome on which the 5' 
bcr exon b3 is located 30 kb s' of c-abl exon al, whereas on 
the original Ph1 chromosome the distance between these two 
coding regions is more than 100 kb. This second recombination 
could either be necessary to remove chromosome 9 inhibitory 
or regulatory sequences in order to allow transcription of 
the chimeric bcr/c-abl rnRNA, or it provides the 
leukemic cell with growth advantages so that it has 
the normal stern cells and original Phl positive 
resulting 
replaced 
leukemic 
cells. In other CML's, such as CML 0319129 (6) where the 
recombination took place at chromosome 9 sequences located 14 
kb 5' of c-abl exon al, no such secondary recombinations are 
necessary. The breakpoint sequences of this patient (CML 
0319129) showed a perfect conservative break without loss of 
chromosome 9 or 22 sequences. Comparison of_the DNA sequences 
at the breakpoint regions of CML 83-H84, K562 (20) and two 
other CML patients (6) suggests that homologous recombination 
is unlikely since there is no apparent homology between 
chromosome 9 and 22 breakpoint sequences. Nor is there any 
evidence for crossover within an homologous oligonucleotide. 
centromere 
n 
A C" 
9 q + ..11:'::::::= 
1-- o---< 
9q+ ~A.!ijfiC" 
8 
22q- I bJ C:B' i 
ill 
22q- I bd C:B' • 
Fig. 5. Hypothetical model of the Ph1 translocation and 
secondary recombination in CML patient 83-H854. 
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I. The normal chromosome 9 and (closed bars) chromosome 22 
(open bars). 
II. The resulting translocation products of the initial Ph1 
translocation and 
III. The result of either a recombination of the 22q- chromo-
some (IIA) or the 9q+ chromosome (IIB) A,A',B,B'are chromo-
some 9 sequences; C, C',c'' are chromosome 22 sequences, 
A/C'' represents the 9q+ breakpoint whereas C/B' represents 
the 22q- breakpoints shown in figure 1B and 1D resp. -it-
indicates a gap of at least 70 kb. b3 = bcr exon b3 (6) a1 
c-abl exon a1 (8). The distances are not in scale. 
Similar results have been obtained from sequence analysis of 
the t(8;14) translocations in Burkitt lymphoma, in which no 
obvious homology was detectable between the recombined se-
quences on chromosome 8 or 14 (21,22). However, in CML there 
is some evidence that Alu-repetitive sequences are involved. 
In CML 83-H84 both the 22q- and the 9q+ breakpoint occur 
within an Alu-repetitive sequence. Similar homology to Alu-
repetitive sequences are present at the breakpoints of two 
other CML patients (6,12) the cell. line K562 (20) and the 
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22q- breakpoint of a Ph1 positive Acute Lymphoblastic Leuke-
mia (ALL) patient (23). Illegitimate recombination within Alu 
sequences has also been reported in non-CML related recom-
bination events (24,25). Therefore it is well conceivable 
that Alu-repetitive sequences are hot spots for recombination 
and as such play a role in the juxtaposition of the 5' bcr 
and c-abl sequences. The apparent transcription of a chimeric 
bcr/c-abl mRNA (9,26) could be facilitated by secondary re-
combination events, bringing the bcr exons in closer proximi-
ty to the c-abl coding regions. But the question remains open 
whether the translocation product of this mRNA, the 210 kD 
abnormal c-abl protein is the cause or merely a consequence 
of transformation in CML. 
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her Rearrangement and Translocation of the c-ab/ Oncogene in Philadelphia 
Positive Acute Lymphoblastic Leukemia 
By A. De Klein, A. Hagemeijer, C.R. Bartram, R. Houwen, L. Hoefsloot, F. Carbonell, L. Chan, M. Barnett, M. Greaves, 
E. Kleihauer, N. Heisterkamp, J. Groffen, and G. Grosveld 
The Philadelphia (Ph1) chromosome, the cytogenetic hall-
mark of chronic myeloid leukemia (CMLL has also been 
detected in a significant number of acute lymphoblastic 
leukemias (ALL). Using in situ hybridization, we demon-
strate that in accordance with observations in CML the Ph 1 
chromosome in All patients is the result of a reciprocal 
translocation of the c-ab/ oncogene to the Ph 1 ·chromo-
some. Southern blot analysis using bcr probes, however, 
Suggests that Ph 1-positive ALL includes heterogeneous 
leukemic subtypes: six ALL patients showed bcr rearrange-
ments as observed in CML; in three other patients recom-
bination involving 5' bcr sequences could be demonstrated, 
but the corresponding translocated 3' bcr sequences were 
not detectable. A third group of five patients did not show 
any bcr rearrangements at all. Northern blot analysis using 
RNA from three Ph 1 -positive ALL patients revealed that in 
the leukemic cells of two patients larger c-ab/ mRNA 
transcripts were present as in CML In the RNA of one 
patient without a detectable bcr rearrangement, only the 
normal c-ab/ mANA transcripts are present. The observed 
heterogeneity in bcr rearrangements of this group of 
Ph 1 -positive ALL patients is in contrast with the consist eat 
results obtained in more than 50 Ph 1-positive CML patients 
investigated in chronic and acute states. 
• 1986 by Grune & Stratton, Inc. 
THE PHILADELPHIA (Ph') chromosome. an abnormal chromosome 22, is strongly associated with one type of 
human leukemia. chronic myeloid leukemia (CML).1.2 It is 
found in the leukemic cells of more than 90% of all CML 
patients, both in the chronic and acute (blast crisis) phase of 
the disease., The Ph 1 chromosome has also been reported in 
other malignant hematopoietic disorders,< including dif-
ferent subtypes of acute leukemias in which no preceding 
chronic phase has been observed.s-• The Ph' chromosome is 
found in the leukemic cells of 2% to 3% of the patients 
presenting with acute myeloid leukemia (AML) and a 
similar incidence (2% to 6%) is reported for childhood acute 
lymphoblastic leukemia (ALL).•-10 In adult ALL the Ph' 
chromosome is the most frequent chromosomal abnormality 
with an incidence of 17% to 25%.'·'' The clinical distinction 
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between blast crisis of CML and de novo Ph1-positive acute 
leukemia is not always clear.s.1:z.n However, at the time of 
blast crisis the majority of the CML patients exhibit a 
karyotypic evolution characterized by additional nonrandom 
chromosomal aberrations such as trisomy 8 and 19, a second 
Ph' or isochromosome 17q3• Furthermore, the presence of 
Ph '-negative cells in the bone marrow during the acute phase 
and the elimination of Ph1-positive cells from the bone 
marrow during remission are typical features of cases pre-
senting as Ph1-positive acute leukemias with no known prior 
CML. 
In CML as well as in acute leukemias, the Ph' chromo-
some usually results from a translocation between chromo-
some 9 and 22t(9;22)(q34;qll). Previous studies using the 
leukemic cells of Ph1-positive CML patients indicated that in 
CML this translocation is reciprocal." A consistent translo-
cation of the human c-ab/ oncogene, normally located on 
chromosome 9q34, to the Ph' chromosome was observed in 
standard and variant translocations.l5 In all these Ph1-
positive CML patients the c-ab/ oncogene was translocated 
to a specific, limited area on chromosome 22, the breakpoint 
cluster region (ber).16 Recently we have established that her 
is part of a gene11 and as a consequence of the Ph'-
translocation the "bcr" gene located in this area is disrupted 
and c-ab/ sequences are linked to the 5' her sequences." 
Transcription of this DNA segment results in a new 8.5-kb 
mRNA species, which contains 5' her and 3'c-abl 
sequenceS.I9-23 
Since the Ph' chromosomes of CML and acute leukemias 
are cytogenetically indistinguishable, it was of interest to 
investigate whether the described molecular aspects of the 
Ph1 chromosome in CML are also present in Ph1-positive 
acute leukemia. Here we report studies on the Ph' chromo-
some in ALL patients which demonstrate that similar molec-
ular characteristics can be found in some but not all Ph'-
positive ALL patients. 
MATERIAL AND METHODS 
Patients. We investigated the leukemic cells of 22 ALL patients 
referred to the cytogenetic units at Rotterdam (patients R 1 through 
R7), Ulm (patients Ul through U6) and London (patients Ll 
through L9 ). The ALL diagnosis was based on clinical and hemato-
logic data, bone marrow morphology, cytochemistry, and immuno-
logic studies of the blast cells. Patient Rl, a 23-year-old female, was 
studied during complete remission of Ph1-positive cALL. Cytoge-
netic studies revealed a normal karyotype (46,XX). Relevant clini-
cal, hematologic, and cytogenetic data of all other patients are given 
in Tables I, 2, and 3. 
Southern blot analysis. DNA was prepared from bone marrow 
or peripheral blood samples as described.,. DNA (10 ,g) was 
digested with restriction enzymes. electrophoresed on 0.7% Agarose 
gels and blotted according to Southern., Isolation of probes, hybrid-
ization, and washing conditions were as described in previous 
publications.1~.J6 The bcr probes used are indicated in Fig 1. 
In situ hybridization. Metaphases obtained from bone marrow 
or peripheral blood for cytogenetic analysis of the leukemic cells 
were also used for in situ hybridization. Technical procedures and 
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Table 1. Ph 1 -Negative ALL Patients 
Cytogenetics 
Patient Age/Sex wac %Blast Cells Rearranged 
No. {Years) 10°/L aM Pa lmmunophenotype Analyzed Karyotype bcr• 
L2 19M 4.3 95 51 cALL 20 46,XY 
L3 44M 16.0 50 25 ALLt 20 46,XY 
L4 67 F 60.6 80 78 T-ALL 20 46,XX 
LS 36M 70.4 99 89 cALL 20 46,XY 
L6 25M 15.1 99 57 cALL 50 46,XY 
L7 17M 21.7 95 69 cALL 8 46,XY 
Abbreviations: BM, bone marrow; PB, peripheral blood; WBC, white blood cells. 
• No bcr rearrangements. 
tUnclassified ALL. 
c-ab/ probes used were as described.26 
In one case (U3), where the banding was poor, grain distribution 
on the chromosomes not involved in the translocation was calculated 
for the chromosomes in morphological groups (A, B, C, etc). In cases 
of mosaicism (R5, R6) only the hybridization data on the Ph'-
positive metaphases have been tabulated. The expected number of 
grains based on the relative DNA content of the given chromosome 
according to Mendelsohm1 was corrected for sex and translocation of 
part of chromosomal material. 
RNA analysis. Total RNA was isolated using the LiCljurea20 
method' (K562, Hela, human testes, and bone marrow of ALL 
patient U6) or using the guanidine thiocyanate20 method (bone 
marrow of patient R6 and peripheral blood of patient R2). 20 l'g of 
total RNA was electrophoresed on a l% Agarose gel in the presence 
of formaldehyde., After blotting, the nitrocellulose filters were 
hybridized to c-ab/ and bcr probes as described.22 Recombinant 
plasmid and cosmid clones were handled under the containment 
conditions following the guidelines of the Dutch Committee on 
Recombinant DNA Research. 
RESULTS 
Bcr rearrangements in ALL patients. DNA from the 
leukemic cells of 21 different ALL patients was screened on 
Southern blots using the bcr probes I to IV indicated in Fig I. 
In the DNA of six ALL patients having leukemic cells 
without a Ph1 chromosome or other karyotypic maFkers 
(Table I), no rearrangements of the bcr could be detected. 
Bglll-digested DNA, hybridized to bcr probes I and III, 
showed a hybridization signal with the normal 5.0-kb Bglll 
fragment on chromosome 22 (L4, shown in Fig 2A). Similar-
ly, Hindlll-digested DNA showed the normal!O.O-, 1.8- and 
4.5-kb fragments after hybridization with probes I, II, and 
III, respectively (data not shown). Additional hybridizing 
bands were not observed. 
One case (Rl) of Ph1-positive ALL was studied after 
achievement of complete remission. Cytogenetic studies of 
bone marrow cells revealed a normal karyotype ( 46,XX). In 
the DNA made at this Ph1-negative stage, only the normal 
bcr fragments were detected (Fig 2B). Of the ALL patients 
showing a Ph1 chromosome either in the acute or in the 
relapse phase, listed in Tables 2 and 3 the DNA of 14 
patients was studied. Using different digests and probes we 
could detect bcr rearrangements in the DNA of nine of these 
ALL patients. In five patients no bcr rearrangements were 
observed. In the DNA of eight Ph1-positive ALL patients bcr 
rearrangements were observed. In three of these DNAs (U3, 
U4, and R6) only the newly generated fragment present on 
chromosome 22q- could be detected (R6, Fig 2E) besides 
the normal 5.0-kb Bglll fragment. While the rearranged 3' 
Table 2. Ph 1 -Positive ALL Patients 
Cytogenetics 
Patient Age/Sex Survival wac %Blasts Cells 
No. {Years) Week 1011/L aM ?a lmmunophenatype Material Analyzed Karyotype• 
L8 19 F 44 22.7 90 90 cALL BM 20 46,XX Ph' 
L9 52 F 28 121.0 84 86 cALL BM 30 46,XX Ph' 
R2 3M 67 88.2 87 89 cALL PB 45 46,XY,t(9;22)(q34;q11) +add 
R3 41 M 54 9.0 95 4.5 cALL BM 80 46,XY,t(9;22)(q34;q11) +add 
R4 19M 46 3.6 99 45 cALL BMt 30 46,XY,t(14;22)(q32;q11) 
RS 43 M 30 1.2 65 6 cALL BM/PB 34 45,XY,t(9;22)(q34;q11) +add 
U1 38 F 28 23.8 80 42 ALL§ PB 30 46,XX,t(14;22llp22;q11) 
U2 44M 64 202.0 90 93 mixed ALII PB 31 46,XY,t(9;22)(q34;q11) 
U3 39M 48 129.0 50 15 mixed ALII BM 40 46,XY. t(5;9;22)(q 13;q34;q 11) 
U4 31M 12t 98.0 89 63 cALL PB 30 46,XY,t(9;22)(q34;q11) 
us 21M 12t 34.0 77 34 ALL§ BM 20 46,XY,t(9;22)(q34;q11) 
For abbreviations see Table 1; -, no bcr rearrangements; + with bcr rearrangements. NO, no data available. 
•Ph 1 stands for 22q- without further information of karyotype chaRges. 
%Ph1 
Cells 
90 
80 
91 
55 
83 
70 
30 
81 
100 
100 
100 
Rearranged 
bcr 
+ 
+ 
+ 
+ 
+ 
+ 
NO 
The more complex karyotypes were as follows: R2: 46,XY,t(9;22). t(3;9llq26;p21). t(4;9q+)(p14;q21), t(5;17llp14;q11); R3: 46, XY, 
t(9;22li12.5%)/47,XY, t(9;22). +22q-(11%)/49,XY,t(9;22). + 18, +21, +22q-(31.5%). RS; 45,XY, t(1;9)(q25;p21). -8, 9p+q+ 
[8qter- q13::9p21- q34::22q11- qter], 22q-. 
tWas known as Ph 1-positive CML at age 9, achieved clinical remission and normal blood count until age 19. 
:tFrozen BM from diagnostic phase after Ficoll. 
§Unclassified ALL. 
1\ Both cALL -antigen- and various myeloid-antigen-positive cells. 
Bg Bg H Bg Bg Bg 
5' Ell I 
Ba I I II I 
-+--- centromere 
Fig 1. Restriction enzyme map of the human bcr locus on 
chromosome 22. BamHI = Ba. Bg/11 = Bg. EcoRI = E, Hind Ill = H. 
The 5.8-kb bcr indicated on top is artificially divided into five 
subregions (0-4). The probes used are indicated by solid boxes 
below the map. I, 2.0-kb Bg-H; II. 1.2-kb H-Xholl; Ill. 1.2-kb H-Bg; 
IV, 0.3-kb Bg-E. 
bcr sequences (translocated to the 9q + chromosome in 
CML) are not visible. Of patients R6 and U6 (Table 3) 
material was available from a relapse ALL phase. In each 
patient both Bglll digested ALL- and relapse ALL-DNA 
showed identical aberrant Bglll fragments (R6, Fig 2E). 
Two of the ALL patients, Ll and R7 (Table 3) recurred 
with CML after 4 and 2 years of complete remission, 
respectively. Although the initial ALL phase of L1 was not 
karyotyped, the finding of a bcr rearrangement (Fig 2C) 
strongly suggests the presence of a Ph 1 chromosome. At the 
CML phase, a standard t(9;22) was found in the bone 
marrow cells, but unfortunately no DNA was available, and 
comparison of the molecular rearrangement of both phases 
was not possible. In patient R7, DNA from the ALL phase 
showed no bcr rearrangement; in contrast, DNA obtained in 
the CML phase did show a breakpoint in the bcr (Fig 2D). 
These results were confirmed by in situ hybridization of bcr 
probes showing segregation of the 5' and 3' bcr probes (data 
not shown). 
Sub/ocalization of the bcr breakpoints: Evidence for 
deletions in the bcr. To localize the bcr breakpoints more 
precisely, we arbitrarily divided the 5.8-kb bcr into the five 
segments shown in Fig I. In a manner analogous to the 
mapping of the Ph 1 breakpoints in CML patients (16) we 
bcr 
I I I I I 
0 1 2 3 4 
Bg Hsa H 
Bg Bg 
I II I IE s'a Ill 
--I - III• II IV 
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lkb 
H 
I 3' 
sublocalized the 5' and for 3' breakpoints of the 10 bcr ( +) 
DNAs (nine ALL and the CML phase of patient R7). 
Usually the break in chromosome 22 splits the bcr in two 
segments: the 5' bcr segment, oriented towards the centro-
mere and remaining on the 22q- chromosome, and a 3' bcr 
Ph 1 translocation. These segments are identified by Southern 
blot analysis using the 5' and the 3' bcr probe (probes I and 
III, respectively, Fig I). The results are given in Table 4. In 
six patients the breakpoint regions determined with various 
probes and digests are not located in the same subregion of 
the bcr. In two of these patients (LI and L9) both break-
points could be localized, although in a different subregion. 
In patient L1 probe I and probe III (5' bcr and 3' bcr, 
respectively, Fig I) detect two different new hybridizing 
bands in Bg/II-digested L1 DNA. This indicates that both 
breakpoints are situated within the bcr. In Hind!II-digested 
Ll-DNA, probe II and probe III .detect different extra 
hybridizing bands. Since probe II detects only the 5' bcr 
segment in Bg/II-digested Ll-DNA, the 5' breakpoint is 
located in the 1.8-kb Hindiii fragment (region I + 2). The 
3' breakpoint is located in segment 3 and a minimum of 300 
bp of bcr sequences is deleted. (The distance between the 3' 
end of probe II and the 5' end of probe Ill.) In four other 
patients (U3, U4, R6, and R 7) only one of the breakpoints 
could be assigned. For instance, in patient R6 the 5' break-
point could be mapped 3' of the Bam HI site in segment 2 of 
the bcr: abnormal Bg/II fragments with probe I and probe II, 
normal Bam HI fragments with both probes, and an aberrant 
Hindlll fragment with probe II. Probes III or IV detect only 
Table 3. Ph1-Positive All Patients Studied in Acute and Relapse Phases 
Survival Cytogenetics 
Patient Age/Sex Week (w) WBC %Blasts Cells 
No. (Years) Years (y) 109/L BM PB lmmunophenotype Material Analyzed Karyotype 
R6 61 F 56w 209 75 60 cALL BM 0 38 46,XX,t(9;11;22)(q34;p15;q11) 
28.5 90 67 cALL BM R• 57 idem/49,XXX,t(9; 11 ;22),3p- ,6q-
+7.+8p-.+21 
U6 23M 48w 66.0 95 71 cALL PB 0 15 46.XY,t(9;22)(q34;q11) 
NO NO NO cALL PB Rt NO NO 
L 1 31M 11 y 102 90 94 cALLt NO NO NO 
17.5 2 0 CML BM§ 20 46,XY,Ph 1 
R7ij 50F 156 w 33.7 61 71 cALL BM 32 46,XX.t(9;14;22Jiq33;q32;q11) 
89.8 3.2 4 CML BM 21 46,XX.ti9:22)/46,XX,9q + ,i(22q- I 
Abbreviations: see Table 1. 0, diagnostic; A, relapse; NO, no data available. 
*Relapse ALL occurred after 11 months of clinical complete remission, but a Ph 1-positive bone marrow. 
tRelapse ALL occurred after complete remission with Ph 1-negative bone marrow. 
+Common ALL immunophenotype but hematologic diagnosis of acute undifferent'tated leukemia. 
§CML occurred after 4 years of complete remission. 
%Ph1 
1+1 Rearranged 
Cells bcr 
60 + 
51/32 + 
53 + 
NO + 
NO + 
100 NO 
60 
70/30 + 
liThe karyotype of the ALL phase has been published.:J9 During the 28 months of complete remission cytogenetic analysis of the bone marrow showed 
a normal karyotype with a residual standard t(9;22) in three out of 220 metaphases karyotyped. Leukemia relapsed as a Ph 1-positive AML that, after 
treatment, transformed in CML, chronic phase. Fatal myeloid blast crisis occurred 4 months later. 
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the normal bcr fragments in either a Bglii, Hindlll, Bam HI, 
or EcoRI digest. Thus apparently the 3' part of the bcr is 
deleted and the 3' breakpoint of patient R6 maps outside the 
bcr. 
In situ hybridization. Translocation of the c-ab/ onco-
gene was studied by in situ hybridization of c-ab/ specific 
sequences to metaphase chromosomes from five Ph1-positive 
ALL patients (U3, U5, R2, R5, and R6). Distribution of 
silver grains was uniform and at random on all chromosomes 
except the specific signals (P < 0.01) on chromosomes 
9(q34) and Ph1 in all cases investigated (Table 5). 
This indicates that c-ab/ sequences are translocated to the 
Ph' chromosome. In two of the patients (R2, R5) the bcrwas 
not rearranged, which suggests that in these two cases 
recombination of c-ab/ with chromosome 22 sequences is 
different from that in CML 
c-ab! transcription in ALL For the detection of c-ab/ 
mRNA a human 0.6-kb EcoRI-BamHI DNA fragment was 
used as a probe. This fragment contains the most 5' human 
v-abl hybridizing exon.JO In order to examine whether the 
translocation resulted in a modification of the mRNA tran-
script as found in CML, RNA was isolated from the 
leukemic cells of 3 Ph1-positive ALL patients. As a control, 
RNA isolated from human testes or Hela cells was used as 
well as the RNA of a Ph1-positivc CML blast ci-isis cell line, 
K562. As shown in Fig 3, in all RNA species the c-
ab/-specific probe detects the normal 6.0- and 7.0-kb 
mRNA transcripts. In addition a novel c-ab/ mRNA of 8-.5 
kb is present in the RNA of patients U6 (lane 2) and R6 
(lane 4) as well as in K562 RNA (lane 3). This 8.5-kb 
mRNA is not present in the RNA of Hela cells (lane 1) or 
normal human testes (lane 6) or the leukemic cells of patient 
R2 (lane 5) exhibiting no bcr rearrangements in Southern 
blots. 
The Northern blot containing the RNA of K562, patient 
R6, and patient R2, and human testes RNA was also 
hybridized to a 5' her eDNA probe.n In all RNA species the 
normal her transcripts of 7.0 kb and 4.5 kb were present. In 
the RNA of patient R6 and K562 cells, this 5' her-specific 
probe detects an additional hybridizing band of 8.5 kb (not 
shown). 
Table 4. Analysis of bcr Breakpoints 
5' 
Breakpoint 
Patient No. in Segment 
L8 1,2 
L9 1,2 
U1 2 
U2 1,2 
U3 2 
U4 3 
R6t 2 
U6t 1 
L1 1,2 
R7 
bcr segments are indicated in Fig 1. 
*Deletion of bcrsequences has occurred. 
tldentical breakpoints in initial and relapsed phase. 
DISCUSSION 
3' 
Breakpoint 
in Segment 
1,2 
3• 
2 
1,2 
1 
3• 
2• 
Recently we showed that in CML the Ph1 chromosome is 
the result of a consistent juxtaposition of the c-ab/ oncogene 
and the chromosome 22 her sequenceS.I6,26 In the present 
studies, using in situ hybridization, we demonstrate a trans-
Table 5. Results of In Situ Hybridization Studies With c-ab/ Probes 
Patient Cells Total of Grains Grains on Chromosomes 
No. Analyzed On Chromosome/Back17ound Chromosome• Observed Expected x' 
U3 26 189/68 5 6.0 0.2 
5q- 2.7 1.1 
9 13 4.5 16.1 
9q+ 8.5 1.4 
22 3 1.6 1.2 
22q- 14 1.0 169.0 
us 43 243/75 9 27 5.8 77.5 
9q+ 2 6.5 3.1 
22 0 2.1 2.1 
22q- 19 1.3 241.0 
R2 30 113/54 9p-t 12 2.5 36.1 
9p+q+ 4 3.1 0.3 
22 0 0.9 0.9 
22q- 5 0.6 32.3 
RS 31 103/46 9p+~ 13 3.1 21.6 
9p+q+ 3 3.7 0.1 
22 0 0.9 0.9 
22q- 9 0.5 144.5 
R6 28 85/36 9 10 1.9 34.5 
9q+ 2 2.1 0.0 
11 2 1.9 0.0 
11p+ 2 1.9 0.0 
22 0 0.7 0.7 
22q- 0.4 108.9 
•Karyotype of patients as given in Table 2 and 3. t9P- ~ der19) t(3;9)(q27;p21); 9p+q+ ~ [4pter ~ p14::9p21 ~ q34::22q11 ~ qter] 
~9p+ ~ der(9) tl1;9)(q25;p21); 9p+q+ ~ [8qter ~ q13::9p21 ~ q34::22q11 ~ qter] 
A B c 
1 2 2 
-+ •• 
D E 
2 3 4 2 3 4 
Fig 2. Southern blot analysis of Bg/11-digested DNA (10 ~g) of 
the leukemic cells of five ALL patients. (A) All patient L4; (B) All 
patient R1; (C) ALL patient l1; (D) ALL {lane 1 and 2) and CML 
phase (lane 3 and 4) of patient R7; {E) All (lane 1 and 2) and 
relapse All {lane 3 and 4) of patient R6. Arrow indicates the 5.0 kb 
normal Bq/11 fragment. Lanes 1 and 3 are hybridized with probe I 
{5' bcr) and lanes 2 and 4 are hybridized with probe Ill (3' bcr) 
indicated in Fig 1. In (C). lane 1. the hybridization signal (top band) 
of a previous hybridization of the same filter with probe Ill (3' bcr) 
is still visible. 
location of the c-ab/ oncogene from chromosome 9 to chro-
mosome 22 in five Ph1-positive ALL patients. This observa-
tion proves that the Ph1 chromosome in ALL is similar to 
that in CML14 and derives from a reciprocal translocation 
between chromosome 9 and 22. The incidence of variant 
translocations (5/15) is higher than in CML, where only 5% 
to 8% of the patients show translocations different from 
t(9;22). However, in· these variant translocations we also 
could demonstrate a translocation of the c-ab/ oncogene from 
9q 34 to the q II band of chromosome 22. 
In CML, a breakpoint is consistently found in the 5.8-kb 
bcr of the Ph1 chromosome.1• In contrast, Southern blot 
analysis of her of the leukemic cells from 14 Ph1-positive 
ALL patients only showed bcr rearrangements in nine 
patients. Sublocalization of the bcr breakpoints revealed that 
larger deletions involving her sequences frequently occurred 
in Ph1-positive ALL patients as compared to Ph1-positive 
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CML patients. In the rare cases of CML where bcr deletions 
could be observed (D. Bootsma and A. de Klein, unpublished 
results), these measured 100 to 500 bp and did not result in a 
complete deletion of the 3' bcr as in the ALL patients U3, 
U4, and R6. Although we did not observe bcr deletions 
during transition from chronic to acute phase of CML,11 the 
3' bcr sequences are also absent in the cell line K562 
established from pleural fluid of a CML patient in blast 
crisis.22 However, cytogenetic analysis revealed a concordant 
absence of the 9q + chromosome in K562,32.33 whereas in 
Ph1-positive ALL patients the derivative chromosome con-
taining the deleted part of chromosome 22 was present. 
Studies of other Ph1-positive hematologic disorders different 
from CML will be necessary to corroborate whether these 
large deletions are typical features of Ph1-positive ALL. 
Absence of bcr rearrangements were found in 5 cases of 
Ph1-positive ALL. Recently, similar observations have been 
reported in two children with Ph1-positive ALL.1• However, 
in two of our cases studied by in situ hybridization it was 
clear that one copy of the c-ab/ had moved to chromosome 22 
despite the lack of bcr rearrangement. Since the complete bcr 
gene has not yet been identified, the possibility remains that 
in these cases c-ab/ is translocated to the more 5' unidentified 
sequences of the bcr gene. The demonstration of a breakpoint 
within the immunoglobulin light chain geneJS (by in situ 
hybridization) in one Ph1-positive ALL patient suggests that 
sequences which map more proximally on chromosome 22 
than bcr can be involved in the Ph1-translocation in ALL. 
These observations suggest that a proportion of Ph1-positive 
ALL differ from CML by the absence of bcr rearrange-
ments. The previously reported ALL cases were children, 
and the one childhood Ph1-positive ALL case that we studied 
(R2) was also without detectable bcr rearrangement; but 
since four other cases with no bcr rearrangements were 
adults, this does not seem restricted to childhood Ph1-positive 
ALL. 
Ph1-positive ALL patients have a worse prognosis as 
compared to the Ph1-negative ALL patients.J6.l7 In CML, 
Ph1-negative patients with no translocation of c-abhs and no 
bcr rearrangements!• seemed to belong to a distinct subclass 
of leukemia with a poorer prognosis .. Although the number 
of patients we studied is small, our data indicate no differ-
ence in survival time for the Ph1-positive ALL patients with 
or without bcr rearrangements. A much larger series of ALL 
cases should be studied to ascertain any clinical relevance for 
diagnosis and prognosis of the distinction between Ph 1-
positive ALL with or without bcr rearrangement. 
Two Ph1-positive ALL patients (U6 and R6) were studied 
at diagnosis and at relapse, with documented disappearance 
of the Ph1 chromosome from the bone marrow during com-
plete remission in one case (U6). Identical bcr rearrange-
ments were observed in the initial and relapse ALL phase of 
each patient. This suggests that even if complete remission is 
achieved, the Ph1-positive progenitor cell still can remain in 
the hematopoietic system. 
As reviewed by others,I1.Il a rarely observed feature of 
Ph1-positive ALL patients is that after achievement of com-
plete remission, some recur with CML instead of ALL. Two 
such cases are included in this study: patients Ll and R7. 
Although we were unable, despite all efforts using frozen 
cells, to obtain a karyotype of patient LI, the finding of a bcr 
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rearrangement strongly suggests that this was a Ph '-positive 
ALL. The 4-year lapse between the ALL and CML phase 
makes it possible that CML is a secondary leukemia, but 
unfortunately we were not able to compare the bcr regions in 
these two phases, since no CML-DNA was available. Patient 
R7 showed a variant Ph1 translocation in the initial ALL 
phase, and this variant Ph1 was interpreted as a two-step 
rearrangement: first a standard t(9:22), followed by a 
t(9q + ;14).39 During the ALL phase this patient was without 
bcr rearrangements. When CML recurred a bcr breakpoint 
(with deletions) was found. This suggests either a secondary 
rearrangement of the original9q + or Ph1 chromosome or the 
occurrence of a de novo Ph1 translocation in another stem 
cell. 
RNA isolated from Ph 1-positive CML or Ph1-positive cell 
lines all contained the abnormally sized c-ab/ mRNA of 
approximately 8.5 kb.19-22 In two of the three Ph1-positive 
ALL patients analyzed a similar 8.5-kb transcript was 
present. Both these ALL patients contained bcr rearrange-
ments, in contrast to the third patient, and in patient R6 the 
same mRNA hybridizes to a 5' bcr probe. This suggests that, 
as in CML,21-2l in ALL the juxtaposition of c-ab/ or bCI 
sequences can result in the transcription of a chimeric 
mRNA, which contains 5' bcr and 3' c-ab/ sequences. 
Translation of this chimeric mRNA would results in a 
bcrj abl fusion protein. Evidence for the presence of such a 
protein in Ph1-positive CML cells and different CML cell 
lines has been reported.40.4t An abnormally sized 21 0-kd 
c-ab/ protein is present in these cells which, in contrast to the 
normal 150-kd c-ab/, has in vitro tyrosine kinase activity 
similar to the v-abl gene product.42 
In the Ph1-positive ALL cases studied, translocation of the 
c-ab/ oncogene to the 22q- chromosome has been demon-
strated by in situ hybridization. However, regarding the 
observed heterogeneity in respect to the bcr rearrangements 
of Ph1-positive ALL patients, the question remains open 
whether in all the ALL patients a bcrjc-abl chimeric mRNA 
is present. In those cases where neither bcr rearrangement 
nor an altered transcription of c-ab/ or bcr could be demon-
strated, other genes or sequences could contribute to the 
3 4 5 6 
1 2 
Fig 3. Northern blot analysis of RNA from three ALL patients 
and control cells. Total RNA (20 ,u.g) was blotted and hybridized 
with a human c-ab/ probe. Lane 1, Hela cells; lane 2, ALL patient 
U6; lane 3, K562 cells; lane 4, ALL patient R6; lane 5. ALL patient 
R2; lane 6, human testes. The sizes (kb) of the hybridizing bands 
are indicated. 
generation andjor maintenance of ALL. The molecular 
aspects observed in some Ph1-positive ALL patients are 
indistinguishable from CML, reinforcing the possibility that 
in some of these ALL patients there may be lymphoid blast 
crises developing from subclinical CML.s.12 Investigation of 
more patients and follow-up for a longer, time may therefore 
finally reveal the clinical and j or biologic importance of 
molecular differences among these patients. 
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